{"ae947cbb64e3337e68c5681c7865dc8f84669a4a": [["A c c e p t e d M a n u s c r i p t", [["u s", "TEST", 22, 25]]]], "7224f6c9d03b9cb6926c4795ef11f4b13e846810": [["IntroductionThe immune system is made up of a large and complex network of cells, tissues organs, and systems throughout the body.", [["immune system", "ANATOMY", 16, 29], ["cells", "ANATOMY", 75, 80], ["tissues organs", "ANATOMY", 82, 96], ["body", "ANATOMY", 125, 129], ["cells", "CELL", 75, 80], ["tissues organs", "TISSUE", 82, 96], ["body", "ORGANISM_SUBDIVISION", 125, 129], ["a large and complex network of cells", "PROBLEM", 44, 80], ["immune system", "OBSERVATION", 16, 29], ["large", "OBSERVATION_MODIFIER", 46, 51], ["complex", "OBSERVATION_MODIFIER", 56, 63], ["network of cells", "OBSERVATION", 64, 80], ["body", "ANATOMY", 125, 129]]], ["It has two major components: innate and adaptive immunity.", [["innate and adaptive immunity", "TREATMENT", 29, 57], ["two", "OBSERVATION_MODIFIER", 7, 10], ["major", "OBSERVATION_MODIFIER", 11, 16], ["components", "OBSERVATION_MODIFIER", 17, 27]]], ["Innate immunity serves as the first line of defense, consisting of physical barriers that help block the entry of pathogens (eyes, skin, mucus membranes, and the epithelium of the gut), immune cells, and the complement system.", [["eyes", "ANATOMY", 125, 129], ["skin", "ANATOMY", 131, 135], ["mucus membranes", "ANATOMY", 137, 152], ["epithelium", "ANATOMY", 162, 172], ["gut", "ANATOMY", 180, 183], ["immune cells", "ANATOMY", 186, 198], ["eyes", "ORGAN", 125, 129], ["skin", "ORGAN", 131, 135], ["mucus membranes", "MULTI-TISSUE_STRUCTURE", 137, 152], ["epithelium", "TISSUE", 162, 172], ["gut", "ORGAN", 180, 183], ["immune cells", "CELL", 186, 198], ["immune cells", "CELL_TYPE", 186, 198], ["physical barriers", "TREATMENT", 67, 84], ["pathogens (eyes, skin, mucus membranes", "PROBLEM", 114, 152], ["skin", "ANATOMY", 131, 135], ["mucus membranes", "ANATOMY", 137, 152], ["epithelium", "ANATOMY_MODIFIER", 162, 172], ["gut", "ANATOMY", 180, 183]]], ["The cells of the innate immune system, including phagocytes, neutrophils, dendritic cells and natural killer cells (NK), play critical roles in the body's defenses by neutralizing pathogens and facilitating the adaptive immune response.", [["cells", "ANATOMY", 4, 9], ["immune system", "ANATOMY", 24, 37], ["phagocytes", "ANATOMY", 49, 59], ["neutrophils", "ANATOMY", 61, 72], ["dendritic cells", "ANATOMY", 74, 89], ["natural killer cells", "ANATOMY", 94, 114], ["NK", "ANATOMY", 116, 118], ["body", "ANATOMY", 148, 152], ["cells", "CELL", 4, 9], ["immune system", "ANATOMICAL_SYSTEM", 24, 37], ["phagocytes", "CELL", 49, 59], ["neutrophils", "CELL", 61, 72], ["dendritic cells", "CELL", 74, 89], ["natural killer cells", "CELL", 94, 114], ["NK", "CELL", 116, 118], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["phagocytes", "CELL_TYPE", 49, 59], ["neutrophils", "CELL_TYPE", 61, 72], ["dendritic cells", "CELL_TYPE", 74, 89], ["natural killer cells", "CELL_TYPE", 94, 114], ["NK", "CELL_TYPE", 116, 118], ["phagocytes", "TEST", 49, 59], ["neutrophils", "TEST", 61, 72], ["dendritic cells", "PROBLEM", 74, 89], ["neutralizing pathogens", "PROBLEM", 167, 189], ["neutrophils", "ANATOMY", 61, 72], ["dendritic cells", "OBSERVATION", 74, 89], ["natural killer cells", "OBSERVATION", 94, 114], ["neutralizing pathogens", "OBSERVATION", 167, 189]]], ["The adaptive immune system, comprised of T and B cells, mounts a response to specific pathogens and develops immunological memory for future immune challenge.", [["immune system", "ANATOMY", 13, 26], ["T", "ANATOMY", 41, 42], ["B cells", "ANATOMY", 47, 54], ["T", "CELL", 41, 42], ["B cells", "CELL", 47, 54], ["T and B cells", "CELL_TYPE", 41, 54], ["The adaptive immune system", "TREATMENT", 0, 26], ["T and B cells", "TREATMENT", 41, 54], ["specific pathogens", "PROBLEM", 77, 95], ["immunological memory", "PROBLEM", 109, 129], ["future immune challenge", "TREATMENT", 134, 157]]], ["In the innate system, antigen-presenting cells facilitate the development of specific adaptive responses [1] .", [["antigen-presenting cells", "ANATOMY", 22, 46], ["cells", "CELL", 41, 46], ["antigen-presenting cells", "CELL_TYPE", 22, 46]]], ["Micronutrients are critical for every stage of the immune response.", [["immune response", "OBSERVATION", 51, 66]]], ["For instance, vitamin D is known to trigger the production of antimicrobial peptides, and folate, vitamin B6 and B12 are all required for white blood cell production.", [["white blood cell", "ANATOMY", 138, 154], ["vitamin D", "CHEMICAL", 14, 23], ["folate", "CHEMICAL", 90, 96], ["vitamin B6", "CHEMICAL", 98, 108], ["B12", "CHEMICAL", 113, 116], ["vitamin D", "CHEMICAL", 14, 23], ["folate", "CHEMICAL", 90, 96], ["vitamin B6 and B12", "CHEMICAL", 98, 116], ["vitamin D", "SIMPLE_CHEMICAL", 14, 23], ["folate", "SIMPLE_CHEMICAL", 90, 96], ["vitamin B6", "SIMPLE_CHEMICAL", 98, 108], ["B12", "SIMPLE_CHEMICAL", 113, 116], ["white blood cell", "CELL", 138, 154], ["vitamin D", "TREATMENT", 14, 23], ["antimicrobial peptides", "TREATMENT", 62, 84], ["folate", "TREATMENT", 90, 96], ["vitamin B6", "TREATMENT", 98, 108], ["B12", "TREATMENT", 113, 116], ["white blood cell production", "TEST", 138, 165]]], ["Additionally, vitamins A, C, D, E, and zinc, iron, and selenium are all involved in the innate and/or adaptive immunity immune response.", [["vitamins A, C, D, E", "CHEMICAL", 14, 33], ["zinc", "CHEMICAL", 39, 43], ["iron", "CHEMICAL", 45, 49], ["selenium", "CHEMICAL", 55, 63], ["vitamins A, C, D, E", "CHEMICAL", 14, 33], ["zinc", "CHEMICAL", 39, 43], ["iron", "CHEMICAL", 45, 49], ["selenium", "CHEMICAL", 55, 63], ["vitamins A", "SIMPLE_CHEMICAL", 14, 24], ["C", "SIMPLE_CHEMICAL", 26, 27], ["D", "SIMPLE_CHEMICAL", 29, 30], ["E", "SIMPLE_CHEMICAL", 32, 33], ["zinc", "SIMPLE_CHEMICAL", 39, 43], ["iron", "SIMPLE_CHEMICAL", 45, 49], ["selenium", "SIMPLE_CHEMICAL", 55, 63], ["vitamins A, C, D, E", "TEST", 14, 33], ["zinc", "TREATMENT", 39, 43], ["iron", "TREATMENT", 45, 49], ["selenium", "TREATMENT", 55, 63]]], ["Intake of these vitamins and minerals from the diet supports the body's initial and adaptive responses required for defense against pathogens [2, 3] .", [["body", "ANATOMY", 65, 69], ["vitamins", "CHEMICAL", 16, 24], ["minerals", "CHEMICAL", 29, 37], ["vitamins", "CHEMICAL", 16, 24], ["vitamins", "SIMPLE_CHEMICAL", 16, 24], ["minerals", "SIMPLE_CHEMICAL", 29, 37], ["body", "ORGANISM_SUBDIVISION", 65, 69], ["these vitamins and minerals", "TREATMENT", 10, 37], ["pathogens", "PROBLEM", 132, 141]]], ["Unfortunately, there is a high prevalence of inadequate intake of many of these nutrients in the U.S. population.", [["high prevalence", "OBSERVATION_MODIFIER", 26, 41]]], ["The 2015-2020 U.S. Dietary Guidelines (DGAs) has identified underconsumed intake of vitamins A, C, D, and E across all populations, and iron for women of childbearing age [4] .", [["vitamins A", "CHEMICAL", 84, 94], ["iron", "CHEMICAL", 136, 140], ["vitamins A, C, D, and E", "CHEMICAL", 84, 107], ["iron", "CHEMICAL", 136, 140], ["vitamins A", "SIMPLE_CHEMICAL", 84, 94], ["C", "SIMPLE_CHEMICAL", 96, 97], ["D", "SIMPLE_CHEMICAL", 99, 100], ["E", "SIMPLE_CHEMICAL", 106, 107], ["iron", "SIMPLE_CHEMICAL", 136, 140], ["women", "ORGANISM", 145, 150], ["women", "SPECIES", 145, 150], ["vitamins", "TREATMENT", 84, 92], ["iron", "TREATMENT", 136, 140]]], ["Both the 2010 and 2015-2020 DGAs identified the inadequate intake of vitamin D as a public health issue [4, 5] .", [["vitamin D", "CHEMICAL", 69, 78], ["vitamin D", "CHEMICAL", 69, 78], ["vitamin D", "SIMPLE_CHEMICAL", 69, 78], ["vitamin D", "TREATMENT", 69, 78]]], ["Previous NHANES reports showed that for vitamins A, C, D, and E, a high percentage of the population fell below the estimated average requirement (EAR), a nutrient intake value that is estimated to meet the requirement of half the healthy individuals to avoid symptoms of a clinical or subclinical deficiency [6] [7] [8] .", [["vitamins A, C, D, and E", "CHEMICAL", 40, 63], ["vitamins A", "SIMPLE_CHEMICAL", 40, 50], ["C", "SIMPLE_CHEMICAL", 52, 53], ["D", "SIMPLE_CHEMICAL", 55, 56], ["E", "SIMPLE_CHEMICAL", 62, 63], ["Previous NHANES", "TEST", 0, 15], ["vitamins", "TEST", 40, 48], ["a nutrient intake value", "TEST", 153, 176], ["symptoms", "PROBLEM", 260, 268], ["a clinical or subclinical deficiency", "PROBLEM", 272, 308]]], ["Zinc has a large prevalence of inadequacy in older adults [9] .", [["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["Zinc", "TREATMENT", 0, 4], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["Another lifestyle factor that can affect the immune system is inadequate sleep.", [["immune system", "ANATOMY", 45, 58], ["inadequate sleep", "PROBLEM", 62, 78]]], ["Approximately 1/3 of US adults do not meet the recommended number of sleep hours.", [["adults", "ORGANISM", 24, 30]]], ["A recent report showed a high prevalence of vitamins A, C, D, E, and zinc inadequacies are significantly associated with inadequate sleep [10] , which suggested nutrients play interdisciplinary roles in multiple systems that support immune health.", [["vitamins A, C, D, E", "CHEMICAL", 44, 63], ["zinc", "CHEMICAL", 69, 73], ["vitamins A, C, D, E", "CHEMICAL", 44, 63], ["zinc", "CHEMICAL", 69, 73], ["vitamins A", "SIMPLE_CHEMICAL", 44, 54], ["C", "SIMPLE_CHEMICAL", 56, 57], ["D", "SIMPLE_CHEMICAL", 59, 60], ["E", "SIMPLE_CHEMICAL", 62, 63], ["zinc", "SIMPLE_CHEMICAL", 69, 73], ["zinc inadequacies", "PROBLEM", 69, 86]]], ["The World Health Organization has classified the deficiency of vitamin A as a public health issue, especially in children and pregnant women, in over 50% of all countries [11] .", [["vitamin A", "CHEMICAL", 63, 72], ["vitamin A", "CHEMICAL", 63, 72], ["vitamin A", "SIMPLE_CHEMICAL", 63, 72], ["children", "ORGANISM", 113, 121], ["women", "ORGANISM", 135, 140], ["children", "SPECIES", 113, 121], ["women", "SPECIES", 135, 140], ["the deficiency", "PROBLEM", 45, 59], ["vitamin A", "TREATMENT", 63, 72]]], ["Vitamin C inadequacy is common in many countries, specifically with at-risk populations [12] , and almost 1 billion people around the world have low vitamin D levels, regardless of ethnicity or age [13] .", [["Vitamin C", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 149, 158], ["Vitamin C", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 149, 158], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["people", "ORGANISM", 116, 122], ["vitamin D", "SIMPLE_CHEMICAL", 149, 158], ["people", "SPECIES", 116, 122], ["Vitamin C inadequacy", "TREATMENT", 0, 20], ["low vitamin D levels", "PROBLEM", 145, 165]]], ["Only 1/5 of the global population are at the optimal vitamin E status levels [14] .", [["vitamin E", "CHEMICAL", 53, 62], ["vitamin E", "CHEMICAL", 53, 62], ["vitamin E", "SIMPLE_CHEMICAL", 53, 62], ["the optimal vitamin E status levels", "TEST", 41, 76], ["global", "OBSERVATION_MODIFIER", 16, 22], ["population", "OBSERVATION", 23, 33]]], ["In developing countries, zinc deficiency is a health concern [15] .", [["zinc", "CHEMICAL", 25, 29], ["zinc", "CHEMICAL", 25, 29], ["zinc", "SIMPLE_CHEMICAL", 25, 29], ["zinc deficiency", "PROBLEM", 25, 40], ["zinc deficiency", "OBSERVATION", 25, 40]]], ["A large body of research shows micronutrient insufficiencies/deficiencies and inadequate intake can impair immune function and weaken immune response, which may increase the risk of infections and other immune-associated diseases and conditions [2, 3, 12, .IntroductionThe objectives of this paper are to present an analysis of a large cross-sectional U.S. population database on dietary intake, identify the current prevalence of nutrient inadequacies of key micronutrients critical for immune function, review the function of these shortfall nutrients important for the immune system, and discuss strategies for filling dietary nutrient gaps.", [["immune system", "ANATOMY", 572, 585], ["infections", "DISEASE", 182, 192], ["micronutrient insufficiencies/deficiencies", "PROBLEM", 31, 73], ["inadequate intake", "PROBLEM", 78, 95], ["weaken immune response", "PROBLEM", 127, 149], ["infections", "PROBLEM", 182, 192], ["other immune-associated diseases", "PROBLEM", 197, 229], ["immune function", "PROBLEM", 488, 503], ["the immune system", "TEST", 568, 585], ["large", "OBSERVATION_MODIFIER", 2, 7], ["body", "OBSERVATION_MODIFIER", 8, 12], ["micronutrient insufficiencies", "OBSERVATION", 31, 60], ["infections", "OBSERVATION", 182, 192], ["diseases", "OBSERVATION", 221, 229]]], ["Although many essential nutrients are important for immune health, we have chosen to focus this manuscript on vitamins A, C, D, and E due to the substantial nutrient inadequacies we found in the U.S. population, as well as zinc, which was the highest shortfall of the immune-related minerals.MethodsThe National Health and Nutrition Examination Survey (NHANES) is a bi-yearly cross-sectional study of the US population conducted by Centers for Disease Prevention and Control (CDC).", [["vitamins A", "CHEMICAL", 110, 120], ["zinc", "CHEMICAL", 223, 227], ["vitamins A, C, D, and E", "CHEMICAL", 110, 133], ["zinc", "CHEMICAL", 223, 227], ["vitamins A", "SIMPLE_CHEMICAL", 110, 120], ["C", "SIMPLE_CHEMICAL", 122, 123], ["D", "SIMPLE_CHEMICAL", 125, 126], ["E", "SIMPLE_CHEMICAL", 132, 133], ["zinc", "SIMPLE_CHEMICAL", 223, 227], ["vitamins", "TREATMENT", 110, 118], ["the substantial nutrient inadequacies", "PROBLEM", 141, 178], ["Nutrition Examination", "TEST", 323, 344], ["Disease Prevention", "TREATMENT", 444, 462]]], ["Details regarding the study participants, demographics, methods, statistical analyses are described by Ikonte et al. [10] .", [["participants", "SPECIES", 28, 40], ["the study", "TEST", 18, 27]]], ["Briefly, the usual intake, % of population below EAR and % of population above the UL were analyzed using two reliable 24 h dietary recall interviews in 26,282 adults aged 19-99 years.Prevalence of Immune-Related Micronutrient InadequaciesDietary reference intakes (DRIs) is a term used for a group of nutrient reference values set by the National Academy of Medicine.", [["Immune", "TREATMENT", 198, 204]]], ["The set of four values are the estimated average requirement (EAR), recommended dietary allowance (RDA), adequate intake (AI), and the tolerable upper intake level (UL) [42] .", [["upper", "ORGANISM_SUBDIVISION", 145, 150]]], ["The EAR is a nutrient intake value that is estimated to meet the requirement of 50% of healthy individuals in a group, while the RDA is set to provide the nutrient requirements of 97-98% of healthy individuals in a group [42] .", [["EAR", "ANATOMY", 4, 7]]], ["EARs are determined using adequacy values that prevent deficiency signs or symptoms or rely on biomarkers of a nutrient's function or nutrient body stores [8] .", [["body", "ANATOMY", 143, 147], ["adequacy values", "TEST", 26, 41], ["deficiency signs", "PROBLEM", 55, 71], ["symptoms", "PROBLEM", 75, 83]]], ["The prevalence of nutrient inadequacy in population data (NHANES) is determined by assessing the percent of the population that has a nutrient usual intake below the EAR [42] .Prevalence of Immune-Related Micronutrient InadequaciesThe high prevalence of micronutrient inadequacy is a public health concern [4] .", [["Immune", "TREATMENT", 190, 196], ["Micronutrient Inadequacies", "PROBLEM", 205, 231], ["nutrient inadequacy", "OBSERVATION", 18, 37], ["EAR", "ANATOMY", 166, 169]]], ["Per the Dietary Guidelines for Americans and the intake estimates based on the NHANES data, vitamins A, C, D, and E are the largest essential micronutrient inadequacies across all population groups [4, 6, 7] .", [["vitamins A", "CHEMICAL", 92, 102], ["vitamins A, C, D, and E", "CHEMICAL", 92, 115], ["vitamins A", "SIMPLE_CHEMICAL", 92, 102], ["C", "SIMPLE_CHEMICAL", 104, 105], ["D", "SIMPLE_CHEMICAL", 107, 108], ["E", "SIMPLE_CHEMICAL", 114, 115], ["the NHANES data", "TEST", 75, 90], ["vitamins", "TREATMENT", 92, 100], ["micronutrient inadequacies", "OBSERVATION", 142, 168]]], ["Zinc has a large prevalence of inadequacy in older adults [9] .", [["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["Zinc", "TREATMENT", 0, 4], ["large", "OBSERVATION_MODIFIER", 11, 16]]], ["Older adults are at greater risk of impaired immune function with shifts in microbiome, increased medication intake, involution of the thymus and lower T cell production and multiple underlying health conditions-all of which increase risk of infection [43] .Prevalence of Inadequate Intake from Food Only, the 2005-2016 NHANESOur study shows that a significant number of Americans did not meet recommendations for micronutrients essential for immunocompetence.", [["thymus", "ANATOMY", 135, 141], ["T cell", "ANATOMY", 152, 158], ["infection", "DISEASE", 242, 251], ["adults", "ORGANISM", 6, 12], ["thymus", "ORGAN", 135, 141], ["T cell", "CELL", 152, 158], ["impaired immune function", "PROBLEM", 36, 60], ["increased medication intake", "PROBLEM", 88, 115], ["the thymus", "PROBLEM", 131, 141], ["lower T cell production", "PROBLEM", 146, 169], ["multiple underlying health conditions", "PROBLEM", 174, 211], ["infection", "PROBLEM", 242, 251], ["NHANESOur study", "TEST", 320, 335], ["immunocompetence", "PROBLEM", 443, 459], ["impaired", "OBSERVATION_MODIFIER", 36, 44], ["immune function", "OBSERVATION", 45, 60], ["thymus", "ANATOMY", 135, 141], ["lower T cell production", "OBSERVATION", 146, 169], ["multiple", "OBSERVATION_MODIFIER", 174, 182], ["infection", "OBSERVATION", 242, 251], ["significant", "OBSERVATION_MODIFIER", 349, 360]]], ["Specifically, in all adults (>19 years), 45% of the U.S. population had a prevalence of inadequacy (% of population below EAR) for vitamin A, 46% for vitamin C, 95% for vitamin D, 84% for vitamin E, and 15% for zinc.", [["vitamin A", "CHEMICAL", 131, 140], ["vitamin C", "CHEMICAL", 150, 159], ["vitamin D", "CHEMICAL", 169, 178], ["vitamin E", "CHEMICAL", 188, 197], ["zinc", "CHEMICAL", 211, 215], ["vitamin A", "CHEMICAL", 131, 140], ["vitamin C", "CHEMICAL", 150, 159], ["vitamin D", "CHEMICAL", 169, 178], ["vitamin E", "CHEMICAL", 188, 197], ["zinc", "CHEMICAL", 211, 215], ["vitamin A", "SIMPLE_CHEMICAL", 131, 140], ["vitamin C", "SIMPLE_CHEMICAL", 150, 159], ["vitamin D", "SIMPLE_CHEMICAL", 169, 178], ["vitamin E", "SIMPLE_CHEMICAL", 188, 197], ["zinc", "SIMPLE_CHEMICAL", 211, 215], ["vitamin A", "TREATMENT", 131, 140], ["vitamin C", "TREATMENT", 150, 159], ["vitamin D", "TREATMENT", 169, 178], ["vitamin E", "TREATMENT", 188, 197], ["zinc", "TREATMENT", 211, 215]]], ["There was a smaller prevalence of inadequacy in other essential immune nutrients such as 11% for vitamin B6, 12% for folate, 6% for copper, 5% for iron, and <1% for selenium (Table S1).Prevalence of Inadequate Intake from Food Only, the 2005-2016 NHANESWe found that nutrient inadequacies were considerable across the major immune health vitamins, as was reported in a previous NHANES study [7] .", [["vitamin B6", "CHEMICAL", 97, 107], ["folate", "CHEMICAL", 117, 123], ["copper", "CHEMICAL", 132, 138], ["iron", "CHEMICAL", 147, 151], ["selenium", "CHEMICAL", 165, 173], ["vitamin B6", "CHEMICAL", 97, 107], ["folate", "CHEMICAL", 117, 123], ["copper", "CHEMICAL", 132, 138], ["iron", "CHEMICAL", 147, 151], ["selenium", "CHEMICAL", 165, 173], ["vitamin B6", "SIMPLE_CHEMICAL", 97, 107], ["folate", "SIMPLE_CHEMICAL", 117, 123], ["copper", "SIMPLE_CHEMICAL", 132, 138], ["iron", "SIMPLE_CHEMICAL", 147, 151], ["selenium", "SIMPLE_CHEMICAL", 165, 173], ["vitamins", "SIMPLE_CHEMICAL", 338, 346], ["inadequacy in other essential immune nutrients", "PROBLEM", 34, 80], ["vitamin B6", "TREATMENT", 97, 107], ["folate", "TEST", 117, 123], ["copper", "TEST", 132, 138], ["iron", "TEST", 147, 151], ["nutrient inadequacies", "PROBLEM", 267, 288], ["a previous NHANES study", "TEST", 367, 390], ["smaller", "OBSERVATION_MODIFIER", 12, 19]]], ["The percentage of the population with usual intakes below the EAR in adults (\u226519 years) (the 2005-2016 NHANES vs. the 2003-2007 NHANES) remained substantial for vitamin A (45% vs. 45%) and vitamin E (84% vs. 91%), with a higher prevalence for inadequacy for vitamin C (46% vs. 37%), vitamin D (95% vs. 93%), and zinc (15% vs. 11%) [7] .Effects of Supplement Use on Prevalence of Inadequate Intake, the 2005-2016 NHANESOur research shows that food plus a dietary supplement had a lower prevalence of nutrient inadequacies than food alone.", [["vitamin A", "CHEMICAL", 161, 170], ["vitamin E", "CHEMICAL", 189, 198], ["vitamin C", "CHEMICAL", 258, 267], ["vitamin D", "CHEMICAL", 283, 292], ["zinc", "CHEMICAL", 312, 316], ["vitamin A", "CHEMICAL", 161, 170], ["vitamin E", "CHEMICAL", 189, 198], ["vitamin C", "CHEMICAL", 258, 267], ["vitamin D", "CHEMICAL", 283, 292], ["zinc", "CHEMICAL", 312, 316], ["vitamin A", "SIMPLE_CHEMICAL", 161, 170], ["vitamin E", "SIMPLE_CHEMICAL", 189, 198], ["vitamin C", "SIMPLE_CHEMICAL", 258, 267], ["vitamin D", "SIMPLE_CHEMICAL", 283, 292], ["zinc", "SIMPLE_CHEMICAL", 312, 316], ["vitamin A", "TREATMENT", 161, 170], ["vitamin E", "TREATMENT", 189, 198], ["vitamin C", "TREATMENT", 258, 267], ["vitamin D", "TEST", 283, 292], ["zinc", "TEST", 312, 316], ["a dietary supplement", "TREATMENT", 452, 472], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["EAR", "ANATOMY", 62, 65]]], ["The percentage of the population with usual intakes below the EAR in adults (\u2265 19 years) from food only vs. food + dietary supplements for vitamin A (45 to 35%), vitamin C (46 to 33%), vitamin D (95 to 65%), vitamin E (84 to 60%), and zinc (15 to 11%) ( Figure 1 ). immune function with shifts in microbiome, increased medication intake, involution of the thymus and lower T cell production and multiple underlying health conditions-all of which increase risk of infection [43] .Prevalence of Inadequate Intake from Food Only, the 2005-2016 NHANESOur study shows that a significant number of Americans did not meet recommendations for micronutrients essential for immunocompetence.", [["thymus", "ANATOMY", 356, 362], ["T cell", "ANATOMY", 373, 379], ["vitamin A", "CHEMICAL", 139, 148], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin D", "CHEMICAL", 185, 194], ["vitamin E", "CHEMICAL", 208, 217], ["zinc", "CHEMICAL", 235, 239], ["infection", "DISEASE", 463, 472], ["vitamin A", "CHEMICAL", 139, 148], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin D", "CHEMICAL", 185, 194], ["vitamin E", "CHEMICAL", 208, 217], ["zinc", "CHEMICAL", 235, 239], ["vitamin A", "SIMPLE_CHEMICAL", 139, 148], ["vitamin C", "SIMPLE_CHEMICAL", 162, 171], ["vitamin D", "SIMPLE_CHEMICAL", 185, 194], ["vitamin E", "SIMPLE_CHEMICAL", 208, 217], ["zinc", "SIMPLE_CHEMICAL", 235, 239], ["thymus", "ORGAN", 356, 362], ["T cell", "CELL", 373, 379], ["dietary supplements", "TREATMENT", 115, 134], ["vitamin A", "TREATMENT", 139, 148], ["vitamin C", "TREATMENT", 162, 171], ["vitamin D", "TREATMENT", 185, 194], ["vitamin E", "TREATMENT", 208, 217], ["zinc", "TREATMENT", 235, 239], ["shifts in microbiome", "PROBLEM", 287, 307], ["increased medication intake", "PROBLEM", 309, 336], ["the thymus", "PROBLEM", 352, 362], ["lower T cell production", "PROBLEM", 367, 390], ["multiple underlying health conditions", "PROBLEM", 395, 432], ["infection", "PROBLEM", 463, 472], ["NHANESOur study", "TEST", 541, 556], ["immunocompetence", "PROBLEM", 664, 680], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["EAR", "ANATOMY", 62, 65], ["thymus", "ANATOMY", 356, 362], ["lower", "ANATOMY_MODIFIER", 367, 372], ["T cell production", "OBSERVATION", 373, 390], ["multiple", "OBSERVATION_MODIFIER", 395, 403], ["infection", "OBSERVATION", 463, 472], ["significant", "OBSERVATION_MODIFIER", 570, 581]]], ["Specifically, in all adults (>19 years), 45% of the U.S. population had a prevalence of inadequacy (% of population below EAR) for vitamin A, 46% for vitamin C, 95% for vitamin D, 84% for vitamin E, and 15% for zinc.", [["vitamin A", "CHEMICAL", 131, 140], ["vitamin C", "CHEMICAL", 150, 159], ["vitamin D", "CHEMICAL", 169, 178], ["vitamin E", "CHEMICAL", 188, 197], ["zinc", "CHEMICAL", 211, 215], ["vitamin A", "CHEMICAL", 131, 140], ["vitamin C", "CHEMICAL", 150, 159], ["vitamin D", "CHEMICAL", 169, 178], ["vitamin E", "CHEMICAL", 188, 197], ["zinc", "CHEMICAL", 211, 215], ["vitamin A", "SIMPLE_CHEMICAL", 131, 140], ["vitamin C", "SIMPLE_CHEMICAL", 150, 159], ["vitamin D", "SIMPLE_CHEMICAL", 169, 178], ["vitamin E", "SIMPLE_CHEMICAL", 188, 197], ["zinc", "SIMPLE_CHEMICAL", 211, 215], ["vitamin A", "TREATMENT", 131, 140], ["vitamin C", "TREATMENT", 150, 159], ["vitamin D", "TREATMENT", 169, 178], ["vitamin E", "TREATMENT", 188, 197], ["zinc", "TREATMENT", 211, 215]]], ["There was a smaller prevalence of inadequacy in other essential immune nutrients such as 11% for vitamin B6, 12% for folate, 6% for copper, 5% for iron, and <1% for selenium (Table S1).Prevalence of Inadequate Intake from Food Only, the 2005-2016 NHANESWe found that nutrient inadequacies were considerable across the major immune health vitamins, as was reported in a previous NHANES study [7] .", [["vitamin B6", "CHEMICAL", 97, 107], ["folate", "CHEMICAL", 117, 123], ["copper", "CHEMICAL", 132, 138], ["iron", "CHEMICAL", 147, 151], ["selenium", "CHEMICAL", 165, 173], ["vitamin B6", "CHEMICAL", 97, 107], ["folate", "CHEMICAL", 117, 123], ["copper", "CHEMICAL", 132, 138], ["iron", "CHEMICAL", 147, 151], ["selenium", "CHEMICAL", 165, 173], ["vitamin B6", "SIMPLE_CHEMICAL", 97, 107], ["folate", "SIMPLE_CHEMICAL", 117, 123], ["copper", "SIMPLE_CHEMICAL", 132, 138], ["iron", "SIMPLE_CHEMICAL", 147, 151], ["selenium", "SIMPLE_CHEMICAL", 165, 173], ["vitamins", "SIMPLE_CHEMICAL", 338, 346], ["inadequacy in other essential immune nutrients", "PROBLEM", 34, 80], ["vitamin B6", "TREATMENT", 97, 107], ["folate", "TEST", 117, 123], ["copper", "TEST", 132, 138], ["iron", "TEST", 147, 151], ["nutrient inadequacies", "PROBLEM", 267, 288], ["a previous NHANES study", "TEST", 367, 390], ["smaller", "OBSERVATION_MODIFIER", 12, 19]]], ["The percentage of the population with usual intakes below the EAR in adults (\u226519 years) (the 2005-2016 NHANES vs. the 2003-2007 NHANES) remained substantial for vitamin A (45% vs. 45%) and vitamin E (84% vs. 91%) , with a higher prevalence for inadequacy for vitamin C (46% vs. 37%), vitamin D (95% vs. 93%), and zinc (15% vs. 11%) [7] .Effects of Supplement Use on Prevalence of Inadequate Intake, the 2005-2016 NHANESOur research shows that food plus a dietary supplement had a lower prevalence of nutrient inadequacies than food alone.", [["vitamin A", "CHEMICAL", 161, 170], ["vitamin E", "CHEMICAL", 189, 198], ["vitamin C", "CHEMICAL", 259, 268], ["vitamin D", "CHEMICAL", 284, 293], ["zinc", "CHEMICAL", 313, 317], ["vitamin A", "CHEMICAL", 161, 170], ["vitamin E", "CHEMICAL", 189, 198], ["vitamin C", "CHEMICAL", 259, 268], ["vitamin D", "CHEMICAL", 284, 293], ["zinc", "CHEMICAL", 313, 317], ["vitamin A", "SIMPLE_CHEMICAL", 161, 170], ["vitamin E", "SIMPLE_CHEMICAL", 189, 198], ["vitamin C", "SIMPLE_CHEMICAL", 259, 268], ["vitamin D", "SIMPLE_CHEMICAL", 284, 293], ["zinc", "SIMPLE_CHEMICAL", 313, 317], ["vitamin A", "TREATMENT", 161, 170], ["vitamin E", "TREATMENT", 189, 198], ["vitamin C", "TREATMENT", 259, 268], ["vitamin D", "TEST", 284, 293], ["zinc", "TEST", 313, 317], ["a dietary supplement", "TREATMENT", 453, 473], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["EAR", "ANATOMY", 62, 65]]], ["The percentage of the population with usual intakes below the EAR in adults (\u2265 19 years) from food only vs. food + dietary supplements for vitamin A (45 to 35%), vitamin C (46 to 33%), vitamin D (95 to 65%), vitamin E (84 to 60%), and zinc (15 to 11%) ( Figure 1 ).", [["vitamin A", "CHEMICAL", 139, 148], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin D", "CHEMICAL", 185, 194], ["vitamin E", "CHEMICAL", 208, 217], ["zinc", "CHEMICAL", 235, 239], ["vitamin A", "CHEMICAL", 139, 148], ["vitamin C", "CHEMICAL", 162, 171], ["vitamin D", "CHEMICAL", 185, 194], ["vitamin E", "CHEMICAL", 208, 217], ["zinc", "CHEMICAL", 235, 239], ["vitamin A", "SIMPLE_CHEMICAL", 139, 148], ["vitamin C", "SIMPLE_CHEMICAL", 162, 171], ["vitamin D", "SIMPLE_CHEMICAL", 185, 194], ["vitamin E", "SIMPLE_CHEMICAL", 208, 217], ["zinc", "SIMPLE_CHEMICAL", 235, 239], ["dietary supplements", "TREATMENT", 115, 134], ["vitamin A", "TREATMENT", 139, 148], ["vitamin C", "TREATMENT", 162, 171], ["vitamin D", "TREATMENT", 185, 194], ["vitamin E", "TREATMENT", 208, 217], ["zinc", "TREATMENT", 235, 239], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["EAR", "ANATOMY", 62, 65]]], ["The strength of this analysis was the use of a large, nationally representative, population-based sample (based on six NHANES cycles, 2005-2016).", [["this analysis", "TEST", 16, 29], ["large", "OBSERVATION_MODIFIER", 47, 52]]], ["The limitation of the analysis was probable bias measurement errors due to self-reported data.Vitamin DFor more than a century, both sunlight and dietary sources of vitamin D (cod liver oil) have been used to treat tuberculosis, a bacterial infection of the lungs [44] .", [["liver oil", "ANATOMY", 180, 189], ["lungs", "ANATOMY", 258, 263], ["Vitamin DFor", "CHEMICAL", 94, 106], ["vitamin D", "CHEMICAL", 165, 174], ["tuberculosis", "DISEASE", 215, 227], ["bacterial infection", "DISEASE", 231, 250], ["Vitamin DFor", "CHEMICAL", 94, 106], ["vitamin D", "CHEMICAL", 165, 174], ["Vitamin", "SIMPLE_CHEMICAL", 94, 101], ["vitamin D", "SIMPLE_CHEMICAL", 165, 174], ["liver oil", "ORGANISM_SUBSTANCE", 180, 189], ["lungs", "ORGAN", 258, 263], ["the analysis", "TEST", 18, 30], ["bias measurement errors", "PROBLEM", 44, 67], ["Vitamin DFor", "TREATMENT", 94, 106], ["vitamin D (cod liver oil", "TREATMENT", 165, 189], ["tuberculosis", "PROBLEM", 215, 227], ["a bacterial infection of the lungs", "PROBLEM", 229, 263], ["liver", "ANATOMY", 180, 185], ["tuberculosis", "OBSERVATION", 215, 227], ["bacterial", "OBSERVATION_MODIFIER", 231, 240], ["infection", "OBSERVATION", 241, 250], ["lungs", "ANATOMY", 258, 263]]], ["Vitamin D regulates the innate as well as the adaptive immune systems.", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D regulates", "TREATMENT", 0, 19], ["the adaptive immune systems", "TREATMENT", 42, 69]]], ["Vitamin D impacts the innate immune system in several ways.", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D impacts", "TREATMENT", 0, 17], ["the innate immune system", "TREATMENT", 18, 42]]], ["It enhances barrier function of epithelial cells in the eyes and intestinal tract [45, 46] .", [["barrier", "ANATOMY", 12, 19], ["epithelial cells", "ANATOMY", 32, 48], ["eyes", "ANATOMY", 56, 60], ["intestinal tract", "ANATOMY", 65, 81], ["barrier", "TISSUE", 12, 19], ["epithelial cells", "CELL", 32, 48], ["eyes", "ORGAN", 56, 60], ["intestinal tract", "ORGAN", 65, 81], ["epithelial cells", "CELL_TYPE", 32, 48], ["barrier function", "OBSERVATION", 12, 28], ["epithelial cells", "OBSERVATION", 32, 48], ["eyes", "ANATOMY", 56, 60], ["intestinal tract", "ANATOMY", 65, 81]]], ["Additionally, vitamin D enhances chemotactic, phagocytic, and bactericidal activities of key innate immune cells including monocytes, macrophages, and neutrophils [28] .", [["immune cells", "ANATOMY", 100, 112], ["monocytes", "ANATOMY", 123, 132], ["macrophages", "ANATOMY", 134, 145], ["neutrophils", "ANATOMY", 151, 162], ["vitamin D", "CHEMICAL", 14, 23], ["vitamin D", "CHEMICAL", 14, 23], ["vitamin D", "SIMPLE_CHEMICAL", 14, 23], ["innate immune cells", "CELL", 93, 112], ["monocytes", "CELL", 123, 132], ["macrophages", "CELL", 134, 145], ["neutrophils", "CELL", 151, 162], ["innate immune cells", "CELL_TYPE", 93, 112], ["monocytes", "CELL_TYPE", 123, 132], ["macrophages", "CELL_TYPE", 134, 145], ["neutrophils", "CELL_TYPE", 151, 162], ["vitamin D enhances chemotactic", "TREATMENT", 14, 44], ["phagocytic", "TEST", 46, 56], ["bactericidal activities", "TEST", 62, 85], ["monocytes", "TEST", 123, 132], ["macrophages", "TEST", 134, 145], ["neutrophils", "TEST", 151, 162]]], ["Cathelicidin and defensin are antimicrobial proteins that protect the body by killing pathogens and are regulated by calcitriol, the active form of vitamin D [2, [47] [48] [49] .", [["body", "ANATOMY", 70, 74], ["Cathelicidin", "CHEMICAL", 0, 12], ["calcitriol", "CHEMICAL", 117, 127], ["vitamin D", "CHEMICAL", 148, 157], ["2, [47] [48", "CHEMICAL", 159, 170], ["calcitriol", "CHEMICAL", 117, 127], ["vitamin D", "CHEMICAL", 148, 157], ["Cathelicidin", "GENE_OR_GENE_PRODUCT", 0, 12], ["defensin", "GENE_OR_GENE_PRODUCT", 17, 25], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["calcitriol", "SIMPLE_CHEMICAL", 117, 127], ["vitamin D", "SIMPLE_CHEMICAL", 148, 157], ["2, [47] [48] [49]", "SIMPLE_CHEMICAL", 159, 176], ["Cathelicidin", "PROTEIN", 0, 12], ["defensin", "PROTEIN", 17, 25], ["antimicrobial proteins", "PROTEIN", 30, 52], ["Cathelicidin", "TREATMENT", 0, 12], ["defensin", "TREATMENT", 17, 25], ["antimicrobial proteins", "TREATMENT", 30, 52], ["killing pathogens", "PROBLEM", 78, 95], ["calcitriol", "TREATMENT", 117, 127], ["vitamin D", "TREATMENT", 148, 157]]], ["Antimicrobial peptide expression in epithelial cells of the respiratory tract, helps protect the lungs from infection [49] .", [["epithelial cells", "ANATOMY", 36, 52], ["respiratory tract", "ANATOMY", 60, 77], ["lungs", "ANATOMY", 97, 102], ["infection", "DISEASE", 108, 117], ["epithelial cells", "CELL", 36, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["lungs", "ORGAN", 97, 102], ["epithelial cells", "CELL_TYPE", 36, 52], ["Antimicrobial peptide expression", "TREATMENT", 0, 32], ["infection", "PROBLEM", 108, 117], ["epithelial cells", "OBSERVATION", 36, 52], ["respiratory tract", "ANATOMY", 60, 77], ["lungs", "ANATOMY", 97, 102], ["infection", "OBSERVATION", 108, 117]]], ["Vitamin D also impacts the adaptive immune system, which governs the body's specific immune responses.", [["immune system", "ANATOMY", 36, 49], ["body", "ANATOMY", 69, 73], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["immune system", "ANATOMICAL_SYSTEM", 36, 49], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["Vitamin D", "TREATMENT", 0, 9], ["the adaptive immune system", "TREATMENT", 23, 49]]], ["Vitamin D helps facilitate the differentiation of na\u00efve T cells into effector T cells including \"killer\" or \"helper\" T cells.", [["T cells", "ANATOMY", 56, 63], ["effector T cells", "ANATOMY", 69, 85], ["killer", "ANATOMY", 97, 103], ["helper\" T cells", "ANATOMY", 109, 124], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["na\u00efve T cells", "CELL", 50, 63], ["effector T cells", "CELL", 69, 85], ["killer", "CELL", 97, 103], ["T cells", "CELL", 117, 124], ["na\u00efve T cells", "CELL_TYPE", 50, 63], ["effector T cells", "CELL_TYPE", 69, 85], ["killer\" or \"helper\" T cells", "CELL_TYPE", 97, 124], ["Vitamin D", "TREATMENT", 0, 9]]], ["Insufficient vitamin D levels impair the differentiation of naive T cells into effector T cells [50] .", [["T cells", "ANATOMY", 66, 73], ["effector T cells", "ANATOMY", 79, 95], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "CHEMICAL", 13, 22], ["vitamin D", "SIMPLE_CHEMICAL", 13, 22], ["naive T cells", "CELL", 60, 73], ["effector T cells", "CELL", 79, 95], ["naive T cells", "CELL_TYPE", 60, 73], ["effector T cells", "CELL_TYPE", 79, 95], ["Insufficient vitamin D levels", "TEST", 0, 29]]], ["Vitamin D also regulates inflammation by altering the cytokine balance in favor of anti-inflammatory cytokines [32, 48, 51] .", [["Vitamin D", "CHEMICAL", 0, 9], ["inflammation", "DISEASE", 25, 37], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["cytokine", "PROTEIN", 54, 62], ["anti-inflammatory cytokines", "PROTEIN", 83, 110], ["Vitamin D", "TREATMENT", 0, 9], ["inflammation", "PROBLEM", 25, 37], ["anti-inflammatory cytokines", "TREATMENT", 83, 110]]], ["Interestingly, vitamin D increases the oxidative activity of macrophages, which has been linked to alternative-like polarization and production of anti-inflammatory cytokines [52] .", [["macrophages", "ANATOMY", 61, 72], ["vitamin D", "CHEMICAL", 15, 24], ["vitamin D", "CHEMICAL", 15, 24], ["vitamin D", "SIMPLE_CHEMICAL", 15, 24], ["macrophages", "CELL", 61, 72], ["macrophages", "CELL_TYPE", 61, 72], ["anti-inflammatory cytokines", "PROTEIN", 147, 174], ["vitamin D", "TREATMENT", 15, 24], ["the oxidative activity of macrophages", "TREATMENT", 35, 72], ["anti-inflammatory cytokines", "PROBLEM", 147, 174], ["oxidative activity", "OBSERVATION_MODIFIER", 39, 57], ["macrophages", "OBSERVATION", 61, 72]]], ["In adaptive immunity, vitamin D inhibits T cell proliferation of Th1-cells and enhances proliferation of Th2 cells-the balance of which is thought to be an important regulator of autoimmunity [23] .", [["T cell", "ANATOMY", 41, 47], ["Th1-cells", "ANATOMY", 65, 74], ["Th2 cells", "ANATOMY", 105, 114], ["vitamin D", "CHEMICAL", 22, 31], ["autoimmunity", "DISEASE", 179, 191], ["vitamin D", "CHEMICAL", 22, 31], ["vitamin D", "SIMPLE_CHEMICAL", 22, 31], ["T cell", "CELL", 41, 47], ["Th1-cells", "CELL", 65, 74], ["Th2 cells", "CELL", 105, 114], ["Th1-cells", "CELL_TYPE", 65, 74], ["Th2 cells", "CELL_TYPE", 105, 114], ["vitamin D", "TREATMENT", 22, 31], ["enhances proliferation of Th2 cells", "PROBLEM", 79, 114], ["proliferation", "OBSERVATION_MODIFIER", 88, 101], ["Th2 cells", "OBSERVATION", 105, 114], ["thought to be", "UNCERTAINTY", 139, 152]]], ["Additionally, vitamin D has been shown to promote regulatory T cells, which actively suppress inflammation [19] .", [["regulatory T cells", "ANATOMY", 50, 68], ["vitamin D", "CHEMICAL", 14, 23], ["inflammation", "DISEASE", 94, 106], ["vitamin D", "CHEMICAL", 14, 23], ["vitamin D", "SIMPLE_CHEMICAL", 14, 23], ["T cells", "CELL", 61, 68], ["regulatory T cells", "CELL_TYPE", 50, 68], ["vitamin D", "TREATMENT", 14, 23]]], ["Thus, vitamin D plays roles in strengthening the body's barriers and innate immune defenses, while also regulating inflammation to support healthy immune responses.Clinical RelevanceMaintaining adequate levels of vitamin D is important for optimal immune health.", [["body", "ANATOMY", 49, 53], ["vitamin D", "CHEMICAL", 6, 15], ["inflammation", "DISEASE", 115, 127], ["vitamin D", "CHEMICAL", 213, 222], ["vitamin D", "CHEMICAL", 6, 15], ["vitamin D", "CHEMICAL", 213, 222], ["vitamin D", "SIMPLE_CHEMICAL", 6, 15], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["vitamin D", "SIMPLE_CHEMICAL", 213, 222], ["vitamin D plays roles", "TREATMENT", 6, 27], ["vitamin D", "TREATMENT", 213, 222], ["inflammation", "OBSERVATION", 115, 127]]], ["Low vitamin D status is a global public health problem in developed as well as developing countries, with approximately 1 billion people worldwide with deficient or insufficient levels of vitamin D [53] .", [["vitamin D", "CHEMICAL", 4, 13], ["vitamin D", "CHEMICAL", 188, 197], ["vitamin D", "CHEMICAL", 4, 13], ["vitamin D [53]", "CHEMICAL", 188, 202], ["vitamin D", "SIMPLE_CHEMICAL", 4, 13], ["people", "ORGANISM", 130, 136], ["vitamin D", "SIMPLE_CHEMICAL", 188, 197], ["people", "SPECIES", 130, 136], ["Low vitamin D status", "PROBLEM", 0, 20], ["a global public health problem", "PROBLEM", 24, 54], ["vitamin D", "TREATMENT", 188, 197]]], ["Vitamin D does not occur naturally in many foods and people generally do not get enough sun exposure to produce adequate levels of vitamin D. Vitamin D status tends to be at its lowest in late winter and spring [54] .", [["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D.", "CHEMICAL", 131, 141], ["Vitamin D", "CHEMICAL", 142, 151], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 142, 151], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["people", "ORGANISM", 53, 59], ["vitamin D.", "SIMPLE_CHEMICAL", 131, 141], ["Vitamin D", "SIMPLE_CHEMICAL", 142, 151], ["people", "SPECIES", 53, 59], ["Vitamin D", "TREATMENT", 0, 9], ["vitamin D. Vitamin D status", "TREATMENT", 131, 158]]], ["Declining levels of vitamin D may be linked to the seasonal prevalence of common viral infections.", [["vitamin D", "CHEMICAL", 20, 29], ["viral infections", "DISEASE", 81, 97], ["vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "SIMPLE_CHEMICAL", 20, 29], ["vitamin D", "TREATMENT", 20, 29], ["common viral infections", "PROBLEM", 74, 97], ["viral infections", "OBSERVATION", 81, 97]]], ["Accordingly, UVB exposure (representing vitamin D status) was negatively correlated with case fatality rates during the 1918-1919 influenza pandemic [54] .", [["UVB", "CHEMICAL", 13, 16], ["vitamin D", "CHEMICAL", 40, 49], ["influenza", "DISEASE", 130, 139], ["vitamin D", "CHEMICAL", 40, 49], ["UVB", "SIMPLE_CHEMICAL", 13, 16], ["vitamin D", "SIMPLE_CHEMICAL", 40, 49], ["1918-1919 influenza pandemic", "SPECIES", 120, 148], ["UVB exposure", "TREATMENT", 13, 25], ["vitamin D status", "TEST", 40, 56]]], ["The \"Spanish flu\" pandemic killed more than 20 million people worldwide.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["Vitamin D activates the vitamin D receptor (VDR) to produce cathelicidin, which has antimicrobial activities in the lungs.", [["lungs", "ANATOMY", 116, 121], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 24, 33], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 24, 33], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["vitamin D receptor", "GENE_OR_GENE_PRODUCT", 24, 42], ["VDR", "GENE_OR_GENE_PRODUCT", 44, 47], ["cathelicidin", "GENE_OR_GENE_PRODUCT", 60, 72], ["lungs", "ORGAN", 116, 121], ["vitamin D receptor", "PROTEIN", 24, 42], ["VDR", "PROTEIN", 44, 47], ["cathelicidin", "PROTEIN", 60, 72], ["Vitamin D", "TREATMENT", 0, 9], ["the vitamin D receptor (VDR)", "TREATMENT", 20, 48], ["cathelicidin", "TREATMENT", 60, 72], ["antimicrobial activities in the lungs", "PROBLEM", 84, 121], ["antimicrobial activities", "OBSERVATION", 84, 108], ["lungs", "ANATOMY", 116, 121]]], ["An additional benefit of Vitamin D is reduced proinflammatory cytokine production, which may play a protective role during infections that cause a cytokine storm [54] .", [["Vitamin D", "CHEMICAL", 25, 34], ["infections", "DISEASE", 123, 133], ["Vitamin D", "CHEMICAL", 25, 34], ["Vitamin D", "SIMPLE_CHEMICAL", 25, 34], ["proinflammatory cytokine", "PROTEIN", 46, 70], ["cytokine", "PROTEIN", 147, 155], ["Vitamin D", "TREATMENT", 25, 34], ["reduced proinflammatory cytokine production", "PROBLEM", 38, 81]]], ["To avoid worsening of respiratory infections, Edlich et al. recommended that testing and treating vitamin D deficiency in health care providers and patients [55] .Clinical RelevanceCoronaviruses are a family of viruses that can cause the common cold and upper respiratory infections, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [56] .", [["respiratory", "ANATOMY", 22, 33], ["respiratory", "ANATOMY", 260, 271], ["respiratory infections", "DISEASE", 22, 44], ["vitamin D", "CHEMICAL", 98, 107], ["upper respiratory infections", "DISEASE", 254, 282], ["acute respiratory syndrome", "DISEASE", 291, 317], ["SARS", "DISEASE", 319, 323], ["Middle East respiratory syndrome", "DISEASE", 329, 361], ["vitamin D", "CHEMICAL", 98, 107], ["vitamin D", "SIMPLE_CHEMICAL", 98, 107], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["Middle East respiratory syndrome (MERS)", "SPECIES", 329, 368], ["respiratory infections", "PROBLEM", 22, 44], ["testing", "TEST", 77, 84], ["vitamin D deficiency", "PROBLEM", 98, 118], ["the common cold", "PROBLEM", 234, 249], ["upper respiratory infections", "PROBLEM", 254, 282], ["severe acute respiratory syndrome", "PROBLEM", 284, 317], ["SARS)", "PROBLEM", 319, 324], ["Middle East respiratory syndrome", "PROBLEM", 329, 361], ["worsening", "OBSERVATION_MODIFIER", 9, 18], ["respiratory", "ANATOMY", 22, 33], ["infections", "OBSERVATION", 34, 44], ["upper", "ANATOMY_MODIFIER", 254, 259], ["respiratory", "ANATOMY", 260, 271], ["infections", "OBSERVATION", 272, 282], ["severe", "OBSERVATION_MODIFIER", 284, 290], ["acute", "OBSERVATION_MODIFIER", 291, 296], ["respiratory syndrome", "OBSERVATION", 297, 317], ["Middle", "ANATOMY_MODIFIER", 329, 335], ["respiratory syndrome", "OBSERVATION", 341, 361]]], ["Recent research suggests that vitamin D may influence the severity of infection of pathogenic coronaviruses that have emerged in the 21st century, such as severe acute respiratory syndrome-related coronavirus (SARS-CoV).", [["vitamin D", "CHEMICAL", 30, 39], ["infection", "DISEASE", 70, 79], ["acute respiratory syndrome-related coronavirus (SARS-CoV)", "DISEASE", 162, 219], ["vitamin D", "CHEMICAL", 30, 39], ["vitamin D", "SIMPLE_CHEMICAL", 30, 39], ["coronaviruses", "ORGANISM", 94, 107], ["severe acute respiratory syndrome-related coronavirus", "ORGANISM", 155, 208], ["SARS-CoV", "ORGANISM", 210, 218], ["severe acute respiratory syndrome-related coronavirus", "SPECIES", 155, 208], ["SARS-CoV", "SPECIES", 210, 218], ["vitamin D", "TREATMENT", 30, 39], ["infection", "PROBLEM", 70, 79], ["pathogenic coronaviruses", "PROBLEM", 83, 107], ["severe acute respiratory syndrome", "PROBLEM", 155, 188], ["coronavirus", "PROBLEM", 197, 208], ["infection", "OBSERVATION", 70, 79], ["pathogenic coronaviruses", "OBSERVATION", 83, 107], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["respiratory syndrome", "OBSERVATION", 168, 188]]], ["The VDR is highly expressed in the lung and in vivo and animal research shows it may help prevent lung injury and pneumonia [57] [58] [59] [60] .", [["lung", "ANATOMY", 35, 39], ["lung", "ANATOMY", 98, 102], ["lung injury", "DISEASE", 98, 109], ["pneumonia", "DISEASE", 114, 123], ["pneumonia [57] [58] [59] [60]", "CHEMICAL", 114, 143], ["VDR", "GENE_OR_GENE_PRODUCT", 4, 7], ["lung", "ORGAN", 35, 39], ["lung", "ORGAN", 98, 102], ["VDR", "PROTEIN", 4, 7], ["lung injury", "PROBLEM", 98, 109], ["pneumonia", "PROBLEM", 114, 123], ["lung", "ANATOMY", 35, 39], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109], ["pneumonia", "OBSERVATION", 114, 123]]], ["The SARS-CoV virus enters human cells via angiotensin-converting enzyme 2 (ACE2) [58] .", [["cells", "ANATOMY", 32, 37], ["SARS", "DISEASE", 4, 8], ["angiotensin", "CHEMICAL", 42, 53], ["SARS-CoV virus", "ORGANISM", 4, 18], ["human", "ORGANISM", 26, 31], ["cells", "CELL", 32, 37], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 42, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["human cells", "CELL_TYPE", 26, 37], ["angiotensin-converting enzyme 2", "PROTEIN", 42, 73], ["ACE2", "PROTEIN", 75, 79], ["human", "SPECIES", 26, 31], ["SARS-CoV virus", "SPECIES", 4, 18], ["human", "SPECIES", 26, 31], ["The SARS-CoV virus", "PROBLEM", 0, 18], ["angiotensin", "TEST", 42, 53], ["converting enzyme", "TEST", 54, 71]]], ["In animal research, vitamin D-VDR signaling attenuated lung injury by blocking the renin-angiotensin system [59] .", [["lung", "ANATOMY", 55, 59], ["vitamin D", "CHEMICAL", 20, 29], ["lung injury", "DISEASE", 55, 66], ["angiotensin", "CHEMICAL", 89, 100], ["vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "SIMPLE_CHEMICAL", 20, 29], ["VDR", "GENE_OR_GENE_PRODUCT", 30, 33], ["lung", "ORGAN", 55, 59], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 83, 100], ["VDR", "PROTEIN", 30, 33], ["renin", "PROTEIN", 83, 88], ["vitamin D", "TREATMENT", 20, 29], ["VDR signaling attenuated lung injury", "PROBLEM", 30, 66], ["the renin-angiotensin system", "TREATMENT", 79, 107], ["attenuated", "OBSERVATION_MODIFIER", 44, 54], ["lung", "ANATOMY", 55, 59], ["injury", "OBSERVATION", 60, 66]]], ["In an experimental interstitial pneumonitis mouse model, vitamin D3 led to supersession of lung inflammation and fibrosis markers [60] .", [["lung", "ANATOMY", 91, 95], ["interstitial pneumonitis", "DISEASE", 19, 43], ["vitamin D3", "CHEMICAL", 57, 67], ["lung inflammation", "DISEASE", 91, 108], ["fibrosis", "DISEASE", 113, 121], ["vitamin D3", "CHEMICAL", 57, 67], ["mouse", "ORGANISM", 44, 49], ["vitamin D3", "SIMPLE_CHEMICAL", 57, 67], ["lung", "ORGAN", 91, 95], ["mouse", "SPECIES", 44, 49], ["mouse", "SPECIES", 44, 49], ["an experimental interstitial pneumonitis mouse model", "PROBLEM", 3, 55], ["vitamin D3", "TREATMENT", 57, 67], ["lung inflammation", "PROBLEM", 91, 108], ["fibrosis markers", "PROBLEM", 113, 129], ["interstitial", "ANATOMY_MODIFIER", 19, 31], ["pneumonitis", "OBSERVATION", 32, 43], ["lung", "ANATOMY", 91, 95], ["inflammation", "OBSERVATION", 96, 108], ["fibrosis", "OBSERVATION", 113, 121]]], ["Two reports assessed global data on persons with COVID-19 and found potential associations between low vitamin D status and increased risk of COVID-19 [61, 62] .", [["vitamin D", "CHEMICAL", 103, 112], ["vitamin D", "CHEMICAL", 103, 112], ["COVID-19", "CHEMICAL", 142, 150], ["persons", "ORGANISM", 36, 43], ["vitamin D", "SIMPLE_CHEMICAL", 103, 112], ["persons", "SPECIES", 36, 43], ["COVID", "TEST", 49, 54], ["low vitamin D status", "PROBLEM", 99, 119], ["COVID", "TEST", 142, 147]]], ["Vitamin D status has been shown to be significantly associated with severity of clinical outcomes in people with COVID-19.", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["Vitamin D status", "TEST", 0, 16], ["COVID", "TEST", 113, 118]]], ["An analysis of 212 cases of people with COVID-19 found that those with vitamin D deficiency had a 19.61-fold higher risk of having a critical outcome compared to those with sufficient vitamin D blood levels (p < 0.001) [63] .", [["blood", "ANATOMY", 194, 199], ["vitamin D", "CHEMICAL", 71, 80], ["vitamin D", "CHEMICAL", 184, 193], ["vitamin D", "CHEMICAL", 71, 80], ["vitamin D", "CHEMICAL", 184, 193], ["people", "ORGANISM", 28, 34], ["vitamin D", "SIMPLE_CHEMICAL", 71, 80], ["vitamin D", "SIMPLE_CHEMICAL", 184, 193], ["blood", "ORGANISM_SUBSTANCE", 194, 199], ["people", "SPECIES", 28, 34], ["An analysis", "TEST", 0, 11], ["COVID", "TEST", 40, 45], ["vitamin D deficiency", "PROBLEM", 71, 91], ["a critical outcome", "PROBLEM", 131, 149], ["sufficient vitamin D blood levels", "TEST", 173, 206]]], ["It has been hypothesized that vitamin D supplementation reduces the risk of morbidity and mortality related to influenza and COVID-19.", [["vitamin D", "CHEMICAL", 30, 39], ["influenza", "DISEASE", 111, 120], ["vitamin D", "CHEMICAL", 30, 39], ["vitamin D", "SIMPLE_CHEMICAL", 30, 39], ["vitamin D supplementation", "TREATMENT", 30, 55], ["morbidity", "PROBLEM", 76, 85], ["influenza", "PROBLEM", 111, 120], ["COVID", "TEST", 125, 130], ["morbidity", "OBSERVATION", 76, 85]]], ["Grant et al. recommended raising 25(OH)D concentration above 40 ng/mL, which requires 5000-10,000 IU/day of vitamin D3 per day [64] .Clinical RelevanceThe Endocrine Society defines vitamin D deficiency as a serum level 25(OH)D of <20 ng/mL (50 nmol/L), vitamin D insufficiency at levels ranging from 21 to 29 ng/mL (52-72 nmol/L) and vitamin D sufficiency at levels > 30 ng/mL (75 nmol/L).", [["serum", "ANATOMY", 207, 212], ["OH)D", "CHEMICAL", 36, 40], ["vitamin D3", "CHEMICAL", 108, 118], ["vitamin D", "CHEMICAL", 181, 190], ["vitamin D", "CHEMICAL", 253, 262], ["vitamin D", "CHEMICAL", 334, 343], ["25(OH)D", "CHEMICAL", 33, 40], ["vitamin D3", "CHEMICAL", 108, 118], ["vitamin D", "CHEMICAL", 181, 190], ["25(OH)D", "CHEMICAL", 219, 226], ["vitamin D", "CHEMICAL", 253, 262], ["vitamin D", "CHEMICAL", 334, 343], ["25(OH)D", "SIMPLE_CHEMICAL", 33, 40], ["vitamin D3", "SIMPLE_CHEMICAL", 108, 118], ["vitamin D", "SIMPLE_CHEMICAL", 181, 190], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["25(OH)D", "SIMPLE_CHEMICAL", 219, 226], ["vitamin D", "SIMPLE_CHEMICAL", 253, 262], ["vitamin D", "SIMPLE_CHEMICAL", 334, 343], ["raising 25(OH)D concentration", "TREATMENT", 25, 54], ["vitamin D3", "TREATMENT", 108, 118], ["vitamin D deficiency", "PROBLEM", 181, 201], ["a serum level", "TEST", 205, 218], ["vitamin D insufficiency", "PROBLEM", 253, 276], ["vitamin D sufficiency", "TEST", 334, 355], ["levels", "TEST", 359, 365], ["insufficiency", "OBSERVATION", 263, 276]]], ["A target level of 25(OH)D 40 ng/mL (100 nmol/L) ensures the individual's \"true\" vitamin D value (ensures a 30 ng/mL due to lab variability) [65] .", [["vitamin D", "CHEMICAL", 80, 89], ["25(OH)D", "CHEMICAL", 18, 25], ["vitamin D", "CHEMICAL", 80, 89], ["25(OH)D", "SIMPLE_CHEMICAL", 18, 25], ["vitamin D", "SIMPLE_CHEMICAL", 80, 89], ["A target level", "TEST", 0, 14], ["vitamin D value", "TREATMENT", 80, 95]]], ["A large body of research has linked low vitamin D levels to respiratory disorders including influenza [23] .", [["respiratory", "ANATOMY", 60, 71], ["vitamin D", "CHEMICAL", 40, 49], ["respiratory disorders", "DISEASE", 60, 81], ["influenza", "DISEASE", 92, 101], ["vitamin D", "CHEMICAL", 40, 49], ["vitamin D", "SIMPLE_CHEMICAL", 40, 49], ["low vitamin D levels", "PROBLEM", 36, 56], ["respiratory disorders", "PROBLEM", 60, 81], ["influenza", "PROBLEM", 92, 101], ["large", "OBSERVATION_MODIFIER", 2, 7], ["body", "OBSERVATION_MODIFIER", 8, 12], ["low vitamin D", "OBSERVATION_MODIFIER", 36, 49], ["respiratory", "ANATOMY", 60, 71]]], ["An analysis of NHANES demonstrated an increased prevalence of upper respiratory tract infection among individuals with deficient and insufficient status of vitamin D, when compared to those with sufficient levels [66] .", [["upper respiratory tract", "ANATOMY", 62, 85], ["respiratory tract infection", "DISEASE", 68, 95], ["vitamin D", "CHEMICAL", 156, 165], ["vitamin D", "CHEMICAL", 156, 165], ["upper respiratory", "ORGANISM_SUBDIVISION", 62, 79], ["tract", "ORGANISM_SUBDIVISION", 80, 85], ["vitamin D", "SIMPLE_CHEMICAL", 156, 165], ["An analysis of NHANES", "TEST", 0, 21], ["upper respiratory tract infection", "PROBLEM", 62, 95], ["vitamin D", "TREATMENT", 156, 165], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["infection", "OBSERVATION", 86, 95]]], ["The association is important given that analysis of 2001-2010 NHANES data showed that 29% of the US population is vitamin D deficient (<20 ng/mL) and an additional 41% are vitamin D insufficient (<30 ng/mL) [67] .", [["vitamin D", "CHEMICAL", 114, 123], ["vitamin D", "CHEMICAL", 172, 181], ["vitamin D", "CHEMICAL", 114, 123], ["vitamin D", "CHEMICAL", 172, 181], ["vitamin D", "SIMPLE_CHEMICAL", 114, 123], ["vitamin D", "SIMPLE_CHEMICAL", 172, 181], ["NHANES data", "TEST", 62, 73], ["the US population", "TEST", 93, 110], ["vitamin D deficient", "PROBLEM", 114, 133], ["vitamin D insufficient", "TEST", 172, 194]]], ["In a prospective, observational study, it was seen that individuals with 25(OH)D levels at or above 38 ng/mL had a significant reduction in acute respiratory tract infections [68] .", [["respiratory tract", "ANATOMY", 146, 163], ["OH)D", "CHEMICAL", 76, 80], ["acute respiratory tract infections", "DISEASE", 140, 174], ["25(OH)D", "CHEMICAL", 73, 80], ["25(OH)D", "SIMPLE_CHEMICAL", 73, 80], ["tract", "ORGANISM_SUBDIVISION", 158, 163], ["observational study", "TEST", 18, 37], ["OH)D levels", "TEST", 76, 87], ["a significant reduction", "PROBLEM", 113, 136], ["acute respiratory tract infections", "PROBLEM", 140, 174], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["reduction", "OBSERVATION_MODIFIER", 127, 136], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory tract infections", "OBSERVATION", 146, 174]]], ["Furthermore, in a study looking at 25(OH)D levels in patients with community acquired pneumonia, 15% of the population with 25(OH)D levels < 12 ng/mL, indicating severe vitamin D deficiency, was associated with a higher 30-day mortality compared with patients with 25(OH)D levels > 12 ng/mL (p = 0.004) [30] .Clinical RelevanceIn two randomized controlled trials, vitamin D did not reduce the risk of upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 401, 424], ["OH)D", "CHEMICAL", 38, 42], ["pneumonia", "DISEASE", 86, 95], ["OH)D", "CHEMICAL", 127, 131], ["vitamin D", "CHEMICAL", 169, 178], ["vitamin D", "CHEMICAL", 364, 373], ["respiratory tract infections", "DISEASE", 407, 435], ["25(OH)D", "CHEMICAL", 35, 42], ["25(OH)D", "CHEMICAL", 124, 131], ["vitamin D", "CHEMICAL", 169, 178], ["25(OH)D", "CHEMICAL", 265, 272], ["vitamin D", "CHEMICAL", 364, 373], ["25(OH)D", "SIMPLE_CHEMICAL", 35, 42], ["patients", "ORGANISM", 53, 61], ["25(OH)D", "SIMPLE_CHEMICAL", 124, 131], ["vitamin D", "SIMPLE_CHEMICAL", 169, 178], ["patients", "ORGANISM", 251, 259], ["25(OH)D", "SIMPLE_CHEMICAL", 265, 272], ["vitamin D", "SIMPLE_CHEMICAL", 364, 373], ["upper", "ORGANISM_SUBDIVISION", 401, 406], ["respiratory tract", "ORGANISM_SUBDIVISION", 407, 424], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 251, 259], ["a study", "TEST", 16, 23], ["OH)D levels", "TEST", 38, 49], ["community acquired pneumonia", "PROBLEM", 67, 95], ["the population", "TEST", 104, 118], ["OH)D levels", "TEST", 127, 138], ["severe vitamin D deficiency", "PROBLEM", 162, 189], ["D levels", "TEST", 271, 279], ["Clinical RelevanceIn two randomized controlled trials", "TREATMENT", 309, 362], ["vitamin D", "TREATMENT", 364, 373], ["upper respiratory tract infections", "PROBLEM", 401, 435], ["pneumonia", "OBSERVATION", 86, 95], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["vitamin D deficiency", "OBSERVATION", 169, 189], ["upper", "ANATOMY_MODIFIER", 401, 406], ["respiratory tract", "ANATOMY", 407, 424], ["infections", "OBSERVATION", 425, 435]]], ["The VIDARIS randomized controlled trial found a monthly dose of 100,000 IUs of vitamin D3 for 18 months did not reduce the risk of upper respiratory tract infection over placebo.", [["upper respiratory tract", "ANATOMY", 131, 154], ["vitamin D3", "CHEMICAL", 79, 89], ["respiratory tract infection", "DISEASE", 137, 164], ["vitamin D3", "CHEMICAL", 79, 89], ["vitamin D3", "SIMPLE_CHEMICAL", 79, 89], ["upper respiratory", "ORGANISM_SUBDIVISION", 131, 148], ["tract", "ORGANISM_SUBDIVISION", 149, 154], ["The VIDARIS randomized controlled trial", "TREATMENT", 0, 39], ["vitamin D3", "TREATMENT", 79, 89], ["upper respiratory tract infection", "PROBLEM", 131, 164], ["upper", "ANATOMY_MODIFIER", 131, 136], ["respiratory tract", "ANATOMY", 137, 154], ["infection", "OBSERVATION", 155, 164]]], ["The average 25(OH)D level at baseline was 29 ng/mL, which is considered close to a sufficient level [69] .", [["OH)D", "CHEMICAL", 15, 19], ["25(OH)D", "CHEMICAL", 12, 19], ["25(OH)D", "SIMPLE_CHEMICAL", 12, 19], ["The average 25(OH)D level", "TEST", 0, 25]]], ["The vitamin D Outcomes and Interventions in Toddlers trial was conducted in children aged between 1 and 5 years [70] .", [["vitamin D", "CHEMICAL", 4, 13], ["vitamin D", "CHEMICAL", 4, 13], ["vitamin D", "SIMPLE_CHEMICAL", 4, 13], ["children", "ORGANISM", 76, 84], ["children", "SPECIES", 76, 84], ["The vitamin D Outcomes", "TREATMENT", 0, 22], ["Interventions", "TREATMENT", 27, 40]]], ["The study found 2000 IU vitamin D per day did not reduce risk of respiratory tract infection over 400 IU per day.", [["respiratory tract", "ANATOMY", 65, 82], ["vitamin D", "CHEMICAL", 24, 33], ["respiratory tract infection", "DISEASE", 65, 92], ["vitamin D", "CHEMICAL", 24, 33], ["vitamin D", "SIMPLE_CHEMICAL", 24, 33], ["respiratory tract", "ORGANISM_SUBDIVISION", 65, 82], ["The study", "TEST", 0, 9], ["2000 IU vitamin D", "TREATMENT", 16, 33], ["respiratory tract infection", "PROBLEM", 65, 92], ["respiratory tract", "ANATOMY", 65, 82], ["infection", "OBSERVATION", 83, 92]]], ["Respective mean baseline blood levels of vitamin D for the two groups were 35.9 and 36.9 ng/mL, which are sufficient blood levels of vitamin D. Participants in these trials had adequate vitamin D levels, so the applicability of these trials to broader US populations is unclear given the high prevalence of vitamin D insufficiency and deficiency.", [["blood", "ANATOMY", 25, 30], ["blood", "ANATOMY", 117, 122], ["vitamin D", "CHEMICAL", 41, 50], ["vitamin D.", "CHEMICAL", 133, 143], ["vitamin D", "CHEMICAL", 186, 195], ["vitamin D", "CHEMICAL", 307, 316], ["vitamin D", "CHEMICAL", 41, 50], ["vitamin D.", "CHEMICAL", 133, 143], ["vitamin D", "CHEMICAL", 186, 195], ["vitamin D", "CHEMICAL", 307, 316], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["vitamin D", "SIMPLE_CHEMICAL", 41, 50], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["vitamin", "SIMPLE_CHEMICAL", 133, 140], ["vitamin D", "SIMPLE_CHEMICAL", 186, 195], ["vitamin D", "SIMPLE_CHEMICAL", 307, 316], ["Participants", "SPECIES", 144, 156], ["Respective mean baseline blood levels", "TEST", 0, 37], ["vitamin D", "TREATMENT", 41, 50], ["vitamin D.", "TREATMENT", 133, 143], ["adequate vitamin D levels", "TEST", 177, 202], ["these trials", "TREATMENT", 228, 240], ["broader US populations", "PROBLEM", 244, 266], ["vitamin D insufficiency", "PROBLEM", 307, 330], ["deficiency", "PROBLEM", 335, 345]]], ["A broader approach using systematic review and meta-analysis has revealed potential benefits of vitamin D supplementation.", [["vitamin D", "CHEMICAL", 96, 105], ["vitamin D", "CHEMICAL", 96, 105], ["vitamin D", "SIMPLE_CHEMICAL", 96, 105], ["systematic review", "TEST", 25, 42], ["meta-analysis", "TEST", 47, 60], ["vitamin D supplementation", "TREATMENT", 96, 121]]], ["Individual participant data from 25 randomized controlled trials involving 11,321 participants age 0 to 95 year examined the effects of vitamin D on acute respiratory tract infections [71] .", [["respiratory tract", "ANATOMY", 155, 172], ["vitamin D", "CHEMICAL", 136, 145], ["acute respiratory tract infections", "DISEASE", 149, 183], ["vitamin D", "CHEMICAL", 136, 145], ["vitamin D", "SIMPLE_CHEMICAL", 136, 145], ["respiratory tract", "ORGANISM_SUBDIVISION", 155, 172], ["participants", "SPECIES", 82, 94], ["vitamin D", "TREATMENT", 136, 145], ["acute respiratory tract infections", "PROBLEM", 149, 183], ["respiratory tract", "ANATOMY", 155, 172]]], ["They found that vitamin D supplementation significantly lowered risk for acute respiratory tract infections by 12%, however, there was a 70% lower risk of respiratory infection with vitamin D supplementation in participants whose baseline 25(OH)D levels were <10 ng/mL than in those with baseline 25(OH)D levels >10 ng/mL.Current FindingsA large body of research shows a growing concern of the impact of inadequate intake of vitamin D and suboptimal/deficiency status on immune health.", [["respiratory tract", "ANATOMY", 79, 96], ["respiratory", "ANATOMY", 155, 166], ["vitamin D", "CHEMICAL", 16, 25], ["acute respiratory tract infections", "DISEASE", 73, 107], ["respiratory infection", "DISEASE", 155, 176], ["vitamin D", "CHEMICAL", 182, 191], ["25(OH)D", "CHEMICAL", 239, 246], ["vitamin D", "CHEMICAL", 425, 434], ["vitamin D", "CHEMICAL", 16, 25], ["vitamin D", "CHEMICAL", 182, 191], ["25(OH)D", "CHEMICAL", 239, 246], ["25(OH)D", "CHEMICAL", 297, 304], ["vitamin D", "CHEMICAL", 425, 434], ["vitamin D", "SIMPLE_CHEMICAL", 16, 25], ["respiratory tract", "ORGANISM_SUBDIVISION", 79, 96], ["vitamin D", "SIMPLE_CHEMICAL", 182, 191], ["25(OH)D", "SIMPLE_CHEMICAL", 239, 246], ["25(OH)D", "SIMPLE_CHEMICAL", 297, 304], ["vitamin D", "SIMPLE_CHEMICAL", 425, 434], ["participants", "SPECIES", 211, 223], ["vitamin D supplementation", "TREATMENT", 16, 41], ["acute respiratory tract infections", "PROBLEM", 73, 107], ["respiratory infection", "PROBLEM", 155, 176], ["vitamin D supplementation", "TREATMENT", 182, 207], ["OH)D levels", "TEST", 242, 253], ["D levels", "TEST", 303, 311], ["vitamin D", "TREATMENT", 425, 434], ["suboptimal/deficiency status", "PROBLEM", 439, 467], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["respiratory tract", "ANATOMY", 79, 96], ["respiratory", "ANATOMY", 155, 166], ["infection", "OBSERVATION", 167, 176], ["large", "OBSERVATION_MODIFIER", 340, 345]]], ["Our findings contribute to this concern of vitamin D inadequacy.", [["vitamin D", "CHEMICAL", 43, 52], ["vitamin D", "CHEMICAL", 43, 52], ["vitamin D", "SIMPLE_CHEMICAL", 43, 52], ["vitamin D inadequacy", "PROBLEM", 43, 63]]], ["Our data show that the percent of the population with intake below the EAR of 400 IU (10 \u00b5g) was 95% (food only) and 65% (food + supplement).", [["Our data", "TEST", 0, 8]]], ["Vitamin D usual intake was 188 IU (4.7 \u00b5g) (food only) and 556 IU (13.9 \u00b5g) (food + supplement) ( Table S1 ).", [["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin D usual intake", "TEST", 0, 22]]], ["The RDA for vitamin D is 600-800 IU (15-20 \u00b5g)/day [72] .", [["vitamin D", "CHEMICAL", 12, 21], ["vitamin D", "CHEMICAL", 12, 21], ["RDA", "SIMPLE_CHEMICAL", 4, 7], ["vitamin D", "SIMPLE_CHEMICAL", 12, 21], ["vitamin D", "TEST", 12, 21]]], ["However, this recommendation is limited to bone health.", [["bone", "ANATOMY", 43, 47], ["bone", "TISSUE", 43, 47]]], ["The Endocrine Society recommends 1500-2000 IU (38-50 \u00b5g) to maintain a minimum of serum 25(OH)D concentration of 30 ng/mL [65] .", [["serum", "ANATOMY", 82, 87], ["25(OH)D", "CHEMICAL", 88, 95], ["25(OH)D", "CHEMICAL", 88, 95], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["25(OH)D", "SIMPLE_CHEMICAL", 88, 95], ["a minimum of serum 25(OH)D concentration", "TREATMENT", 69, 109]]], ["For adults aged 19 years and older, higher doses (up to 10,000 IU/day), may be necessary to correct, treat, and prevent vitamin D deficiency [65] .Vitamin EVitamin E is a potent lipid-soluble antioxidant that influences immune health.", [["vitamin D", "CHEMICAL", 120, 129], ["Vitamin", "CHEMICAL", 147, 154], ["EVitamin E", "CHEMICAL", 155, 165], ["vitamin D", "CHEMICAL", 120, 129], ["Vitamin", "CHEMICAL", 147, 154], ["EVitamin E", "CHEMICAL", 155, 165], ["vitamin D", "SIMPLE_CHEMICAL", 120, 129], ["Vitamin EVitamin E", "SIMPLE_CHEMICAL", 147, 165], ["vitamin D deficiency", "PROBLEM", 120, 140], ["Vitamin EVitamin E", "TREATMENT", 147, 165], ["a potent lipid-soluble antioxidant", "TREATMENT", 169, 203]]], ["Its importance in immune function is evident by the fact its concentration is up to 30-fold higher in white blood cells than in red blood cells [73] .", [["white blood cells", "ANATOMY", 102, 119], ["red blood cells", "ANATOMY", 128, 143], ["white blood cells", "CELL", 102, 119], ["red blood cells", "CELL", 128, 143], ["white blood cells", "CELL_TYPE", 102, 119], ["red blood cells", "CELL_TYPE", 128, 143], ["white blood cells", "TEST", 102, 119], ["red blood cells", "TEST", 128, 143], ["immune function", "OBSERVATION", 18, 33]]], ["Vitamin E's main role in every step of the immune system is as a lipid soluble antioxidant that protects the cell membranes against lipid peroxidation from free radical attack.", [["cell membranes", "ANATOMY", 109, 123], ["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["cell membranes", "CELLULAR_COMPONENT", 109, 123], ["lipid", "SIMPLE_CHEMICAL", 132, 137], ["free radical", "SIMPLE_CHEMICAL", 156, 168], ["Vitamin E", "TREATMENT", 0, 9], ["a lipid soluble antioxidant", "TREATMENT", 63, 90], ["the cell membranes", "TREATMENT", 105, 123], ["lipid peroxidation", "PROBLEM", 132, 150], ["free radical attack", "PROBLEM", 156, 175], ["cell membranes", "OBSERVATION", 109, 123], ["free", "OBSERVATION_MODIFIER", 156, 160], ["radical attack", "OBSERVATION", 161, 175]]], ["In the innate immune system, vitamin E supports epithelial barrier by protecting cell membranes from oxidative damage.", [["epithelial barrier", "ANATOMY", 48, 66], ["cell membranes", "ANATOMY", 81, 95], ["vitamin E", "CHEMICAL", 29, 38], ["vitamin E", "CHEMICAL", 29, 38], ["vitamin E", "SIMPLE_CHEMICAL", 29, 38], ["epithelial barrier", "TISSUE", 48, 66], ["cell membranes", "CELLULAR_COMPONENT", 81, 95], ["vitamin E", "TREATMENT", 29, 38], ["epithelial barrier", "TREATMENT", 48, 66], ["oxidative damage", "PROBLEM", 101, 117], ["protecting cell membranes", "OBSERVATION", 70, 95], ["oxidative damage", "OBSERVATION", 101, 117]]], ["It has been shown to improve the function of many innate immune cells, such as cytotoxic activity of natural killer (NK) cells, as well as neutrophil movement and phagocytosis [74] .", [["immune cells", "ANATOMY", 57, 69], ["natural killer (NK) cells", "ANATOMY", 101, 126], ["neutrophil", "ANATOMY", 139, 149], ["innate immune cells", "CELL", 50, 69], ["natural killer (NK) cells", "CELL", 101, 126], ["neutrophil", "CELL", 139, 149], ["innate immune cells", "CELL_TYPE", 50, 69], ["natural killer (NK) cells", "CELL_TYPE", 101, 126], ["many innate immune cells", "PROBLEM", 45, 69], ["neutrophil movement", "TEST", 139, 158], ["phagocytosis", "TEST", 163, 175], ["immune cells", "OBSERVATION", 57, 69], ["neutrophil movement", "OBSERVATION", 139, 158]]], ["Phagocytes produce reactive oxygen species (ROS) to help kill pathogens and vitamin E helps quench these oxidative bursts to prevent cellular damage.", [["cellular", "ANATOMY", 133, 141], ["oxygen", "CHEMICAL", 28, 34], ["ROS", "CHEMICAL", 44, 47], ["vitamin E", "CHEMICAL", 76, 85], ["oxygen", "CHEMICAL", 28, 34], ["vitamin E", "CHEMICAL", 76, 85], ["reactive oxygen species", "SIMPLE_CHEMICAL", 19, 42], ["ROS", "SIMPLE_CHEMICAL", 44, 47], ["vitamin E", "SIMPLE_CHEMICAL", 76, 85], ["cellular", "CELL", 133, 141], ["Phagocytes", "CELL_TYPE", 0, 10], ["Phagocytes", "TEST", 0, 10], ["reactive oxygen species", "PROBLEM", 19, 42], ["vitamin E", "TREATMENT", 76, 85], ["these oxidative bursts", "TREATMENT", 99, 121], ["cellular damage", "PROBLEM", 133, 148], ["reactive", "OBSERVATION_MODIFIER", 19, 27], ["oxygen species", "OBSERVATION", 28, 42], ["cellular damage", "OBSERVATION", 133, 148]]], ["One study showed that vitamin E supplements increased phagocytic capacity, but decreased bactericidal activity, which may due to vitamin E's function as an antioxidant.", [["vitamin E", "CHEMICAL", 22, 31], ["vitamin E", "CHEMICAL", 129, 138], ["vitamin E", "CHEMICAL", 22, 31], ["vitamin E", "CHEMICAL", 129, 138], ["vitamin E", "SIMPLE_CHEMICAL", 22, 31], ["vitamin E", "SIMPLE_CHEMICAL", 129, 138], ["One study", "TEST", 0, 9], ["vitamin E supplements", "TREATMENT", 22, 43], ["phagocytic capacity", "PROBLEM", 54, 73], ["decreased bactericidal activity", "PROBLEM", 79, 110], ["vitamin E's function", "TEST", 129, 149], ["phagocytic capacity", "OBSERVATION", 54, 73], ["decreased", "OBSERVATION_MODIFIER", 79, 88], ["bactericidal activity", "OBSERVATION", 89, 110]]], ["Vitamin E influences dendritic cell activity, which links innate and adaptive immune systems [74] .", [["dendritic cell", "ANATOMY", 21, 35], ["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["dendritic cell", "CELL", 21, 35], ["Vitamin E", "TREATMENT", 0, 9], ["dendritic cell activity", "OBSERVATION", 21, 44]]], ["In the adaptive immune system, vitamin E enhances lymphocyte proliferation, interleukin-2 (IL-2) production, and inhibits production of prostaglandin E2 (PGE2), which indirectly protects the function of T cells [2] .", [["immune system", "ANATOMY", 16, 29], ["lymphocyte", "ANATOMY", 50, 60], ["T cells", "ANATOMY", 203, 210], ["vitamin E", "CHEMICAL", 31, 40], ["prostaglandin E2", "CHEMICAL", 136, 152], ["PGE2", "CHEMICAL", 154, 158], ["vitamin E", "CHEMICAL", 31, 40], ["prostaglandin E2", "CHEMICAL", 136, 152], ["PGE2", "CHEMICAL", 154, 158], ["immune system", "ANATOMICAL_SYSTEM", 16, 29], ["vitamin E", "SIMPLE_CHEMICAL", 31, 40], ["lymphocyte", "CELL", 50, 60], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 76, 89], ["IL-2", "GENE_OR_GENE_PRODUCT", 91, 95], ["prostaglandin E2", "SIMPLE_CHEMICAL", 136, 152], ["PGE2", "SIMPLE_CHEMICAL", 154, 158], ["T cells", "CELL", 203, 210], ["PGE2", "PROTEIN", 154, 158], ["T cells", "CELL_TYPE", 203, 210], ["vitamin E enhances lymphocyte proliferation", "TEST", 31, 74], ["interleukin", "TEST", 76, 87], ["prostaglandin E2 (PGE2", "TREATMENT", 136, 158], ["lymphocyte proliferation", "OBSERVATION", 50, 74]]], ["Vitamin E improves efficacy in immune synapse formation in naive T cells to ensure activation of T cell signals and modulates Th1/Th2 balance [74] .Clinical RelevanceOne of vitamin E's most studied effects in immunity is prevention of immunosenescence seen with aging.", [["immune synapse", "ANATOMY", 31, 45], ["T cells", "ANATOMY", 65, 72], ["T cell", "ANATOMY", 97, 103], ["Vitamin E", "CHEMICAL", 0, 9], ["vitamin E", "CHEMICAL", 173, 182], ["Vitamin E", "CHEMICAL", 0, 9], ["vitamin E", "CHEMICAL", 173, 182], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["immune synapse", "CELL", 31, 45], ["naive T cells", "CELL", 59, 72], ["T cell", "CELL", 97, 103], ["Th1", "GENE_OR_GENE_PRODUCT", 126, 129], ["Th2", "GENE_OR_GENE_PRODUCT", 130, 133], ["vitamin E", "SIMPLE_CHEMICAL", 173, 182], ["naive T cells", "CELL_TYPE", 59, 72], ["Vitamin E", "TREATMENT", 0, 9], ["immune synapse formation", "TREATMENT", 31, 55], ["naive T cells", "TREATMENT", 59, 72], ["T cell signals", "TEST", 97, 111], ["Th1/Th2 balance", "TEST", 126, 141], ["vitamin E's", "TREATMENT", 173, 184], ["immunosenescence", "PROBLEM", 235, 251], ["immune synapse", "OBSERVATION", 31, 45]]], ["In aging, there is a decline in T cell-mediated immunity caused by thymic involution, decreased naive T cells and decreased IL-2-simulated T cell proliferation capacity [39] .", [["T cell", "ANATOMY", 32, 38], ["thymic", "ANATOMY", 67, 73], ["T cells", "ANATOMY", 102, 109], ["T cell", "ANATOMY", 139, 145], ["T cell", "CELL", 32, 38], ["thymic", "ORGAN", 67, 73], ["T cells", "CELL", 102, 109], ["IL-2", "GENE_OR_GENE_PRODUCT", 124, 128], ["T cell", "CELL", 139, 145], ["naive T cells", "CELL_TYPE", 96, 109], ["a decline in T cell", "PROBLEM", 19, 38], ["thymic involution", "PROBLEM", 67, 84], ["decreased naive T cells", "PROBLEM", 86, 109], ["decreased IL", "PROBLEM", 114, 126], ["simulated T cell proliferation capacity", "PROBLEM", 129, 168], ["decline", "OBSERVATION_MODIFIER", 21, 28], ["thymic", "ANATOMY", 67, 73], ["involution", "OBSERVATION", 74, 84], ["decreased", "OBSERVATION_MODIFIER", 86, 95], ["naive T cells", "OBSERVATION", 96, 109], ["cell proliferation", "OBSERVATION", 141, 159]]], ["Vitamin E deficiency impairs immune function in both animal and human studies and the repletion of vitamin E is able to restore it [39] .Clinical RelevanceMeydani et al. showed that giving 800 IU vitamin E/day for 1 month to healthy adults over 60 years of age had reduced levels of lipid peroxides and improved measures of immune function including, increased delayed-type hypersensitivity response and ex vivo T cell proliferation [33] .", [["T cell", "ANATOMY", 412, 418], ["Vitamin E", "CHEMICAL", 0, 9], ["vitamin E", "CHEMICAL", 99, 108], ["vitamin E", "CHEMICAL", 196, 205], ["hypersensitivity", "DISEASE", 374, 390], ["Vitamin E", "CHEMICAL", 0, 9], ["vitamin E", "CHEMICAL", 99, 108], ["vitamin E", "CHEMICAL", 196, 205], ["peroxides", "CHEMICAL", 289, 298], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["human", "ORGANISM", 64, 69], ["vitamin E", "SIMPLE_CHEMICAL", 99, 108], ["vitamin E", "SIMPLE_CHEMICAL", 196, 205], ["lipid peroxides", "SIMPLE_CHEMICAL", 283, 298], ["T cell", "CELL", 412, 418], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["Vitamin E deficiency", "PROBLEM", 0, 20], ["immune function", "PROBLEM", 29, 44], ["human studies", "TEST", 64, 77], ["the repletion of vitamin E", "TREATMENT", 82, 108], ["IU vitamin E", "TREATMENT", 193, 205], ["lipid peroxides", "TREATMENT", 283, 298], ["immune function", "PROBLEM", 324, 339], ["increased delayed-type hypersensitivity response", "PROBLEM", 351, 399], ["ex vivo T cell proliferation", "TREATMENT", 404, 432], ["deficiency", "OBSERVATION", 10, 20], ["immune function", "OBSERVATION", 29, 44], ["-type", "OBSERVATION_MODIFIER", 368, 373], ["hypersensitivity response", "OBSERVATION", 374, 399]]], ["A follow-up trial showed that vitamin E (200 IU/day of dl-\u03b1-tocopherol) improved efficacy of hepatitis B and tetanus vaccines in older adults [77] .", [["vitamin E", "CHEMICAL", 30, 39], ["dl-\u03b1-tocopherol", "CHEMICAL", 55, 70], ["hepatitis B", "DISEASE", 93, 104], ["tetanus", "DISEASE", 109, 116], ["vitamin E", "CHEMICAL", 30, 39], ["dl-\u03b1-tocopherol", "CHEMICAL", 55, 70], ["vitamin E", "SIMPLE_CHEMICAL", 30, 39], ["dl-\u03b1-tocopherol", "SIMPLE_CHEMICAL", 55, 70], ["hepatitis B", "ORGANISM", 93, 104], ["tetanus vaccines", "ORGANISM", 109, 125], ["hepatitis B", "SPECIES", 93, 104], ["vitamin E", "TREATMENT", 30, 39], ["dl-\u03b1-tocopherol", "TREATMENT", 55, 70], ["hepatitis B", "TREATMENT", 93, 104], ["tetanus vaccines", "TREATMENT", 109, 125], ["hepatitis", "OBSERVATION", 93, 102]]], ["These results were confirmed in another study that showed 200 IU/day vitamin E also improved markers of both innate and adaptive immune function [18] .Clinical RelevanceIn several human clinical studies, Vitamin E supplementation has shown a clinical benefit in reducing respiratory infections in older adults.", [["respiratory", "ANATOMY", 271, 282], ["vitamin E", "CHEMICAL", 69, 78], ["Vitamin E", "CHEMICAL", 204, 213], ["respiratory infections", "DISEASE", 271, 293], ["vitamin E", "CHEMICAL", 69, 78], ["Vitamin E", "CHEMICAL", 204, 213], ["vitamin E", "SIMPLE_CHEMICAL", 69, 78], ["human", "ORGANISM", 180, 185], ["Vitamin E", "SIMPLE_CHEMICAL", 204, 213], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["another study", "TEST", 32, 45], ["vitamin E", "TREATMENT", 69, 78], ["Vitamin E supplementation", "TREATMENT", 204, 229], ["reducing respiratory infections", "PROBLEM", 262, 293], ["respiratory infections", "OBSERVATION", 271, 293]]], ["In older adults with pneumonia, those who received vitamin E supplements had an associated lower rate of self-reported rehospitalization [78] .", [["pneumonia", "DISEASE", 21, 30], ["vitamin E", "CHEMICAL", 51, 60], ["vitamin E", "CHEMICAL", 51, 60], ["vitamin E", "SIMPLE_CHEMICAL", 51, 60], ["pneumonia", "PROBLEM", 21, 30], ["vitamin E supplements", "TREATMENT", 51, 72], ["pneumonia", "OBSERVATION", 21, 30]]], ["In a randomized, double-blind, placebo-controlled trial, 600 nursing home residents (\u226565 years old) who supplemented with 200 IU vitamin E/day (dl-\u03b1-tocopherol) vs. placebo reduced the incidence of upper respiratory infection by 20% [34] .", [["respiratory", "ANATOMY", 204, 215], ["vitamin E", "CHEMICAL", 129, 138], ["dl-\u03b1-tocopherol", "CHEMICAL", 144, 159], ["upper respiratory infection", "DISEASE", 198, 225], ["vitamin E", "CHEMICAL", 129, 138], ["dl-\u03b1-tocopherol", "CHEMICAL", 144, 159], ["vitamin E", "SIMPLE_CHEMICAL", 129, 138], ["dl-\u03b1-tocopherol", "SIMPLE_CHEMICAL", 144, 159], ["upper respiratory", "ORGANISM_SUBDIVISION", 198, 215], ["placebo", "TREATMENT", 31, 38], ["vitamin E", "TREATMENT", 129, 138], ["dl-\u03b1-tocopherol)", "TREATMENT", 144, 160], ["placebo", "TREATMENT", 165, 172], ["upper respiratory infection", "PROBLEM", 198, 225], ["upper", "ANATOMY_MODIFIER", 198, 203], ["respiratory", "ANATOMY", 204, 215], ["infection", "OBSERVATION", 216, 225]]], ["In elderly adults, vitamin E supplementation did not impact self-reported respiratory infections, although participants with absence of respiratory infection were not confirmed, which may have resulted in reporting biases [22] .Clinical RelevanceAlthough most clinical research on vitamin E shows an effective reduction in risk of viral infections of the upper respiratory tract (mostly the common cold), it may hold promise for a protective role against influenza viruses.", [["respiratory", "ANATOMY", 74, 85], ["respiratory", "ANATOMY", 136, 147], ["upper respiratory tract", "ANATOMY", 355, 378], ["vitamin E", "CHEMICAL", 19, 28], ["respiratory infections", "DISEASE", 74, 96], ["respiratory infection", "DISEASE", 136, 157], ["vitamin E", "CHEMICAL", 281, 290], ["viral infections of the upper respiratory tract", "DISEASE", 331, 378], ["influenza viruses", "DISEASE", 455, 472], ["vitamin E", "CHEMICAL", 19, 28], ["vitamin E", "CHEMICAL", 281, 290], ["vitamin E", "SIMPLE_CHEMICAL", 19, 28], ["vitamin E", "SIMPLE_CHEMICAL", 281, 290], ["upper respiratory", "ORGANISM_SUBDIVISION", 355, 372], ["tract", "ORGANISM_SUBDIVISION", 373, 378], ["influenza viruses", "ORGANISM", 455, 472], ["participants", "SPECIES", 107, 119], ["vitamin E supplementation", "TREATMENT", 19, 44], ["respiratory infections", "PROBLEM", 74, 96], ["respiratory infection", "PROBLEM", 136, 157], ["vitamin E", "TREATMENT", 281, 290], ["viral infections of the upper respiratory tract", "PROBLEM", 331, 378], ["influenza viruses", "PROBLEM", 455, 472], ["respiratory", "ANATOMY", 74, 85], ["infections", "OBSERVATION", 86, 96], ["respiratory", "ANATOMY", 136, 147], ["infection", "OBSERVATION", 148, 157], ["effective", "OBSERVATION_MODIFIER", 300, 309], ["reduction", "OBSERVATION_MODIFIER", 310, 319], ["viral infections", "OBSERVATION", 331, 347], ["upper", "ANATOMY_MODIFIER", 355, 360], ["respiratory tract", "ANATOMY", 361, 378]]], ["Influenza viruses induce significant oxidative burst in the lungs, which can rapidly result in organ damage and impaired function [79] .", [["lungs", "ANATOMY", 60, 65], ["organ", "ANATOMY", 95, 100], ["Influenza viruses", "DISEASE", 0, 17], ["organ damage", "DISEASE", 95, 107], ["Influenza viruses", "ORGANISM", 0, 17], ["lungs", "ORGAN", 60, 65], ["organ", "ORGAN", 95, 100], ["Influenza viruses", "SPECIES", 0, 17], ["Influenza viruses", "PROBLEM", 0, 17], ["significant oxidative burst in the lungs", "PROBLEM", 25, 65], ["organ damage", "PROBLEM", 95, 107], ["impaired function", "PROBLEM", 112, 129], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["oxidative burst", "OBSERVATION", 37, 52], ["lungs", "ANATOMY", 60, 65]]], ["Vitamin E is the most prevalent scavenger of lipid peroxyl radicals in the lipid membrane and quickly breaks peroxyl chain propagation reactions in vivo [79] .", [["lipid membrane", "ANATOMY", 75, 89], ["Vitamin E", "CHEMICAL", 0, 9], ["peroxyl", "CHEMICAL", 51, 58], ["peroxyl", "CHEMICAL", 109, 116], ["Vitamin E", "CHEMICAL", 0, 9], ["peroxyl", "CHEMICAL", 51, 58], ["peroxyl", "CHEMICAL", 109, 116], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["lipid peroxyl radicals", "SIMPLE_CHEMICAL", 45, 67], ["lipid membrane", "CELLULAR_COMPONENT", 75, 89], ["Vitamin E", "TREATMENT", 0, 9], ["lipid peroxyl radicals in the lipid membrane", "TREATMENT", 45, 89], ["breaks peroxyl chain propagation reactions", "TREATMENT", 102, 144], ["most prevalent", "OBSERVATION_MODIFIER", 17, 31], ["peroxyl radicals", "OBSERVATION", 51, 67], ["lipid membrane", "ANATOMY", 75, 89], ["peroxyl chain", "OBSERVATION", 109, 122]]], ["In animal studies, vitamin E was the most efficient antioxidant at reducing lipid peroxidation levels induced by influenza virus A infection [79] .", [["vitamin E", "CHEMICAL", 19, 28], ["influenza virus A infection", "DISEASE", 113, 140], ["vitamin E", "CHEMICAL", 19, 28], ["vitamin E", "SIMPLE_CHEMICAL", 19, 28], ["lipid", "SIMPLE_CHEMICAL", 76, 81], ["influenza virus A", "ORGANISM", 113, 130], ["influenza virus", "SPECIES", 113, 128], ["influenza virus A", "SPECIES", 113, 130], ["animal studies", "TEST", 3, 17], ["vitamin E", "TREATMENT", 19, 28], ["lipid peroxidation levels", "TREATMENT", 76, 101], ["influenza virus A infection", "PROBLEM", 113, 140], ["influenza virus", "OBSERVATION", 113, 128]]], ["More research is needed to understand the role of vitamin E in influenza virus infections.Clinical RelevanceIt is estimated that~34% of the US population has metabolic syndrome [80] and recent studies indicate vitamin E needs may be higher in people with metabolic syndrome [81] .", [["vitamin E", "CHEMICAL", 50, 59], ["influenza virus infections", "DISEASE", 63, 89], ["metabolic syndrome", "DISEASE", 158, 176], ["vitamin E", "CHEMICAL", 210, 219], ["metabolic syndrome", "DISEASE", 255, 273], ["vitamin E", "CHEMICAL", 50, 59], ["vitamin E", "CHEMICAL", 210, 219], ["vitamin E", "SIMPLE_CHEMICAL", 50, 59], ["influenza virus", "ORGANISM", 63, 78], ["vitamin E", "SIMPLE_CHEMICAL", 210, 219], ["people", "ORGANISM", 243, 249], ["influenza virus", "SPECIES", 63, 78], ["people", "SPECIES", 243, 249], ["influenza virus", "SPECIES", 63, 78], ["vitamin E", "TREATMENT", 50, 59], ["influenza virus infections", "PROBLEM", 63, 89], ["the US population", "TEST", 136, 153], ["metabolic syndrome", "PROBLEM", 158, 176], ["recent studies", "TEST", 186, 200], ["vitamin E needs", "TREATMENT", 210, 225], ["metabolic syndrome", "PROBLEM", 255, 273], ["metabolic syndrome", "OBSERVATION", 158, 176], ["metabolic syndrome", "OBSERVATION", 255, 273]]], ["Evidence also suggests that individual components of metabolic syndrome, such as obesity and diabetes are associated with higher mortality related to H1N1 influenza [82, 83] .", [["metabolic syndrome", "DISEASE", 53, 71], ["obesity", "DISEASE", 81, 88], ["diabetes", "DISEASE", 93, 101], ["influenza", "DISEASE", 155, 164], ["H1N1 influenza", "ORGANISM", 150, 164], ["H1N1 influenza", "SPECIES", 150, 164], ["metabolic syndrome", "PROBLEM", 53, 71], ["obesity", "PROBLEM", 81, 88], ["diabetes", "PROBLEM", 93, 101], ["higher mortality", "PROBLEM", 122, 138], ["H1N1 influenza", "PROBLEM", 150, 164], ["metabolic syndrome", "OBSERVATION", 53, 71], ["obesity", "OBSERVATION", 81, 88], ["diabetes", "OBSERVATION", 93, 101]]], ["Recent data has suggested that diabetes, hypertension and cardiovascular disease worsens COVID-19 infections [84] .", [["cardiovascular", "ANATOMY", 58, 72], ["diabetes", "DISEASE", 31, 39], ["hypertension", "DISEASE", 41, 53], ["cardiovascular disease", "DISEASE", 58, 80], ["infections", "DISEASE", 98, 108], ["COVID-19", "GENE_OR_GENE_PRODUCT", 89, 97], ["Recent data", "TEST", 0, 11], ["diabetes", "PROBLEM", 31, 39], ["hypertension", "PROBLEM", 41, 53], ["cardiovascular disease", "PROBLEM", 58, 80], ["COVID", "TEST", 89, 94], ["diabetes", "OBSERVATION", 31, 39], ["hypertension", "OBSERVATION", 41, 53], ["cardiovascular", "ANATOMY", 58, 72], ["disease", "OBSERVATION", 73, 80]]], ["Since individuals with metabolic syndrome may be more vulnerable to infection-related severity and/or mortality, future research is needed to understand whether optimizing vitamin E intake levels can improve immune response, as seen in older populations.Current FindingsOur data show that the percent of vitamin E intake below the EAR (18 IU/12 mg) was 84% (food only) and 60% (food + supplement).", [["metabolic syndrome", "DISEASE", 23, 41], ["infection", "DISEASE", 68, 77], ["vitamin E", "CHEMICAL", 172, 181], ["vitamin E", "CHEMICAL", 304, 313], ["vitamin E", "CHEMICAL", 172, 181], ["vitamin E", "CHEMICAL", 304, 313], ["vitamin E", "SIMPLE_CHEMICAL", 172, 181], ["vitamin E", "SIMPLE_CHEMICAL", 304, 313], ["metabolic syndrome", "PROBLEM", 23, 41], ["infection", "PROBLEM", 68, 77], ["severity", "PROBLEM", 86, 94], ["mortality", "PROBLEM", 102, 111], ["vitamin E intake levels", "TEST", 172, 195], ["Our data", "TEST", 270, 278], ["vitamin E intake", "TREATMENT", 304, 320], ["the EAR", "TREATMENT", 327, 334], ["metabolic syndrome", "OBSERVATION", 23, 41], ["infection", "OBSERVATION", 68, 77], ["EAR", "ANATOMY", 331, 334]]], ["The prevalence of inadequacy of 84% has decreased from previous NHANES data that showed a 91% inadequacy [7] .", [["previous NHANES data", "TEST", 55, 75]]], ["Vitamin E usual intake was 9 mg (food only) and 28 mg (food + supplement) ( Table S1 ).", [["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "CHEMICAL", 0, 9], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin E usual intake", "TREATMENT", 0, 22]]], ["The RDA for vitamin E is 15 mg/day (22.4 IU) [85] and optimal daily intake for immune health for older adults is 134 mg/day (200 IU) [86] .", [["vitamin E", "CHEMICAL", 12, 21], ["vitamin E", "CHEMICAL", 12, 21], ["RDA", "SIMPLE_CHEMICAL", 4, 7], ["vitamin E", "SIMPLE_CHEMICAL", 12, 21], ["vitamin E", "TREATMENT", 12, 21]]], ["Additionally, there is an emerging area of research around higher vitamin E needs in people with metabolic syndrome, who are at greater risk of infection [81] .Vitamin AVitamin A plays a role in innate and adaptive immunity.", [["vitamin E", "CHEMICAL", 66, 75], ["metabolic syndrome", "DISEASE", 97, 115], ["infection", "DISEASE", 144, 153], ["Vitamin", "CHEMICAL", 160, 167], ["AVitamin A", "CHEMICAL", 168, 178], ["vitamin E", "CHEMICAL", 66, 75], ["Vitamin AVitamin A", "CHEMICAL", 160, 178], ["vitamin E", "SIMPLE_CHEMICAL", 66, 75], ["people", "ORGANISM", 85, 91], ["Vitamin AVitamin A", "SIMPLE_CHEMICAL", 160, 178], ["people", "SPECIES", 85, 91], ["higher vitamin E needs", "TREATMENT", 59, 81], ["metabolic syndrome", "PROBLEM", 97, 115], ["infection", "PROBLEM", 144, 153], ["Vitamin AVitamin", "TREATMENT", 160, 176], ["area", "OBSERVATION_MODIFIER", 35, 39], ["metabolic syndrome", "OBSERVATION", 97, 115], ["infection", "OBSERVATION", 144, 153]]], ["From the early days of its recognition in the early 20th century, vitamin A was associated with resistance to infection [87] , to the extent that it was referred to as \"the anti-infective vitamin\".", [["vitamin A", "CHEMICAL", 66, 75], ["infection", "DISEASE", 110, 119], ["vitamin", "CHEMICAL", 188, 195], ["vitamin A", "CHEMICAL", 66, 75], ["vitamin", "CHEMICAL", 188, 195], ["vitamin A", "SIMPLE_CHEMICAL", 66, 75], ["vitamin", "SIMPLE_CHEMICAL", 188, 195], ["vitamin A", "TREATMENT", 66, 75], ["resistance to infection", "PROBLEM", 96, 119], ["the anti-infective vitamin\"", "TREATMENT", 169, 196], ["infection", "OBSERVATION", 110, 119]]], ["In innate immunity, it is responsible for helping maintain the physical barriers of the body-the skin, and epithelial mucosal cells of the respiratory and GI tracts.", [["body", "ANATOMY", 88, 92], ["skin", "ANATOMY", 97, 101], ["epithelial mucosal cells", "ANATOMY", 107, 131], ["respiratory", "ANATOMY", 139, 150], ["GI tracts", "ANATOMY", 155, 164], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["skin", "ORGAN", 97, 101], ["epithelial mucosal cells", "CELL", 107, 131], ["GI tracts", "PATHOLOGICAL_FORMATION", 155, 164], ["epithelial mucosal cells", "CELL_TYPE", 107, 131], ["skin", "ANATOMY", 97, 101], ["epithelial mucosal", "ANATOMY", 107, 125], ["respiratory", "ANATOMY", 139, 150], ["GI tracts", "ANATOMY", 155, 164]]], ["Vitamin A is essential for directing innate immune cells to the mucosa in the intestine, where they reside to help prevent the entry of pathogens [88] .", [["immune cells", "ANATOMY", 44, 56], ["mucosa", "ANATOMY", 64, 70], ["intestine", "ANATOMY", 78, 87], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["innate immune cells", "CELL", 37, 56], ["mucosa", "MULTI-TISSUE_STRUCTURE", 64, 70], ["intestine", "ORGAN", 78, 87], ["innate immune cells", "CELL_TYPE", 37, 56], ["Vitamin A", "TREATMENT", 0, 9], ["directing innate immune cells", "TREATMENT", 27, 56], ["pathogens", "PROBLEM", 136, 145], ["mucosa", "ANATOMY", 64, 70], ["intestine", "ANATOMY", 78, 87]]], ["Vitamin A plays vital roles in the regulation of the various aspects of innate immune cells, such as differentiation, maturation and function [89] .", [["immune cells", "ANATOMY", 79, 91], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["innate immune cells", "CELL", 72, 91], ["innate immune cells", "CELL_TYPE", 72, 91], ["Vitamin", "TREATMENT", 0, 7], ["innate immune cells", "TREATMENT", 72, 91], ["immune cells", "OBSERVATION", 79, 91]]], ["It regulates the function of NK cells and macrophage phagocytosis [2] .", [["NK cells", "ANATOMY", 29, 37], ["macrophage", "ANATOMY", 42, 52], ["NK cells", "CELL", 29, 37], ["macrophage", "CELL", 42, 52], ["NK cells", "CELL_TYPE", 29, 37], ["macrophage phagocytosis", "TEST", 42, 65], ["NK cells", "OBSERVATION", 29, 37], ["macrophage phagocytosis", "OBSERVATION", 42, 65]]], ["Recent reports show that retinoic acid plays a role in dendritic cell differentiation, the key antigen-presenting cells for activating naive T cells [90] .", [["dendritic cell", "ANATOMY", 55, 69], ["cells", "ANATOMY", 114, 119], ["T cells", "ANATOMY", 141, 148], ["retinoic acid", "CHEMICAL", 25, 38], ["retinoic acid", "CHEMICAL", 25, 38], ["retinoic acid", "SIMPLE_CHEMICAL", 25, 38], ["dendritic cell", "CELL", 55, 69], ["cells", "CELL", 114, 119], ["T cells", "CELL", 141, 148], ["antigen-presenting cells", "CELL_TYPE", 95, 119], ["naive T cells", "CELL_TYPE", 135, 148], ["retinoic acid", "PROBLEM", 25, 38], ["dendritic cell differentiation", "PROBLEM", 55, 85], ["activating naive T cells", "PROBLEM", 124, 148], ["retinoic acid", "OBSERVATION", 25, 38], ["dendritic cell differentiation", "OBSERVATION", 55, 85]]], ["In adaptive immunity, vitamin A is involved in the development and differentiation of Th1 and Th2 cells and the normal function of B cells [2] .Clinical RelevanceSeveral human studies have linked low plasma or serum vitamin A to impairment in immunity [89] .", [["Th2 cells", "ANATOMY", 94, 103], ["B cells", "ANATOMY", 131, 138], ["plasma", "ANATOMY", 200, 206], ["serum", "ANATOMY", 210, 215], ["vitamin A", "CHEMICAL", 22, 31], ["vitamin A", "CHEMICAL", 216, 225], ["vitamin A", "CHEMICAL", 22, 31], ["vitamin A", "CHEMICAL", 216, 225], ["vitamin A", "SIMPLE_CHEMICAL", 22, 31], ["Th1", "CELL", 86, 89], ["Th2 cells", "CELL", 94, 103], ["B cells", "CELL", 131, 138], ["human", "ORGANISM", 170, 175], ["plasma", "ORGANISM_SUBSTANCE", 200, 206], ["serum", "ORGANISM_SUBSTANCE", 210, 215], ["vitamin A", "SIMPLE_CHEMICAL", 216, 225], ["Th1 and Th2 cells", "CELL_TYPE", 86, 103], ["B cells", "CELL_TYPE", 131, 138], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 170, 175], ["vitamin A", "TREATMENT", 22, 31], ["Clinical RelevanceSeveral human studies", "TEST", 144, 183], ["low plasma", "PROBLEM", 196, 206], ["serum vitamin A", "PROBLEM", 210, 225], ["Th2 cells", "OBSERVATION", 94, 103]]], ["Most clinical studies on vitamin A have been limited to children with vitamin A deficiencies.", [["vitamin A", "CHEMICAL", 25, 34], ["vitamin A", "CHEMICAL", 70, 79], ["vitamin A", "CHEMICAL", 25, 34], ["vitamin A", "CHEMICAL", 70, 79], ["vitamin A", "SIMPLE_CHEMICAL", 25, 34], ["children", "ORGANISM", 56, 64], ["vitamin A", "SIMPLE_CHEMICAL", 70, 79], ["children", "SPECIES", 56, 64], ["Most clinical studies", "TEST", 0, 21], ["vitamin A", "TREATMENT", 25, 34], ["vitamin A deficiencies", "PROBLEM", 70, 92]]], ["Vitamin A deficiency is a global public health problem and increases risk of infectious diseases [89] .", [["Vitamin A", "CHEMICAL", 0, 9], ["infectious diseases", "DISEASE", 77, 96], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin A deficiency", "PROBLEM", 0, 20], ["a global public health problem", "PROBLEM", 24, 54], ["infectious diseases", "PROBLEM", 77, 96], ["deficiency", "OBSERVATION", 10, 20], ["global", "OBSERVATION_MODIFIER", 26, 32], ["infectious", "OBSERVATION", 77, 87]]], ["Vitamin A supplementation on a large scale in third-world countries is a cost-effective intervention to improve vitamin A status [91] .", [["Vitamin A", "CHEMICAL", 0, 9], ["vitamin A", "CHEMICAL", 112, 121], ["Vitamin A", "CHEMICAL", 0, 9], ["vitamin A", "CHEMICAL", 112, 121], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["vitamin A", "SIMPLE_CHEMICAL", 112, 121], ["Vitamin A supplementation", "TREATMENT", 0, 25], ["a large scale", "TREATMENT", 29, 42], ["a cost-effective intervention", "TREATMENT", 71, 100]]], ["In a meta-analysis that included 43 randomized controlled trials studying children 6 months to 5 years of age found a 24% reduction in risk of all-cause mortality due to vitamin A supplementation.", [["vitamin A", "CHEMICAL", 170, 179], ["vitamin A", "CHEMICAL", 170, 179], ["children", "ORGANISM", 74, 82], ["vitamin A", "SIMPLE_CHEMICAL", 170, 179], ["children", "SPECIES", 74, 82], ["vitamin A supplementation", "TREATMENT", 170, 195]]], ["Measles morbidity was reduced by 50%.", [["Measles", "DISEASE", 0, 7], ["Measles morbidity", "PROBLEM", 0, 17]]], ["However, there was no impact on incidence of respiratory disease or hospitalizations due to diarrhea or pneumonia [92] .", [["respiratory", "ANATOMY", 45, 56], ["respiratory disease", "DISEASE", 45, 64], ["diarrhea", "DISEASE", 92, 100], ["pneumonia", "DISEASE", 104, 113], ["respiratory disease", "PROBLEM", 45, 64], ["diarrhea", "PROBLEM", 92, 100], ["pneumonia", "PROBLEM", 104, 113], ["respiratory disease", "OBSERVATION", 45, 64], ["pneumonia", "OBSERVATION", 104, 113]]], ["In HIV-infected adults, low vitamin A status has been associated with increases in disease progression and mortality, however results from studies are inconsistent [93] .Current FindingsOur data show that the percent of the population with intakes below the EAR (500-625 \u00b5g) for vitamin A was 45% (food only) and 35% (food + supplement).", [["HIV-infected", "DISEASE", 3, 15], ["vitamin A", "CHEMICAL", 28, 37], ["vitamin A", "CHEMICAL", 279, 288], ["vitamin A", "CHEMICAL", 28, 37], ["vitamin A", "CHEMICAL", 279, 288], ["HIV", "ORGANISM", 3, 6], ["adults", "ORGANISM", 16, 22], ["vitamin A", "SIMPLE_CHEMICAL", 28, 37], ["vitamin A", "SIMPLE_CHEMICAL", 279, 288], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 3, 6], ["low vitamin A status", "PROBLEM", 24, 44], ["disease progression", "PROBLEM", 83, 102], ["studies", "TEST", 139, 146], ["vitamin A", "TREATMENT", 279, 288], ["infected", "OBSERVATION", 7, 15], ["increases", "OBSERVATION_MODIFIER", 70, 79], ["disease", "OBSERVATION", 83, 90], ["EAR", "ANATOMY", 258, 261]]], ["Vitamin A usual intake was 639 \u00b5g (food only) and 977 \u00b5g (food + supplement) ( Table S1 ).", [["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "CHEMICAL", 0, 9], ["Vitamin A", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin", "TREATMENT", 0, 7]]], ["The RDA for vitamin A is 700-900 \u00b5g/day [85] .Vitamin CVitamin C contributes to both the innate and adaptive immune system.", [["immune system", "ANATOMY", 109, 122], ["vitamin A", "CHEMICAL", 12, 21], ["Vitamin", "CHEMICAL", 46, 53], ["CVitamin C", "CHEMICAL", 54, 64], ["vitamin A", "CHEMICAL", 12, 21], ["Vitamin CVitamin C", "CHEMICAL", 46, 64], ["RDA", "SIMPLE_CHEMICAL", 4, 7], ["vitamin A", "SIMPLE_CHEMICAL", 12, 21], ["Vitamin CVitamin C", "SIMPLE_CHEMICAL", 46, 64], ["immune system", "ANATOMICAL_SYSTEM", 109, 122], ["vitamin A", "TREATMENT", 12, 21], ["Vitamin CVitamin C", "TREATMENT", 46, 64], ["the innate and adaptive immune system", "TREATMENT", 85, 122]]], ["In the first line of innate immunity, vitamin C supports the epithelial barrier though synthesis of collagen and protection from ROS [12] .", [["epithelial barrier", "ANATOMY", 61, 79], ["vitamin C", "CHEMICAL", 38, 47], ["ROS", "CHEMICAL", 129, 132], ["vitamin C", "CHEMICAL", 38, 47], ["vitamin C", "SIMPLE_CHEMICAL", 38, 47], ["epithelial barrier", "TISSUE", 61, 79], ["collagen", "GENE_OR_GENE_PRODUCT", 100, 108], ["ROS", "SIMPLE_CHEMICAL", 129, 132], ["collagen", "PROTEIN", 100, 108], ["innate immunity", "TREATMENT", 21, 36], ["vitamin C", "TREATMENT", 38, 47], ["the epithelial barrier", "TREATMENT", 57, 79], ["synthesis of collagen and protection", "TREATMENT", 87, 123], ["epithelial", "ANATOMY", 61, 71]]], ["Vitamin C stimulates production and function of leukocytes, enhances chemotaxis and clears left-over debris from neutrophil attack (neutrophil extracellular trap) [12] .", [["leukocytes", "ANATOMY", 48, 58], ["neutrophil", "ANATOMY", 113, 123], ["neutrophil extracellular", "ANATOMY", 132, 156], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["leukocytes", "CELL", 48, 58], ["neutrophil", "CELL", 113, 123], ["neutrophil", "CELL", 132, 142], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 156], ["leukocytes", "CELL_TYPE", 48, 58], ["Vitamin C stimulates production", "TREATMENT", 0, 31], ["leukocytes", "TEST", 48, 58], ["enhances chemotaxis", "PROBLEM", 60, 79], ["debris", "PROBLEM", 101, 107], ["neutrophil attack", "PROBLEM", 113, 130], ["neutrophil extracellular trap", "TEST", 132, 161], ["leukocytes", "ANATOMY", 48, 58], ["chemotaxis", "OBSERVATION_MODIFIER", 69, 79], ["debris", "OBSERVATION", 101, 107], ["neutrophil attack", "OBSERVATION", 113, 130]]], ["Throughout the innate system, vitamin C is an effective water-soluble antioxidant that protects cells by combating ROS generated by immune cells and regenerates oxidized glutathione and vitamin E. In adaptive immunity, vitamin C plays a role in B and T lymphocyte differentiation and proliferation, possibly through gene regulation.", [["cells", "ANATOMY", 96, 101], ["immune cells", "ANATOMY", 132, 144], ["B", "ANATOMY", 245, 246], ["T lymphocyte", "ANATOMY", 251, 263], ["vitamin C", "CHEMICAL", 30, 39], ["ROS", "CHEMICAL", 115, 118], ["glutathione", "CHEMICAL", 170, 181], ["vitamin", "CHEMICAL", 186, 193], ["vitamin C", "CHEMICAL", 219, 228], ["vitamin C", "CHEMICAL", 30, 39], ["glutathione", "CHEMICAL", 170, 181], ["vitamin E.", "CHEMICAL", 186, 196], ["vitamin C", "CHEMICAL", 219, 228], ["vitamin C", "SIMPLE_CHEMICAL", 30, 39], ["cells", "CELL", 96, 101], ["ROS", "SIMPLE_CHEMICAL", 115, 118], ["immune cells", "CELL", 132, 144], ["glutathione", "SIMPLE_CHEMICAL", 170, 181], ["vitamin E.", "SIMPLE_CHEMICAL", 186, 196], ["vitamin C", "SIMPLE_CHEMICAL", 219, 228], ["B", "CELL", 245, 246], ["T lymphocyte", "CELL", 251, 263], ["immune cells", "CELL_TYPE", 132, 144], ["vitamin C", "TREATMENT", 30, 39], ["an effective water-soluble antioxidant", "TREATMENT", 43, 81], ["immune cells", "TREATMENT", 132, 144], ["regenerates oxidized glutathione", "TREATMENT", 149, 181], ["vitamin E.", "TREATMENT", 186, 196], ["vitamin C", "TREATMENT", 219, 228], ["lymphocyte differentiation", "OBSERVATION", 253, 279]]], ["It increases circulating immune system defenses including antibodies and complement proteins [12] .Clinical RelevanceExtensive research has shown that vitamin C is a pivotal nutrient in immune health.", [["immune system", "ANATOMY", 25, 38], ["vitamin C", "CHEMICAL", 151, 160], ["vitamin C", "CHEMICAL", 151, 160], ["immune system", "ANATOMICAL_SYSTEM", 25, 38], ["vitamin C", "SIMPLE_CHEMICAL", 151, 160], ["immune", "ANATOMICAL_SYSTEM", 186, 192], ["antibodies", "PROTEIN", 58, 68], ["complement proteins", "PROTEIN", 73, 92], ["complement proteins", "TEST", 73, 92], ["vitamin C", "PROBLEM", 151, 160], ["immune system", "OBSERVATION", 25, 38]]], ["Almost 150 animal studies have shown that vitamin C may alleviate or prevent bacterial or viral infections [94] .", [["vitamin C", "CHEMICAL", 42, 51], ["bacterial or viral infections", "DISEASE", 77, 106], ["vitamin C", "CHEMICAL", 42, 51], ["vitamin C", "SIMPLE_CHEMICAL", 42, 51], ["animal studies", "TEST", 11, 25], ["vitamin C", "TREATMENT", 42, 51], ["bacterial or viral infections", "PROBLEM", 77, 106], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["infections", "OBSERVATION", 96, 106]]], ["Numerous clinical trials have investigated Vitamin C supplementation for the prevention and treatment of the common cold with conflicting findings due to various study designs and differing doses.", [["Vitamin C", "CHEMICAL", 43, 52], ["Vitamin C", "CHEMICAL", 43, 52], ["Vitamin C", "SIMPLE_CHEMICAL", 43, 52], ["Vitamin C supplementation", "TREATMENT", 43, 68], ["the prevention", "TREATMENT", 73, 87], ["treatment", "TREATMENT", 92, 101], ["the common cold", "PROBLEM", 105, 120], ["conflicting findings", "PROBLEM", 126, 146], ["various study designs", "TEST", 154, 175]]], ["Very few studies on vitamin C and the common cold have measured vitamin C status.", [["vitamin C", "CHEMICAL", 20, 29], ["vitamin C", "CHEMICAL", 64, 73], ["vitamin C", "CHEMICAL", 20, 29], ["vitamin C", "CHEMICAL", 64, 73], ["vitamin C", "SIMPLE_CHEMICAL", 20, 29], ["vitamin C", "SIMPLE_CHEMICAL", 64, 73], ["vitamin C", "TREATMENT", 20, 29], ["vitamin C status", "TREATMENT", 64, 80]]], ["A study conducted on 28 healthy men between 18 and 35 years with plasma vitamin C < 45 \u00b5mol/L showed that 1000 mg vitamin C per day taken for eight weeks reduced duration of colds by 59% compared to placebo [95] .", [["plasma", "ANATOMY", 65, 71], ["vitamin C", "CHEMICAL", 72, 81], ["vitamin C", "CHEMICAL", 114, 123], ["colds", "DISEASE", 174, 179], ["vitamin C", "CHEMICAL", 72, 81], ["vitamin C", "CHEMICAL", 114, 123], ["men", "ORGANISM", 32, 35], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["vitamin C", "SIMPLE_CHEMICAL", 72, 81], ["vitamin C", "SIMPLE_CHEMICAL", 114, 123], ["men", "SPECIES", 32, 35], ["A study", "TEST", 0, 7], ["plasma vitamin C", "TEST", 65, 81], ["vitamin C", "TREATMENT", 114, 123]]], ["In 2013, a Cochrane review that included 24 trials found that vitamin C (at least 200 mg) did not significantly reduce the risk of common cold in the general population, but found a 52% reduction in cold in 5 trials with 598 marathon runners, skiers and soldiers engaged in subarctic exercises, indicating a higher need for those exposed to physical stress.", [["vitamin C", "CHEMICAL", 62, 71], ["vitamin C", "CHEMICAL", 62, 71], ["vitamin C", "SIMPLE_CHEMICAL", 62, 71], ["vitamin C", "TREATMENT", 62, 71], ["common cold", "PROBLEM", 131, 142], ["subarctic exercises", "TREATMENT", 274, 293], ["subarctic exercises", "OBSERVATION", 274, 293]]], ["In the general population, although there was no risk reduction in the common cold, at least 200 mg vitamin C reduced cold duration by 8% in adults and 14% in children.", [["vitamin C", "CHEMICAL", 100, 109], ["vitamin C", "CHEMICAL", 100, 109], ["vitamin C", "SIMPLE_CHEMICAL", 100, 109], ["children", "ORGANISM", 159, 167], ["children", "SPECIES", 159, 167], ["risk reduction", "PROBLEM", 49, 63], ["vitamin C reduced cold duration", "TREATMENT", 100, 131], ["no", "UNCERTAINTY", 46, 48], ["common cold", "ANATOMY", 71, 82]]], ["In children, 1 to 2 g/day vitamin C shortened colds by 18%.", [["vitamin C", "CHEMICAL", 26, 35], ["colds", "DISEASE", 46, 51], ["vitamin C", "CHEMICAL", 26, 35], ["children", "ORGANISM", 3, 11], ["vitamin C", "SIMPLE_CHEMICAL", 26, 35], ["children", "SPECIES", 3, 11], ["vitamin C shortened colds", "TREATMENT", 26, 51]]], ["When taken after the onset of cold symptoms, vitamin C (1-8 g) did not affect cold duration or symptom severity [96] .Clinical RelevanceVitamin C may help prevent age-induced impairments of immune function.", [["vitamin C", "CHEMICAL", 45, 54], ["RelevanceVitamin C", "CHEMICAL", 127, 145], ["vitamin C", "CHEMICAL", 45, 54], ["RelevanceVitamin C", "CHEMICAL", 127, 145], ["vitamin C", "SIMPLE_CHEMICAL", 45, 54], ["RelevanceVitamin C", "SIMPLE_CHEMICAL", 127, 145], ["cold symptoms", "PROBLEM", 30, 43], ["vitamin C", "TREATMENT", 45, 54], ["symptom severity", "PROBLEM", 95, 111], ["Clinical RelevanceVitamin C", "TREATMENT", 118, 145], ["immune function", "PROBLEM", 190, 205], ["immune function", "OBSERVATION", 190, 205]]], ["Preclinical researchers found high vitamin C intake in mice inhibited the age-related thymic involution and maintained T cell production, which is key to preventing the decline in T cell function commonly seen with age [36] .", [["thymic", "ANATOMY", 86, 92], ["T cell", "ANATOMY", 119, 125], ["T cell", "ANATOMY", 180, 186], ["vitamin C", "CHEMICAL", 35, 44], ["vitamin C", "CHEMICAL", 35, 44], ["vitamin C", "SIMPLE_CHEMICAL", 35, 44], ["mice", "ORGANISM", 55, 59], ["thymic", "ORGAN", 86, 92], ["T cell", "CELL", 119, 125], ["T cell", "CELL", 180, 186], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["high vitamin C intake", "PROBLEM", 30, 51], ["thymic involution", "PROBLEM", 86, 103], ["T cell production", "PROBLEM", 119, 136], ["the decline in T cell function", "PROBLEM", 165, 195], ["thymic", "ANATOMY", 86, 92], ["involution", "OBSERVATION", 93, 103], ["cell production", "OBSERVATION", 121, 136]]], ["Low vitamin C status has been observed in the independent and institutionalized elderly population indicated by lowered plasma and leukocyte vitamin C concentrations.", [["plasma", "ANATOMY", 120, 126], ["leukocyte", "ANATOMY", 131, 140], ["vitamin C", "CHEMICAL", 4, 13], ["vitamin C", "CHEMICAL", 141, 150], ["vitamin C", "CHEMICAL", 4, 13], ["vitamin C", "CHEMICAL", 141, 150], ["vitamin C", "SIMPLE_CHEMICAL", 4, 13], ["plasma", "ORGANISM_SUBSTANCE", 120, 126], ["leukocyte", "CELL", 131, 140], ["vitamin C", "SIMPLE_CHEMICAL", 141, 150], ["Low vitamin C status", "PROBLEM", 0, 20], ["leukocyte vitamin C concentrations", "TREATMENT", 131, 165]]], ["Low vitamin C plasma level concentrations (<17 \u00b5mol/L) in people aged 75-84 years was a predictor of all-cause mortality [97] .", [["vitamin C", "CHEMICAL", 4, 13], ["vitamin C", "CHEMICAL", 4, 13], ["vitamin C", "SIMPLE_CHEMICAL", 4, 13], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["Low vitamin C plasma level concentrations", "PROBLEM", 0, 41]]], ["Research has shown vitamin C (500 mg-1 g) can improve vitamin C status and generation of ROS by neutrophils [27] .", [["neutrophils", "ANATOMY", 96, 107], ["vitamin C", "CHEMICAL", 19, 28], ["vitamin C", "CHEMICAL", 54, 63], ["ROS", "CHEMICAL", 89, 92], ["vitamin C", "CHEMICAL", 19, 28], ["vitamin C", "CHEMICAL", 54, 63], ["vitamin C", "SIMPLE_CHEMICAL", 19, 28], ["vitamin C", "SIMPLE_CHEMICAL", 54, 63], ["ROS", "SIMPLE_CHEMICAL", 89, 92], ["neutrophils", "CELL", 96, 107], ["neutrophils", "CELL_TYPE", 96, 107], ["vitamin C", "TREATMENT", 19, 28], ["vitamin C status", "PROBLEM", 54, 70], ["neutrophils", "TEST", 96, 107]]], ["Clinical trials found vitamin C beneficial in patients with pneumonia with low vitamin C status.", [["vitamin C", "CHEMICAL", 22, 31], ["pneumonia", "DISEASE", 60, 69], ["vitamin C", "CHEMICAL", 79, 88], ["vitamin C", "CHEMICAL", 22, 31], ["vitamin C", "CHEMICAL", 79, 88], ["vitamin C", "SIMPLE_CHEMICAL", 22, 31], ["patients", "ORGANISM", 46, 54], ["vitamin C", "SIMPLE_CHEMICAL", 79, 88], ["patients", "SPECIES", 46, 54], ["Clinical trials", "TREATMENT", 0, 15], ["vitamin C beneficial", "TREATMENT", 22, 42], ["pneumonia", "PROBLEM", 60, 69], ["low vitamin C status", "PROBLEM", 75, 95], ["pneumonia", "OBSERVATION", 60, 69]]], ["A randomized double-blind trial showed that vitamin C (200 mg) taken for 4 weeks in 57 elderly hospitalized pneumonia patients reduced the respiratory symptom score in those with low vitamin C levels [98] .", [["respiratory", "ANATOMY", 139, 150], ["vitamin C", "CHEMICAL", 44, 53], ["pneumonia", "DISEASE", 108, 117], ["vitamin C", "CHEMICAL", 183, 192], ["vitamin C", "CHEMICAL", 44, 53], ["vitamin C", "CHEMICAL", 183, 192], ["vitamin C", "SIMPLE_CHEMICAL", 44, 53], ["patients", "ORGANISM", 118, 126], ["vitamin C", "SIMPLE_CHEMICAL", 183, 192], ["patients", "SPECIES", 118, 126], ["A randomized double-blind trial", "TREATMENT", 0, 31], ["vitamin C", "TREATMENT", 44, 53], ["pneumonia", "PROBLEM", 108, 117], ["the respiratory symptom score", "PROBLEM", 135, 164], ["low vitamin C levels", "PROBLEM", 179, 199], ["pneumonia", "OBSERVATION", 108, 117], ["respiratory symptom", "OBSERVATION", 139, 158]]], ["Previous research in pneumonia patients showed that vitamin C (250 mg-800 mg/day) reduced days in hospital by 19%, whereas higher dosing of vitamin C (500 mg-1.6 g/day) reduced days in hospital by 36% compared to a placebo [94] .Current FindingsOur findings show that the percent of intake below the EAR (60-70 mg) for vitamin C was 46% (food only) and 33% (food + supplement).", [["pneumonia", "DISEASE", 21, 30], ["vitamin C", "CHEMICAL", 52, 61], ["vitamin C", "CHEMICAL", 140, 149], ["vitamin C", "CHEMICAL", 319, 328], ["vitamin C", "CHEMICAL", 52, 61], ["vitamin C", "CHEMICAL", 140, 149], ["vitamin C", "CHEMICAL", 319, 328], ["patients", "ORGANISM", 31, 39], ["vitamin C", "SIMPLE_CHEMICAL", 52, 61], ["vitamin C", "SIMPLE_CHEMICAL", 140, 149], ["vitamin C", "SIMPLE_CHEMICAL", 319, 328], ["patients", "SPECIES", 31, 39], ["pneumonia", "PROBLEM", 21, 30], ["vitamin C", "TREATMENT", 52, 61], ["vitamin C", "TREATMENT", 140, 149], ["the EAR", "TREATMENT", 296, 303], ["vitamin C", "TREATMENT", 319, 328], ["pneumonia", "OBSERVATION", 21, 30], ["EAR", "ANATOMY", 300, 303]]], ["The prevalence of inadequacy of 46% is higher than previous NHANES data that showed a 37% inadequacy [7] .", [["previous NHANES data", "TEST", 51, 71]]], ["Vitamin C usual intake was 83 mg (food only) and 168 mg (food + supplement) ( Table S1 ).", [["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin C usual intake", "TREATMENT", 0, 22]]], ["The RDA for vitamin C is 75-90 mg/day [85] .", [["vitamin C", "CHEMICAL", 12, 21], ["vitamin C", "CHEMICAL", 12, 21], ["RDA", "SIMPLE_CHEMICAL", 4, 7], ["vitamin C", "SIMPLE_CHEMICAL", 12, 21], ["vitamin C", "TREATMENT", 12, 21]]], ["Optimal daily intake is at least 200 mg/day, the amount to reach 60 \u00b5mol/L for optimal cell and tissue levels [99] and minimum dose found to decrease the duration of the common cold [96] .ZincNormal development and function of the innate and adaptive immune system relies on zinc [100] .", [["cell", "ANATOMY", 87, 91], ["tissue", "ANATOMY", 96, 102], ["ZincNormal", "CHEMICAL", 188, 198], ["zinc", "CHEMICAL", 275, 279], ["zinc", "CHEMICAL", 275, 279], ["cell", "CELL", 87, 91], ["tissue", "TISSUE", 96, 102], ["tissue levels", "TEST", 96, 109], ["ZincNormal development", "TREATMENT", 188, 210]]], ["In innate immunity, zinc helps maintain mucosal integrity.", [["mucosal", "ANATOMY", 40, 47], ["zinc", "CHEMICAL", 20, 24], ["zinc", "CHEMICAL", 20, 24], ["zinc", "SIMPLE_CHEMICAL", 20, 24], ["mucosal", "MULTI-TISSUE_STRUCTURE", 40, 47], ["zinc", "TREATMENT", 20, 24], ["mucosal integrity", "OBSERVATION", 40, 57]]], ["It is a cofactor for many metalloenzymes that are involved in maintenance of the cell membrane [2] .", [["cell membrane", "ANATOMY", 81, 94], ["cell membrane", "CELLULAR_COMPONENT", 81, 94], ["many metalloenzymes", "PROBLEM", 21, 40], ["cell membrane", "OBSERVATION", 81, 94]]], ["Zinc enhances the phagocytic activity of NK cells, monocytes, neutrophils and macrophages [29] .", [["NK cells", "ANATOMY", 41, 49], ["monocytes", "ANATOMY", 51, 60], ["neutrophils", "ANATOMY", 62, 73], ["macrophages", "ANATOMY", 78, 89], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["NK cells", "CELL", 41, 49], ["monocytes", "CELL", 51, 60], ["neutrophils", "CELL", 62, 73], ["macrophages", "CELL", 78, 89], ["NK cells", "CELL_TYPE", 41, 49], ["monocytes", "CELL_TYPE", 51, 60], ["neutrophils", "CELL_TYPE", 62, 73], ["macrophages", "CELL_TYPE", 78, 89], ["Zinc enhances", "TEST", 0, 13], ["NK cells", "TEST", 41, 49], ["monocytes", "TEST", 51, 60], ["neutrophils", "TEST", 62, 73], ["macrophages", "TEST", 78, 89], ["phagocytic activity", "OBSERVATION", 18, 37], ["NK cells", "OBSERVATION", 41, 49]]], ["In the adaptive immune system, zinc is a major player in T cell development, differentiation, and T cells and B cells activation signaling.", [["immune system", "ANATOMY", 16, 29], ["T cell", "ANATOMY", 57, 63], ["T cells", "ANATOMY", 98, 105], ["B cells", "ANATOMY", 110, 117], ["zinc", "CHEMICAL", 31, 35], ["zinc", "CHEMICAL", 31, 35], ["immune system", "ANATOMICAL_SYSTEM", 16, 29], ["zinc", "SIMPLE_CHEMICAL", 31, 35], ["T cell", "CELL", 57, 63], ["T cells", "CELL", 98, 105], ["B cells", "CELL", 110, 117], ["T cells", "CELL_TYPE", 98, 105], ["B cells", "CELL_TYPE", 110, 117], ["T cell", "OBSERVATION_MODIFIER", 57, 63]]], ["It induces proliferation of T helper (Th1) and T killer cells which help coordinate and attack pathogens.", [["T helper", "ANATOMY", 28, 36], ["T killer cells", "ANATOMY", 47, 61], ["T helper", "CELL", 28, 36], ["Th1", "CELL", 38, 41], ["T killer cells", "CELL", 47, 61], ["T helper (Th1) and T killer cells", "CELL_TYPE", 28, 61], ["T killer cells", "TREATMENT", 47, 61], ["pathogens", "PROBLEM", 95, 104], ["proliferation", "OBSERVATION_MODIFIER", 11, 24]]], ["Zinc also induces development of regulator T cells (Tregs) which help control the immune response by suppressing T cell proliferation and pro-inflammatory cytokine production.", [["regulator T cells", "ANATOMY", 33, 50], ["Tregs", "ANATOMY", 52, 57], ["T cell", "ANATOMY", 113, 119], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["T cells", "CELL", 43, 50], ["Tregs", "CELL", 52, 57], ["T cell", "CELL", 113, 119], ["regulator T cells", "CELL_TYPE", 33, 50], ["Tregs", "CELL_TYPE", 52, 57], ["cytokine", "PROTEIN", 155, 163], ["Zinc", "TREATMENT", 0, 4], ["regulator T cells", "PROBLEM", 33, 50], ["suppressing T cell proliferation", "PROBLEM", 101, 133], ["pro-inflammatory cytokine production", "PROBLEM", 138, 174], ["regulator T cells", "OBSERVATION", 33, 50], ["cell proliferation", "OBSERVATION", 115, 133], ["pro-inflammatory cytokine production", "OBSERVATION", 138, 174]]], ["Collectively, this helps maintain homeostasis and self-tolerance, which is a critical role in preventing autoimmunity [37] .", [["autoimmunity", "DISEASE", 105, 117]]], ["Zinc acts as a co-factor for enzymes that protect against oxidative damage as part of the antioxidant defense system [101] .Clinical RelevanceThe critical need for adequate zinc intake for maintaining the integrity of the immune system has been shown in animal and human studies.", [["immune system", "ANATOMY", 222, 235], ["Zinc", "CHEMICAL", 0, 4], ["zinc", "CHEMICAL", 173, 177], ["Zinc", "CHEMICAL", 0, 4], ["zinc", "CHEMICAL", 173, 177], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["zinc", "SIMPLE_CHEMICAL", 173, 177], ["immune system", "ANATOMICAL_SYSTEM", 222, 235], ["human", "ORGANISM", 265, 270], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["Zinc acts", "TREATMENT", 0, 9], ["enzymes", "TEST", 29, 36], ["oxidative damage", "PROBLEM", 58, 74], ["adequate zinc intake", "TREATMENT", 164, 184], ["animal and human studies", "TEST", 254, 278]]], ["The impact of inadequate zinc intake on the immune system is rapid and extensive.", [["immune system", "ANATOMY", 44, 57], ["zinc", "CHEMICAL", 25, 29], ["zinc", "CHEMICAL", 25, 29], ["zinc", "SIMPLE_CHEMICAL", 25, 29], ["inadequate zinc intake", "PROBLEM", 14, 36], ["inadequate zinc intake", "OBSERVATION", 14, 36], ["rapid", "OBSERVATION_MODIFIER", 61, 66], ["extensive", "OBSERVATION_MODIFIER", 71, 80]]], ["Mouse models demonstrate that low zinc intake can lead to impaired immune function [20] .", [["zinc", "CHEMICAL", 34, 38], ["zinc", "CHEMICAL", 34, 38], ["Mouse", "ORGANISM", 0, 5], ["zinc", "SIMPLE_CHEMICAL", 34, 38], ["Mouse", "SPECIES", 0, 5], ["low zinc intake", "PROBLEM", 30, 45], ["impaired immune function", "PROBLEM", 58, 82]]], ["Zinc deficiency causes thymic involution, leading to reduced T cell production and an imbalance of T helper cells (Th2 > Th1) and an altered cytokine production which can lead to increased inflammation and oxidative stress.", [["thymic", "ANATOMY", 23, 29], ["T cell", "ANATOMY", 61, 67], ["T helper cells", "ANATOMY", 99, 113], ["Zinc", "CHEMICAL", 0, 4], ["thymic involution", "DISEASE", 23, 40], ["inflammation", "DISEASE", 189, 201], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "GENE_OR_GENE_PRODUCT", 0, 4], ["thymic", "ORGAN", 23, 29], ["T cell", "CELL", 61, 67], ["T helper cells", "CELL", 99, 113], ["Th2", "GENE_OR_GENE_PRODUCT", 115, 118], ["Th1", "GENE_OR_GENE_PRODUCT", 121, 124], ["T helper cells", "CELL_TYPE", 99, 113], ["Th2", "CELL_TYPE", 115, 118], ["Th1", "CELL_TYPE", 121, 124], ["cytokine", "PROTEIN", 141, 149], ["Zinc deficiency", "PROBLEM", 0, 15], ["thymic involution", "PROBLEM", 23, 40], ["reduced T cell production", "PROBLEM", 53, 78], ["an imbalance of T helper cells", "PROBLEM", 83, 113], ["an altered cytokine production", "PROBLEM", 130, 160], ["increased inflammation", "PROBLEM", 179, 201], ["oxidative stress", "PROBLEM", 206, 222], ["deficiency", "OBSERVATION", 5, 15], ["thymic involution", "OBSERVATION", 23, 40], ["reduced", "OBSERVATION_MODIFIER", 53, 60], ["T cell production", "OBSERVATION", 61, 78], ["altered", "OBSERVATION_MODIFIER", 133, 140], ["cytokine production", "OBSERVATION", 141, 160], ["increased", "OBSERVATION_MODIFIER", 179, 188], ["inflammation", "OBSERVATION", 189, 201], ["oxidative stress", "OBSERVATION", 206, 222]]], ["These changes mimic the changes seen in the aging immune system, so even marginal zinc intake in older adults may have a deleterious impact on immune health [24] .", [["immune system", "ANATOMY", 50, 63], ["zinc", "CHEMICAL", 82, 86], ["zinc", "CHEMICAL", 82, 86], ["zinc", "SIMPLE_CHEMICAL", 82, 86], ["the changes", "PROBLEM", 20, 31]]], ["An earlier analysis found that 35-45% of US adults > 60 years had zinc intakes below the EAR [102] .", [["zinc", "CHEMICAL", 66, 70], ["zinc", "CHEMICAL", 66, 70], ["zinc", "SIMPLE_CHEMICAL", 66, 70], ["An earlier analysis", "TEST", 0, 19], ["zinc intakes", "PROBLEM", 66, 78], ["EAR", "ANATOMY", 89, 92]]], ["Previous reports that plasma zinc concentration declines with age may be due to decreased absorption or uptake, or epigenetic alterations [24, 38] .Clinical RelevanceSeveral randomized controlled trials and meta-analyses have shown that 10-45 mg zinc/day improves several aspects of immune function in older adults.", [["plasma", "ANATOMY", 22, 28], ["zinc", "CHEMICAL", 29, 33], ["zinc", "CHEMICAL", 246, 250], ["zinc", "CHEMICAL", 29, 33], ["zinc", "CHEMICAL", 246, 250], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["zinc", "SIMPLE_CHEMICAL", 29, 33], ["immune", "ANATOMICAL_SYSTEM", 283, 289], ["plasma zinc concentration declines", "PROBLEM", 22, 56], ["decreased absorption or uptake", "PROBLEM", 80, 110], ["epigenetic alterations", "PROBLEM", 115, 137], ["meta-analyses", "TEST", 207, 220]]], ["A randomized, double-blind, placebo-controlled trial showed 45 mg zinc (zinc gluconate) in forty people aged 56-83 years reduced IL-6, secretory phospholipase A, malondialdehyde and hydroxyalkyls, markers of inflammation and oxidative stress [103] .", [["zinc", "CHEMICAL", 66, 70], ["zinc gluconate", "CHEMICAL", 72, 86], ["malondialdehyde", "CHEMICAL", 162, 177], ["hydroxyalkyls", "CHEMICAL", 182, 195], ["inflammation", "DISEASE", 208, 220], ["zinc", "CHEMICAL", 66, 70], ["zinc gluconate", "CHEMICAL", 72, 86], ["malondialdehyde", "CHEMICAL", 162, 177], ["hydroxyalkyls", "CHEMICAL", 182, 195], ["zinc", "SIMPLE_CHEMICAL", 66, 70], ["zinc gluconate", "SIMPLE_CHEMICAL", 72, 86], ["people", "ORGANISM", 97, 103], ["IL-6", "GENE_OR_GENE_PRODUCT", 129, 133], ["secretory phospholipase A", "GENE_OR_GENE_PRODUCT", 135, 160], ["malondialdehyde", "SIMPLE_CHEMICAL", 162, 177], ["hydroxyalkyls", "SIMPLE_CHEMICAL", 182, 195], ["IL-6", "PROTEIN", 129, 133], ["secretory phospholipase A", "PROTEIN", 135, 160], ["people", "SPECIES", 97, 103], ["double-blind", "TREATMENT", 14, 26], ["placebo", "TREATMENT", 28, 35], ["45 mg zinc (zinc gluconate", "TREATMENT", 60, 86], ["IL", "TEST", 129, 131], ["malondialdehyde", "TREATMENT", 162, 177], ["hydroxyalkyls", "TREATMENT", 182, 195], ["inflammation", "PROBLEM", 208, 220], ["oxidative stress", "PROBLEM", 225, 241], ["inflammation", "OBSERVATION", 208, 220]]], ["Another randomized, double-blind, placebo-controlled trial in 100 older adults (aged 50-70 years) with normal blood zinc concentrations gave 15-30 mg zinc supplementation for six months.", [["blood", "ANATOMY", 110, 115], ["zinc", "CHEMICAL", 116, 120], ["zinc", "CHEMICAL", 150, 154], ["zinc", "CHEMICAL", 116, 120], ["zinc", "CHEMICAL", 150, 154], ["adults", "ORGANISM", 72, 78], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["zinc", "SIMPLE_CHEMICAL", 116, 120], ["zinc", "SIMPLE_CHEMICAL", 150, 154], ["double-blind", "TREATMENT", 20, 32], ["placebo", "TREATMENT", 34, 41], ["normal blood zinc concentrations", "TREATMENT", 103, 135], ["zinc supplementation", "TREATMENT", 150, 170]]], ["Lower doses of zinc (15 mg zinc/day) significantly increased the proportion of helper T cells to that of cytotoxic T cells at six months [25] .", [["helper T cells", "ANATOMY", 79, 93], ["cytotoxic T cells", "ANATOMY", 105, 122], ["zinc", "CHEMICAL", 15, 19], ["zinc", "CHEMICAL", 15, 19], ["zinc", "CHEMICAL", 27, 31], ["zinc", "SIMPLE_CHEMICAL", 15, 19], ["helper T cells", "CELL", 79, 93], ["cytotoxic T cells", "CELL", 105, 122], ["helper T cells", "CELL_TYPE", 79, 93], ["cytotoxic T cells", "CELL_TYPE", 105, 122], ["zinc", "TREATMENT", 15, 19], ["helper T cells", "TREATMENT", 79, 93], ["cytotoxic T cells", "TREATMENT", 105, 122]]], ["Maintaining adequate zinc status may help prevent immune dysfunction in the older nursing home population.", [["zinc", "CHEMICAL", 21, 25], ["immune dysfunction", "DISEASE", 50, 68], ["zinc", "CHEMICAL", 21, 25], ["zinc", "SIMPLE_CHEMICAL", 21, 25], ["immune dysfunction", "PROBLEM", 50, 68]]], ["A one-year study of 420 nursing home patients found that participants with plasma concentrations of zinc >70 \u00b5g/dL had a lower risk of pneumonia [104] .", [["plasma", "ANATOMY", 75, 81], ["zinc", "CHEMICAL", 100, 104], ["pneumonia", "DISEASE", 135, 144], ["zinc", "CHEMICAL", 100, 104], ["patients", "ORGANISM", 37, 45], ["participants", "ORGANISM", 57, 69], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["zinc", "SIMPLE_CHEMICAL", 100, 104], ["patients", "SPECIES", 37, 45], ["participants", "SPECIES", 57, 69], ["plasma concentrations", "TEST", 75, 96], ["zinc", "TEST", 100, 104], ["pneumonia", "PROBLEM", 135, 144], ["pneumonia", "OBSERVATION", 135, 144]]], ["Several clinical studies have shown zinc supplementation may reduce risk of common cold, although results are mixed.", [["zinc", "CHEMICAL", 36, 40], ["zinc", "CHEMICAL", 36, 40], ["zinc", "SIMPLE_CHEMICAL", 36, 40], ["Several clinical studies", "TEST", 0, 24], ["zinc supplementation", "TREATMENT", 36, 56], ["common cold", "PROBLEM", 76, 87]]], ["A recent meta-analysis of seven randomized trials with 575 participants with naturally acquired common colds concluded that zinc (zinc gluconate or zinc acetate, 80 to 92 mg per day) supplementation starting at the beginning of the first cold symptoms resulted in a 33% reduction in cold duration.", [["colds", "DISEASE", 103, 108], ["zinc", "CHEMICAL", 124, 128], ["zinc gluconate", "CHEMICAL", 130, 144], ["zinc acetate", "CHEMICAL", 148, 160], ["zinc", "CHEMICAL", 124, 128], ["zinc gluconate", "CHEMICAL", 130, 144], ["zinc acetate", "CHEMICAL", 148, 160], ["zinc", "SIMPLE_CHEMICAL", 124, 128], ["zinc gluconate", "SIMPLE_CHEMICAL", 130, 144], ["zinc acetate", "SIMPLE_CHEMICAL", 148, 160], ["participants", "SPECIES", 59, 71], ["A recent meta-analysis", "TEST", 0, 22], ["naturally acquired common colds", "PROBLEM", 77, 108], ["zinc (zinc gluconate", "TREATMENT", 124, 144], ["zinc acetate", "TREATMENT", 148, 160], ["supplementation", "TREATMENT", 183, 198], ["the first cold symptoms", "PROBLEM", 228, 251], ["a 33% reduction", "TREATMENT", 264, 279]]], ["Zinc acetate lozenges shortened colds by 40% and zinc gluconate by 28%.", [["Zinc acetate", "CHEMICAL", 0, 12], ["colds", "DISEASE", 32, 37], ["zinc gluconate", "CHEMICAL", 49, 63], ["Zinc acetate", "CHEMICAL", 0, 12], ["zinc gluconate", "CHEMICAL", 49, 63], ["Zinc acetate", "SIMPLE_CHEMICAL", 0, 12], ["zinc gluconate", "SIMPLE_CHEMICAL", 49, 63], ["Zinc acetate lozenges shortened colds", "TREATMENT", 0, 37], ["zinc gluconate", "TREATMENT", 49, 63]]], ["Zinc supplementation at 192-207 mg/day had a similar effect on cold duration [105] .", [["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["Zinc supplementation", "TREATMENT", 0, 20]]], ["Researchers are beginning to explore the effect of zinc on influenza virus.", [["zinc", "CHEMICAL", 51, 55], ["zinc", "CHEMICAL", 51, 55], ["zinc", "SIMPLE_CHEMICAL", 51, 55], ["influenza virus", "ORGANISM", 59, 74], ["influenza virus", "SPECIES", 59, 74], ["influenza virus", "SPECIES", 59, 74], ["zinc on influenza virus", "PROBLEM", 51, 74]]], ["A recent in vitro study showed that zinc oxide had inhibitory effects on H1N1 influenza virus [106] .", [["zinc oxide", "CHEMICAL", 36, 46], ["influenza", "DISEASE", 78, 87], ["zinc oxide", "CHEMICAL", 36, 46], ["zinc oxide", "SIMPLE_CHEMICAL", 36, 46], ["H1N1 influenza virus", "ORGANISM", 73, 93], ["H1N1 influenza virus", "SPECIES", 73, 93], ["H1N1 influenza virus", "SPECIES", 73, 93], ["A recent in vitro study", "TEST", 0, 23], ["zinc oxide", "TREATMENT", 36, 46], ["inhibitory effects", "PROBLEM", 51, 69], ["H1N1 influenza virus", "PROBLEM", 73, 93]]], ["Future research is needed to extend these finding to in vivo models.Current FindingsOur research shows, for all adults (\u226519 years), the percent of intake below the EAR (6.8-9.4 mg) for zinc was 15% (food only) and 11% (food + supplement).", [["zinc", "CHEMICAL", 185, 189], ["zinc", "CHEMICAL", 185, 189], ["zinc", "SIMPLE_CHEMICAL", 185, 189], ["the EAR", "TREATMENT", 160, 167], ["zinc", "TREATMENT", 185, 189], ["EAR", "ANATOMY", 164, 167]]], ["The prevalence of inadequacy of 15% is slightly higher than previous NHANES data, which showed a 11% inadequacy [7] .", [["previous NHANES data", "TEST", 60, 80]]], ["Zinc usual intake was 12 mg (food only) and 16 mg (food + supplement) ( Table S1 ).", [["Zinc", "CHEMICAL", 0, 4], ["Zinc", "CHEMICAL", 0, 4], ["Zinc", "SIMPLE_CHEMICAL", 0, 4], ["Zinc usual intake", "TREATMENT", 0, 17]]], ["The RDA for vitamin zinc is 8-11 mg, which is adequate for healthy populations [107] .", [["vitamin zinc", "CHEMICAL", 12, 24], ["vitamin zinc", "CHEMICAL", 12, 24], ["RDA", "SIMPLE_CHEMICAL", 4, 7], ["vitamin zinc", "SIMPLE_CHEMICAL", 12, 24], ["The RDA", "TREATMENT", 0, 7], ["vitamin zinc", "TREATMENT", 12, 24]]], ["The optimal daily intake for immune health for older adults at high risk for infection has been suggested at 30 mg/day [16] .Food and Dietary Supplements to fill Nutrient GapsIdeally, a healthy, nutrient-dense diet, including a variety of colorful fruits and vegetables (vitamin A and C), whole grains, nuts, seeds, oils (vitamin E), meats and legumes (zinc), and dairy and seafood (vitamin D) can provide the nutrients needed to meet daily requirements (Table 1 ).", [["fruits", "ANATOMY", 248, 254], ["vegetables", "ANATOMY", 259, 269], ["grains", "ANATOMY", 295, 301], ["nuts", "ANATOMY", 303, 307], ["seeds", "ANATOMY", 309, 314], ["oils", "ANATOMY", 316, 320], ["meats", "ANATOMY", 334, 339], ["infection", "DISEASE", 77, 86], ["vitamin A and C", "CHEMICAL", 271, 286], ["nuts, seeds, oils", "CHEMICAL", 303, 320], ["vitamin E", "CHEMICAL", 322, 331], ["zinc", "CHEMICAL", 353, 357], ["vitamin D", "CHEMICAL", 383, 392], ["vitamin A and C", "CHEMICAL", 271, 286], ["vitamin E", "CHEMICAL", 322, 331], ["zinc", "CHEMICAL", 353, 357], ["vitamin D", "CHEMICAL", 383, 392], ["fruits", "ORGANISM_SUBDIVISION", 248, 254], ["vegetables", "ORGANISM_SUBDIVISION", 259, 269], ["vitamin A", "SIMPLE_CHEMICAL", 271, 280], ["C", "SIMPLE_CHEMICAL", 285, 286], ["nuts", "ORGANISM_SUBDIVISION", 303, 307], ["vitamin E", "SIMPLE_CHEMICAL", 322, 331], ["meats", "ORGANISM_SUBDIVISION", 334, 339], ["legumes", "ORGANISM_SUBDIVISION", 344, 351], ["zinc", "SIMPLE_CHEMICAL", 353, 357], ["dairy", "ORGANISM_SUBDIVISION", 364, 369], ["seafood", "ORGANISM_SUBDIVISION", 374, 381], ["vitamin D", "SIMPLE_CHEMICAL", 383, 392], ["meats", "SPECIES", 334, 339], ["infection", "PROBLEM", 77, 86], ["vegetables (vitamin A and C), whole grains, nuts", "TREATMENT", 259, 307], ["oils (vitamin E)", "TREATMENT", 316, 332], ["legumes (zinc)", "TREATMENT", 344, 358], ["dairy and seafood (vitamin D)", "TREATMENT", 364, 393], ["the nutrients", "TREATMENT", 406, 419], ["infection", "OBSERVATION", 77, 86]]], ["However, research shows Americans are not eating the foods necessary to meet their needs for key micronutrients [108] which has contributed to micronutrient inadequacies that have been reported for almost 15 years [6, 7, 109] .", [["Americans", "ORGANISM", 24, 33], ["micronutrient inadequacies", "PROBLEM", 143, 169]]], ["Findings from our data show a decade of substantial shortfalls in nutrients that support immune health (vitamin A, C, D, E) and that some shortfalls are higher (vitamin C, D, and zinc) than previously reported [7] .Food and Dietary Supplements to fill Nutrient GapsStudies looking at the effects of dietary supplements on immune health have been inconsistent, which may be due to failure to control for factors such as measuring baseline nutrient status, which eliminates groups with inadequacy who can benefit the most from the nutrient.", [["vitamin A", "CHEMICAL", 104, 113], ["vitamin C", "CHEMICAL", 161, 170], ["vitamin A, C, D, E", "CHEMICAL", 104, 122], ["vitamin C", "CHEMICAL", 161, 170], ["D", "CHEMICAL", 172, 173], ["zinc", "CHEMICAL", 179, 183], ["vitamin A", "SIMPLE_CHEMICAL", 104, 113], ["C", "SIMPLE_CHEMICAL", 115, 116], ["D", "SIMPLE_CHEMICAL", 118, 119], ["E", "SIMPLE_CHEMICAL", 121, 122], ["vitamin C", "SIMPLE_CHEMICAL", 161, 170], ["D", "SIMPLE_CHEMICAL", 172, 173], ["zinc", "SIMPLE_CHEMICAL", 179, 183], ["our data", "TEST", 14, 22], ["vitamin A", "TEST", 104, 113], ["vitamin C, D, and zinc)", "PROBLEM", 161, 184], ["Dietary Supplements", "TREATMENT", 224, 243], ["Nutrient GapsStudies", "TREATMENT", 252, 272], ["dietary supplements", "TREATMENT", 299, 318], ["failure to control for factors", "PROBLEM", 380, 410], ["substantial", "OBSERVATION_MODIFIER", 40, 51], ["shortfalls", "OBSERVATION", 52, 62]]], ["Other factors that may impact outcome are timing and duration of the nutrient dose.", [["the nutrient dose", "TREATMENT", 65, 82]]], ["This was seen in the vitamin C Cochrane review.", [["vitamin", "CHEMICAL", 21, 28], ["vitamin C", "CHEMICAL", 21, 30], ["vitamin C", "SIMPLE_CHEMICAL", 21, 30]]], ["Vitamin C was only effective as a continuous prophylaxis, but had no impact if taken after the onset of cold symptoms [96] .Food and Dietary Supplements to fill Nutrient GapsOur research shows that food plus a dietary supplement had a lower prevalence of nutrient inadequacies than food alone.", [["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "CHEMICAL", 0, 9], ["Vitamin C", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin C", "TREATMENT", 0, 9], ["a continuous prophylaxis", "TREATMENT", 32, 56], ["cold symptoms", "PROBLEM", 104, 117], ["Dietary Supplements", "TREATMENT", 133, 152], ["a dietary supplement", "TREATMENT", 208, 228]]], ["Previous research has shown food fortification [7, 110] and the consumption of dietary supplements increase overall nutrient intake and decrease the prevalence of nutrient inadequacies [6, 7, 109] .", [["dietary supplements", "TREATMENT", 79, 98]]], ["Specifically, Blumberg et al. showed that the use of a multivitamin/mineral supplement (at least 100% of the RDA or AI for at least nine nutrients), compared with food alone, was associated with a lower prevalence of inadequacy for most 15 nutrients (including vitamins A, C, E and zinc), except for vitamin D [6] .", [["multivitamin", "CHEMICAL", 55, 67], ["vitamins A, C, E and zinc", "CHEMICAL", 261, 286], ["vitamin D", "CHEMICAL", 300, 309], ["multivitamin", "CHEMICAL", 55, 67], ["vitamins A, C, E", "CHEMICAL", 261, 277], ["zinc", "CHEMICAL", 282, 286], ["vitamin D", "CHEMICAL", 300, 309], ["multivitamin", "SIMPLE_CHEMICAL", 55, 67], ["vitamins A", "SIMPLE_CHEMICAL", 261, 271], ["C", "SIMPLE_CHEMICAL", 273, 274], ["E", "SIMPLE_CHEMICAL", 276, 277], ["zinc", "SIMPLE_CHEMICAL", 282, 286], ["vitamin D", "SIMPLE_CHEMICAL", 300, 309], ["a multivitamin/mineral supplement", "TREATMENT", 53, 86], ["AI", "TREATMENT", 116, 118], ["vitamins A, C, E and zinc)", "TREATMENT", 261, 287], ["vitamin D", "TREATMENT", 300, 309]]], ["Those with the highest compliance (>21 days per month) had the most impact on eliminating inadequacies and lowered the odds ratios of deficiency for most blood biomarkers.", [["blood", "ANATOMY", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["deficiency", "PROBLEM", 134, 144], ["most blood biomarkers", "TEST", 149, 170]]], ["A multivitamin/mineral supplement is an excellent tool, as an addition to a healthy diet, to ensure adequate intake of essential nutrients for general health.", [["multivitamin", "CHEMICAL", 2, 14], ["multivitamin", "CHEMICAL", 2, 14], ["multivitamin", "SIMPLE_CHEMICAL", 2, 14], ["A multivitamin/mineral supplement", "TREATMENT", 0, 33], ["a healthy diet", "TREATMENT", 74, 88]]], ["A multivitamin/mineral supplement that offers 100% of the RDA can fill the nutrient gaps of most essential nutrients for immune health but may fall short of optimal levels recommended by scientific groups for vitamin C (200 mg) [99] and vitamin D (1500-2000 IU) [65] .", [["multivitamin", "CHEMICAL", 2, 14], ["vitamin C", "CHEMICAL", 209, 218], ["vitamin D", "CHEMICAL", 237, 246], ["vitamin C", "CHEMICAL", 209, 218], ["vitamin D", "CHEMICAL", 237, 246], ["multivitamin", "SIMPLE_CHEMICAL", 2, 14], ["RDA", "SIMPLE_CHEMICAL", 58, 61], ["vitamin C", "SIMPLE_CHEMICAL", 209, 218], ["vitamin D", "SIMPLE_CHEMICAL", 237, 246], ["A multivitamin/mineral supplement", "TREATMENT", 0, 33], ["vitamin C", "TREATMENT", 209, 218], ["vitamin D", "TREATMENT", 237, 246]]], ["Older adults or those with suboptimal status may have higher needs in vitamin E and zinc, as well.", [["vitamin E", "CHEMICAL", 70, 79], ["zinc", "CHEMICAL", 84, 88], ["vitamin E", "CHEMICAL", 70, 79], ["zinc", "CHEMICAL", 84, 88], ["vitamin E", "SIMPLE_CHEMICAL", 70, 79], ["zinc", "SIMPLE_CHEMICAL", 84, 88], ["vitamin E", "TREATMENT", 70, 79], ["zinc", "TREATMENT", 84, 88]]], ["For those with a vitamin D insufficiency/deficiency, higher doses may be required to raise vitamin D levels to a minimum of serum 25(OH)D concentration of 30 ng/mL [65] .", [["serum", "ANATOMY", 124, 129], ["vitamin D", "CHEMICAL", 17, 26], ["vitamin D", "CHEMICAL", 91, 100], ["25(OH)D", "CHEMICAL", 130, 137], ["vitamin D", "CHEMICAL", 17, 26], ["vitamin D", "CHEMICAL", 91, 100], ["25(OH)D", "CHEMICAL", 130, 137], ["vitamin D", "SIMPLE_CHEMICAL", 17, 26], ["vitamin D", "SIMPLE_CHEMICAL", 91, 100], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["25(OH)D", "SIMPLE_CHEMICAL", 130, 137], ["a vitamin D insufficiency/deficiency", "PROBLEM", 15, 51], ["vitamin D levels", "TEST", 91, 107], ["a minimum of serum 25(OH)D concentration", "TREATMENT", 111, 151]]], ["In such cases, higher dose dietary supplements may be needed to reach optimal levels.ConclusionsA well-functioning immune system is essential to survival.", [["immune system", "ANATOMY", 115, 128], ["higher dose dietary supplements", "TREATMENT", 15, 46]]], ["Micronutrients are a fundamental part of the immune system and require optimal levels for effective immune function.", [["immune system", "ANATOMY", 45, 58], ["immune system", "ANATOMICAL_SYSTEM", 45, 58]]], ["Nutrient insufficiency/deficiency of one nutrient can adversely affect immune health, while multiple inadequacies may put the immune system at a bigger deficit.", [["immune system", "ANATOMY", 126, 139], ["Nutrient insufficiency", "DISEASE", 0, 22], ["immune system", "ANATOMICAL_SYSTEM", 126, 139], ["Nutrient insufficiency", "PROBLEM", 0, 22], ["deficiency", "PROBLEM", 23, 33], ["a bigger deficit", "PROBLEM", 143, 159], ["insufficiency", "OBSERVATION", 9, 22], ["deficiency", "OBSERVATION", 23, 33]]], ["The prevalence of inadequate nutrient intakes that support the immune system (vitamin A, C, D, E) remain substantial and some are higher (vitamins C, D, and zinc) than previously reported [7] .", [["vitamin A", "CHEMICAL", 78, 87], ["vitamin A, C, D, E", "CHEMICAL", 78, 96], ["vitamins C, D", "CHEMICAL", 138, 151], ["zinc", "CHEMICAL", 157, 161], ["vitamin A", "SIMPLE_CHEMICAL", 78, 87], ["C", "SIMPLE_CHEMICAL", 89, 90], ["D", "SIMPLE_CHEMICAL", 92, 93], ["E", "SIMPLE_CHEMICAL", 95, 96], ["vitamins C", "SIMPLE_CHEMICAL", 138, 148], ["D", "SIMPLE_CHEMICAL", 150, 151], ["zinc", "SIMPLE_CHEMICAL", 157, 161], ["inadequate nutrient intakes", "PROBLEM", 18, 45], ["the immune system", "TEST", 59, 76], ["vitamin A, C, D, E)", "TEST", 78, 97], ["vitamins C, D, and zinc)", "PROBLEM", 138, 162], ["substantial", "OBSERVATION_MODIFIER", 105, 116], ["higher", "OBSERVATION_MODIFIER", 130, 136]]], ["Given the long-term and widening of nutrient gaps in the U.S.-specifically in critical nutrients that support immune health-public health measures should adopt guidelines to ensure an adequate intake of these micronutrients, especially in vulnerable populations.", [["public health measures", "TREATMENT", 124, 146], ["long-term", "OBSERVATION_MODIFIER", 10, 19], ["widening", "OBSERVATION_MODIFIER", 24, 32], ["nutrient gaps", "OBSERVATION", 36, 49]]], ["Future research is needed to better understand the interactions and complexities of multiple nutrient shortfalls on immune health and assess and identify optimal levels of intake and nutrient status in at-risk populations.", [["immune health", "TREATMENT", 116, 129]]]], "131dbcca5405d7c55533aeb8838bbcdb4a606e66": [["IntroductionBaltimore classified viruses into six classes by the means of their genomes.", [["viruses", "OBSERVATION", 33, 40]]], ["One class is shared between RNA and DNA viruses, while three of them are occupied solely by RNA viruses reflecting their great diversity and different replicative mechanisms (Baltimore, 1971) .", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["DNA viruses", "PROBLEM", 36, 47], ["RNA viruses", "PROBLEM", 92, 103], ["DNA viruses", "OBSERVATION", 36, 47], ["RNA viruses", "OBSERVATION", 92, 103], ["great", "OBSERVATION_MODIFIER", 121, 126], ["diversity", "OBSERVATION_MODIFIER", 127, 136]]], ["Over the past few decades, many human infectious diseases including ebola virus disease (EVD), avian influenza, severe acute respiratory syndrome (SARS) resulted from the interspecies transmission of zoonotic RNA viruses (Epstein et al., 2005; Leroy et al., 2005; \u2265 1.6 indicates overrepresented or putative preferred codons (Duret and Mouchiroud, 1999; Liu et al., 2010; Mandal et al., 2020; Sharp and Li, 1987) .Introduction(2)Introduction(1)Effective number of codons (ENc)The effective number of codons (ENc) determines the degree of preference for the unbalanced use of codons, regardless of the gene length and numbers of amino acids.", [["infectious diseases", "DISEASE", 38, 57], ["ebola virus disease", "DISEASE", 68, 87], ["EVD", "DISEASE", 89, 92], ["avian influenza", "DISEASE", 95, 110], ["acute respiratory syndrome", "DISEASE", 119, 145], ["SARS", "DISEASE", 147, 151], ["zoonotic RNA viruses", "DISEASE", 200, 220], ["amino acids", "CHEMICAL", 628, 639], ["amino acids", "CHEMICAL", 628, 639], ["human", "ORGANISM", 32, 37], ["ebola virus", "ORGANISM", 68, 79], ["avian influenza", "ORGANISM", 95, 110], ["amino acids", "AMINO_ACID", 628, 639], ["ENc", "PROTEIN", 508, 511], ["human", "SPECIES", 32, 37], ["ebola virus disease", "SPECIES", 68, 87], ["avian influenza", "SPECIES", 95, 110], ["human", "SPECIES", 32, 37], ["ebola virus", "SPECIES", 68, 79], ["many human infectious diseases", "PROBLEM", 27, 57], ["ebola virus disease", "PROBLEM", 68, 87], ["EVD", "TREATMENT", 89, 92], ["avian influenza", "PROBLEM", 95, 110], ["severe acute respiratory syndrome", "PROBLEM", 112, 145], ["SARS", "PROBLEM", 147, 151], ["codons (ENc)", "TREATMENT", 464, 476], ["codons (ENc)", "TREATMENT", 500, 512], ["codons", "TREATMENT", 575, 581], ["amino acids", "TREATMENT", 628, 639], ["infectious", "OBSERVATION_MODIFIER", 38, 48], ["ebola virus disease", "OBSERVATION", 68, 87], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory syndrome", "OBSERVATION", 125, 145]]], ["ENc values range from 20, indicating extreme codon usage bias as only one synonymous codon is used for the corresponding amino acid, to 61, indicating no bias but the use of all possible synonymous codons equally.", [["amino acid", "CHEMICAL", 121, 131], ["amino acid", "CHEMICAL", 121, 131], ["amino acid", "AMINO_ACID", 121, 131], ["ENc", "PROTEIN", 0, 3], ["ENc values range", "TEST", 0, 16], ["extreme codon usage bias", "PROBLEM", 37, 61], ["the corresponding amino acid", "TEST", 103, 131], ["synonymous codons", "OBSERVATION", 187, 204]]], ["Therefore, the ENc value correlates negatively with the codon usage bias.", [["ENc", "GENE_OR_GENE_PRODUCT", 15, 18], ["ENc", "PROTEIN", 15, 18], ["the ENc value", "TEST", 11, 24]]], ["Also, it is generally accepted that genes have significant codon usage bias when the ENc value is \u2264 35 (Comeron and Aguad\u00e9, 1998) , (Wright, 1990) .", [["the ENc value", "TEST", 81, 94]]], ["ENc was calculatedNeutrality PlotNeutrality plot is used to estimate the effect of mutation pressure and natural selection on codon usage bias.", [["Neutrality PlotNeutrality plot", "TREATMENT", 18, 48], ["mutation pressure", "TREATMENT", 83, 100], ["natural selection", "TREATMENT", 105, 122]]], ["In this study, the GC contents at the first, second and third codon positions (GC1, GC2, GC3, respectively) of the 13 SARS-CoV-2 isolates were analyzed.", [["SARS-CoV-2", "ORGANISM", 118, 128], ["first, second and third codon positions", "DNA", 38, 77], ["GC1", "DNA", 79, 82], ["GC2", "DNA", 84, 87], ["GC3", "DNA", 89, 92], ["this study", "TEST", 3, 13], ["the GC contents", "TEST", 15, 30], ["GC1", "TEST", 79, 82], ["GC2", "TEST", 84, 87], ["GC3", "TEST", 89, 92], ["the 13 SARS", "TEST", 111, 122], ["CoV", "TEST", 123, 126], ["GC contents", "OBSERVATION", 19, 30], ["third codon", "ANATOMY", 56, 67], ["positions", "ANATOMY_MODIFIER", 68, 77]]], ["Then, GC12Neutrality Plotrepresenting the average GC content at the first and second codon positions of each isolate was obtained.", [["GC12Neutrality", "DNA", 6, 20], ["first and second codon positions", "DNA", 68, 100], ["GC12Neutrality", "TREATMENT", 6, 20]]], ["Both GC12 and GC3 values were used for neutrality plot analysis.", [["GC12", "DNA", 5, 9], ["GC3", "DNA", 14, 17], ["Both GC12 and GC3 values", "TEST", 0, 24], ["neutrality plot analysis", "TEST", 39, 63]]], ["If the correlation between GC12 and GC3 is statistically significant and the slope of the regression line is close to 1, mutation pressure is assumed to be the main force structuring codon usage bias.", [["GC12", "GENE_OR_GENE_PRODUCT", 27, 31], ["GC12", "DNA", 27, 31], ["GC3", "DNA", 36, 39], ["GC12", "TEST", 27, 31], ["the regression line", "TREATMENT", 86, 105], ["mutation pressure", "TEST", 121, 138], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["slope", "OBSERVATION_MODIFIER", 77, 82], ["regression line", "OBSERVATION", 90, 105], ["codon usage", "OBSERVATION", 183, 194]]], ["Conversely, natural selection would have higher odds leading to a narrow distribution of GC content and a lack of correlation between GC12 and GC3 (Jia and Xue, 2009; Song et al., 2017; Wu et al., 2015) .Grand Average of Hydropathicity (GRAVY) and Aromaticity (AROMO)The GRAVY value is calculated by dividing the sum of hydropathy values of all amino acids in a sequence by the number of residues (Kyte and Doolittle, 1982) .", [["amino acids", "CHEMICAL", 345, 356], ["amino acids", "CHEMICAL", 345, 356], ["amino acids", "AMINO_ACID", 345, 356], ["GC3", "DNA", 143, 146], ["GRAVY", "PROTEIN", 271, 276], ["a narrow distribution of GC content", "PROBLEM", 64, 99], ["GC12", "TEST", 134, 138], ["The GRAVY value", "TEST", 267, 282], ["hydropathy values", "TEST", 320, 337], ["all amino acids", "TREATMENT", 341, 356], ["narrow", "OBSERVATION_MODIFIER", 66, 72], ["GC content", "OBSERVATION", 89, 99]]], ["GRAVY values range between -2.0 and +2.0, with positive values indicating protein hydrophobicity, while negative values indicate protein hydrophilicity.Grand Average of Hydropathicity (GRAVY) and Aromaticity (AROMO)The AROMO value reflects the recurrence of aromatic amino acids such as tryptophan, phenylalanine, and histidine in a given amino acid sequence.PR2-bias Plot AnalysisThe Parity Rule 2 (PR2) bias was calculated based on the values of A/U-bias 'A3 / (A3 + U3)' and G/C-bias 'G3 / (G3 + C3)', they were plotted as the ordinate and abscissa, respectively.", [["amino acids", "CHEMICAL", 267, 278], ["tryptophan", "CHEMICAL", 287, 297], ["phenylalanine", "CHEMICAL", 299, 312], ["histidine", "CHEMICAL", 318, 327], ["amino acid", "CHEMICAL", 339, 349], ["aromatic amino acids", "CHEMICAL", 258, 278], ["tryptophan", "CHEMICAL", 287, 297], ["phenylalanine", "CHEMICAL", 299, 312], ["histidine", "CHEMICAL", 318, 327], ["amino acid", "CHEMICAL", 339, 349], ["aromatic", "SIMPLE_CHEMICAL", 258, 266], ["amino acids", "AMINO_ACID", 267, 278], ["tryptophan", "AMINO_ACID", 287, 297], ["phenylalanine", "AMINO_ACID", 299, 312], ["histidine", "AMINO_ACID", 318, 327], ["amino acid", "AMINO_ACID", 339, 349], ["amino acid sequence", "PROTEIN", 339, 358], ["PR2", "PROTEIN", 359, 362], ["GRAVY values", "TEST", 0, 12], ["protein hydrophobicity", "PROBLEM", 74, 96], ["protein hydrophilicity", "PROBLEM", 129, 151], ["Hydropathicity", "PROBLEM", 169, 183], ["The AROMO value", "TEST", 215, 230], ["aromatic amino acids", "TREATMENT", 258, 278], ["tryptophan", "TREATMENT", 287, 297], ["phenylalanine", "TREATMENT", 299, 312], ["histidine", "TREATMENT", 318, 327], ["amino acid sequence", "TREATMENT", 339, 358], ["PR2", "TEST", 359, 362], ["Plot Analysis", "TEST", 368, 381], ["The Parity Rule", "TEST", 381, 396], ["bias", "TEST", 405, 409], ["A/U", "TEST", 448, 451], ["G/C", "TEST", 478, 481], ["protein hydrophobicity", "OBSERVATION", 74, 96], ["protein hydrophilicity", "OBSERVATION", 129, 151], ["aromatic amino acids", "OBSERVATION", 258, 278]]], ["The centre of the plot is the place where both coordinates are 0.5, as well as, A = U and G = C according to Chargaff's rule (PR2) (Rapoport and Trifonov, 2013) .Codon Adaptation Index (CAI)Codon adaptation index (CAI) uses a reference set of highly expressed genes (e.g. ribosomal genes), this measure is an indicator of gene expression levels and natural selection; it ranges from 0 to 1 with higher values indicating stronger bias with respect to the reference set, therefore this method is an indicator of selection for a bias toward translational efficiency (Ran and Higgs, 2012; Sharp and Li, 1987) .", [["G = C", "GENE_OR_GENE_PRODUCT", 90, 95], ["ribosomal", "CELLULAR_COMPONENT", 272, 281], ["ribosomal genes", "DNA", 272, 287], ["Codon Adaptation Index (CAI)Codon adaptation index (CAI)", "TREATMENT", 162, 218], ["gene expression levels", "PROBLEM", 322, 344], ["a bias toward translational efficiency", "PROBLEM", 524, 562]]], ["Codon adaptation index (CAI) was calculated by the equation given by (Lee, 2018; Ran and Higgs, 2012) :Codon Adaptation Index (CAI)where L is the count of codons in the gene and w c(k) is the relative adaptiveness value for the k-th codon in the gene.Codon Adaptation Index (CAI)Twelve genes with the highest level of expression in the lung tissues for human were collected from the human protein atlas project database (https://www.proteinatlas.org/humanproteome/tissue/lung).", [["lung tissues", "ANATOMY", 336, 348], ["w c(k)", "GENE_OR_GENE_PRODUCT", 178, 184], ["k-th", "GENE_OR_GENE_PRODUCT", 228, 232], ["lung tissues", "TISSUE", 336, 348], ["human", "ORGANISM", 353, 358], ["human", "ORGANISM", 383, 388], ["k-th codon", "DNA", 228, 238], ["human", "SPECIES", 353, 358], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 353, 358], ["human", "SPECIES", 383, 388], ["Codon Adaptation Index (CAI", "TREATMENT", 103, 130], ["the k-th codon", "TREATMENT", 224, 238], ["Codon Adaptation Index (CAI)", "TREATMENT", 251, 279], ["lung tissues", "ANATOMY", 336, 348]]], ["Then, CAI values for the 13 isolates were calculated based on those 12 genes as a reference set.tRNA Adaptation Index (tAI)The tRNA Adaptation Index (tAI) is a measure of tRNA usage by a CDS considering the fact that the tRNA gene copy number of some genomes has a high positive correlation with tRNA abundance within a cell, as well as, codon usage preferences (dos Reis et al., 2004) .", [["cell", "ANATOMY", 320, 324], ["cell", "CELL", 320, 324], ["CDS", "DNA", 187, 190], ["CAI values", "TEST", 6, 16], ["tRNA Adaptation Index", "TEST", 96, 117], ["The tRNA Adaptation Index", "TEST", 123, 148]]], ["Recently, a novel approach was developed that estimates species-specific tAI wobble weights by optimizing the correlation between a measure of codon usage bias and tAI, without the need to utilize the gene expression measurements of the test organism (based on the CUB) (Renana and Tamir, 2014) .", [["tAI", "DNA", 73, 76], ["estimates species", "PROBLEM", 46, 63], ["codon usage bias", "TREATMENT", 143, 159], ["tAI", "TREATMENT", 164, 167], ["the test organism", "TEST", 233, 250]]], ["The frequencies of tRNAs of Homo sapiens was obtained from the GtRNAdb (http://gtrnadb.ucsc.edu/) (Chan and Lowe, 2009).Relative Codon Deoptimization Index (RCDI)The relative codon deoptimization index (RCDI) is a comparative measure that is used to determine the codon deoptimization trends by comparing the similarity in codon usage between a given coding sequence and a reference genome (Mueller et al., 2006) .", [["Homo sapiens", "ORGANISM", 28, 40], ["reference genome", "DNA", 373, 389], ["Homo sapiens", "SPECIES", 28, 40], ["Homo sapiens", "SPECIES", 28, 40], ["Homo sapiens", "PROBLEM", 28, 40], ["Relative Codon Deoptimization Index (RCDI", "TREATMENT", 120, 161], ["The relative codon deoptimization index", "TREATMENT", 162, 201]]], ["If the tested coding sequence of a virus has a similar codon usage pattern to the human genome, the RCDI value would be closer to or equal 1, which may indicate a high translation rate, as well as, a better adaptation to the host.", [["human", "ORGANISM", 82, 87], ["human genome", "DNA", 82, 94], ["RCDI", "DNA", 100, 104], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["a virus", "PROBLEM", 33, 40], ["the RCDI value", "TEST", 96, 110], ["a high translation rate", "PROBLEM", 161, 184], ["high translation", "OBSERVATION", 163, 179]]], ["RCDI values greater than 1 indicates a deviation from the normal human codon usage bias (deoptimized viral genome).", [["human", "ORGANISM", 65, 70], ["RCDI", "PROTEIN", 0, 4], ["deoptimized viral genome", "DNA", 89, 113], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["RCDI values", "TEST", 0, 11], ["a deviation", "PROBLEM", 37, 48], ["normal human codon", "OBSERVATION", 58, 76], ["viral genome", "OBSERVATION", 101, 113]]], ["In this study, the synonymous codon usage patterns for Homo sapiens were used as a reference and obtained from the CUD.Relative Codon Deoptimization Index (RCDI)Non-synonymous codons and termination codons were excluded from the analysis.", [["Homo sapiens", "ORGANISM", 55, 67], ["Homo sapiens", "SPECIES", 55, 67], ["Homo sapiens", "SPECIES", 55, 67], ["this study", "TEST", 3, 13], ["Relative Codon Deoptimization Index (RCDI)", "TREATMENT", 119, 161], ["Non-synonymous codons and termination codons", "PROBLEM", 161, 205], ["the analysis", "TEST", 225, 237], ["Non-synonymous codons", "OBSERVATION", 161, 182]]], ["The RCDI was calculated using the following equation (Mueller et al., 2006) :Relative Codon Deoptimization Index (RCDI)Where C i F a is the observed relative frequency of codon i to other synonymous codons for the same amino acid in the tested CDS; C i F h is the normal relative frequency of codon i for a specific amino acid in the reference genome sequence; N Ci is the number of incidences of codon i in the CDS; and N is the total number of codons in the CDS.Phylogenetic AnalysisA dendrogram was constructed using 13 complete genomic sequences of 13 SARS-CoV-2Phylogenetic Analysisisolates obtained from different geo-locations (Countries).", [["amino acid", "CHEMICAL", 219, 229], ["amino acid", "CHEMICAL", 316, 326], ["amino acid", "CHEMICAL", 219, 229], ["amino acid", "CHEMICAL", 316, 326], ["C i F", "GENE_OR_GENE_PRODUCT", 125, 130], ["amino acid", "AMINO_ACID", 219, 229], ["C i F", "GENE_OR_GENE_PRODUCT", 249, 254], ["amino acid", "AMINO_ACID", 316, 326], ["N Ci", "GENE_OR_GENE_PRODUCT", 361, 365], ["CDS", "DNA", 244, 247], ["reference genome sequence", "DNA", 334, 359], ["N Ci", "PROTEIN", 361, 365], ["CDS", "DNA", 412, 415], ["CDS", "DNA", 460, 463], ["genomic sequences", "DNA", 532, 549], ["SARS-CoV-2Phylogenetic Analysisisolates", "SPECIES", 556, 595], ["codon i", "TREATMENT", 171, 178], ["synonymous codons", "TREATMENT", 188, 205], ["the same amino acid", "PROBLEM", 210, 229], ["a specific amino acid", "TEST", 305, 326], ["codon i", "PROBLEM", 397, 404], ["Phylogenetic AnalysisA dendrogram", "TEST", 464, 497], ["13 complete genomic sequences", "TEST", 520, 549], ["13 SARS", "TEST", 553, 560], ["CoV", "TEST", 561, 564], ["2Phylogenetic Analysisisolates", "TREATMENT", 565, 595], ["synonymous codons", "OBSERVATION", 188, 205]]], ["Evolutionary relationships were inferred by using maximum-likelihood statistical method with general time-reversible (GTR) model implemented in MEGA-X software (v10.1) (Tamura et al., 2011) .", [["MEGA-X software", "TEST", 144, 159], ["v", "TEST", 161, 162]]], ["The bootstrap method with 1000 replicates was used to test the reliability of the phylogenetic tree.", [["The bootstrap method", "TREATMENT", 0, 20], ["phylogenetic tree", "OBSERVATION", 82, 99]]], ["For each isolate, the following data are given: Species and country of origin.Software and Statistical analysisSpearman's rank correlation and linear regression analyses were performed using R isolates.", [["Software", "TEST", 78, 86], ["Statistical analysisSpearman's rank correlation", "TEST", 91, 138], ["linear regression analyses", "TEST", 143, 169], ["R isolates", "TREATMENT", 191, 201]]], ["The RCDI was calculated using a python script (available upon request). tAI was calculated using stAIcalc (Sabi et al., 2017) .", [["RCDI", "DNA", 4, 8]]], ["The cluster analysis (Heat map) was performed using CIMminer (https://discover.nci.nih.gov/cimminer/) based on the RSCU values obtained from the tested isolates.", [["The cluster analysis", "TEST", 0, 20], ["Heat map", "TEST", 22, 30], ["CIMminer", "TEST", 52, 60], ["the RSCU values", "TEST", 111, 126]]], ["Multiple sequence alignments for the whole genome of the 13 SARS-CoV-2 was done with MAFFT software (v7.450) and the phylogenetic analysis was performed with MEGA-X software (v10.1).Nucleotide and Dinucleotide Composition AnalysisThe analysis of nucleotide content of the coding sequences (CDSs) in all tested SARS-CoV-2Nucleotide and Dinucleotide Composition Analysisisolates showed A and U nucleotides richness, in comparison to G and C nucleotides, as well as, AU bias in all codon positions (Supplementary file 2, and Figure 1 ).", [["nucleotide", "CHEMICAL", 246, 256], ["Nucleotide", "CHEMICAL", 182, 192], ["nucleotide", "CHEMICAL", 246, 256], ["nucleotides", "CHEMICAL", 392, 403], ["nucleotides", "CHEMICAL", 439, 450], ["13 SARS-CoV-2", "DNA", 57, 70], ["coding sequences", "DNA", 272, 288], ["CDSs", "DNA", 290, 294], ["SARS-CoV-2Nucleotide and Dinucleotide Composition Analysisisolates", "DNA", 310, 376], ["codon positions", "DNA", 479, 494], ["SARS-CoV", "SPECIES", 310, 318], ["Multiple sequence alignments", "TEST", 0, 28], ["MAFFT software", "TEST", 85, 99], ["the phylogenetic analysis", "TEST", 113, 138], ["MEGA", "TEST", 158, 162], ["v", "TEST", 175, 176], ["Nucleotide", "TREATMENT", 182, 192], ["Dinucleotide Composition Analysis", "TEST", 197, 230], ["The analysis", "TEST", 230, 242], ["nucleotide content", "TEST", 246, 264], ["the coding sequences", "TEST", 268, 288], ["CDSs)", "TEST", 290, 295], ["all tested SARS", "TEST", 299, 314], ["CoV", "TEST", 315, 318], ["2Nucleotide", "TREATMENT", 319, 330], ["Dinucleotide Composition Analysisisolates", "TEST", 335, 376], ["A and U nucleotides richness", "PROBLEM", 384, 412], ["G and C nucleotides", "TREATMENT", 431, 450]]], ["The average usage (%) of U was the highest (33.24 \u00b1 4.75%) among the four nucleotides; A (28.91 \u00b1 3.74%)Nucleotide and Dinucleotide Composition Analysisshowed the highest usage after U, followed by C (19.50 \u00b1 2.88%), while G showed the lowest usage (18.32 \u00b1 2.22%).", [["nucleotides", "CHEMICAL", 74, 85], ["U", "TEST", 25, 26], ["Nucleotide", "TREATMENT", 104, 114], ["Dinucleotide Composition", "TEST", 119, 143], ["C", "TEST", 198, 199]]], ["A similar trend of nucleotides content at the third positions of synonymous codons was observed (U3% > A3% > C3% > G3%); where U3% (40.07 \u00b1 4.51%) and A3% (27.68 \u00b1 3.83%) were higher than C3% (18.37 \u00b1 3.92%) and G3% (13.86 \u00b1 2.47%).", [["nucleotides", "CHEMICAL", 19, 30], ["nucleotides", "CHEMICAL", 19, 30], ["A similar trend of nucleotides content", "PROBLEM", 0, 38], ["synonymous codons", "TEST", 65, 82], ["U3", "TEST", 97, 99], ["C3", "TEST", 109, 111], ["U3", "TEST", 127, 129], ["A3", "TEST", 151, 153], ["C3", "TEST", 188, 190], ["G3", "TEST", 212, 214], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["trend", "OBSERVATION_MODIFIER", 10, 15], ["nucleotides content", "OBSERVATION", 19, 38], ["synonymous codons", "OBSERVATION", 65, 82]]], ["The mean AU and GC values were 62.16 \u00b1 4.78% and 37.83 \u00b1 4.78%, and the mean AU3% and GC3% values were 67.79 \u00b1 5.01% and 32.20 \u00b1 5.014%, respectively.Nucleotide and Dinucleotide Composition AnalysisSynonymous Dinucleotide Usage (SDU) was employed to reveal underrepresented and overrepresented dinucleotides in the second and third codon positions (frame 2).", [["Nucleotide", "CHEMICAL", 150, 160], ["dinucleotides", "CHEMICAL", 294, 307], ["second and third codon positions", "DNA", 315, 347], ["The mean AU", "TEST", 0, 11], ["GC values", "TEST", 16, 25], ["the mean AU3", "TEST", 68, 80], ["GC3", "TEST", 86, 89], ["Nucleotide", "TREATMENT", 150, 160], ["Dinucleotide Composition AnalysisSynonymous Dinucleotide Usage (SDU)", "TREATMENT", 165, 233]]], ["The average SDU values for each dinucleotide in all examined isolates were reported by a bar plot ( Figure 2 ).", [["dinucleotide", "CHEMICAL", 32, 44], ["dinucleotide", "CHEMICAL", 32, 44], ["SDU", "DNA", 12, 15], ["each dinucleotide", "TREATMENT", 27, 44]]], ["Seven dinucleotides exhibited overrepresentation (SDU > 1), in descending order (CpU, UpU, ApA, GpU, CpA, UpA, and ApU).", [["dinucleotides", "CHEMICAL", 6, 19], ["CpU", "GENE_OR_GENE_PRODUCT", 81, 84], ["UpU", "GENE_OR_GENE_PRODUCT", 86, 89], ["ApA", "GENE_OR_GENE_PRODUCT", 91, 94], ["GpU", "GENE_OR_GENE_PRODUCT", 96, 99], ["CpA", "GENE_OR_GENE_PRODUCT", 101, 104], ["UpA", "GENE_OR_GENE_PRODUCT", 106, 109], ["ApU", "GENE_OR_GENE_PRODUCT", 115, 118], ["CpU", "DNA", 81, 84], ["UpU", "DNA", 86, 89], ["ApA", "DNA", 91, 94], ["GpU", "DNA", 96, 99], ["CpA", "DNA", 101, 104], ["UpA", "DNA", 106, 109], ["ApU", "DNA", 115, 118], ["Seven dinucleotides", "PROBLEM", 0, 19], ["SDU", "TEST", 50, 53], ["descending", "ANATOMY", 63, 73]]], ["All these dinucleotides are A/U-ended (A-ended: 3, U-ended: 4) reflecting the A/U-bias of SARS-CoV-2 genomes at the third codon positions.Nucleotide and Dinucleotide Composition AnalysisOn the other hand, nine dinucleotides showed underrepresentation (SDU < 1), in ascending order (CpC, GpG, ApG, CpG, UpG, GpC, UpC, ApC, and GpA).", [["SARS", "DISEASE", 90, 94], ["Nucleotide", "CHEMICAL", 138, 148], ["dinucleotides", "CHEMICAL", 10, 23], ["Nucleotide", "CHEMICAL", 138, 148], ["dinucleotides", "CHEMICAL", 210, 223], ["CpG", "CHEMICAL", 297, 300], ["U", "GENE_OR_GENE_PRODUCT", 80, 81], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["ApG", "GENE_OR_GENE_PRODUCT", 292, 295], ["UpG", "GENE_OR_GENE_PRODUCT", 302, 305], ["GpC", "GENE_OR_GENE_PRODUCT", 307, 310], ["UpC", "GENE_OR_GENE_PRODUCT", 312, 315], ["ApC", "GENE_OR_GENE_PRODUCT", 317, 320], ["GpA", "GENE_OR_GENE_PRODUCT", 326, 329], ["SARS-CoV-2 genomes", "DNA", 90, 108], ["third codon positions", "DNA", 116, 137], ["CpC", "DNA", 282, 285], ["GpG", "DNA", 287, 290], ["ApG", "DNA", 292, 295], ["CpG", "DNA", 297, 300], ["UpG", "DNA", 302, 305], ["GpC", "DNA", 307, 310], ["UpC", "DNA", 312, 315], ["ApC", "DNA", 317, 320], ["GpA", "DNA", 326, 329], ["A/U", "TEST", 28, 31], ["the A/U", "TEST", 74, 81], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["Nucleotide", "TREATMENT", 138, 148], ["Dinucleotide Composition AnalysisOn", "TEST", 153, 188], ["CpC", "TEST", 282, 285], ["GpG", "TEST", 287, 290], ["ApG", "TEST", 292, 295], ["CpG", "TEST", 297, 300], ["UpG", "TEST", 302, 305], ["GpC", "TEST", 307, 310], ["UpC", "TEST", 312, 315], ["ApC", "TEST", 317, 320], ["dinucleotides", "OBSERVATION", 10, 23], ["ascending", "ANATOMY", 265, 274]]], ["Eight out of the nine underrepresented dinucleotides were G/C-ended (G-ended: 4, C-ended: 4).Relative Synonymous Codon Usage (RSCU) and Cluster (Heat map) analysesIn According to the cluster analysis, the following isolates showed similar synonymous codon usage patterns: (i) India and Spain, (ii) China, Pakistan, Vietnam, Nepal, and Taiwan, (iii)Relative Synonymous Codon Usage (RSCU) and Cluster (Heat map) analysesAustralia, Sweden, Brazil, and Italy.", [["dinucleotides", "CHEMICAL", 39, 52], ["dinucleotides", "TEST", 39, 52], ["G/C", "TEST", 58, 61], ["Relative Synonymous Codon Usage", "TREATMENT", 93, 124], ["Cluster (Heat map)", "TREATMENT", 136, 154], ["the cluster analysis", "TEST", 179, 199], ["Synonymous Codon Usage", "TREATMENT", 357, 379], ["Cluster (Heat map", "TREATMENT", 391, 408], ["Synonymous Codon", "OBSERVATION", 102, 118], ["synonymous codon", "OBSERVATION", 239, 255], ["Synonymous Codon", "OBSERVATION", 357, 373]]], ["Meanwhile, both, South Korea and USA isolates grouped themselves from the remaining ones reflecting their unique synonymous codon usage patterns.", [["USA isolates", "TEST", 33, 45], ["synonymous codon", "OBSERVATION", 113, 129]]], ["Interestingly, cluster analysis results were comparable with the phylogenetic analysis suggesting that patterns of synonymous codon usage were able to reflect the evolutionary relationships between tested isolates ( Figure S1 ).Effective number of codons (ENc) and ENc-GC3 plotIn theory, ENc correlates negatively with CUB.", [["CUB", "CHEMICAL", 319, 322], ["ENc-GC3", "GENE_OR_GENE_PRODUCT", 265, 272], ["CUB", "GENE_OR_GENE_PRODUCT", 319, 322], ["ENc", "DNA", 256, 259], ["ENc", "DNA", 265, 268], ["GC3", "DNA", 269, 272], ["ENc", "DNA", 288, 291], ["CUB", "PROTEIN", 319, 322], ["cluster analysis", "TEST", 15, 31], ["the phylogenetic analysis", "TEST", 61, 86], ["synonymous codon usage", "PROBLEM", 115, 137], ["codons (ENc)", "TREATMENT", 248, 260], ["ENc", "TEST", 265, 268], ["synonymous codon", "OBSERVATION", 115, 131]]], ["To better understand the relations between SARS-CoV-2 genes composition and codon usage bias, an ENc-GC3 plot was drawn.", [["SARS", "DISEASE", 43, 47], ["CoV-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["SARS-CoV-2 genes", "DNA", 43, 59], ["ENc", "DNA", 97, 100], ["GC3 plot", "DNA", 101, 109], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["codon usage bias", "TEST", 76, 92], ["an ENc-GC3 plot", "TEST", 94, 109]]], ["If the codon usage pattern is only affected by GC3 resulting from mutation pressure, the data points should be just on or near the expected curve drawn by equation (5) and shown in (Figure 4 ).", [["GC3", "DNA", 47, 50], ["the codon usage pattern", "PROBLEM", 3, 26], ["mutation pressure", "TEST", 66, 83]]], ["The results indicated that codon usage bias tended to be stronger when GC contents were lower, and vice versa.", [["codon usage bias", "PROBLEM", 27, 43], ["GC contents", "TEST", 71, 82]]], ["Therefore, U will be preferred over A and likewise C will be preferred over G, in other words, pyrimidines are preferred over purines in SARS-CoV-2.Neutrality analysisENc-GC3 plot and parity analyses reflected the main factors influencing the codon usage bias of SARS-CoV-2, but they did not estimate precisely which of mutation pressure or natural selection was more important.", [["pyrimidines", "CHEMICAL", 95, 106], ["purines", "CHEMICAL", 126, 133], ["SARS", "DISEASE", 263, 267], ["pyrimidines", "CHEMICAL", 95, 106], ["purines", "CHEMICAL", 126, 133], ["U", "GENE_OR_GENE_PRODUCT", 11, 12], ["pyrimidines", "SIMPLE_CHEMICAL", 95, 106], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 137, 147], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 263, 273], ["SARS-CoV", "SPECIES", 137, 145], ["SARS-CoV", "SPECIES", 263, 271], ["pyrimidines", "TREATMENT", 95, 106], ["Neutrality analysisENc-GC3 plot", "TEST", 148, 179], ["parity analyses", "TEST", 184, 199], ["CoV", "TEST", 268, 271], ["mutation pressure", "PROBLEM", 320, 337], ["main", "OBSERVATION_MODIFIER", 214, 218]]], ["Then a neutrality plot was constructed based on the average GC3 and GC12 contents of SARS-CoV-2 genes ( Figure 6 ).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["GC3", "DNA", 60, 63], ["GC12", "DNA", 68, 72], ["SARS-CoV-2 genes", "DNA", 85, 101], ["SARS-CoV", "SPECIES", 85, 93], ["a neutrality plot", "TEST", 5, 22], ["the average GC3", "TEST", 48, 63], ["SARS", "PROBLEM", 85, 89]]], ["The plot revealed a narrow distribution range (0.262-0.39) of GC3 contents, while GC12 contents were relatively wide (0.274-0.518).", [["GC3", "SIMPLE_CHEMICAL", 62, 65], ["GC12", "SIMPLE_CHEMICAL", 82, 86], ["The plot", "TEST", 0, 8], ["GC12 contents", "TEST", 82, 95], ["narrow", "OBSERVATION_MODIFIER", 20, 26], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["relatively", "OBSERVATION_MODIFIER", 101, 111], ["wide", "OBSERVATION_MODIFIER", 112, 116]]], ["The correlation between GC1 and GC2 was strong (r = 0.76, P =.016), meanwhile, neither GC1 nor GC2 showed significant correlation with GC3 (r = 0.14, P =.69), reflecting that codon usage is affected by mutation pressure to a very limited degree.", [["GC1", "GENE_OR_GENE_PRODUCT", 24, 27], ["GC2", "GENE_OR_GENE_PRODUCT", 32, 35], ["GC1", "GENE_OR_GENE_PRODUCT", 87, 90], ["GC2", "GENE_OR_GENE_PRODUCT", 95, 98], ["GC1", "DNA", 24, 27], ["GC1", "PROTEIN", 87, 90], ["GC2", "PROTEIN", 95, 98], ["GC3", "DNA", 135, 138], ["GC1", "TEST", 24, 27], ["GC2", "TEST", 32, 35], ["P", "TEST", 58, 59], ["GC3", "TEST", 135, 138], ["P", "TEST", 150, 151], ["mutation pressure", "TEST", 202, 219], ["codon usage", "OBSERVATION", 175, 186]]], ["In addition, the slope of the regression line revealed that mutation pressure only accounted for 18.4% of SARS-CoV-2 codon usage, while natural selection together with some other factors accounted for the remaining 81.6%.Codon Adaptation Index (CAI)To determine the degree of adaptation of SARS-CoV-2 codon usage to Homo sapiens, the CAI values for the complete coding region and individual genes of each isolate was calculated using the most expressed genes in human lung tissues (the reservoir of viral host cells) as a reference set.", [["lung tissues", "ANATOMY", 468, 480], ["cells", "ANATOMY", 510, 515], ["SARS", "DISEASE", 106, 110], ["SARS", "DISEASE", 290, 294], ["Homo sapiens", "ORGANISM", 316, 328], ["human", "ORGANISM", 462, 467], ["lung tissues", "TISSUE", 468, 480], ["viral host cells", "CELL", 499, 515], ["SARS-CoV-2 codon", "DNA", 290, 306], ["CAI", "DNA", 334, 337], ["viral host cells", "CELL_TYPE", 499, 515], ["Homo sapiens", "SPECIES", 316, 328], ["human", "SPECIES", 462, 467], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 290, 298], ["Homo sapiens", "SPECIES", 316, 328], ["human", "SPECIES", 462, 467], ["the regression line", "TEST", 26, 45], ["mutation pressure", "TEST", 60, 77], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["natural selection", "TREATMENT", 136, 153], ["Codon Adaptation Index (CAI)", "TREATMENT", 221, 249], ["SARS", "PROBLEM", 290, 294], ["CoV-2 codon usage", "TREATMENT", 295, 312], ["the CAI values", "TEST", 330, 344], ["the complete coding region", "PROBLEM", 349, 375], ["viral host cells", "TREATMENT", 499, 515], ["pressure", "OBSERVATION_MODIFIER", 69, 77], ["lung tissues", "ANATOMY", 468, 480]]], ["The average CAI value for the complete coding region was 0.54 \u00b1 0.0003 (Supplementary file 4) .", [["CAI", "DNA", 12, 15], ["The average CAI value", "TEST", 0, 21]]], ["In addition, the CAI values of different genes ranged from 0.48 to 0.62 (Figure 7 , and Supplementary file 2).", [["CAI", "DNA", 17, 20], ["the CAI values", "TEST", 13, 27]]], ["The N, ORF7a, and S genes had the highest average CAI values (0.62 \u00b1 0.0008, 0.58 \u00b1 0.0000, 0.56 \u00b1 0.0002, respectively) among other genes, while the E gene had the lowest CAI value (0.48 \u00b1 0.001).Relative Codon Deoptimization Index (RCDI)The relative codon deoptimization index (RCDI) was measured by comparing the codon usage of SARS-CoV-2 to Homo sapiens.tRNA Adaptation Index (tAI)In order to assess the influence of translational selection on SARS-CoV-2 codon usage bias,A/U Richness of the SARS-CoV-2 GenomeThe nucleotide compositions in the genes of SARS-CoV-2 were analyzed and correlated with the RSCU patterns.", [["SARS", "DISEASE", 496, 500], ["nucleotide", "CHEMICAL", 517, 527], ["nucleotide", "CHEMICAL", 517, 527], ["ORF7a", "GENE_OR_GENE_PRODUCT", 7, 12], ["E", "GENE_OR_GENE_PRODUCT", 150, 151], ["SARS-CoV-2", "ORGANISM", 331, 341], ["Homo sapiens", "ORGANISM", 345, 357], ["SARS-CoV-2", "ORGANISM", 557, 567], ["N, ORF7a, and S genes", "DNA", 4, 25], ["CAI", "DNA", 50, 53], ["E gene", "DNA", 150, 156], ["SARS-CoV-2 codon", "DNA", 448, 464], ["SARS-CoV-2 Genome", "DNA", 496, 513], ["SARS-CoV-2", "DNA", 557, 567], ["Homo sapiens", "SPECIES", 345, 357], ["SARS-CoV", "SPECIES", 331, 339], ["Homo sapiens", "SPECIES", 345, 357], ["SARS-CoV", "SPECIES", 448, 456], ["SARS-CoV", "SPECIES", 496, 504], ["SARS-CoV", "SPECIES", 557, 565], ["The N, ORF7a", "TEST", 0, 12], ["Relative Codon Deoptimization Index", "TEST", 197, 232], ["The relative codon deoptimization index", "TEST", 239, 278], ["SARS", "PROBLEM", 331, 335], ["tRNA Adaptation Index", "TEST", 358, 379], ["translational selection", "TREATMENT", 421, 444], ["SARS", "TEST", 448, 452], ["CoV", "TEST", 453, 456], ["the SARS", "PROBLEM", 492, 500], ["CoV", "TEST", 501, 504], ["The nucleotide compositions", "TREATMENT", 513, 540], ["SARS-CoV", "TEST", 557, 565]]], ["The SARS-CoV-2 genome is found to be rich in AU as compared to GC overall content, as well as, in all codon positions.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["SARS-CoV-2 genome", "DNA", 4, 21], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8]]], ["In addition, all overrepresented codons were A/U-ended, whereas overwhelming majorities of underrepresented codons were G/Cended.Compositional Constraints Versus Natural SelectionDuring the course of evolution, many vertebrate RNA viruses tended to exhibit reduced frequencies of CpG-containing codons, such observation can be explained by a host specific selection pressure acting against CpG dinucleotides driven by their innate immune response (Belalov and Lukashev, 2013) .", [["CpG", "CHEMICAL", 280, 283], ["CpG dinucleotides", "CHEMICAL", 390, 407], ["CpG dinucleotides", "DNA", 390, 407], ["A/U", "TEST", 45, 48], ["Compositional Constraints", "PROBLEM", 129, 154], ["many vertebrate RNA viruses", "PROBLEM", 211, 238], ["reduced frequencies of CpG", "PROBLEM", 257, 283], ["codons", "TREATMENT", 295, 301], ["a host specific selection pressure", "TREATMENT", 340, 374], ["CpG dinucleotides", "TREATMENT", 390, 407], ["RNA viruses", "OBSERVATION", 227, 238]]], ["In this study, CpG dinucleotide was among the most four underrepresented dinucleotides in frame 2 (second and third codon positions) of SARS-CoV-genes (ORF6, ORF7a, and ORF8), indicating that mutation pressure may be a factor in the formation of SARS-CoV-2 codon usage bias, but other independent factors such as natural selection strongly affected the codon usage bias pattern reflecting their importance over the mutation pressure.", [["dinucleotide", "CHEMICAL", 19, 31], ["SARS", "DISEASE", 246, 250], ["CpG", "CHEMICAL", 15, 18], ["dinucleotides", "CHEMICAL", 73, 86], ["CpG dinucleotide", "SIMPLE_CHEMICAL", 15, 31], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 136, 144], ["ORF6", "GENE_OR_GENE_PRODUCT", 152, 156], ["ORF7a", "GENE_OR_GENE_PRODUCT", 158, 163], ["ORF8", "GENE_OR_GENE_PRODUCT", 169, 173], ["frame 2", "DNA", 90, 97], ["second and third codon positions", "DNA", 99, 131], ["SARS-CoV-genes", "DNA", 136, 150], ["ORF6", "DNA", 152, 156], ["ORF7a", "DNA", 158, 163], ["ORF8", "DNA", 169, 173], ["this study", "TEST", 3, 13], ["CpG dinucleotide", "PROBLEM", 15, 31], ["SARS", "PROBLEM", 136, 140], ["mutation pressure", "PROBLEM", 192, 209], ["SARS", "PROBLEM", 246, 250], ["CoV", "TEST", 251, 254], ["the mutation pressure", "TEST", 411, 432]]], ["Then, a PR2 bias plot was generated to confirm that the pattern of codon usage is not only affected by mutation pressure.", [["PR2", "DNA", 8, 11], ["a PR2 bias plot", "TEST", 6, 21], ["codon usage", "TREATMENT", 67, 78], ["mutation pressure", "TEST", 103, 120], ["codon usage", "OBSERVATION", 67, 78]]], ["The results showed a clear bias in the third codon position of four-codon amino acids in SARS-CoV-2 genes.", [["amino acids", "CHEMICAL", 74, 85], ["amino acids", "CHEMICAL", 74, 85], ["amino acids", "AMINO_ACID", 74, 85], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["SARS-CoV-2 genes", "DNA", 89, 105], ["codon amino acids", "TEST", 68, 85], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97], ["clear bias", "OBSERVATION", 21, 31]]], ["This observation also indicated that natural selection pressure might play a major role in SARS-CoV-2 codon usage bias, and mutation pressure would be a minor factor.", [["SARS-CoV", "SPECIES", 91, 99], ["natural selection pressure", "TREATMENT", 37, 63], ["SARS", "TEST", 91, 95], ["CoV", "TEST", 96, 99], ["mutation pressure", "TEST", 124, 141], ["a minor factor", "PROBLEM", 151, 165]]], ["In order to accurately estimate the effect of mutation pressure and natural selection on the CUB, a neutrality plot was drawn.", [["CUB", "PROTEIN", 93, 96], ["mutation pressure", "TREATMENT", 46, 63], ["a neutrality plot", "TEST", 98, 115]]], ["When the CUB is only affected by mutation pressure, the quantitative relation between GC3 and GC12Compositional Constraints Versus Natural Selectionshould be nearly equal, and the slope would be 1.", [["CUB", "CHEMICAL", 9, 12], ["CUB", "GENE_OR_GENE_PRODUCT", 9, 12], ["CUB", "DNA", 9, 12], ["GC3", "DNA", 86, 89], ["mutation pressure", "TEST", 33, 50], ["the quantitative relation between GC3 and GC12Compositional Constraints", "PROBLEM", 52, 123]]], ["In this study, GC1 and GC2 showed no significant correlation with GC3 and the slope of regression line revealed that mutation pressure only accounted for 18.4% of SARS-CoV-2 codon usage, while natural selection together with some other factors accounted for the remaining 81.6%.", [["SARS", "DISEASE", 163, 167], ["GC1", "GENE_OR_GENE_PRODUCT", 15, 18], ["GC2", "GENE_OR_GENE_PRODUCT", 23, 26], ["GC1", "DNA", 15, 18], ["GC2", "DNA", 23, 26], ["GC3", "DNA", 66, 69], ["SARS-CoV", "SPECIES", 163, 171], ["this study", "TEST", 3, 13], ["GC1", "TEST", 15, 18], ["GC3", "TEST", 66, 69], ["mutation pressure", "TEST", 117, 134], ["SARS", "TEST", 163, 167], ["CoV", "TEST", 168, 171], ["natural selection", "TREATMENT", 193, 210], ["pressure", "OBSERVATION_MODIFIER", 126, 134]]], ["Accordingly, natural selection played a very important or even a dominant role in the formation of SARS-CoV-2 codon usage.", [["SARS", "DISEASE", 99, 103], ["SARS-CoV-2 codon", "DNA", 99, 115], ["SARS-CoV", "SPECIES", 99, 107], ["natural selection", "TREATMENT", 13, 30], ["SARS", "PROBLEM", 99, 103]]], ["Furthermore, to determine whether codon choices were influenced by hydropathicity, a correlation analysis was performed between ENc, GRAVY, and AROMO (Table 1) .", [["ENc", "PROTEIN", 128, 131], ["codon choices", "PROBLEM", 34, 47], ["a correlation analysis", "TEST", 83, 105]]], ["The results showed no correlation between codon usage and aromaticity; however, a significant positive correlation was found between codon usage and hydrophobicity of SARS-CoV-2 coding sequences reflecting its effect on CUB.", [["SARS", "DISEASE", 167, 171], ["CUB", "CHEMICAL", 220, 223], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 167, 177], ["CUB", "GENE_OR_GENE_PRODUCT", 220, 223], ["SARS-CoV-2 coding sequences", "DNA", 167, 194], ["CUB", "PROTEIN", 220, 223], ["SARS-CoV", "SPECIES", 167, 175], ["a significant positive correlation", "PROBLEM", 80, 114], ["hydrophobicity of SARS", "PROBLEM", 149, 171], ["CoV", "TEST", 172, 175]]], ["The link between hydropathy and codon usage may be caused by the fact that the expressed sequences are hydrophilic just because they accomplish their function in the aqueous media of the cell (Zhong et al., 2007) .Compositional Constraints Versus Natural SelectionFurthermore, a correlation analysis was performed between the average tAI and ENc values of SARS-CoV-2 genes.", [["cell", "ANATOMY", 187, 191], ["cell", "CELL", 187, 191], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 356, 366], ["SARS-CoV-2 genes", "DNA", 356, 372], ["SARS-CoV", "SPECIES", 356, 364], ["hydropathy", "PROBLEM", 17, 27], ["codon usage", "TREATMENT", 32, 43], ["a correlation analysis", "TEST", 277, 299], ["ENc values", "TEST", 342, 352], ["SARS", "TEST", 356, 360], ["hydropathy", "OBSERVATION", 17, 27], ["codon usage", "OBSERVATION", 32, 43], ["cell", "ANATOMY", 187, 191]]], ["The analysis revealed a positive significant correlation (r = 0.66, P =.04) (Table 1) , which implies that translational selection significantly influenced the pattern of codon usage in SARS-CoV-2.", [["SARS", "DISEASE", 186, 190], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 186, 196], ["SARS-CoV", "SPECIES", 186, 194], ["The analysis", "TEST", 0, 12], ["P", "TEST", 68, 69], ["translational selection", "PROBLEM", 107, 130], ["codon usage", "PROBLEM", 171, 182], ["CoV", "TEST", 191, 194], ["codon usage", "OBSERVATION", 171, 182]]], ["These results combined confirm the dominance of natural selection over mutation pressure in shaping the CUB of SARS-CoV-2.Moderate Adaptation of SARS-CoV-2 to Homo sapiensIn order to determine to what extent SARS-CoV-2 is adapted to Homo sapiens, two adaptation indices were used (CAI and RCDI).", [["SARS", "DISEASE", 111, 115], ["SARS", "DISEASE", 145, 149], ["SARS", "DISEASE", 208, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["Homo sapiens", "ORGANISM", 159, 171], ["SARS-CoV-2", "ORGANISM", 208, 218], ["Homo sapiens", "ORGANISM", 233, 245], ["CUB", "PROTEIN", 104, 107], ["Homo sapiens", "SPECIES", 159, 171], ["Homo sapiens", "SPECIES", 233, 245], ["SARS-CoV", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 145, 153], ["Homo sapiens", "SPECIES", 159, 171], ["SARS-CoV", "SPECIES", 208, 216], ["Homo sapiens", "SPECIES", 233, 245], ["mutation pressure", "TEST", 71, 88], ["CoV", "TEST", 116, 119], ["Moderate Adaptation of SARS", "PROBLEM", 122, 149], ["CAI and RCDI", "TREATMENT", 281, 293], ["natural selection", "OBSERVATION", 48, 65], ["CUB", "OBSERVATION_MODIFIER", 104, 107]]], ["The codon adaptation index (CAI) is an indicator of gene expression, and is normally used to design nucleotide sequences suitable for maximal protein production (Gustafsson et al., 2012) .", [["nucleotide", "CHEMICAL", 100, 110], ["nucleotide", "CHEMICAL", 100, 110], ["nucleotide sequences", "DNA", 100, 120], ["The codon adaptation index", "TEST", 0, 26], ["nucleotide sequences", "TEST", 100, 120], ["maximal protein production", "PROBLEM", 134, 160], ["index", "OBSERVATION_MODIFIER", 21, 26], ["gene expression", "OBSERVATION", 52, 67]]], ["The higher the CAI value the higher the gene expression, and vice versa.", [["CAI", "DNA", 15, 18], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["The 13 SARS-CoV-2 isolates used in the analysis showed an overall average CAI value of 0.54 \u00b1 0.0003 for the complete coding region, which is comparatively slightly lower than the CAI values of viruses from other studies in relation to Homo sapiens, indicating moderate SARS-CoV-2 adaptation to Homo sapiens (Butt et al., 2016; Khandia et al., 2019; Kumar et al., 2018) .", [["SARS-CoV-2", "ORGANISM", 7, 17], ["Homo sapiens", "ORGANISM", 236, 248], ["CoV-2", "ORGANISM", 275, 280], ["Homo sapiens", "ORGANISM", 295, 307], ["Homo sapiens", "SPECIES", 236, 248], ["Homo sapiens", "SPECIES", 295, 307], ["Homo sapiens", "SPECIES", 236, 248], ["Homo sapiens", "SPECIES", 295, 307], ["The 13 SARS", "TEST", 0, 11], ["the analysis", "TEST", 35, 47], ["viruses", "PROBLEM", 194, 201], ["other studies", "TEST", 207, 220], ["Homo sapiens", "TEST", 236, 248], ["moderate SARS", "PROBLEM", 261, 274], ["slightly", "OBSERVATION_MODIFIER", 156, 164], ["lower", "OBSERVATION_MODIFIER", 165, 170], ["viruses", "OBSERVATION", 194, 201], ["Homo sapiens", "OBSERVATION", 236, 248], ["moderate", "OBSERVATION_MODIFIER", 261, 269], ["SARS", "OBSERVATION", 270, 274]]], ["However, at the individual genes level, different CAI values have been observed.", [["CAI", "DNA", 50, 53], ["different CAI values", "TEST", 40, 60]]], ["The highest CAI value was recorded for the N gene encoding for the nucleocapsid protein (0.62 \u00b1 0.0008) which plays a fundamental role during viral self-assembly (Nelson et al., 2005) .", [["CAI", "DNA", 12, 15], ["N gene", "DNA", 43, 49], ["nucleocapsid protein", "PROTEIN", 67, 87], ["The highest CAI value", "TEST", 0, 21], ["the nucleocapsid protein", "TEST", 63, 87]]], ["ORF7a encoding for the 7a accessory protein recorded the second highest CAI value of 0.58 \u00b1 0.0000, which may play a role in viral assembly or budding events unique to SARS-CoV (Chang et al., 2014) .", [["SARS", "DISEASE", 168, 172], ["ORF7a", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "ORGANISM", 168, 176], ["ORF7a", "PROTEIN", 0, 5], ["7a accessory protein", "PROTEIN", 23, 43], ["SARS-CoV", "SPECIES", 168, 176], ["the 7a accessory protein", "TEST", 19, 43]]], ["Interestingly, only a small amounts of the envelope protein encoded by the E gene is sufficient to trigger the formation of virus-like particles (Nelson et al., 2005) , which may explain its lowest CAIConclusionIn summary, the findings of this study revealed that the codon usage of SARS-CoV-2 is slightly biased similar to most studied RNA viruses, and the influence of natural selection is more profound than that of mutation pressure in shaping the codon usage pattern of SARS-CoV-2.", [["SARS", "DISEASE", 283, 287], ["SARS", "DISEASE", 475, 479], ["E", "GENE_OR_GENE_PRODUCT", 75, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 475, 485], ["envelope protein", "PROTEIN", 43, 59], ["E gene", "DNA", 75, 81], ["SARS-CoV-2", "DNA", 283, 293], ["SARS-CoV", "SPECIES", 283, 291], ["SARS-CoV", "SPECIES", 475, 483], ["the envelope protein", "PROBLEM", 39, 59], ["virus", "PROBLEM", 124, 129], ["this study", "TEST", 239, 249], ["SARS", "PROBLEM", 283, 287], ["slightly biased", "PROBLEM", 297, 312], ["RNA viruses", "PROBLEM", 337, 348], ["mutation pressure", "PROBLEM", 419, 436], ["CoV", "TEST", 480, 483], ["small", "OBSERVATION_MODIFIER", 22, 27], ["amounts", "OBSERVATION_MODIFIER", 28, 35], ["virus", "OBSERVATION", 124, 129], ["viruses", "OBSERVATION", 341, 348], ["more profound", "OBSERVATION_MODIFIER", 392, 405]]], ["Other factors including compositional constraints and hydrophobicity also affected SARS-CoV-2 CUB.", [["CUB", "CHEMICAL", 94, 97], ["SARS-CoV-2 CUB", "PROTEIN", 83, 97], ["Other factors", "PROBLEM", 0, 13], ["compositional constraints", "PROBLEM", 24, 49], ["hydrophobicity", "PROBLEM", 54, 68], ["affected SARS", "PROBLEM", 74, 87], ["compositional constraints", "OBSERVATION", 24, 49], ["hydrophobicity", "OBSERVATION_MODIFIER", 54, 68]]], ["Overall, the 13 SARS-CoV-2 isolates used in the analysis showed almost identical patterns of codon usage reflecting the small evolutionary changes between them.", [["SARS-CoV-2", "ORGANISM", 16, 26], ["the analysis", "TEST", 44, 56], ["codon usage", "PROBLEM", 93, 104], ["the small evolutionary changes", "PROBLEM", 116, 146], ["codon usage", "OBSERVATION", 93, 104], ["small", "OBSERVATION_MODIFIER", 120, 125], ["evolutionary changes", "OBSERVATION", 126, 146]]], ["The findings of this study may help in understanding the underlying factors involved in SARS-CoV-2 evolution, adaptation, and fitness toward Homo sapiens.23-29.Wu, Y., Zhao, D., Tao (iv). the frequency of each nucleotide at the third codon position (A3%, U3%, G3%, C3%)", [["SARS", "DISEASE", 88, 92], ["nucleotide", "CHEMICAL", 210, 220], ["nucleotide", "CHEMICAL", 210, 220], ["CoV-2", "ORGANISM", 93, 98], ["Homo sapiens", "ORGANISM", 141, 153], ["third codon position", "DNA", 228, 248], ["Homo sapiens", "SPECIES", 141, 153], ["Homo sapiens", "SPECIES", 141, 153], ["this study", "TEST", 16, 26], ["the underlying factors", "PROBLEM", 53, 75], ["SARS", "PROBLEM", 88, 92], ["U3", "TEST", 255, 257]]]], "PMC7217124": [["Case ReportOn March 11, an active 44-year-old male with known COVID-19 contacts and a family member with a viral prodrome presented with a 3-day history of shortness of breath and fever.", [["viral prodrome", "DISEASE", 107, 121], ["shortness of breath", "DISEASE", 156, 175], ["fever", "DISEASE", 180, 185], ["a viral prodrome", "PROBLEM", 105, 121], ["shortness of breath", "PROBLEM", 156, 175], ["fever", "PROBLEM", 180, 185], ["active", "OBSERVATION_MODIFIER", 27, 33], ["viral prodrome", "OBSERVATION", 107, 121], ["fever", "OBSERVATION", 180, 185]]], ["Pertinent medical history included hypertension (on lisinopril) and hyperlipidemia (on atorvastatin).", [["hypertension", "DISEASE", 35, 47], ["lisinopril", "CHEMICAL", 52, 62], ["hyperlipidemia", "DISEASE", 68, 82], ["atorvastatin", "CHEMICAL", 87, 99], ["lisinopril", "CHEMICAL", 52, 62], ["atorvastatin", "CHEMICAL", 87, 99], ["lisinopril", "SIMPLE_CHEMICAL", 52, 62], ["atorvastatin", "SIMPLE_CHEMICAL", 87, 99], ["hypertension", "PROBLEM", 35, 47], ["lisinopril", "TREATMENT", 52, 62], ["hyperlipidemia", "PROBLEM", 68, 82], ["atorvastatin", "TREATMENT", 87, 99], ["hypertension", "OBSERVATION", 35, 47], ["hyperlipidemia", "OBSERVATION", 68, 82]]], ["Pulse was 135 bpm, temperature 39.5\u00b0C, blood pressure 159/91 mm Hg, respiratory rate 20 breaths/minute, and oxygen saturation 95% on room air.", [["blood", "ANATOMY", 39, 44], ["respiratory", "ANATOMY", 68, 79], ["oxygen", "CHEMICAL", 108, 114], ["Hg", "CHEMICAL", 64, 66], ["oxygen", "CHEMICAL", 108, 114], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["Pulse", "TEST", 0, 5], ["temperature", "TEST", 19, 30], ["C", "TEST", 36, 37], ["blood pressure", "TEST", 39, 53], ["Hg", "TEST", 64, 66], ["respiratory rate", "TEST", 68, 84], ["breaths/minute", "TEST", 88, 102], ["oxygen saturation", "TEST", 108, 125]]], ["The examination was otherwise unremarkable.", [["The examination", "TEST", 0, 15], ["unremarkable", "OBSERVATION", 30, 42]]], ["Lab results were notable for lymphopenia (450 cells/\u00b5L).", [["cells", "ANATOMY", 46, 51], ["lymphopenia", "DISEASE", 29, 40], ["lymphopenia", "PROBLEM", 29, 40], ["cells", "TEST", 46, 51], ["lymphopenia", "OBSERVATION", 29, 40]]], ["Chest x-ray revealed a small right upper lobe infiltrate.", [["right upper lobe infiltrate", "ANATOMY", 29, 56], ["small right upper lobe infiltrate", "DISEASE", 23, 56], ["Chest x-ray", "TEST", 0, 11], ["a small right upper lobe infiltrate", "PROBLEM", 21, 56], ["small", "OBSERVATION_MODIFIER", 23, 28], ["right upper lobe", "ANATOMY", 29, 45], ["infiltrate", "OBSERVATION", 46, 56]]], ["A viral panel and PCR for SARS-CoV-2 were negative.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["SARS-CoV", "SPECIES", 26, 34], ["A viral panel", "TEST", 0, 13], ["PCR", "TEST", 18, 21], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34]]], ["He was discharged on azithromycin and cefuroxime for community-acquired pneumonia.Case ReportTwenty-four hours later, he returned with persistent fever and worsening dyspnea.", [["azithromycin", "CHEMICAL", 21, 33], ["cefuroxime", "CHEMICAL", 38, 48], ["pneumonia", "DISEASE", 72, 81], ["fever", "DISEASE", 146, 151], ["dyspnea", "DISEASE", 166, 173], ["azithromycin", "CHEMICAL", 21, 33], ["cefuroxime", "CHEMICAL", 38, 48], ["azithromycin", "SIMPLE_CHEMICAL", 21, 33], ["cefuroxime", "SIMPLE_CHEMICAL", 38, 48], ["azithromycin", "TREATMENT", 21, 33], ["cefuroxime", "TREATMENT", 38, 48], ["community-acquired pneumonia", "PROBLEM", 53, 81], ["persistent fever", "PROBLEM", 135, 151], ["worsening dyspnea", "PROBLEM", 156, 173], ["pneumonia", "OBSERVATION", 72, 81], ["persistent", "OBSERVATION_MODIFIER", 135, 145], ["fever", "OBSERVATION", 146, 151], ["worsening", "OBSERVATION_MODIFIER", 156, 165], ["dyspnea", "OBSERVATION", 166, 173]]], ["On examination, he remained tachycardic, febrile, and hypertensive with mildly increased work of breathing and diffuse rhonchi, but now oxygen saturation 96% on 3 L/min oxygen.", [["febrile", "DISEASE", 41, 48], ["hypertensive", "DISEASE", 54, 66], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 169, 175], ["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 169, 175], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["examination", "TEST", 3, 14], ["tachycardic", "PROBLEM", 28, 39], ["febrile", "PROBLEM", 41, 48], ["hypertensive", "PROBLEM", 54, 66], ["mildly increased work of breathing", "PROBLEM", 72, 106], ["diffuse rhonchi", "PROBLEM", 111, 126], ["oxygen saturation", "TEST", 136, 153], ["oxygen", "TREATMENT", 169, 175], ["tachycardic", "OBSERVATION", 28, 39], ["febrile", "OBSERVATION", 41, 48], ["mildly", "OBSERVATION_MODIFIER", 72, 78], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["work of breathing", "OBSERVATION", 89, 106], ["diffuse", "OBSERVATION_MODIFIER", 111, 118], ["rhonchi", "OBSERVATION", 119, 126]]], ["Laboratories revealed worsening lymphopenia (370 cells/\u00b5L) and elevated C-reactive protein (415 mg/L).", [["cells", "ANATOMY", 49, 54], ["lymphopenia", "DISEASE", 32, 43], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 72, 90], ["C-reactive protein", "PROTEIN", 72, 90], ["Laboratories", "TEST", 0, 12], ["worsening lymphopenia", "PROBLEM", 22, 43], ["cells", "TEST", 49, 54], ["\u00b5L", "TEST", 55, 57], ["elevated C-reactive protein", "PROBLEM", 63, 90], ["worsening", "OBSERVATION_MODIFIER", 22, 31], ["lymphopenia", "OBSERVATION", 32, 43]]], ["Repeat PCR for SARS-CoV-2 returned positive.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["SARS-CoV", "SPECIES", 15, 23], ["Repeat PCR", "TEST", 0, 10], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["positive", "OBSERVATION", 35, 43]]], ["He worsened rapidly requiring endotracheal intubation, lung-protective ventilation, inhaled epoprostenol, pronation within 12 hours, and escalation in fraction of inhaled oxygen (FiO2) to 80% and positive end-expiratory pressure (PEEP) to 14 cm H2O.", [["endotracheal", "ANATOMY", 30, 42], ["lung", "ANATOMY", 55, 59], ["epoprostenol", "CHEMICAL", 92, 104], ["oxygen", "CHEMICAL", 171, 177], ["H2O", "CHEMICAL", 245, 248], ["epoprostenol", "CHEMICAL", 92, 104], ["oxygen", "CHEMICAL", 171, 177], ["FiO2", "CHEMICAL", 179, 183], ["H2O", "CHEMICAL", 245, 248], ["lung", "ORGAN", 55, 59], ["epoprostenol", "SIMPLE_CHEMICAL", 92, 104], ["oxygen", "SIMPLE_CHEMICAL", 171, 177], ["FiO2", "SIMPLE_CHEMICAL", 179, 183], ["endotracheal intubation", "TREATMENT", 30, 53], ["lung-protective ventilation", "TREATMENT", 55, 82], ["inhaled epoprostenol", "TREATMENT", 84, 104], ["pronation", "TREATMENT", 106, 115], ["inhaled oxygen", "TREATMENT", 163, 177], ["FiO2", "TREATMENT", 179, 183], ["expiratory pressure", "TEST", 209, 228], ["PEEP", "TREATMENT", 230, 234], ["worsened", "OBSERVATION_MODIFIER", 3, 11], ["rapidly", "OBSERVATION_MODIFIER", 12, 19], ["endotracheal intubation", "OBSERVATION", 30, 53], ["lung", "ANATOMY", 55, 59], ["protective ventilation", "OBSERVATION", 60, 82], ["inhaled oxygen", "OBSERVATION", 163, 177]]], ["At the time of pronation, his partial pressure of arterial oxygen (PaO2):FiO2 ratio was 104.", [["arterial", "ANATOMY", 50, 58], ["oxygen", "CHEMICAL", 59, 65], ["oxygen", "CHEMICAL", 59, 65], ["PaO2", "CHEMICAL", 67, 71], ["FiO2", "CHEMICAL", 73, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 50, 58], ["oxygen", "SIMPLE_CHEMICAL", 59, 65], ["PaO2", "SIMPLE_CHEMICAL", 67, 71], ["pronation", "TEST", 15, 24], ["his partial pressure", "TEST", 26, 46], ["arterial oxygen", "TEST", 50, 65], ["PaO2", "TEST", 67, 71], ["FiO2 ratio", "TEST", 73, 83], ["arterial", "ANATOMY", 50, 58]]], ["He did not require paralysis.", [["paralysis", "DISEASE", 19, 28], ["paralysis", "PROBLEM", 19, 28], ["paralysis", "OBSERVATION", 19, 28]]], ["Transthoracic echocardiogram was normal.", [["Transthoracic echocardiogram", "TEST", 0, 28], ["normal", "OBSERVATION", 33, 39]]], ["He was continued on azithromycin and ceftriaxone and treated with hydroxychloroquine 400 mg daily.", [["azithromycin", "CHEMICAL", 20, 32], ["ceftriaxone", "CHEMICAL", 37, 48], ["hydroxychloroquine", "CHEMICAL", 66, 84], ["azithromycin", "CHEMICAL", 20, 32], ["ceftriaxone", "CHEMICAL", 37, 48], ["hydroxychloroquine", "CHEMICAL", 66, 84], ["He", "ORGANISM", 0, 2], ["azithromycin", "SIMPLE_CHEMICAL", 20, 32], ["ceftriaxone", "SIMPLE_CHEMICAL", 37, 48], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 66, 84], ["azithromycin", "TREATMENT", 20, 32], ["ceftriaxone", "TREATMENT", 37, 48], ["hydroxychloroquine", "TREATMENT", 66, 84]]], ["He developed worsening PaO2:FiO2 (nadir 84), acute kidney injury, and abrupt onset hypotension that required dobutamine 5 \u00b5g/kg/min and norepinephrine 15 \u00b5g/min.", [["kidney", "ANATOMY", 51, 57], ["acute kidney injury", "DISEASE", 45, 64], ["hypotension", "DISEASE", 83, 94], ["dobutamine", "CHEMICAL", 109, 119], ["norepinephrine", "CHEMICAL", 136, 150], ["FiO2", "CHEMICAL", 28, 32], ["dobutamine", "CHEMICAL", 109, 119], ["norepinephrine", "CHEMICAL", 136, 150], ["kidney", "ORGAN", 51, 57], ["norepinephrine", "SIMPLE_CHEMICAL", 136, 150], ["worsening PaO2", "PROBLEM", 13, 27], ["FiO2", "TEST", 28, 32], ["nadir", "TEST", 34, 39], ["acute kidney injury", "PROBLEM", 45, 64], ["abrupt onset hypotension", "PROBLEM", 70, 94], ["dobutamine", "TREATMENT", 109, 119], ["norepinephrine", "TREATMENT", 136, 150], ["worsening", "OBSERVATION_MODIFIER", 13, 22], ["PaO2", "OBSERVATION", 23, 27], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["kidney", "ANATOMY", 51, 57], ["injury", "OBSERVATION", 58, 64], ["abrupt", "OBSERVATION_MODIFIER", 70, 76], ["onset", "OBSERVATION_MODIFIER", 77, 82], ["hypotension", "OBSERVATION", 83, 94]]], ["He stabilized hemodynamically and LVEF on dobutamine 2.5 \u00b5g/kg/min was 50%.", [["dobutamine", "CHEMICAL", 42, 52], ["dobutamine", "CHEMICAL", 42, 52], ["LVEF", "TEST", 34, 38], ["dobutamine", "TREATMENT", 42, 52]]], ["Creatine kinase increased from 312 to 1,582 units/L. Troponin was negative.", [["Creatine", "CHEMICAL", 0, 8], ["Creatine", "CHEMICAL", 0, 8], ["Creatine kinase", "GENE_OR_GENE_PRODUCT", 0, 15], ["Troponin", "GENE_OR_GENE_PRODUCT", 53, 61], ["Creatine kinase", "PROTEIN", 0, 15], ["Troponin", "PROTEIN", 53, 61], ["Creatine kinase", "TEST", 0, 15], ["Troponin", "TEST", 53, 61]]], ["Interleukin (IL)-6 was severely elevated (2,436.7 pg/ml, resulted hospital day 14).", [["Interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 0, 18], ["Interleukin (IL)-6", "PROTEIN", 0, 18], ["Interleukin (IL)", "TEST", 0, 16], ["severely elevated", "PROBLEM", 23, 40], ["elevated", "OBSERVATION_MODIFIER", 32, 40]]], ["Based on the Extracorporeal Life Support Organization guidelines (www.elso.com), he met indication for VV-ECMO: hypoxemic respiratory failure with 80% mortality risk as predicted by PaO2:FiO2 <100 despite optimal care, and was transferred on hospital day 4 (ECMO day 0).", [["respiratory", "ANATOMY", 122, 133], ["hypoxemic respiratory failure", "DISEASE", 112, 141], ["hypoxemic respiratory failure", "PROBLEM", 112, 141], ["80% mortality risk", "PROBLEM", 147, 165], ["PaO2", "TEST", 182, 186], ["FiO2", "TEST", 187, 191], ["hypoxemic", "OBSERVATION_MODIFIER", 112, 121], ["respiratory failure", "OBSERVATION", 122, 141]]], ["On arrival, vasoactive medications included dobutamine 2.5 \u00b5g/kg/min, norepinephrine 6 \u00b5g/min, and epoprostenol 50 ng/kg/min, with pulse 105 bpm, arterial blood pressure 125/46 mm Hg, oxygen saturation 90% on 100% FiO2 with tidal volume 6 ml/kg, and PEEP 16 cm H2O.", [["arterial", "ANATOMY", 146, 154], ["blood", "ANATOMY", 155, 160], ["dobutamine", "CHEMICAL", 44, 54], ["norepinephrine", "CHEMICAL", 70, 84], ["epoprostenol", "CHEMICAL", 99, 111], ["oxygen", "CHEMICAL", 184, 190], ["H2O", "CHEMICAL", 261, 264], ["dobutamine", "CHEMICAL", 44, 54], ["norepinephrine", "CHEMICAL", 70, 84], ["epoprostenol", "CHEMICAL", 99, 111], ["Hg", "CHEMICAL", 180, 182], ["oxygen", "CHEMICAL", 184, 190], ["H2O", "CHEMICAL", 261, 264], ["dobutamine", "SIMPLE_CHEMICAL", 44, 54], ["norepinephrine", "SIMPLE_CHEMICAL", 70, 84], ["epoprostenol", "SIMPLE_CHEMICAL", 99, 111], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 146, 160], ["oxygen", "SIMPLE_CHEMICAL", 184, 190], ["vasoactive medications", "TREATMENT", 12, 34], ["dobutamine", "TREATMENT", 44, 54], ["norepinephrine", "TREATMENT", 70, 84], ["epoprostenol", "TREATMENT", 99, 111], ["pulse", "TEST", 131, 136], ["arterial blood pressure", "TEST", 146, 169], ["Hg", "TEST", 180, 182], ["oxygen saturation", "TEST", 184, 201], ["100% FiO2", "TREATMENT", 209, 218], ["tidal volume", "TEST", 224, 236], ["PEEP", "TEST", 250, 254]]], ["Arterial blood gas showed pH 7.292, partial pressure of carbon dioxide 45.7 mm Hg, and PaO2 84 mm Hg (PaO2:FiO2 84).Case ReportWe confirmed normal biventricular function by echocardiogram, initiated femoral-femoral VV-ECMO (4.8 L/min, 3,700 rpm, 100% FiO2, sweep 4 L/min), and started continuous renal replacement therapy (CRRT).", [["Arterial blood", "ANATOMY", 0, 14], ["biventricular", "ANATOMY", 147, 160], ["femoral", "ANATOMY", 199, 206], ["femoral", "ANATOMY", 207, 214], ["renal", "ANATOMY", 296, 301], ["carbon dioxide", "CHEMICAL", 56, 70], ["carbon dioxide", "CHEMICAL", 56, 70], ["Hg", "CHEMICAL", 79, 81], ["PaO2", "CHEMICAL", 87, 91], ["Hg", "CHEMICAL", 98, 100], ["PaO2", "CHEMICAL", 102, 106], ["FiO2", "CHEMICAL", 107, 111], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["renal", "ORGAN", 296, 301], ["Arterial blood gas", "TEST", 0, 18], ["pH", "TEST", 26, 28], ["partial pressure", "TEST", 36, 52], ["carbon dioxide", "TEST", 56, 70], ["Hg", "TEST", 79, 81], ["PaO2", "TEST", 87, 91], ["mm Hg", "TEST", 95, 100], ["PaO2", "TEST", 102, 106], ["FiO2", "TEST", 107, 111], ["echocardiogram", "TEST", 173, 187], ["ECMO", "TREATMENT", 218, 222], ["FiO2", "TREATMENT", 251, 255], ["sweep", "TEST", 257, 262], ["continuous renal replacement therapy", "TREATMENT", 285, 321], ["CRRT", "TREATMENT", 323, 327], ["biventricular function", "OBSERVATION", 147, 169], ["femoral", "ANATOMY", 199, 206], ["femoral VV", "ANATOMY", 207, 217], ["renal", "ANATOMY", 296, 301], ["replacement", "OBSERVATION", 302, 313]]], ["ECMO configuration: Quadrox-ID adult oxygenator and Levitronix Centrimag device, 25F multistage cannula with tip the cavoatrial junction, and 21F multistage cannula in the abdominal inferior vena cava.", [["cavoatrial junction", "ANATOMY", 117, 136], ["abdominal inferior vena cava", "ANATOMY", 172, 200], ["abdominal inferior vena cava", "MULTI-TISSUE_STRUCTURE", 172, 200], ["Quadrox-ID adult oxygenator", "TREATMENT", 20, 47], ["Levitronix Centrimag device", "TREATMENT", 52, 79], ["25F multistage cannula", "TREATMENT", 81, 103], ["tip the cavoatrial junction", "TREATMENT", 109, 136], ["21F multistage cannula in the abdominal inferior vena cava", "TREATMENT", 142, 200], ["cavoatrial junction", "ANATOMY", 117, 136], ["multistage cannula", "OBSERVATION", 146, 164], ["abdominal inferior vena cava", "ANATOMY", 172, 200]]], ["We used a bifemoral approach to avoid instrumentation near the airway and the need for transesophageal echocardiography used in single cannula configuration.Case ReportHis oxygen saturation increased to 97% and PaO2 to 100 mm Hg without changing ventilation settings.", [["airway", "ANATOMY", 63, 69], ["oxygen", "CHEMICAL", 172, 178], ["oxygen", "CHEMICAL", 172, 178], ["Hg", "CHEMICAL", 226, 228], ["airway", "MULTI-TISSUE_STRUCTURE", 63, 69], ["oxygen", "SIMPLE_CHEMICAL", 172, 178], ["a bifemoral approach", "TREATMENT", 8, 28], ["instrumentation near the airway", "TREATMENT", 38, 69], ["transesophageal echocardiography", "TEST", 87, 119], ["single cannula configuration", "TREATMENT", 128, 156], ["oxygen saturation", "TEST", 172, 189], ["PaO2", "TEST", 211, 215], ["changing ventilation settings", "TREATMENT", 237, 266], ["instrumentation", "OBSERVATION", 38, 53], ["airway", "ANATOMY", 63, 69]]], ["Repeat IL-6 was severely elevated (>3,000 pg/ml, resulted on hospital day 19).", [["IL-6", "GENE_OR_GENE_PRODUCT", 7, 11], ["IL-6", "PROTEIN", 7, 11], ["Repeat IL", "TEST", 0, 9], ["severely elevated", "PROBLEM", 16, 33]]], ["He was continued on hydroxychloroquine 400 mg daily, azithromycin, and ceftriaxone.Case ReportBy ECMO day 1, he was off epoprostenol, dobutamine, and norepinephrine; on 70% FiO2 with PaO2 72 mm Hg; and on cisatracurium.", [["hydroxychloroquine", "CHEMICAL", 20, 38], ["azithromycin", "CHEMICAL", 53, 65], ["ceftriaxone", "CHEMICAL", 71, 82], ["epoprostenol", "CHEMICAL", 120, 132], ["dobutamine", "CHEMICAL", 134, 144], ["norepinephrine", "CHEMICAL", 150, 164], ["cisatracurium", "CHEMICAL", 205, 218], ["hydroxychloroquine", "CHEMICAL", 20, 38], ["azithromycin", "CHEMICAL", 53, 65], ["ceftriaxone", "CHEMICAL", 71, 82], ["epoprostenol", "CHEMICAL", 120, 132], ["dobutamine", "CHEMICAL", 134, 144], ["norepinephrine", "CHEMICAL", 150, 164], ["FiO2", "CHEMICAL", 173, 177], ["Hg", "CHEMICAL", 194, 196], ["cisatracurium", "CHEMICAL", 205, 218], ["He", "ORGANISM", 0, 2], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 20, 38], ["azithromycin", "SIMPLE_CHEMICAL", 53, 65], ["ceftriaxone", "SIMPLE_CHEMICAL", 71, 82], ["epoprostenol", "SIMPLE_CHEMICAL", 120, 132], ["dobutamine", "SIMPLE_CHEMICAL", 134, 144], ["norepinephrine", "SIMPLE_CHEMICAL", 150, 164], ["hydroxychloroquine", "TREATMENT", 20, 38], ["azithromycin", "TREATMENT", 53, 65], ["ceftriaxone", "TREATMENT", 71, 82], ["epoprostenol", "TREATMENT", 120, 132], ["dobutamine", "TREATMENT", 134, 144], ["norepinephrine", "TREATMENT", 150, 164], ["70% FiO2", "TREATMENT", 169, 177], ["PaO2", "TEST", 183, 187], ["cisatracurium", "TREATMENT", 205, 218]]], ["Laboratory evaluation was notable for lymphopenia, marked elevation in C-reactive protein, and hyperferritinemia (Table 1).", [["lymphopenia", "DISEASE", 38, 49], ["hyperferritinemia", "DISEASE", 95, 112], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 71, 89], ["C-reactive protein", "PROTEIN", 71, 89], ["Laboratory evaluation", "TEST", 0, 21], ["lymphopenia", "PROBLEM", 38, 49], ["marked elevation in C-reactive protein", "PROBLEM", 51, 89], ["hyperferritinemia", "PROBLEM", 95, 112], ["lymphopenia", "OBSERVATION", 38, 49], ["marked", "OBSERVATION_MODIFIER", 51, 57], ["elevation", "OBSERVATION_MODIFIER", 58, 67], ["reactive protein", "OBSERVATION", 73, 89], ["hyperferritinemia", "OBSERVATION", 95, 112]]], ["We initiated tocilizumab 800 mg every 8 hours for 3 doses, started hydralazine and clonidine for hypertension, and removed net 2 L of fluid with CRRT.Case ReportOn ECMO day 3, C-reactive protein decreased substantially, lymphopenia resolved (Figure 1 and Table 1), and antibiotic therapy completed.", [["hydralazine", "CHEMICAL", 67, 78], ["clonidine", "CHEMICAL", 83, 92], ["hypertension", "DISEASE", 97, 109], ["lymphopenia", "DISEASE", 220, 231], ["hydralazine", "CHEMICAL", 67, 78], ["clonidine", "CHEMICAL", 83, 92], ["tocilizumab", "SIMPLE_CHEMICAL", 13, 24], ["hydralazine", "SIMPLE_CHEMICAL", 67, 78], ["clonidine", "SIMPLE_CHEMICAL", 83, 92], ["fluid", "ORGANISM_SUBSTANCE", 134, 139], ["C-reactive", "GENE_OR_GENE_PRODUCT", 176, 186], ["C-reactive protein", "PROTEIN", 176, 194], ["tocilizumab", "TREATMENT", 13, 24], ["hydralazine", "TREATMENT", 67, 78], ["clonidine", "TREATMENT", 83, 92], ["hypertension", "PROBLEM", 97, 109], ["CRRT", "TREATMENT", 145, 149], ["C-reactive protein", "TEST", 176, 194], ["lymphopenia", "PROBLEM", 220, 231], ["antibiotic therapy", "TREATMENT", 269, 287], ["lymphopenia", "OBSERVATION", 220, 231]]], ["Lung function started to improve based on reduced ventilator FiO2 and ECMO sweep requirements (Figure 2).Case ReportOn ECMO day 4, we started high-dose vitamin C 5,000 mg every 6 hours.", [["Lung", "ANATOMY", 0, 4], ["vitamin C", "CHEMICAL", 152, 161], ["vitamin C", "CHEMICAL", 152, 161], ["Lung", "ORGAN", 0, 4], ["vitamin C", "SIMPLE_CHEMICAL", 152, 161], ["Lung function", "TEST", 0, 13], ["reduced ventilator FiO2", "TREATMENT", 42, 65], ["ECMO sweep requirements", "TREATMENT", 70, 93], ["high-dose vitamin C", "TREATMENT", 142, 161], ["function", "OBSERVATION", 5, 13], ["ventilator FiO2", "OBSERVATION", 50, 65]]], ["His condition rapidly improved and given an anticipated supply shortage, we discontinued hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 89, 107], ["hydroxychloroquine", "CHEMICAL", 89, 107], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 89, 107], ["hydroxychloroquine", "TREATMENT", 89, 107], ["rapidly", "OBSERVATION_MODIFIER", 14, 21], ["improved", "OBSERVATION_MODIFIER", 22, 30]]], ["By ECMO day 7, he was on 21% FiO2 on the ECMO circuit, sweep 0.5 L/min, PEEP 10 cm H2O, and tidal volume 6 ml/kg (Figure 2).", [["H2O", "CHEMICAL", 83, 86], ["FiO2", "CHEMICAL", 29, 33], ["H2O", "CHEMICAL", 83, 86], ["21% FiO2", "TREATMENT", 25, 33], ["the ECMO circuit", "TREATMENT", 37, 53], ["PEEP", "TREATMENT", 72, 76], ["tidal volume", "TEST", 92, 104]]], ["We successfully decannulated him after 160 hours of VV-ECMO support and extubated him 4 days later.", [["VV", "SPECIES", 52, 54], ["VV-ECMO support", "TREATMENT", 52, 67], ["decannulated", "OBSERVATION", 16, 28]]], ["Repeat SARS-CoV-2 test was negative on hospital day 21.", [["Repeat SARS", "TEST", 0, 11], ["CoV-2 test", "TEST", 12, 22]]], ["On hospital day 24, he was discharged home without need for supplemental oxygen or renal replacement therapy.DiscussionWe postulate that support with VV-ECMO, mechanical ventilation, and CRRT provided time for our patient to benefit from: (1) hydroxychloroquine possibly reduced viral load; (2) IL-6 receptor blockade likely abrogated hyperinflammation; and (3) high-dose vitamin C possibly reduced inflammation and enhanced lung recovery.", [["renal", "ANATOMY", 83, 88], ["lung", "ANATOMY", 425, 429], ["oxygen", "CHEMICAL", 73, 79], ["hydroxychloroquine", "CHEMICAL", 243, 261], ["hyperinflammation", "DISEASE", 335, 352], ["vitamin C", "CHEMICAL", 372, 381], ["inflammation", "DISEASE", 399, 411], ["oxygen", "CHEMICAL", 73, 79], ["hydroxychloroquine", "CHEMICAL", 243, 261], ["vitamin C", "CHEMICAL", 372, 381], ["oxygen", "SIMPLE_CHEMICAL", 73, 79], ["renal", "ORGAN", 83, 88], ["patient", "ORGANISM", 214, 221], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 243, 261], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 295, 308], ["vitamin C", "SIMPLE_CHEMICAL", 372, 381], ["lung", "ORGAN", 425, 429], ["IL-6 receptor", "PROTEIN", 295, 308], ["patient", "SPECIES", 214, 221], ["VV", "SPECIES", 150, 152], ["supplemental oxygen", "TREATMENT", 60, 79], ["renal replacement therapy", "TREATMENT", 83, 108], ["ECMO", "TREATMENT", 153, 157], ["mechanical ventilation", "TREATMENT", 159, 181], ["CRRT", "TREATMENT", 187, 191], ["hydroxychloroquine", "TREATMENT", 243, 261], ["reduced viral load", "PROBLEM", 271, 289], ["IL-6 receptor blockade", "TREATMENT", 295, 317], ["abrogated hyperinflammation", "PROBLEM", 325, 352], ["high-dose vitamin C", "TREATMENT", 362, 381], ["reduced inflammation", "PROBLEM", 391, 411], ["enhanced lung recovery", "PROBLEM", 416, 438], ["renal", "ANATOMY", 83, 88], ["replacement", "OBSERVATION", 89, 100], ["reduced", "OBSERVATION_MODIFIER", 391, 398], ["inflammation", "OBSERVATION", 399, 411], ["lung", "ANATOMY", 425, 429]]], ["Further, anecdotal data indicate that no COVID-19 patient with multiorgan failure has survived ECMO, prompting several institutions to set multiorgan failure as a contraindication.", [["multiorgan", "ANATOMY", 63, 73], ["multiorgan", "ANATOMY", 139, 149], ["multiorgan failure", "DISEASE", 63, 81], ["multiorgan failure", "DISEASE", 139, 157], ["patient", "ORGANISM", 50, 57], ["multiorgan", "ORGAN", 63, 73], ["patient", "SPECIES", 50, 57], ["anecdotal data", "TEST", 9, 23], ["COVID", "TEST", 41, 46], ["multiorgan failure", "PROBLEM", 63, 81], ["ECMO", "TREATMENT", 95, 99], ["multiorgan failure", "PROBLEM", 139, 157], ["multiorgan", "ANATOMY", 63, 73], ["failure", "OBSERVATION", 74, 81], ["failure", "OBSERVATION", 150, 157]]], ["Based on our patient, multiorgan failure including acute renal failure may not signify an insurmountable scenario to contraindicate the use of VV-ECMO in COVID-19 patients.DiscussionRemdesivir is an investigational antiviral agent in COVID-19; however, it was contraindicated in our patient.", [["multiorgan", "ANATOMY", 22, 32], ["renal", "ANATOMY", 57, 62], ["multiorgan failure", "DISEASE", 22, 40], ["acute renal failure", "DISEASE", 51, 70], ["DiscussionRemdesivir", "CHEMICAL", 172, 192], ["patient", "ORGANISM", 13, 20], ["multiorgan", "ORGAN", 22, 32], ["renal", "ORGAN", 57, 62], ["patients", "ORGANISM", 163, 171], ["patient", "ORGANISM", 283, 290], ["patient", "SPECIES", 13, 20], ["patients", "SPECIES", 163, 171], ["patient", "SPECIES", 283, 290], ["VV", "SPECIES", 143, 145], ["multiorgan failure", "PROBLEM", 22, 40], ["acute renal failure", "PROBLEM", 51, 70], ["an insurmountable scenario", "PROBLEM", 87, 113], ["VV", "TREATMENT", 143, 145], ["ECMO", "TREATMENT", 146, 150], ["an investigational antiviral agent", "TREATMENT", 196, 230], ["multiorgan failure", "OBSERVATION", 22, 40], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["renal", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70]]], ["A recent study reported a reduced detection of SARS-CoV-2 RNA in upper respiratory tract specimens from patients treated with hydroxychloroquine.3 Hydroxychloroquine may also suppress proinflammatory cytokines (Tumor Necrosis Factor [TNF]-alpha and IL-6) associated with coronavirus-induced ARDS.4 Based on this information and limited anecdotal data, we treated our patient with hydroxychloroquine.", [["upper respiratory tract specimens", "ANATOMY", 65, 98], ["hydroxychloroquine", "CHEMICAL", 126, 144], ["Hydroxychloroquine", "CHEMICAL", 147, 165], ["ARDS", "DISEASE", 291, 295], ["hydroxychloroquine", "CHEMICAL", 380, 398], ["hydroxychloroquine", "CHEMICAL", 126, 144], ["Hydroxychloroquine", "CHEMICAL", 147, 165], ["hydroxychloroquine", "CHEMICAL", 380, 398], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["upper respiratory tract specimens", "CANCER", 65, 98], ["patients", "ORGANISM", 104, 112], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 126, 144], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 147, 165], ["Tumor Necrosis Factor [TNF]-alpha", "GENE_OR_GENE_PRODUCT", 211, 244], ["IL-6", "GENE_OR_GENE_PRODUCT", 249, 253], ["coronavirus", "ORGANISM", 271, 282], ["patient", "ORGANISM", 367, 374], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 380, 398], ["SARS-CoV-2 RNA", "RNA", 47, 61], ["proinflammatory cytokines", "PROTEIN", 184, 209], ["Tumor Necrosis Factor [TNF]-alpha and IL-6", "PROTEIN", 211, 253], ["patients", "SPECIES", 104, 112], ["patient", "SPECIES", 367, 374], ["SARS-CoV", "SPECIES", 47, 55], ["A recent study", "TEST", 0, 14], ["SARS", "PROBLEM", 47, 51], ["CoV", "TEST", 52, 55], ["2 RNA in upper respiratory tract specimens", "PROBLEM", 56, 98], ["hydroxychloroquine", "TREATMENT", 126, 144], ["Hydroxychloroquine", "TREATMENT", 147, 165], ["proinflammatory cytokines", "PROBLEM", 184, 209], ["Tumor Necrosis Factor", "PROBLEM", 211, 232], ["TNF", "TEST", 234, 237], ["alpha and IL", "TREATMENT", 239, 251], ["coronavirus", "PROBLEM", 271, 282], ["induced ARDS", "PROBLEM", 283, 295], ["hydroxychloroquine", "TREATMENT", 380, 398], ["upper", "ANATOMY_MODIFIER", 65, 70], ["respiratory tract", "ANATOMY", 71, 88], ["ARDS", "OBSERVATION", 291, 295]]], ["In our patient, IL-6 levels continued to rise despite being on hydroxychloroquine and we cannot determine what effect hydroxychloroquine had, if any, on IL-6 levels.DiscussionCytokine profiling from 40 COVID-19 patients from Wuhan, China demonstrated increased IL-1, monocyte chemotactic protein-1, TNF-alpha, IL-6, C-reactive protein, and ferritin levels (preprint: Liu et al., MedRxiv 2020).", [["hydroxychloroquine", "CHEMICAL", 63, 81], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["hydroxychloroquine", "CHEMICAL", 63, 81], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["patient", "ORGANISM", 7, 14], ["IL-6", "GENE_OR_GENE_PRODUCT", 16, 20], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 63, 81], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 118, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 153, 157], ["patients", "ORGANISM", 211, 219], ["IL-1", "GENE_OR_GENE_PRODUCT", 261, 265], ["monocyte chemotactic protein-1", "GENE_OR_GENE_PRODUCT", 267, 297], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 299, 308], ["IL-6", "GENE_OR_GENE_PRODUCT", 310, 314], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 316, 334], ["ferritin", "GENE_OR_GENE_PRODUCT", 340, 348], ["IL-6", "PROTEIN", 16, 20], ["IL", "PROTEIN", 153, 155], ["IL-1", "PROTEIN", 261, 265], ["monocyte chemotactic protein-1", "PROTEIN", 267, 297], ["TNF", "PROTEIN", 299, 302], ["IL-6", "PROTEIN", 310, 314], ["C-reactive protein", "PROTEIN", 316, 334], ["ferritin", "PROTEIN", 340, 348], ["patient", "SPECIES", 7, 14], ["patients", "SPECIES", 211, 219], ["hydroxychloroquine", "TREATMENT", 63, 81], ["hydroxychloroquine", "TREATMENT", 118, 136], ["DiscussionCytokine profiling", "TEST", 165, 193], ["increased IL", "TEST", 251, 263], ["monocyte chemotactic protein", "TEST", 267, 295], ["TNF", "TEST", 299, 302], ["alpha", "TEST", 303, 308], ["IL", "TEST", 310, 312], ["C-reactive protein", "TEST", 316, 334], ["ferritin levels", "TEST", 340, 355]]], ["C-reactive protein expression is induced by IL-6, is increased in CRS, and may be clinically relevant as a marker of IL-6 activity.5 Tocilizumab, an IL-6 receptor antagonist, is FDA approved and used in the management of CAR T-cell\u2013related CRS.5 Based on partial clinical and biologic overlap with CRS, there is biologic plausibility to administer tocilizumab in severe and critical illness due to COVID-19.", [["CRS", "DISEASE", 66, 69], ["Tocilizumab", "CHEMICAL", 133, 144], ["CRS", "DISEASE", 298, 301], ["tocilizumab", "CHEMICAL", 348, 359], ["Tocilizumab", "CHEMICAL", 133, 144], ["COVID-19", "CHEMICAL", 398, 406], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["IL-6", "GENE_OR_GENE_PRODUCT", 44, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 117, 121], ["Tocilizumab", "SIMPLE_CHEMICAL", 133, 144], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 149, 162], ["CAR T", "CANCER", 221, 226], ["tocilizumab", "SIMPLE_CHEMICAL", 348, 359], ["C-reactive protein", "PROTEIN", 0, 18], ["IL-6", "PROTEIN", 44, 48], ["IL", "PROTEIN", 117, 119], ["reactive protein expression", "PROBLEM", 2, 29], ["CRS", "PROBLEM", 66, 69], ["Tocilizumab", "TREATMENT", 133, 144], ["an IL-6 receptor antagonist", "TREATMENT", 146, 173], ["CRS", "PROBLEM", 298, 301], ["tocilizumab", "TREATMENT", 348, 359], ["critical illness", "PROBLEM", 374, 390], ["COVID", "TEST", 398, 403], ["reactive protein expression", "OBSERVATION", 2, 29], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["CRS", "OBSERVATION", 66, 69], ["may be", "UNCERTAINTY", 75, 81]]], ["In support of this, 19 of 21 severely and critically ill COVID-19 patients in China treated with tocilizumab survived to discharge and >80% had improved fever, supplemental oxygenation needs, or inflammatory markers (preprint: Xu et al., ChinaXiv 2020).DiscussionChinese CDC oxygenation criteria for severe illness in COVID-19 parallel the ASTCT criteria for grade 2 CRS, essentially requiring supplemental oxygen, whereas the criteria for critical illness in COVID-19 parallel the ASTCT criteria for grade 4 CRS, including patients with shock or requiring mechanical ventilation.", [["critically ill", "DISEASE", 42, 56], ["tocilizumab", "CHEMICAL", 97, 108], ["fever", "DISEASE", 153, 158], ["illness", "DISEASE", 307, 314], ["CRS", "DISEASE", 367, 370], ["oxygen", "CHEMICAL", 407, 413], ["CRS", "DISEASE", 509, 512], ["shock", "DISEASE", 538, 543], ["oxygen", "CHEMICAL", 407, 413], ["patients", "ORGANISM", 66, 74], ["oxygen", "SIMPLE_CHEMICAL", 407, 413], ["patients", "ORGANISM", 524, 532], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 524, 532], ["tocilizumab", "TREATMENT", 97, 108], ["improved fever", "PROBLEM", 144, 158], ["supplemental oxygenation needs", "TREATMENT", 160, 190], ["inflammatory markers", "PROBLEM", 195, 215], ["severe illness", "PROBLEM", 300, 314], ["COVID", "TEST", 318, 323], ["grade 2 CRS", "PROBLEM", 359, 370], ["supplemental oxygen", "TREATMENT", 394, 413], ["critical illness", "PROBLEM", 440, 456], ["COVID", "TEST", 460, 465], ["grade 4 CRS", "PROBLEM", 501, 512], ["shock", "PROBLEM", 538, 543], ["mechanical ventilation", "TREATMENT", 557, 579], ["inflammatory", "OBSERVATION_MODIFIER", 195, 207], ["shock", "OBSERVATION", 538, 543], ["mechanical ventilation", "OBSERVATION", 557, 579]]], ["In clinical trials, grade 4 CRS is reversible in all patients treated with tocilizumab 8 mg/kg (maximum dose 800 mg) every 8 hours, maximum 3 doses in 24 hours.6 Given the critical illness in our patient, we used this dosing regimen.", [["CRS", "DISEASE", 28, 31], ["patients", "ORGANISM", 53, 61], ["tocilizumab", "SIMPLE_CHEMICAL", 75, 86], ["patient", "ORGANISM", 196, 203], ["patients", "SPECIES", 53, 61], ["patient", "SPECIES", 196, 203], ["grade 4 CRS", "PROBLEM", 20, 31], ["tocilizumab", "TREATMENT", 75, 86], ["this dosing regimen", "TREATMENT", 213, 232], ["reversible", "OBSERVATION_MODIFIER", 35, 45]]], ["After administration of tocilizumab, our patient had a rapid and sustained decrease in C-reactive protein (Figure 1).", [["tocilizumab", "CHEMICAL", 24, 35], ["tocilizumab", "SIMPLE_CHEMICAL", 24, 35], ["patient", "ORGANISM", 41, 48], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 87, 105], ["C-reactive protein", "PROTEIN", 87, 105], ["patient", "SPECIES", 41, 48], ["tocilizumab", "TREATMENT", 24, 35], ["a rapid and sustained decrease in C-reactive protein", "PROBLEM", 53, 105], ["decrease", "OBSERVATION_MODIFIER", 75, 83]]], ["This demonstrates that tocilizumab given while on VV-ECMO is effective at blocking IL-6 signaling.", [["tocilizumab", "CHEMICAL", 23, 34], ["tocilizumab", "SIMPLE_CHEMICAL", 23, 34], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-6", "PROTEIN", 83, 87], ["VV", "SPECIES", 50, 52], ["tocilizumab", "TREATMENT", 23, 34], ["ECMO", "TREATMENT", 53, 57], ["tocilizumab", "OBSERVATION", 23, 34]]], ["The progressive improvement in oxygenation and decannulation from ECMO suggests blocking excessive IL-6 activity facilitates recovery from COVID-19 respiratory failure.DiscussionVitamin C may also reduce the proinflammatory state and be beneficial in recovery of acute lung injury based on animal data.7 Although the CITRIS-ALI study8 failed to demonstrate improvement in sepsis-related ARDS with vitamin C in primary endpoints, secondary analysis suggested lower mortality and more intensive care unit-free days with vitamin C (p < 0.05).", [["respiratory", "ANATOMY", 148, 159], ["lung", "ANATOMY", 269, 273], ["respiratory failure", "DISEASE", 148, 167], ["Vitamin C", "CHEMICAL", 178, 187], ["acute lung injury", "DISEASE", 263, 280], ["ALI", "DISEASE", 324, 327], ["sepsis", "DISEASE", 372, 378], ["ARDS", "DISEASE", 387, 391], ["vitamin C", "CHEMICAL", 397, 406], ["vitamin C", "CHEMICAL", 518, 527], ["Vitamin C", "CHEMICAL", 178, 187], ["vitamin C", "CHEMICAL", 397, 406], ["vitamin C", "CHEMICAL", 518, 527], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["Vitamin C", "SIMPLE_CHEMICAL", 178, 187], ["lung", "ORGAN", 269, 273], ["vitamin C", "SIMPLE_CHEMICAL", 397, 406], ["vitamin C", "SIMPLE_CHEMICAL", 518, 527], ["IL-6", "PROTEIN", 99, 103], ["decannulation", "TREATMENT", 47, 60], ["ECMO", "TREATMENT", 66, 70], ["blocking excessive IL", "TREATMENT", 80, 101], ["COVID", "TEST", 139, 144], ["respiratory failure", "PROBLEM", 148, 167], ["Vitamin C", "TREATMENT", 178, 187], ["the proinflammatory state", "PROBLEM", 204, 229], ["acute lung injury", "PROBLEM", 263, 280], ["animal data", "TEST", 290, 301], ["the CITRIS-ALI study8", "TEST", 313, 334], ["sepsis", "PROBLEM", 372, 378], ["ARDS", "PROBLEM", 387, 391], ["vitamin C", "TREATMENT", 397, 406], ["secondary analysis", "TEST", 429, 447], ["lower mortality", "PROBLEM", 458, 473], ["vitamin C", "TREATMENT", 518, 527], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["improvement", "OBSERVATION_MODIFIER", 16, 27], ["oxygenation", "OBSERVATION_MODIFIER", 31, 42], ["decannulation", "OBSERVATION", 47, 60], ["respiratory failure", "OBSERVATION", 148, 167], ["acute", "OBSERVATION_MODIFIER", 263, 268], ["lung", "ANATOMY", 269, 273], ["injury", "OBSERVATION", 274, 280], ["improvement", "OBSERVATION_MODIFIER", 357, 368], ["sepsis", "OBSERVATION", 372, 378], ["ARDS", "OBSERVATION", 387, 391]]], ["Based on anecdotal reports on COVID-19 patients (reference not available), potential benefit, and lack of adverse effects,8 we elected to treat our patient with high-dose intravenous vitamin C using the CITRIS-ALI protocol.8 The rapid improvement in oxygenation and lung compliance in our patient after initiation of high-dose vitamin C is impressive but could be coincidental.DiscussionBecause of the rapid recovery of our patient, it is enticing to speculate that targeting hyperinflammation in critical COVID-19 illness will reduce the duration of support needed from VV-ECMO and/or mechanical ventilation.", [["intravenous", "ANATOMY", 171, 182], ["lung", "ANATOMY", 266, 270], ["vitamin C", "CHEMICAL", 183, 192], ["ALI", "DISEASE", 210, 213], ["vitamin C", "CHEMICAL", 327, 336], ["hyperinflammation", "DISEASE", 476, 493], ["illness", "DISEASE", 515, 522], ["vitamin C", "CHEMICAL", 183, 192], ["vitamin C", "CHEMICAL", 327, 336], ["patients", "ORGANISM", 39, 47], ["patient", "ORGANISM", 148, 155], ["intravenous vitamin C", "SIMPLE_CHEMICAL", 171, 192], ["lung", "ORGAN", 266, 270], ["patient", "ORGANISM", 289, 296], ["vitamin C", "SIMPLE_CHEMICAL", 327, 336], ["patient", "ORGANISM", 424, 431], ["patients", "SPECIES", 39, 47], ["patient", "SPECIES", 148, 155], ["patient", "SPECIES", 289, 296], ["patient", "SPECIES", 424, 431], ["VV", "SPECIES", 571, 573], ["high-dose intravenous vitamin C", "TREATMENT", 161, 192], ["the CITRIS-ALI protocol", "TREATMENT", 199, 222], ["high-dose vitamin C", "TREATMENT", 317, 336], ["targeting hyperinflammation", "PROBLEM", 466, 493], ["VV", "TREATMENT", 571, 573], ["ECMO", "TREATMENT", 574, 578], ["mechanical ventilation", "TREATMENT", 586, 608], ["rapid", "OBSERVATION_MODIFIER", 229, 234], ["improvement", "OBSERVATION_MODIFIER", 235, 246], ["oxygenation", "OBSERVATION_MODIFIER", 250, 261], ["lung", "ANATOMY", 266, 270], ["compliance", "OBSERVATION", 271, 281], ["mechanical ventilation", "OBSERVATION", 586, 608]]], ["However, the applicability of our single-patient experience must be cautioned.", [["patient", "ORGANISM", 41, 48], ["patient", "SPECIES", 41, 48]]], ["Neither tocilizumab nor vitamin C is FDA approved for use in COVID-19 patients, and further investigation is needed to determine their benefit.", [["vitamin C", "CHEMICAL", 24, 33], ["vitamin C", "CHEMICAL", 24, 33], ["tocilizumab", "SIMPLE_CHEMICAL", 8, 19], ["vitamin C", "SIMPLE_CHEMICAL", 24, 33], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["tocilizumab", "TREATMENT", 8, 19], ["vitamin C", "TREATMENT", 24, 33], ["further investigation", "TEST", 84, 105]]], ["Accordingly, our patient has been added to the Real world Evidence for Anti-Cytokine Therapy in COVID-19 Registry.", [["patient", "ORGANISM", 17, 24], ["Anti-Cytokine", "SIMPLE_CHEMICAL", 71, 84], ["patient", "SPECIES", 17, 24], ["Anti-Cytokine Therapy", "TREATMENT", 71, 92]]]], "a7b4fe140e8f3c0d4b697ce346c7cb25979a4791": [["J o u r n a l P r e -p r o o f released an integrated treatment program to be implemented.", [["an integrated treatment program", "TREATMENT", 40, 71]]], ["Classical herbal formulas, such as Yu Ping Feng San, Sang Ju Yin and Yin Qiao San, were highly sought out for prevention and treatment of In this issue of The American Journal of Emergency Medicine, Sun and coworkers present an adept metanalysis supporting the clinical efficacy and safety of using TCM herbal prescriptions for the treatment of COVID-19.", [["Classical herbal formulas", "TREATMENT", 0, 25], ["Sang Ju Yin", "TREATMENT", 53, 64], ["treatment", "TREATMENT", 125, 134], ["an adept metanalysis", "TREATMENT", 225, 245], ["TCM herbal prescriptions", "TREATMENT", 299, 323], ["COVID", "TEST", 345, 350], ["herbal formulas", "OBSERVATION", 10, 25]]], ["7 The article incorporates, in detail, the results from seven studies, with 681 participants utilizing TCM as a therapeutic course of treatment.", [["participants", "SPECIES", 80, 92], ["seven studies", "TEST", 56, 69], ["TCM", "TREATMENT", 103, 106], ["a therapeutic course of treatment", "TREATMENT", 110, 143]]], ["However, we suggest that we recognize that these outcomes may have some intrinsic issues.", [["some intrinsic issues", "PROBLEM", 67, 88]]], ["For example, we are concerned that the depicted results reflect a steady state of illness, whereas in TCM, measures can vary depending on which herbal formulations are administered, and the stage or rate of infection in each patient.", [["illness", "DISEASE", 82, 89], ["infection", "DISEASE", 207, 216], ["patient", "ORGANISM", 225, 232], ["patient", "SPECIES", 225, 232], ["illness", "PROBLEM", 82, 89], ["herbal formulations", "TREATMENT", 144, 163], ["infection", "PROBLEM", 207, 216], ["infection", "OBSERVATION", 207, 216]]], ["TCM methodology used to diagnose and treat any pathology heavily relies on the time of exposure for all ailments.", [["TCM methodology", "TREATMENT", 0, 15], ["any pathology", "PROBLEM", 43, 56]]], ["Other limitations of this metanalysis include the many variables of patient demographics, different herbal preparations, and access to funding to purchase such preparations.", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["this metanalysis", "TEST", 21, 37], ["different herbal preparations", "TREATMENT", 90, 119], ["such preparations", "TREATMENT", 155, 172]]], ["The authors are transparent and need to be applauded for their data analysis.", [["their data analysis", "TEST", 57, 76]]]], "f224700370cecf9ca9f19d750d38a35efe8a8126": [], "440060cc1599f19caf3f37ec041c35a0c3cb8e87": [["Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients Cyrielle Despres 1 , Yannick Brunin 1 , Francis Berthier 1 , Sebastien Pili-Floury 1,2 and Guillaume Besch 1,2* Dear Editor, A massive outbreak of coronavirus disease 2019 (Covid-19) occurred in France in March and April 2020.", [["nasal", "ANATOMY", 42, 47], ["oxygen", "CHEMICAL", 64, 70], ["coronavirus disease", "DISEASE", 254, 273], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["patients", "ORGANISM", 98, 106], ["coronavirus", "ORGANISM", 254, 265], ["patients", "SPECIES", 98, 106], ["coronavirus", "SPECIES", 254, 265], ["Prone positioning", "TREATMENT", 0, 17], ["high-flow nasal", "TREATMENT", 32, 47], ["conventional oxygen therapy", "TREATMENT", 51, 78], ["coronavirus disease", "PROBLEM", 254, 273], ["Covid", "TEST", 280, 285], ["nasal", "ANATOMY", 42, 47], ["massive", "OBSERVATION_MODIFIER", 234, 241], ["outbreak", "OBSERVATION_MODIFIER", 242, 250], ["coronavirus disease", "OBSERVATION", 254, 273]]], ["About 20% of Covid-19 patients develop acute respiratory distress syndrome (ARDS), with mortality ranging from 20 to 50%.", [["respiratory", "ANATOMY", 45, 56], ["acute respiratory distress syndrome", "DISEASE", 39, 74], ["ARDS", "DISEASE", 76, 80], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["Covid", "TEST", 13, 18], ["acute respiratory distress syndrome", "PROBLEM", 39, 74], ["ARDS", "PROBLEM", 76, 80], ["mortality", "TEST", 88, 97], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory distress", "OBSERVATION", 45, 65], ["ARDS", "OBSERVATION", 76, 80]]], ["Since the publication of the PROSEVA study [1] , prone positioning (PP) has become a cornerstone of management of mechanically ventilated severe ARDS patients.", [["ARDS", "DISEASE", 145, 149], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["the PROSEVA study", "TEST", 25, 42], ["management", "TREATMENT", 100, 110], ["mechanically ventilated severe ARDS patients", "PROBLEM", 114, 158], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["ARDS", "OBSERVATION", 145, 149]]]], "bb33e6a05be765ade1bcd0ed71c793360212ea98": [["integrate the clinical and laboratory diagnosis to establish an accurate microbiologic diagnosis for these infectious diseases.PharyngitisAcute pharyngitis is a common illness that sends nearly 1% of all children and adults to seek care from physicians and emergency rooms each year.", [["infectious diseases", "DISEASE", 107, 126], ["PharyngitisAcute pharyngitis", "DISEASE", 127, 155], ["children", "ORGANISM", 204, 212], ["children", "SPECIES", 204, 212], ["these infectious diseases", "PROBLEM", 101, 126], ["PharyngitisAcute pharyngitis", "PROBLEM", 127, 155], ["infectious", "OBSERVATION", 107, 117], ["pharyngitis", "OBSERVATION", 144, 155]]], ["Searching for a specific organism, Streptococcus pyogenes, as the causative pathogen is the most common infectious disease diagnostic effort performed on the oral cavity.", [["oral cavity", "ANATOMY", 158, 169], ["Streptococcus pyogenes", "DISEASE", 35, 57], ["Streptococcus pyogenes", "ORGANISM", 35, 57], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 158, 169], ["Streptococcus pyogenes", "SPECIES", 35, 57], ["Streptococcus pyogenes", "SPECIES", 35, 57], ["a specific organism", "PROBLEM", 14, 33], ["Streptococcus pyogenes", "PROBLEM", 35, 57], ["the causative pathogen", "PROBLEM", 62, 84], ["Streptococcus pyogenes", "OBSERVATION", 35, 57], ["most common", "OBSERVATION_MODIFIER", 92, 103], ["infectious", "OBSERVATION_MODIFIER", 104, 114]]], ["The primary cause of most microbial pharyngitis is a virus in most adults; however, S. pyogenes, also known as the group A P-hemolytic streptococcus (GABHS), is the most important organism to recognize.", [["pharyngitis", "DISEASE", 36, 47], ["hemolytic streptococcus", "DISEASE", 125, 148], ["GABHS", "DISEASE", 150, 155], ["S. pyogenes", "ORGANISM", 84, 95], ["A P-hemolytic streptococcus", "ORGANISM", 121, 148], ["S. pyogenes", "SPECIES", 84, 95], ["S. pyogenes", "SPECIES", 84, 95], ["most microbial pharyngitis", "PROBLEM", 21, 47], ["a virus", "PROBLEM", 51, 58], ["S. pyogenes", "PROBLEM", 84, 95], ["hemolytic streptococcus (GABHS", "PROBLEM", 125, 155], ["most microbial", "OBSERVATION_MODIFIER", 21, 35], ["pharyngitis", "OBSERVATION", 36, 47], ["virus", "OBSERVATION", 53, 58], ["pyogenes", "OBSERVATION", 87, 95]]], ["The inflammatory syndrome of the pharynx resulting from S. pyogenes infection is marked by a wide variety of signs and symptoms, and nearly always is accompanied by fever and sore throat.\" 35, It is important for physicians to accurately diagnose which organism is causing the disease because infection with GABHS should be treated with antibiotics such as penicillin and erythromycin, whereas viruses do not respond to such therapy.", [["pharynx", "ANATOMY", 33, 40], ["inflammatory syndrome of the pharynx", "DISEASE", 4, 40], ["S. pyogenes infection", "DISEASE", 56, 77], ["fever", "DISEASE", 165, 170], ["sore throat", "DISEASE", 175, 186], ["infection", "DISEASE", 293, 302], ["GABHS", "DISEASE", 308, 313], ["penicillin", "CHEMICAL", 357, 367], ["erythromycin", "CHEMICAL", 372, 384], ["penicillin", "CHEMICAL", 357, 367], ["erythromycin", "CHEMICAL", 372, 384], ["pharynx", "ORGAN", 33, 40], ["S. pyogenes", "ORGANISM", 56, 67], ["penicillin", "SIMPLE_CHEMICAL", 357, 367], ["erythromycin", "SIMPLE_CHEMICAL", 372, 384], ["S. pyogenes", "SPECIES", 56, 67], ["S. pyogenes", "SPECIES", 56, 67], ["The inflammatory syndrome of the pharynx", "PROBLEM", 0, 40], ["S. pyogenes infection", "PROBLEM", 56, 77], ["signs and symptoms", "PROBLEM", 109, 127], ["fever", "PROBLEM", 165, 170], ["sore throat", "PROBLEM", 175, 186], ["the disease", "PROBLEM", 273, 284], ["infection", "PROBLEM", 293, 302], ["GABHS", "PROBLEM", 308, 313], ["antibiotics", "TREATMENT", 337, 348], ["penicillin", "TREATMENT", 357, 367], ["erythromycin", "TREATMENT", 372, 384], ["such therapy", "TREATMENT", 420, 432], ["inflammatory syndrome", "OBSERVATION", 4, 25], ["pharynx", "ANATOMY", 33, 40], ["pyogenes", "OBSERVATION_MODIFIER", 59, 67], ["infection", "OBSERVATION", 68, 77], ["marked", "OBSERVATION_MODIFIER", 81, 87], ["fever", "OBSERVATION", 165, 170]]], ["S. pyogenes also causes suppurative infections of the tonsils, sinuses, and middle ear, or cellulitis as secondary sequelae after an episode of pharyngitis.", [["tonsils", "ANATOMY", 54, 61], ["sinuses", "ANATOMY", 63, 70], ["middle ear", "ANATOMY", 76, 86], ["suppurative infections of the tonsils", "DISEASE", 24, 61], ["cellulitis", "DISEASE", 91, 101], ["pharyngitis", "DISEASE", 144, 155], ["S. pyogenes", "ORGANISM", 0, 11], ["tonsils", "ORGAN", 54, 61], ["sinuses", "MULTI-TISSUE_STRUCTURE", 63, 70], ["ear", "ORGAN", 83, 86], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "SPECIES", 0, 11], ["S. pyogenes", "PROBLEM", 0, 11], ["suppurative infections of the tonsils", "PROBLEM", 24, 61], ["sinuses, and middle ear", "PROBLEM", 63, 86], ["cellulitis", "PROBLEM", 91, 101], ["secondary sequelae", "PROBLEM", 105, 123], ["pharyngitis", "PROBLEM", 144, 155], ["pyogenes", "OBSERVATION", 3, 11], ["suppurative", "OBSERVATION_MODIFIER", 24, 35], ["infections", "OBSERVATION", 36, 46], ["tonsils", "ANATOMY", 54, 61], ["sinuses", "ANATOMY", 63, 70], ["middle ear", "ANATOMY", 76, 86], ["cellulitis", "OBSERVATION", 91, 101], ["pharyngitis", "OBSERVATION", 144, 155]]], ["Treatment of GABHS pharyngitis is crucial because this can shorten the duration of symptoms and prevent the spread of the organism to other patients.", [["GABHS", "DISEASE", 13, 18], ["pharyngitis", "DISEASE", 19, 30], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["GABHS pharyngitis", "PROBLEM", 13, 30], ["symptoms", "PROBLEM", 83, 91], ["GABHS pharyngitis", "OBSERVATION", 13, 30]]], ["It will also prevent the potential damage that S. pyogenes may cause to the heart and kidneys from rheumatic fever and glomerulonephritis, respectively.PharyngitisThe gold standard diagnostic test for GABHS infection is the throat culture.", [["heart", "ANATOMY", 76, 81], ["kidneys", "ANATOMY", 86, 93], ["throat", "ANATOMY", 224, 230], ["S. pyogenes", "DISEASE", 47, 58], ["rheumatic fever", "DISEASE", 99, 114], ["glomerulonephritis", "DISEASE", 119, 137], ["Pharyngitis", "DISEASE", 152, 163], ["GABHS infection", "DISEASE", 201, 216], ["S. pyogenes", "ORGANISM", 47, 58], ["heart", "ORGAN", 76, 81], ["kidneys", "ORGAN", 86, 93], ["S. pyogenes", "SPECIES", 47, 58], ["S. pyogenes", "SPECIES", 47, 58], ["S. pyogenes", "PROBLEM", 47, 58], ["rheumatic fever", "PROBLEM", 99, 114], ["glomerulonephritis", "PROBLEM", 119, 137], ["Pharyngitis", "PROBLEM", 152, 163], ["diagnostic test", "TEST", 181, 196], ["GABHS infection", "PROBLEM", 201, 216], ["the throat culture", "TEST", 220, 238], ["pyogenes", "OBSERVATION", 50, 58], ["heart", "ANATOMY", 76, 81], ["kidneys", "ANATOMY", 86, 93], ["rheumatic", "OBSERVATION_MODIFIER", 99, 108], ["fever", "OBSERVATION", 109, 114], ["glomerulonephritis", "OBSERVATION", 119, 137]]], ["6 Unfortunately the culture takes 24 to 48 hours to complete.", [["the culture", "TEST", 16, 27]]], ["If the patient leaves their physician or healthcare facility with a prescription for antibiotics, the treatment would then begin before the microbial entity is known.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["antibiotics", "TREATMENT", 85, 96], ["the treatment", "TREATMENT", 98, 111]]], ["In the age of emerging drug resistance, unnecessary antimicrobial agent use must be avoided.", [["emerging drug resistance", "TREATMENT", 14, 38], ["unnecessary antimicrobial agent", "TREATMENT", 40, 71], ["drug resistance", "OBSERVATION", 23, 38]]], ["Because untreated GABHS infection may have serious consequences for the patient, rapid detection methods for S. pyogenes were developed to give nearly immediate results in order to make the diagnosis of streptococcal pharyngitis possible while the patient is still in the office or clinic.", [["GABHS infection", "DISEASE", 18, 33], ["streptococcal pharyngitis", "DISEASE", 203, 228], ["patient", "ORGANISM", 72, 79], ["S. pyogenes", "ORGANISM", 109, 120], ["patient", "ORGANISM", 248, 255], ["patient", "SPECIES", 72, 79], ["S. pyogenes", "SPECIES", 109, 120], ["patient", "SPECIES", 248, 255], ["S. pyogenes", "SPECIES", 109, 120], ["untreated GABHS infection", "PROBLEM", 8, 33], ["rapid detection methods", "TEST", 81, 104], ["S. pyogenes", "PROBLEM", 109, 120], ["streptococcal pharyngitis", "PROBLEM", 203, 228], ["GABHS", "OBSERVATION", 18, 23], ["streptococcal", "OBSERVATION_MODIFIER", 203, 216], ["pharyngitis", "OBSERVATION", 217, 228]]], ["There are several manufacturers of rapid identification test kits for GABHS in the marketplace today.=, 47, 52 The Centers for Disease Control and Prevention (CDC) reviewed 25 published studies that examined the sensitivity of these rapid identification test kits.", [["GABHS", "DISEASE", 70, 75], ["rapid identification test kits", "TEST", 35, 65], ["GABHS", "PROBLEM", 70, 75], ["Disease Control", "TREATMENT", 127, 142], ["published studies", "TEST", 176, 193], ["these rapid identification test kits", "TEST", 227, 263]]], ["18 They found the sensitivity of these tests ranged from 62% to 100%.", [["these tests", "TEST", 33, 44]]], ["Within any one institution, the sensitivity of a single kit varied by as much as 20%.", [["a single kit", "TEST", 47, 59]]], ["Assuming that a good diagnostic screening test should have a sensitivity of at least 95% (so almost all infected patients will be detected), this study showed that a negative rapid identification test for GABHS cannot accurately rule out infection, and that a corresponding culture also is needed.", [["GABHS", "DISEASE", 205, 210], ["infection", "DISEASE", 238, 247], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["a good diagnostic screening test", "TEST", 14, 46], ["this study", "TEST", 141, 151], ["a negative rapid identification test", "PROBLEM", 164, 200], ["GABHS", "PROBLEM", 205, 210], ["infection", "PROBLEM", 238, 247], ["a corresponding culture", "TEST", 258, 281], ["infection", "OBSERVATION", 238, 247]]], ["18 In a national survey, the College of American Pathologists (CAP) sent 2692 laboratories a swab seeded with S. pyogenes to perform a rapid detection test with the kit used at their institution.", [["S. pyogenes", "ORGANISM", 110, 121], ["S. pyogenes", "SPECIES", 110, 121], ["S. pyogenes", "SPECIES", 110, 121], ["a swab", "TEST", 91, 97], ["S. pyogenes", "PROBLEM", 110, 121], ["a rapid detection test", "TEST", 133, 155], ["the kit", "TEST", 161, 168]]], ["Fourteen different types of GABHS kits were assessed.", [["GABHS", "DISEASE", 28, 33], ["GABHS kits", "TREATMENT", 28, 38], ["GABHS", "OBSERVATION", 28, 33]]], ["The number of correct results ranged from 80% to loo%, with only three kits providing 100% accuracy for all participants.", [["participants", "SPECIES", 108, 120]]], ["Based on this survey, and similar performance on previous CAP surveys, both the CAP and CDC recommend that a negative test result generated by a rapid identification test for GABHS must always be followed with a culture.", [["GABHS", "DISEASE", 175, 180], ["this survey", "TEST", 9, 20], ["previous CAP surveys", "TEST", 49, 69], ["a negative test", "TEST", 107, 122], ["a rapid identification test", "TEST", 143, 170], ["GABHS", "PROBLEM", 175, 180], ["a culture", "TEST", 210, 219]]], ["A useful approach is to collect two throat swabs, one for rapid testing and the other for culture.", [["throat swabs", "ANATOMY", 36, 48], ["two throat swabs", "TEST", 32, 48], ["rapid testing", "TEST", 58, 71], ["culture", "TEST", 90, 97]]], ["If the antigen test is positive, the second swab for culture is not needed.", [["the antigen test", "TEST", 3, 19], ["the second swab for culture", "TEST", 33, 60]]], ["If the antigen test is negative, the second swab should be used to perform the culture.", [["the antigen test", "TEST", 3, 19], ["the second swab", "TREATMENT", 33, 48], ["the culture", "TEST", 75, 86]]], ["This approach can be an economic practice for an institution caring for a large number of children.PharyngitisAdults with pharyngitis would more than likely have to have both a rapid screen and a culture performed, as studies have shown that the percentage of adult patients with GABHS disease is low (less than 10% of all cases).", [["PharyngitisAdults", "DISEASE", 99, 116], ["pharyngitis", "DISEASE", 122, 133], ["GABHS disease", "DISEASE", 280, 293], ["children", "ORGANISM", 90, 98], ["patients", "ORGANISM", 266, 274], ["children", "SPECIES", 90, 98], ["patients", "SPECIES", 266, 274], ["pharyngitis", "PROBLEM", 122, 133], ["a rapid screen", "TEST", 175, 189], ["a culture", "TEST", 194, 203], ["GABHS disease", "PROBLEM", 280, 293], ["large", "OBSERVATION_MODIFIER", 74, 79], ["pharyngitis", "OBSERVATION", 122, 133], ["low", "OBSERVATION_MODIFIER", 297, 300]]], ["This is because streptococcal pharyngitis is nearly exclusively a disease of 5to 15-year-0lds.~ Therefore, the chance of having a true positive screen test in an adult population is very low.", [["streptococcal pharyngitis", "DISEASE", 16, 41], ["streptococcal pharyngitis", "PROBLEM", 16, 41], ["a true positive screen test", "PROBLEM", 128, 155], ["streptococcal", "OBSERVATION_MODIFIER", 16, 29], ["pharyngitis", "OBSERVATION", 30, 41]]], ["As previously noted, the rapid, direct tests for S. pyogenes have a reported sensitivity ranging from 62% to loo%, with an excellent specificity of at least 95%; however, with a low GABHS prevalence adult patient population (55%), a full 50% of positive tests would be false-positive results, even with a test that was 100% sensitive and 95% specific (5 true-positive and 5 false-positive patients for each 100 tested).", [["GABHS", "DISEASE", 182, 187], ["S. pyogenes", "ORGANISM", 49, 60], ["patient", "ORGANISM", 205, 212], ["patients", "ORGANISM", 389, 397], ["S. pyogenes", "SPECIES", 49, 60], ["patient", "SPECIES", 205, 212], ["patients", "SPECIES", 389, 397], ["S. pyogenes", "SPECIES", 49, 60], ["direct tests", "TEST", 32, 44], ["S. pyogenes", "PROBLEM", 49, 60], ["positive tests", "PROBLEM", 245, 259], ["a test", "TEST", 303, 309], ["true-positive", "TEST", 354, 367], ["excellent", "OBSERVATION_MODIFIER", 123, 132]]], ["This leads to additional prescribing of unnecessary antibiotics for patients, with the risk of a serious adverse reaction in someone who did not need treatment.", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["unnecessary antibiotics", "TREATMENT", 40, 63], ["a serious adverse reaction", "PROBLEM", 95, 121], ["treatment", "TREATMENT", 150, 159]]], ["A study of 806 community patients with an overall 25.1% prevalence of GABHS recovered by culture, published in 1990, supports this concern.52 Using a direct \"rapid test did not add to a clinical evaluation, and compared to a well-done culture, it resulted in \"delayed treatment, unnecessary treatment, and increased costs.\"", [["GABHS", "DISEASE", 70, 75], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["A study", "TEST", 0, 7], ["GABHS", "PROBLEM", 70, 75], ["culture", "TEST", 89, 96], ["a direct \"rapid test", "TEST", 148, 168], ["a clinical evaluation", "TEST", 184, 205], ["a well-done culture", "TEST", 223, 242], ["delayed treatment", "TREATMENT", 260, 277], ["unnecessary treatment", "TREATMENT", 279, 300]]], ["Compared to culture, the rapid test only had a positive predictive value of 61% and a negative predictive value of 89%.PharyngitisSusceptibility testing generally is not done on any GABHS isolated, as these bacteria have traditionally been susceptible to all agents usually employed for therapy.", [["GABHS", "DISEASE", 182, 187], ["culture", "TEST", 12, 19], ["the rapid test", "TEST", 21, 35], ["PharyngitisSusceptibility testing", "TEST", 119, 152], ["any GABHS", "PROBLEM", 178, 187], ["these bacteria", "PROBLEM", 201, 215], ["all agents", "TREATMENT", 255, 265], ["therapy", "TREATMENT", 287, 294]]], ["When a rapid screen is positive and no culture is done, there is also no viable organism available to perform such testing.", [["a rapid screen", "TEST", 5, 19], ["culture", "TEST", 39, 46], ["viable organism", "PROBLEM", 73, 88], ["such testing", "TEST", 110, 122]]], ["In an era of emerging antibacterial drug resistance, this practice may need to change.", [["emerging antibacterial drug resistance", "TREATMENT", 13, 51], ["this practice", "TREATMENT", 53, 66], ["antibacterial drug resistance", "OBSERVATION", 22, 51]]], ["At Northwestern Memorial Hospital, 66 strains of invasive S. pyogenes were tested for antibiotic susceptibility between 1995 and 1998.", [["S. pyogenes", "ORGANISM", 58, 69], ["S. pyogenes", "SPECIES", 58, 69], ["S. pyogenes", "SPECIES", 58, 69], ["invasive S. pyogenes", "PROBLEM", 49, 69], ["antibiotic susceptibility", "PROBLEM", 86, 111]]], ["Of these, 5% were resistant to erythromycin, the usual firstline therapy for streptococcal pharyngitis.PharyngitisPhysicians can help maintain (or even improve) the sensitivity of the GABHS detection by clinically selecting which patients to culture USE OF THE CLINICAL MICROBIOLOGY LABORATORY 779 and then using proper specimen collection techniques.", [["specimen", "ANATOMY", 320, 328], ["erythromycin", "CHEMICAL", 31, 43], ["streptococcal pharyngitis", "DISEASE", 77, 102], ["GABHS", "DISEASE", 184, 189], ["erythromycin", "CHEMICAL", 31, 43], ["erythromycin", "SIMPLE_CHEMICAL", 31, 43], ["patients", "ORGANISM", 230, 238], ["patients", "SPECIES", 230, 238], ["erythromycin", "TREATMENT", 31, 43], ["the usual firstline therapy", "TREATMENT", 45, 72], ["streptococcal pharyngitis", "PROBLEM", 77, 102], ["the GABHS detection", "TEST", 180, 199], ["proper specimen collection techniques", "TEST", 313, 350], ["streptococcal", "OBSERVATION_MODIFIER", 77, 90], ["pharyngitis", "OBSERVATION", 91, 102]]], ["Adults with signs and symptoms of pharyngeal exudate, swollen anterior cervical lymph nodes, absence of cough, and documented fever of 38\u00b0C or more (2100.5\"F) are three times more likely to have a positive culture for S. pyogenes than those with only two of these findings.", [["pharyngeal exudate", "ANATOMY", 34, 52], ["anterior cervical lymph nodes", "ANATOMY", 62, 91], ["pharyngeal exudate", "DISEASE", 34, 52], ["cough", "DISEASE", 104, 109], ["fever", "DISEASE", 126, 131], ["S. pyogenes", "DISEASE", 218, 229], ["Adults", "ORGANISM", 0, 6], ["pharyngeal exudate", "MULTI-TISSUE_STRUCTURE", 34, 52], ["cervical lymph nodes", "MULTI-TISSUE_STRUCTURE", 71, 91], ["S. pyogenes", "ORGANISM", 218, 229], ["Adults", "SPECIES", 0, 6], ["S. pyogenes", "SPECIES", 218, 229], ["S. pyogenes", "SPECIES", 218, 229], ["signs and symptoms", "PROBLEM", 12, 30], ["pharyngeal exudate", "PROBLEM", 34, 52], ["swollen anterior cervical lymph nodes", "PROBLEM", 54, 91], ["cough", "PROBLEM", 104, 109], ["documented fever of 38\u00b0C", "PROBLEM", 115, 139], ["a positive culture", "PROBLEM", 195, 213], ["S. pyogenes", "PROBLEM", 218, 229], ["pharyngeal", "ANATOMY", 34, 44], ["exudate", "OBSERVATION", 45, 52], ["swollen", "OBSERVATION_MODIFIER", 54, 61], ["anterior", "ANATOMY_MODIFIER", 62, 70], ["cervical", "ANATOMY", 71, 79], ["lymph nodes", "OBSERVATION", 80, 91], ["cough", "OBSERVATION", 104, 109]]], ["With none of these signs or symptoms, only 2.5% of adults with pharyngitis will have a positive culture for GABHS.", [["pharyngitis", "DISEASE", 63, 74], ["GABHS", "DISEASE", 108, 113], ["adults", "ORGANISM", 51, 57], ["these signs", "PROBLEM", 13, 24], ["symptoms", "PROBLEM", 28, 36], ["pharyngitis", "PROBLEM", 63, 74], ["a positive culture", "TEST", 85, 103], ["GABHS", "PROBLEM", 108, 113], ["pharyngitis", "OBSERVATION", 63, 74]]], ["The optimal culture technique when streptococcal pharyngitis is considered likely is to thoroughly swab the palatine tonsils and oropharynx and avoid the tongue.", [["palatine tonsils", "ANATOMY", 108, 124], ["oropharynx", "ANATOMY", 129, 139], ["tongue", "ANATOMY", 154, 160], ["streptococcal pharyngitis", "DISEASE", 35, 60], ["palatine tonsils", "MULTI-TISSUE_STRUCTURE", 108, 124], ["oropharynx", "ORGAN", 129, 139], ["tongue", "ORGAN", 154, 160], ["The optimal culture technique", "TEST", 0, 29], ["streptococcal pharyngitis", "PROBLEM", 35, 60], ["the tongue", "PROBLEM", 150, 160], ["pharyngitis", "OBSERVATION", 49, 60], ["palatine tonsils", "ANATOMY", 108, 124], ["oropharynx", "ANATOMY", 129, 139], ["tongue", "ANATOMY", 154, 160]]], ["Doing this, one can expect that within 48 hours a final culture result, with sensitivity and specificity approaching loo%, will be reported, and only those patients really requiring therapy will receive it.PharyngitisCases of pharyngitis caused by groups B, C, and G, and by nonhemolytic members of these groups of streptococci have been reported.", [["PharyngitisCases", "DISEASE", 206, 222], ["pharyngitis", "DISEASE", 226, 237], ["patients", "ORGANISM", 156, 164], ["C", "GENE_OR_GENE_PRODUCT", 258, 259], ["G", "GENE_OR_GENE_PRODUCT", 265, 266], ["streptococci", "CELL", 315, 327], ["patients", "SPECIES", 156, 164], ["a final culture result", "TEST", 48, 70], ["sensitivity", "TEST", 77, 88], ["specificity", "TEST", 93, 104], ["therapy", "TREATMENT", 182, 189], ["pharyngitis", "PROBLEM", 226, 237], ["groups B, C, and G", "PROBLEM", 248, 266], ["streptococci", "PROBLEM", 315, 327], ["pharyngitis", "OBSERVATION", 226, 237], ["streptococci", "OBSERVATION", 315, 327]]], ["Added to this list of uncommon causes of pharyngitis are mixed anaerobes (Vincent's angina, or gangrenous pharyngitis), N. gonorrhoeae, C. diphtheria, Arcanobacterium huemolyticum (accompanied by a scarlatiniform rash), Yersinia enferocolitica, Yersinia pes tis, Francisella tularensis (pharyngeal tularemia), rhinovirus,'coronavirus, adenovirus, HSV 1 and HSV 2, parainfluenza virus (croup), coxsackievirus A (herpangina), Epstein-Barr virus (EBV mononucleosis), cytomegalovirus (CMV mononucleosis), primary HIV infection, influenza A and B, Mycoplasma pneumoniae, Chlamydia psittaci, and C. pneumoniae.l, 6, 3o Although there are microbes other than S. pyugenes that may cause pharyngitis, it is important to remember that the other streptococci, most alternative bacteria, and the viruses are not known to benefit from specific antimicrobial therapy.", [["pharyngeal", "ANATOMY", 287, 297], ["pharyngitis", "DISEASE", 41, 52], ["Vincent's angina", "DISEASE", 74, 90], ["gangrenous pharyngitis", "DISEASE", 95, 117], ["N. gonorrhoeae", "DISEASE", 120, 134], ["C. diphtheria", "DISEASE", 136, 149], ["Arcanobacterium huemolyticum", "DISEASE", 151, 179], ["rash", "DISEASE", 213, 217], ["Yersinia enferocolitica", "DISEASE", 220, 243], ["Yersinia pes tis", "DISEASE", 245, 261], ["Francisella tularensis", "DISEASE", 263, 285], ["pharyngeal tularemia", "DISEASE", 287, 307], ["rhinovirus,'coronavirus", "DISEASE", 310, 333], ["HSV 1 and HSV 2, parainfluenza virus", "DISEASE", 347, 383], ["croup", "DISEASE", 385, 390], ["coxsackievirus A", "DISEASE", 393, 409], ["Epstein-Barr virus", "DISEASE", 424, 442], ["EBV mononucleosis", "DISEASE", 444, 461], ["cytomegalovirus (CMV mononucleosis", "DISEASE", 464, 498], ["primary HIV infection", "DISEASE", 501, 522], ["influenza A and B", "DISEASE", 524, 541], ["Mycoplasma pneumoniae", "DISEASE", 543, 564], ["Chlamydia psittaci", "DISEASE", 566, 584], ["pharyngitis", "DISEASE", 679, 690], ["N. gonorrhoeae", "ORGANISM", 120, 134], ["C. diphtheria", "ORGANISM", 136, 149], ["Arcanobacterium huemolyticum", "ORGANISM", 151, 179], ["Yersinia enferocolitica", "ORGANISM", 220, 243], ["Yersinia pes tis", "ORGANISM", 245, 261], ["Francisella tularensis", "ORGANISM", 263, 285], ["pharyngeal", "ORGAN", 287, 297], ["tularemia", "ORGANISM", 298, 307], ["rhinovirus", "ORGANISM", 310, 320], ["'coronavirus", "ORGANISM", 321, 333], ["adenovirus", "ORGANISM", 335, 345], ["HSV 1", "ORGANISM", 347, 352], ["HSV 2", "ORGANISM", 357, 362], ["parainfluenza virus", "ORGANISM", 364, 383], ["coxsackievirus A", "ORGANISM", 393, 409], ["herpangina", "CANCER", 411, 421], ["Epstein-Barr virus", "ORGANISM", 424, 442], ["EBV", "ORGANISM", 444, 447], ["cytomegalovirus", "ORGANISM", 464, 479], ["CMV", "ORGANISM", 481, 484], ["HIV", "ORGANISM", 509, 512], ["influenza A", "ORGANISM", 524, 535], ["B", "ORGANISM", 540, 541], ["Mycoplasma pneumoniae", "ORGANISM", 543, 564], ["Chlamydia psittaci", "ORGANISM", 566, 584], ["C. pneumoniae.l", "ORGANISM", 590, 605], ["S. pyugenes", "ORGANISM", 652, 663], ["N. gonorrhoeae", "SPECIES", 120, 134], ["C. diphtheria", "SPECIES", 136, 149], ["Arcanobacterium huemolyticum", "SPECIES", 151, 179], ["Yersinia enferocolitica", "SPECIES", 220, 243], ["Francisella tularensis", "SPECIES", 263, 285], ["rhinovirus", "SPECIES", 310, 320], ["coronavirus", "SPECIES", 322, 333], ["parainfluenza virus", "SPECIES", 364, 383], ["Barr virus", "SPECIES", 432, 442], ["HIV", "SPECIES", 509, 512], ["Mycoplasma pneumoniae", "SPECIES", 543, 564], ["Chlamydia psittaci", "SPECIES", 566, 584], ["S. pyugenes", "SPECIES", 652, 663], ["N. gonorrhoeae", "SPECIES", 120, 134], ["C. diphtheria", "SPECIES", 136, 149], ["Arcanobacterium huemolyticum", "SPECIES", 151, 179], ["Yersinia enferocolitica", "SPECIES", 220, 243], ["Yersinia pes tis", "SPECIES", 245, 261], ["Francisella tularensis", "SPECIES", 263, 285], ["HSV 1", "SPECIES", 347, 352], ["HSV", "SPECIES", 357, 360], ["parainfluenza virus", "SPECIES", 364, 383], ["coxsackievirus A", "SPECIES", 393, 409], ["Epstein-Barr virus", "SPECIES", 424, 442], ["HIV", "SPECIES", 509, 512], ["Mycoplasma pneumoniae", "SPECIES", 543, 564], ["Chlamydia psittaci", "SPECIES", 566, 584], ["C. pneumoniae.l", "SPECIES", 590, 605], ["S. pyugenes", "SPECIES", 652, 663], ["pharyngitis", "PROBLEM", 41, 52], ["mixed anaerobes", "PROBLEM", 57, 72], ["Vincent's angina", "PROBLEM", 74, 90], ["gangrenous pharyngitis", "PROBLEM", 95, 117], ["C. diphtheria", "PROBLEM", 136, 149], ["Arcanobacterium huemolyticum", "PROBLEM", 151, 179], ["a scarlatiniform rash", "PROBLEM", 196, 217], ["Yersinia enferocolitica", "PROBLEM", 220, 243], ["Yersinia pes tis", "PROBLEM", 245, 261], ["Francisella tularensis", "PROBLEM", 263, 285], ["pharyngeal tularemia", "PROBLEM", 287, 307], ["rhinovirus", "PROBLEM", 310, 320], ["'coronavirus", "PROBLEM", 321, 333], ["adenovirus", "PROBLEM", 335, 345], ["HSV", "PROBLEM", 347, 350], ["HSV", "PROBLEM", 357, 360], ["parainfluenza virus (croup)", "PROBLEM", 364, 391], ["coxsackievirus A (herpangina)", "PROBLEM", 393, 422], ["Epstein", "TEST", 424, 431], ["Barr virus", "PROBLEM", 432, 442], ["EBV mononucleosis)", "PROBLEM", 444, 462], ["cytomegalovirus (CMV mononucleosis)", "PROBLEM", 464, 499], ["primary HIV infection", "PROBLEM", 501, 522], ["influenza A", "PROBLEM", 524, 535], ["Mycoplasma pneumoniae", "PROBLEM", 543, 564], ["Chlamydia psittaci", "PROBLEM", 566, 584], ["S. pyugenes", "PROBLEM", 652, 663], ["pharyngitis", "PROBLEM", 679, 690], ["the other streptococci", "PROBLEM", 725, 747], ["most alternative bacteria", "PROBLEM", 749, 774], ["the viruses", "PROBLEM", 780, 791], ["specific antimicrobial therapy", "TREATMENT", 822, 852], ["pharyngitis", "OBSERVATION", 41, 52], ["gangrenous", "OBSERVATION_MODIFIER", 95, 105], ["pharyngitis", "OBSERVATION", 106, 117], ["pharyngeal", "ANATOMY", 287, 297], ["tularemia", "OBSERVATION", 298, 307], ["parainfluenza virus", "OBSERVATION", 364, 383], ["Barr virus", "OBSERVATION", 432, 442], ["cytomegalovirus", "OBSERVATION", 464, 479], ["CMV mononucleosis", "OBSERVATION", 481, 498], ["HIV infection", "OBSERVATION", 509, 522], ["Mycoplasma pneumoniae", "OBSERVATION", 543, 564], ["Chlamydia psittaci", "OBSERVATION", 566, 584], ["may cause", "UNCERTAINTY", 669, 678], ["pharyngitis", "OBSERVATION", 679, 690], ["antimicrobial therapy", "OBSERVATION", 831, 852]]], ["The clinical laboratory does not routinely look for any of these other agents in throat swabs, except in unusual circumstances when specifically requested by the clinician inv01ved.5~DiphtheriaAlthough much less common than streptococcal pharyngitis, C. diphtheriae can still be isolated from patients with sore throat, as well as from those with a more serious systemic disease.", [["throat swabs", "ANATOMY", 81, 93], ["sore throat", "ANATOMY", 307, 318], ["streptococcal pharyngitis", "DISEASE", 224, 249], ["C. diphtheriae", "DISEASE", 251, 265], ["sore throat", "DISEASE", 307, 318], ["C. diphtheriae", "ORGANISM", 251, 265], ["patients", "ORGANISM", 293, 301], ["throat", "ORGANISM_SUBDIVISION", 312, 318], ["C. diphtheriae", "SPECIES", 251, 265], ["patients", "SPECIES", 293, 301], ["C. diphtheriae", "SPECIES", 251, 265], ["throat swabs", "TEST", 81, 93], ["streptococcal pharyngitis", "PROBLEM", 224, 249], ["C. diphtheriae", "PROBLEM", 251, 265], ["sore throat", "PROBLEM", 307, 318], ["a more serious systemic disease", "PROBLEM", 347, 378], ["less common", "OBSERVATION_MODIFIER", 207, 218], ["pharyngitis", "OBSERVATION", 238, 249], ["serious", "OBSERVATION_MODIFIER", 354, 361], ["systemic", "OBSERVATION_MODIFIER", 362, 370], ["disease", "OBSERVATION", 371, 378]]], ["Epidemic diphtheria re-emerged in the former Soviet Union beginning in 1990, resulting in approximately 125,000 cases and 4000 deaths between 1990 and 1995.", [["diphtheria", "DISEASE", 9, 19], ["deaths", "DISEASE", 127, 133], ["Epidemic diphtheria", "PROBLEM", 0, 19]]], ["Although the number of new cases began to decrease in 1996, following a World Health Organization (WHO) strategy to vaccinate 90% of persons aged 3 years or older, cases are still being exported to Europe and other parts of the world.% The introduction of new strains into the United States from exogenous reservoirs can cause outbreaks in homeless populations who are often in poor health and lack basic medical care.", [["persons", "ORGANISM", 133, 140], ["persons", "SPECIES", 133, 140], ["exogenous reservoirs", "TREATMENT", 296, 316], ["new", "OBSERVATION_MODIFIER", 23, 26], ["decrease", "OBSERVATION_MODIFIER", 42, 50], ["exogenous reservoirs", "OBSERVATION", 296, 316]]], ["25 The laboratory diagnosis of diphtheria includes appropriate processing of a throat or nasopharyngeal swab.", [["throat", "ANATOMY", 79, 85], ["nasopharyngeal swab", "ANATOMY", 89, 108], ["diphtheria", "DISEASE", 31, 41], ["throat", "ORGANISM_SUBDIVISION", 79, 85], ["nasopharyngeal swab", "CANCER", 89, 108], ["diphtheria", "PROBLEM", 31, 41], ["a throat or nasopharyngeal swab", "PROBLEM", 77, 108], ["throat", "ANATOMY", 79, 85], ["nasopharyngeal", "ANATOMY", 89, 103], ["swab", "OBSERVATION", 104, 108]]], ["It should be inoculated to blood agar designed to detect P-hemolytic streptococci, and to differential media for C. diphtheriae, such as tellurite agar and a Loeffler slant.\"", [["blood", "ANATOMY", 27, 32], ["tellurite", "CHEMICAL", 137, 146], ["tellurite", "CHEMICAL", 137, 146], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["tellurite", "SIMPLE_CHEMICAL", 137, 146], ["P", "DNA", 57, 58], ["C. diphtheriae", "SPECIES", 113, 127], ["C. diphtheriae", "SPECIES", 113, 127], ["blood agar", "TEST", 27, 37], ["P-hemolytic streptococci", "PROBLEM", 57, 81], ["C. diphtheriae", "PROBLEM", 113, 127]]], ["Colonies appearing on the Loeffler's slant are stained with methylene blue to detect typical cellular morphology.", [["Colonies", "ANATOMY", 0, 8], ["cellular", "ANATOMY", 93, 101], ["methylene blue", "CHEMICAL", 60, 74], ["methylene blue", "CHEMICAL", 60, 74], ["methylene blue", "SIMPLE_CHEMICAL", 60, 74], ["cellular", "CELL", 93, 101], ["methylene blue", "TREATMENT", 60, 74], ["typical", "OBSERVATION_MODIFIER", 85, 92], ["cellular morphology", "OBSERVATION", 93, 112]]], ["Gray to black colonies on tellurite agar are confirmed as C. diphtheriue by biochemical testing, and further referred to a public health laboratory for toxigenicity analysis.", [["colonies", "ANATOMY", 14, 22], ["tellurite", "CHEMICAL", 26, 35], ["tellurite", "CHEMICAL", 26, 35], ["tellurite", "SIMPLE_CHEMICAL", 26, 35], ["C. diphtheriue", "SPECIES", 58, 72], ["black colonies", "PROBLEM", 8, 22], ["tellurite agar", "TEST", 26, 40], ["biochemical testing", "TEST", 76, 95], ["toxigenicity analysis", "TEST", 152, 173], ["black colonies", "OBSERVATION", 8, 22]]], ["Other Corynebacterium spp (C. ulcerans and C. pyogenes) can cause pharyngitis, with or without membrane formation or associated rash, but such infections are rare.Other Bacteria Causing PharyngitisA recently recognized pathogen, Arcunobacteriurn huemolyticurn, may cause as many as 10% of pharyngotonsillitis in patients 10 to 30 years old.", [["membrane", "ANATOMY", 95, 103], ["pharyngitis", "DISEASE", 66, 77], ["rash", "DISEASE", 128, 132], ["infections", "DISEASE", 143, 153], ["PharyngitisA", "CHEMICAL", 186, 198], ["Arcunobacteriurn huemolyticurn", "DISEASE", 229, 259], ["pharyngotonsillitis", "DISEASE", 289, 308], ["Corynebacterium spp", "ORGANISM", 6, 25], ["C. ulcerans", "ORGANISM", 27, 38], ["C. pyogenes", "ORGANISM", 43, 54], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["Arcunobacteriurn huemolyticurn", "ORGANISM", 229, 259], ["pharyngotonsillitis", "CANCER", 289, 308], ["patients", "ORGANISM", 312, 320], ["Corynebacterium spp", "SPECIES", 6, 25], ["C. ulcerans", "SPECIES", 27, 38], ["C. pyogenes", "SPECIES", 43, 54], ["patients", "SPECIES", 312, 320], ["C. ulcerans", "SPECIES", 27, 38], ["C. pyogenes", "SPECIES", 43, 54], ["Arcunobacteriurn huemolyticurn", "SPECIES", 229, 259], ["Other Corynebacterium spp", "TEST", 0, 25], ["C. ulcerans", "PROBLEM", 27, 38], ["C. pyogenes", "PROBLEM", 43, 54], ["pharyngitis", "PROBLEM", 66, 77], ["membrane formation", "PROBLEM", 95, 113], ["associated rash", "PROBLEM", 117, 132], ["such infections", "PROBLEM", 138, 153], ["Other Bacteria", "PROBLEM", 163, 177], ["PharyngitisA", "PROBLEM", 186, 198], ["pharyngotonsillitis", "PROBLEM", 289, 308], ["Corynebacterium spp", "OBSERVATION", 6, 25], ["pharyngitis", "OBSERVATION", 66, 77], ["rash", "OBSERVATION", 128, 132], ["infections", "OBSERVATION", 143, 153], ["Bacteria", "OBSERVATION", 169, 177]]], ["It is typically associated with a rash consisting of erythematous macules and petechiae.", [["erythematous macules", "ANATOMY", 53, 73], ["petechiae", "ANATOMY", 78, 87], ["rash", "DISEASE", 34, 38], ["macules", "DISEASE", 66, 73], ["petechiae", "DISEASE", 78, 87], ["erythematous macules", "PATHOLOGICAL_FORMATION", 53, 73], ["petechiae", "PATHOLOGICAL_FORMATION", 78, 87], ["a rash", "PROBLEM", 32, 38], ["erythematous macules", "PROBLEM", 53, 73], ["petechiae", "PROBLEM", 78, 87], ["rash", "OBSERVATION", 34, 38], ["erythematous", "OBSERVATION_MODIFIER", 53, 65], ["macules", "OBSERVATION", 66, 73], ["petechiae", "OBSERVATION", 78, 87]]], ["Vesicles may also appear with the rash.", [["Vesicles", "ANATOMY", 0, 8], ["rash", "DISEASE", 34, 38], ["Vesicles", "ORGANISM_SUBSTANCE", 0, 8], ["rash", "PATHOLOGICAL_FORMATION", 34, 38], ["the rash", "PROBLEM", 30, 38], ["may also appear with", "UNCERTAINTY", 9, 29], ["rash", "OBSERVATION", 34, 38]]], ["To detect this microbe, a laboratory needs to hold the routine throat culture for 72 hours, as the organism is very slowly hemolytic; or alternatively plate the throat swab on agar containing 5% human blood to enhance hemolysis at 24 hours.2O N. meningitidis, too, occasionally can be recovered from the nasopharynx of carriers, although finding it here is not significant unless the patient has recently been exposed to a patient with N. meningitidis meningitis.", [["throat swab", "ANATOMY", 161, 172], ["blood", "ANATOMY", 201, 206], ["nasopharynx", "ANATOMY", 304, 315], ["hemolytic", "DISEASE", 123, 132], ["hemolysis", "DISEASE", 218, 227], ["N. meningitidis meningitis", "DISEASE", 436, 462], ["throat swab", "ORGANISM_SUBSTANCE", 161, 172], ["human", "ORGANISM", 195, 200], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["2O N. meningitidis", "ORGANISM", 240, 258], ["nasopharynx", "ORGAN", 304, 315], ["patient", "ORGANISM", 384, 391], ["patient", "ORGANISM", 423, 430], ["N. meningitidis", "ORGANISM", 436, 451], ["human", "SPECIES", 195, 200], ["N. meningitidis", "SPECIES", 243, 258], ["patient", "SPECIES", 384, 391], ["patient", "SPECIES", 423, 430], ["N. meningitidis", "SPECIES", 436, 451], ["human", "SPECIES", 195, 200], ["N. meningitidis", "SPECIES", 243, 258], ["N. meningitidis", "SPECIES", 436, 451], ["the routine throat culture", "TEST", 51, 77], ["the organism", "TEST", 95, 107], ["slowly hemolytic", "PROBLEM", 116, 132], ["plate the throat swab", "PROBLEM", 151, 172], ["agar", "TEST", 176, 180], ["hemolysis", "PROBLEM", 218, 227], ["meningitidis", "PROBLEM", 246, 258], ["the nasopharynx of carriers", "PROBLEM", 300, 327], ["N. meningitidis meningitis", "PROBLEM", 436, 462], ["throat", "ANATOMY", 161, 167], ["meningitidis", "OBSERVATION", 246, 258], ["nasopharynx", "ANATOMY", 304, 315], ["meningitidis", "OBSERVATION_MODIFIER", 439, 451], ["meningitis", "OBSERVATION", 452, 462]]], ["N. gonorrhoeae can cause an exutiative pharyngitis.", [["N. gonorrhoeae", "DISEASE", 0, 14], ["pharyngitis", "DISEASE", 39, 50], ["N. gonorrhoeae", "ORGANISM", 0, 14], ["N. gonorrhoeae", "SPECIES", 0, 14], ["N. gonorrhoeae", "SPECIES", 0, 14], ["an exutiative pharyngitis", "PROBLEM", 25, 50], ["exutiative", "OBSERVATION_MODIFIER", 28, 38], ["pharyngitis", "OBSERVATION", 39, 50]]], ["In this setting, as well as in disseminated gonococcal disease, the organism may be isolated from throat cultures.", [["throat cultures", "ANATOMY", 98, 113], ["gonococcal disease", "DISEASE", 44, 62], ["disseminated gonococcal disease", "PROBLEM", 31, 62], ["the organism", "PROBLEM", 64, 76], ["throat cultures", "TEST", 98, 113], ["disseminated", "OBSERVATION_MODIFIER", 31, 43], ["gonococcal disease", "OBSERVATION", 44, 62]]], ["Neisseriu spp require special media for satisfactory cultivation in the laboratory, and therefore consulting with microbiology personnel should be done before collecting and submitting specimens for their detection ( Table 1) .", [["specimens", "ANATOMY", 185, 194], ["Neisseriu spp", "ORGANISM", 0, 13], ["special media", "TREATMENT", 22, 35], ["their detection", "TEST", 199, 214]]], ["Although H. infuenzue, S. uureus, and S. pneumoniue are frequently isolated from nasopharyngeal and throat cultures, they have not been shown to cause pharyngitis.Atypical PathogensMycaplusmu pneumoniue occasionally may cause pharyngitis, and can be isolated from nasopharyngeal aspirates or swabs, when specifically requested.", [["nasopharyngeal", "ANATOMY", 81, 95], ["throat cultures", "ANATOMY", 100, 115], ["nasopharyngeal aspirates", "ANATOMY", 264, 288], ["swabs", "ANATOMY", 292, 297], ["pharyngitis", "DISEASE", 151, 162], ["pharyngitis", "DISEASE", 226, 237], ["H. infuenzue", "ORGANISM", 9, 21], ["S. uureus", "ORGANISM", 23, 32], ["S. pneumoniue", "ORGANISM", 38, 51], ["nasopharyngeal", "CANCER", 81, 95], ["throat cultures", "CELL", 100, 115], ["Mycaplusmu pneumoniue", "ORGANISM", 181, 202], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 264, 288], ["H. infuenzue", "SPECIES", 9, 21], ["S. uureus", "SPECIES", 23, 32], ["S. pneumoniue", "SPECIES", 38, 51], ["H. infuenzue", "SPECIES", 9, 21], ["S. uureus", "SPECIES", 23, 32], ["S. pneumoniue", "SPECIES", 38, 51], ["Mycaplusmu pneumoniue", "SPECIES", 181, 202], ["S. uureus", "PROBLEM", 23, 32], ["S. pneumoniue", "PROBLEM", 38, 51], ["nasopharyngeal and throat cultures", "TEST", 81, 115], ["pharyngitis", "PROBLEM", 151, 162], ["Atypical PathogensMycaplusmu pneumoniue", "PROBLEM", 163, 202], ["pharyngitis", "PROBLEM", 226, 237], ["nasopharyngeal aspirates or swabs", "PROBLEM", 264, 297], ["nasopharyngeal", "ANATOMY", 81, 95], ["throat", "ANATOMY", 100, 106], ["pharyngitis", "OBSERVATION", 151, 162], ["Pathogens", "OBSERVATION", 172, 181], ["may cause", "UNCERTAINTY", 216, 225], ["pharyngitis", "OBSERVATION", 226, 237], ["nasopharyngeal", "ANATOMY", 264, 278], ["aspirates", "OBSERVATION", 279, 288]]], ["The same specimens may also be the most easily collected sample for detection of Chlamydia pneurnoniae, an important consideration in patients with chronic pharyngiti; however, this organism can be difficult to grow in many laboratories, and newer polymerase chain reaction (PCR)-based tests will offer improved detection in the near future.3O.", [["specimens", "ANATOMY", 9, 18], ["sample", "ANATOMY", 57, 63], ["Chlamydia pneurnoniae", "DISEASE", 81, 102], ["chronic pharyngiti", "DISEASE", 148, 166], ["Chlamydia pneurnoniae", "ORGANISM", 81, 102], ["patients", "ORGANISM", 134, 142], ["Chlamydia pneurnoniae", "SPECIES", 81, 102], ["patients", "SPECIES", 134, 142], ["Chlamydia pneurnoniae", "SPECIES", 81, 102], ["Chlamydia pneurnoniae", "PROBLEM", 81, 102], ["chronic pharyngiti", "PROBLEM", 148, 166], ["this organism", "PROBLEM", 177, 190], ["newer polymerase chain reaction", "PROBLEM", 242, 273], ["PCR", "TEST", 275, 278], ["based tests", "TEST", 280, 291], ["may also be", "UNCERTAINTY", 19, 30], ["Chlamydia", "OBSERVATION", 81, 90], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["pharyngiti", "OBSERVATION", 156, 166]]], ["49, As noted earlier, a number of viral infections can result in exudative pharyngitis, including rhinoviruses, adenoviruses, respiratory syncytial virus (RSV), influenza and parainfluenza viruses, coronavims, coxsackieviruses, CMV, and EBV.", [["viral infections", "DISEASE", 34, 50], ["pharyngitis", "DISEASE", 75, 86], ["rhinoviruses", "DISEASE", 98, 110], ["respiratory syncytial virus (RSV)", "DISEASE", 126, 159], ["influenza and parainfluenza viruses", "DISEASE", 161, 196], ["rhinoviruses", "ORGANISM", 98, 110], ["adenoviruses", "ORGANISM", 112, 124], ["respiratory syncytial virus", "ORGANISM", 126, 153], ["RSV", "ORGANISM", 155, 158], ["parainfluenza viruses", "ORGANISM", 175, 196], ["coronavims", "GENE_OR_GENE_PRODUCT", 198, 208], ["CMV", "ORGANISM", 228, 231], ["EBV", "ORGANISM", 237, 240], ["respiratory syncytial virus", "SPECIES", 126, 153], ["parainfluenza", "SPECIES", 175, 188], ["respiratory syncytial virus", "SPECIES", 126, 153], ["RSV", "SPECIES", 155, 158], ["CMV", "SPECIES", 228, 231], ["EBV", "SPECIES", 237, 240], ["viral infections", "PROBLEM", 34, 50], ["exudative pharyngitis", "PROBLEM", 65, 86], ["rhinoviruses", "PROBLEM", 98, 110], ["adenoviruses", "PROBLEM", 112, 124], ["respiratory syncytial virus (RSV)", "PROBLEM", 126, 159], ["influenza", "PROBLEM", 161, 170], ["parainfluenza viruses", "PROBLEM", 175, 196], ["coronavims", "PROBLEM", 198, 208], ["coxsackieviruses", "PROBLEM", 210, 226], ["CMV", "PROBLEM", 228, 231], ["EBV", "PROBLEM", 237, 240], ["viral infections", "OBSERVATION", 34, 50], ["exudative", "OBSERVATION_MODIFIER", 65, 74], ["pharyngitis", "OBSERVATION", 75, 86], ["rhinoviruses", "OBSERVATION", 98, 110], ["respiratory", "ANATOMY", 126, 137], ["syncytial virus", "OBSERVATION", 138, 153], ["parainfluenza viruses", "OBSERVATION", 175, 196]]], ["These are generally not sought in routine diagnostic testing, but when detection is needed, nasopharyngeal washings or tracheal secretions are the specimens of choice for these cultures.", [["nasopharyngeal washings", "ANATOMY", 92, 115], ["tracheal secretions", "ANATOMY", 119, 138], ["specimens", "ANATOMY", 147, 156], ["nasopharyngeal washings", "MULTI-TISSUE_STRUCTURE", 92, 115], ["tracheal secretions", "MULTI-TISSUE_STRUCTURE", 119, 138], ["routine diagnostic testing", "TEST", 34, 60], ["nasopharyngeal washings", "TEST", 92, 115], ["tracheal secretions", "PROBLEM", 119, 138], ["these cultures", "TEST", 171, 185], ["tracheal", "ANATOMY", 119, 127], ["secretions", "OBSERVATION", 128, 138]]], ["Multiplex PCR assays may soon offer the ability to rapidly and reliably detect them.23 A current exception is the need for diagnosis of EBV or CMV mononucleosis.", [["CMV mononucleosis", "DISEASE", 143, 160], ["EBV", "ORGANISM", 136, 139], ["CMV", "ORGANISM", 143, 146], ["EBV", "SPECIES", 136, 139], ["Multiplex PCR assays", "TEST", 0, 20], ["EBV", "PROBLEM", 136, 139], ["CMV mononucleosis", "PROBLEM", 143, 160], ["EBV", "OBSERVATION", 136, 139], ["CMV mononucleosis", "OBSERVATION", 143, 160]]], ["This is most readily accomplished by use of serologic testing for the presence of heterophile antibodies (\"Monospot\" test) to diagnose acute EBV infection, or detection of IgM antibody directed against CMV for diagnosis of CMV mononucleosis.5 Use of accurate, rapid diagnostic tools can limit empiric antimicrobial agent therapy for pharyngitis and help reduce unnecessary use of these agents.= Another rare but important oral infection presentation is oral hairy leukoplakia in persons infected with H1V.Q This infection is best diagnosed by in situ hybridization for EBV from suspected lesions.", [["oral", "ANATOMY", 422, 426], ["oral hairy leukoplakia", "ANATOMY", 453, 475], ["lesions", "ANATOMY", 588, 595], ["acute EBV infection", "DISEASE", 135, 154], ["CMV mononucleosis", "DISEASE", 223, 240], ["pharyngitis", "DISEASE", 333, 344], ["infection", "DISEASE", 427, 436], ["hairy leukoplakia", "DISEASE", 458, 475], ["H1V.Q", "CHEMICAL", 501, 506], ["infection", "DISEASE", 512, 521], ["H1V.Q", "CHEMICAL", 501, 506], ["EBV", "ORGANISM", 141, 144], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 172, 184], ["CMV", "ORGANISM", 202, 205], ["CMV", "ORGANISM", 223, 226], ["oral", "ORGANISM_SUBDIVISION", 422, 426], ["oral", "ORGANISM_SUBDIVISION", 453, 457], ["hairy leukoplakia", "CANCER", 458, 475], ["persons", "ORGANISM", 479, 486], ["EBV", "ORGANISM", 569, 572], ["lesions", "PATHOLOGICAL_FORMATION", 588, 595], ["heterophile antibodies", "PROTEIN", 82, 104], ["IgM antibody", "PROTEIN", 172, 184], ["persons", "SPECIES", 479, 486], ["EBV", "SPECIES", 141, 144], ["CMV", "SPECIES", 202, 205], ["H1V.Q", "SPECIES", 501, 506], ["EBV", "SPECIES", 569, 572], ["serologic testing", "TEST", 44, 61], ["heterophile antibodies", "PROBLEM", 82, 104], ["acute EBV infection", "PROBLEM", 135, 154], ["IgM antibody", "TEST", 172, 184], ["CMV", "PROBLEM", 202, 205], ["CMV mononucleosis", "PROBLEM", 223, 240], ["empiric antimicrobial agent therapy", "TREATMENT", 293, 328], ["pharyngitis", "PROBLEM", 333, 344], ["these agents", "TREATMENT", 380, 392], ["important oral infection presentation", "PROBLEM", 412, 449], ["oral hairy leukoplakia", "PROBLEM", 453, 475], ["This infection", "PROBLEM", 507, 521], ["EBV", "PROBLEM", 569, 572], ["suspected lesions", "PROBLEM", 578, 595], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["EBV infection", "OBSERVATION", 141, 154], ["infection", "OBSERVATION", 427, 436], ["oral hairy", "OBSERVATION_MODIFIER", 453, 463], ["leukoplakia", "OBSERVATION", 464, 475], ["infection", "OBSERVATION", 512, 521], ["lesions", "OBSERVATION", 588, 595]]], ["Therapy is difficult and most responsive to control of the underlying disease.EpiglottitisOral infection with H. injuenzae can cause epiglottitis, leading to airway obstruction if not treated.", [["airway", "ANATOMY", 158, 164], ["infection", "DISEASE", 95, 104], ["H. injuenzae", "DISEASE", 110, 122], ["epiglottitis", "DISEASE", 133, 145], ["airway obstruction", "DISEASE", 158, 176], ["H. injuenzae", "ORGANISM", 110, 122], ["airway", "PATHOLOGICAL_FORMATION", 158, 164], ["H. injuenzae", "SPECIES", 110, 122], ["H. injuenzae", "SPECIES", 110, 122], ["Therapy", "TREATMENT", 0, 7], ["the underlying disease", "PROBLEM", 55, 77], ["EpiglottitisOral infection", "PROBLEM", 78, 104], ["H. injuenzae", "PROBLEM", 110, 122], ["epiglottitis", "PROBLEM", 133, 145], ["airway obstruction", "PROBLEM", 158, 176], ["disease", "OBSERVATION", 70, 77], ["infection", "OBSERVATION", 95, 104], ["epiglottitis", "OBSERVATION", 133, 145], ["airway", "ANATOMY", 158, 164], ["obstruction", "OBSERVATION", 165, 176]]], ["The effects of combined oral cavity anaerobic flora may cause an exudative, gangrenous pharyngitis (Vincent's angina) with a membrane-type lesion that can mimic diphtheria and also occasionally lead to a i b a y compromise.", [["oral", "ANATOMY", 24, 28], ["membrane-type lesion", "ANATOMY", 125, 145], ["pharyngitis", "DISEASE", 87, 98], ["Vincent's angina", "DISEASE", 100, 116], ["diphtheria", "DISEASE", 161, 171], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["combined oral cavity anaerobic flora", "PROBLEM", 15, 51], ["an exudative", "PROBLEM", 62, 74], ["gangrenous pharyngitis", "PROBLEM", 76, 98], ["Vincent's angina", "PROBLEM", 100, 116], ["a membrane-type lesion", "PROBLEM", 123, 145], ["diphtheria", "PROBLEM", 161, 171], ["a i b a y compromise", "PROBLEM", 202, 222], ["may cause", "UNCERTAINTY", 52, 61], ["exudative", "OBSERVATION_MODIFIER", 65, 74], ["gangrenous", "OBSERVATION_MODIFIER", 76, 86], ["pharyngitis", "OBSERVATION", 87, 98], ["lesion", "OBSERVATION", 139, 145]]], ["This may occur alone or in connection with a serious necrotizing ulcerative gingivitis (Vincent's gingivitis, or trench mouth) that is similar in pathogenesis to the pharyngitis bearing the same name.", [["ulcerative", "ANATOMY", 65, 75], ["mouth", "ANATOMY", 120, 125], ["ulcerative gingivitis", "DISEASE", 65, 86], ["Vincent's gingivitis", "DISEASE", 88, 108], ["trench mouth", "DISEASE", 113, 125], ["pharyngitis", "DISEASE", 166, 177], ["ulcerative gingivitis", "PATHOLOGICAL_FORMATION", 65, 86], ["mouth", "ORGANISM_SUBDIVISION", 120, 125], ["a serious necrotizing ulcerative gingivitis", "PROBLEM", 43, 86], ["Vincent's gingivitis", "PROBLEM", 88, 108], ["trench mouth", "PROBLEM", 113, 125], ["the pharyngitis", "PROBLEM", 162, 177], ["serious", "OBSERVATION_MODIFIER", 45, 52], ["necrotizing", "OBSERVATION_MODIFIER", 53, 64], ["ulcerative", "OBSERVATION_MODIFIER", 65, 75], ["gingivitis", "OBSERVATION", 76, 86], ["pharyngitis", "OBSERVATION", 166, 177]]], ["Although this is now a rare disease, it has occurred with increasing frequency in patients infected with HIV28,67; however, the foul odor noted in patients with Vincent's diseases may be useful in separating them from infection due to H. influenzae.", [["Vincent's diseases", "DISEASE", 161, 179], ["infection", "DISEASE", 218, 227], ["H. influenzae", "DISEASE", 235, 248], ["patients", "ORGANISM", 82, 90], ["HIV28,67", "ORGANISM", 105, 113], ["patients", "ORGANISM", 147, 155], ["H. influenzae", "ORGANISM", 235, 248], ["patients", "SPECIES", 82, 90], ["patients", "SPECIES", 147, 155], ["H. influenzae", "SPECIES", 235, 248], ["HIV28", "SPECIES", 105, 110], ["H. influenzae", "SPECIES", 235, 248], ["a rare disease", "PROBLEM", 21, 35], ["the foul odor", "PROBLEM", 124, 137], ["Vincent's diseases", "PROBLEM", 161, 179], ["infection", "PROBLEM", 218, 227], ["H. influenzae", "PROBLEM", 235, 248], ["rare", "OBSERVATION_MODIFIER", 23, 27], ["disease", "OBSERVATION", 28, 35], ["increasing", "OBSERVATION_MODIFIER", 58, 68], ["frequency", "OBSERVATION_MODIFIER", 69, 78], ["infected", "OBSERVATION_MODIFIER", 91, 99], ["infection", "OBSERVATION", 218, 227]]], ["Evidence suggests that Fusobacterium necrophorum is an important causative agent, but that other anaerobes are involved in this typically mixed infection.Peritonsillar AbscessThe predominant organisms in peritonsillar abscess are nonsporeforming anaerobes, including Fusobacterium spp (especially E necrophorum), various Bacteroides spp (including the B. fvagiZis group), PrevoteZZa and Porphyrornonas spp, and anaerobic cocci.", [["peritonsillar abscess", "ANATOMY", 204, 225], ["Fusobacterium necrophorum", "DISEASE", 23, 48], ["infection", "DISEASE", 144, 153], ["peritonsillar abscess", "DISEASE", 204, 225], ["Fusobacterium necrophorum", "ORGANISM", 23, 48], ["peritonsillar abscess", "PATHOLOGICAL_FORMATION", 204, 225], ["Fusobacterium spp", "ORGANISM", 267, 284], ["E necrophorum", "ORGANISM", 297, 310], ["Bacteroides spp", "ORGANISM", 321, 336], ["B. fvagiZis", "ORGANISM", 352, 363], ["PrevoteZZa", "SIMPLE_CHEMICAL", 372, 382], ["Porphyrornonas spp", "ORGANISM", 387, 405], ["Fusobacterium necrophorum", "SPECIES", 23, 48], ["Fusobacterium spp", "SPECIES", 267, 284], ["E necrophorum", "SPECIES", 297, 310], ["Bacteroides spp", "SPECIES", 321, 336], ["B. fvagiZis group", "SPECIES", 352, 369], ["Porphyrornonas spp", "SPECIES", 387, 405], ["Fusobacterium necrophorum", "SPECIES", 23, 48], ["Fusobacterium spp", "SPECIES", 267, 284], ["E necrophorum", "SPECIES", 297, 310], ["B. fvagiZis", "SPECIES", 352, 363], ["Fusobacterium necrophorum", "PROBLEM", 23, 48], ["other anaerobes", "PROBLEM", 91, 106], ["this typically mixed infection", "PROBLEM", 123, 153], ["Peritonsillar Abscess", "PROBLEM", 154, 175], ["peritonsillar abscess", "PROBLEM", 204, 225], ["nonsporeforming anaerobes", "PROBLEM", 230, 255], ["Fusobacterium spp", "PROBLEM", 267, 284], ["E necrophorum", "PROBLEM", 297, 310], ["various Bacteroides spp", "PROBLEM", 313, 336], ["PrevoteZZa", "PROBLEM", 372, 382], ["Porphyrornonas spp", "PROBLEM", 387, 405], ["anaerobic cocci", "PROBLEM", 411, 426], ["Fusobacterium", "OBSERVATION_MODIFIER", 23, 36], ["necrophorum", "OBSERVATION", 37, 48], ["anaerobes", "OBSERVATION", 97, 106], ["mixed", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153], ["Abscess", "OBSERVATION", 168, 175], ["predominant", "OBSERVATION_MODIFIER", 179, 190], ["organisms", "OBSERVATION_MODIFIER", 191, 200], ["peritonsillar", "ANATOMY", 204, 217], ["abscess", "OBSERVATION", 218, 225], ["anaerobes", "OBSERVATION", 246, 255], ["Fusobacterium spp", "OBSERVATION_MODIFIER", 267, 284], ["anaerobic cocci", "OBSERVATION", 411, 426]]], ["Strqtococcus pyogenes and viridans streptococci may also be involved.", [["Strqtococcus pyogenes", "ORGANISM", 0, 21], ["viridans streptococci", "CELL", 26, 47], ["Strqtococcus pyogenes", "SPECIES", 0, 21], ["Strqtococcus pyogenes", "SPECIES", 0, 21], ["Strqtococcus pyogenes", "PROBLEM", 0, 21], ["viridans streptococci", "TREATMENT", 26, 47], ["viridans streptococci", "OBSERVATION", 26, 47]]], ["Culture is helpful in the case of peritonsillar abscess, such as those that frequently accompany Vincent's angina, as specific antimicrobial agent therapy appears benefi-cia1.", [["peritonsillar abscess", "ANATOMY", 34, 55], ["peritonsillar abscess", "DISEASE", 34, 55], ["Vincent's angina", "DISEASE", 97, 113], ["peritonsillar abscess", "PATHOLOGICAL_FORMATION", 34, 55], ["Culture", "TEST", 0, 7], ["peritonsillar abscess", "PROBLEM", 34, 55], ["Vincent's angina", "PROBLEM", 97, 113], ["specific antimicrobial agent therapy", "TREATMENT", 118, 154], ["peritonsillar", "ANATOMY", 34, 47], ["abscess", "OBSERVATION", 48, 55]]], ["68 Here, pus from the drained abscess should be sent to the laboratory for aerobic and anaerobic culture, with susceptibility testing done on isolated pathogens.Infection in ImmunosuppressionImmunosuppressed patients, including very young babies, may develop oral candidiasis, or thrush.", [["pus", "ANATOMY", 9, 12], ["abscess", "ANATOMY", 30, 37], ["oral", "ANATOMY", 259, 263], ["abscess", "DISEASE", 30, 37], ["Infection", "DISEASE", 161, 170], ["candidiasis", "DISEASE", 264, 275], ["thrush", "DISEASE", 280, 286], ["pus", "ORGANISM_SUBSTANCE", 9, 12], ["abscess", "PATHOLOGICAL_FORMATION", 30, 37], ["patients", "ORGANISM", 208, 216], ["babies", "ORGANISM", 239, 245], ["oral", "ORGANISM_SUBDIVISION", 259, 263], ["candidiasis", "PATHOLOGICAL_FORMATION", 264, 275], ["patients", "SPECIES", 208, 216], ["pus", "PROBLEM", 9, 12], ["the drained abscess", "PROBLEM", 18, 37], ["anaerobic culture", "TEST", 87, 104], ["susceptibility testing", "TEST", 111, 133], ["isolated pathogens", "PROBLEM", 142, 160], ["Infection", "PROBLEM", 161, 170], ["oral candidiasis", "PROBLEM", 259, 275], ["thrush", "PROBLEM", 280, 286], ["pus", "OBSERVATION", 9, 12], ["drained", "OBSERVATION_MODIFIER", 22, 29], ["abscess", "OBSERVATION", 30, 37], ["Immunosuppression", "OBSERVATION_MODIFIER", 174, 191], ["Immunosuppressed", "OBSERVATION", 191, 207], ["candidiasis", "OBSERVATION", 264, 275], ["thrush", "OBSERVATION", 280, 286]]], ["Thrush can progress to produce esoph-S. aureus and streptococciRoutine microbiology culture on aspirated purulent material agitis, a common complication in AIDS and other immunosuppressed patients.", [["AIDS", "DISEASE", 156, 160], ["esoph-S. aureus", "ORGANISM", 31, 46], ["patients", "ORGANISM", 188, 196], ["S. aureus", "SPECIES", 37, 46], ["patients", "SPECIES", 188, 196], ["S. aureus", "SPECIES", 37, 46], ["Thrush", "PROBLEM", 0, 6], ["S. aureus", "PROBLEM", 37, 46], ["streptococciRoutine microbiology culture", "TEST", 51, 91], ["aspirated purulent material agitis", "PROBLEM", 95, 129], ["a common complication in AIDS", "PROBLEM", 131, 160], ["other immunosuppressed patients", "TREATMENT", 165, 196], ["esoph", "ANATOMY", 31, 36], ["aureus", "OBSERVATION", 40, 46], ["purulent material agitis", "OBSERVATION", 105, 129]]], ["Pharyngitis in the granulocytopenic patient may be associated with numerous unexpected microbes, including Enterobacteriaceae and S. aureus, as well as Candida spp.", [["Pharyngitis", "DISEASE", 0, 11], ["granulocytopenic", "DISEASE", 19, 35], ["Candida spp", "DISEASE", 152, 163], ["patient", "ORGANISM", 36, 43], ["S. aureus", "ORGANISM", 130, 139], ["Candida spp", "ORGANISM", 152, 163], ["patient", "SPECIES", 36, 43], ["S. aureus", "SPECIES", 130, 139], ["S. aureus", "SPECIES", 130, 139], ["Pharyngitis", "PROBLEM", 0, 11], ["the granulocytopenic", "PROBLEM", 15, 35], ["numerous unexpected microbes", "PROBLEM", 67, 95], ["Enterobacteriaceae", "PROBLEM", 107, 125], ["S. aureus", "PROBLEM", 130, 139], ["Candida spp", "PROBLEM", 152, 163], ["granulocytopenic", "OBSERVATION", 19, 35], ["may be associated with", "UNCERTAINTY", 44, 66], ["microbes", "OBSERVATION", 87, 95], ["Enterobacteriaceae", "OBSERVATION", 107, 125], ["aureus", "OBSERVATION", 133, 139], ["Candida spp", "OBSERVATION", 152, 163]]], ["It is manifested by erythema and sore throat, and occasionally exudate.", [["sore throat", "ANATOMY", 33, 44], ["exudate", "ANATOMY", 63, 70], ["erythema", "DISEASE", 20, 28], ["sore throat", "DISEASE", 33, 44], ["erythema", "PATHOLOGICAL_FORMATION", 20, 28], ["erythema", "PROBLEM", 20, 28], ["sore throat", "PROBLEM", 33, 44], ["occasionally exudate", "PROBLEM", 50, 70], ["erythema", "OBSERVATION", 20, 28], ["sore throat", "ANATOMY", 33, 44], ["occasionally", "OBSERVATION_MODIFIER", 50, 62], ["exudate", "OBSERVATION", 63, 70]]], ["Additionally, in the current era of major advances in cancer treatment and transplantation, a new infectious complication of the oral cavity has emerged: mucositis.", [["cancer", "ANATOMY", 54, 60], ["oral cavity", "ANATOMY", 129, 140], ["cancer", "DISEASE", 54, 60], ["mucositis", "DISEASE", 154, 163], ["cancer", "CANCER", 54, 60], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 129, 140], ["cancer treatment", "TREATMENT", 54, 70], ["transplantation", "TREATMENT", 75, 90], ["a new infectious complication", "PROBLEM", 92, 121], ["the oral cavity", "PROBLEM", 125, 140], ["mucositis", "PROBLEM", 154, 163], ["cancer", "OBSERVATION", 54, 60], ["new", "OBSERVATION_MODIFIER", 94, 97], ["infectious", "OBSERVATION_MODIFIER", 98, 108], ["oral cavity", "ANATOMY", 129, 140], ["mucositis", "OBSERVATION", 154, 163]]], ["Recent work suggests that gram-negative bacilli colonizing or infecting the oral cavity play an important role in the severe forms of mucositis.60 It is now added to the list of differential diagnoses in the febrile neutropenic patient.", [["oral cavity", "ANATOMY", 76, 87], ["mucositis", "DISEASE", 134, 143], ["neutropenic", "DISEASE", 216, 227], ["oral cavity", "ORGANISM_SUBDIVISION", 76, 87], ["mucositis", "PATHOLOGICAL_FORMATION", 134, 143], ["patient", "ORGANISM", 228, 235], ["patient", "SPECIES", 228, 235], ["gram-negative bacilli colonizing", "PROBLEM", 26, 58], ["infecting the oral cavity", "PROBLEM", 62, 87], ["mucositis", "PROBLEM", 134, 143], ["negative", "OBSERVATION_MODIFIER", 31, 39], ["bacilli colonizing", "OBSERVATION", 40, 58], ["oral cavity", "ANATOMY", 76, 87], ["severe", "OBSERVATION_MODIFIER", 118, 124], ["mucositis", "OBSERVATION", 134, 143]]], ["Other unusual oral flora microbes are associated with fever and bacteremia in the immunocompromised patient with mucositis.", [["oral", "ANATOMY", 14, 18], ["fever", "DISEASE", 54, 59], ["bacteremia", "DISEASE", 64, 74], ["mucositis", "DISEASE", 113, 122], ["oral", "ORGANISM_SUBDIVISION", 14, 18], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["Other unusual oral flora microbes", "PROBLEM", 0, 33], ["fever", "PROBLEM", 54, 59], ["bacteremia", "PROBLEM", 64, 74], ["mucositis", "PROBLEM", 113, 122], ["flora", "OBSERVATION", 19, 24], ["fever", "OBSERVATION", 54, 59], ["bacteremia", "OBSERVATION", 64, 74], ["immunocompromised", "OBSERVATION_MODIFIER", 82, 99], ["mucositis", "OBSERVATION", 113, 122]]], ["One of those recently recognized is bacteremia from Capnocytophaga ~p p .", [["bacteremia", "DISEASE", 36, 46], ["bacteremia", "PROBLEM", 36, 46], ["Capnocytophaga", "PROBLEM", 52, 66], ["bacteremia", "OBSERVATION", 36, 46], ["Capnocytophaga", "OBSERVATION", 52, 66]]], ["3~ Infection with herpes simplex virus (HSV) can cause painful lesions in the mouth and the oropharynx (stomatitis), another condition that is also prevalent among immunosuppressed patients, including those with HIV infection.", [["lesions", "ANATOMY", 63, 70], ["mouth", "ANATOMY", 78, 83], ["oropharynx", "ANATOMY", 92, 102], ["herpes simplex virus (HSV)", "DISEASE", 18, 44], ["painful lesions in the mouth and the oropharynx", "DISEASE", 55, 102], ["stomatitis", "DISEASE", 104, 114], ["HIV infection", "DISEASE", 212, 225], ["herpes simplex virus", "ORGANISM", 18, 38], ["HSV", "ORGANISM", 40, 43], ["lesions", "PATHOLOGICAL_FORMATION", 63, 70], ["mouth", "ORGAN", 78, 83], ["oropharynx", "ORGAN", 92, 102], ["patients", "ORGANISM", 181, 189], ["HIV", "ORGANISM", 212, 215], ["herpes simplex virus", "SPECIES", 18, 38], ["patients", "SPECIES", 181, 189], ["HIV", "SPECIES", 212, 215], ["herpes simplex virus", "SPECIES", 18, 38], ["HSV", "SPECIES", 40, 43], ["HIV", "SPECIES", 212, 215], ["Infection", "PROBLEM", 3, 12], ["herpes simplex virus", "PROBLEM", 18, 38], ["HSV", "PROBLEM", 40, 43], ["painful lesions in the mouth and the oropharynx (stomatitis", "PROBLEM", 55, 114], ["HIV infection", "PROBLEM", 212, 225], ["Infection", "OBSERVATION", 3, 12], ["herpes simplex virus", "OBSERVATION", 18, 38], ["painful", "OBSERVATION_MODIFIER", 55, 62], ["lesions", "OBSERVATION", 63, 70], ["mouth", "ANATOMY", 78, 83], ["oropharynx", "ANATOMY", 92, 102], ["stomatitis", "OBSERVATION", 104, 114], ["infection", "OBSERVATION", 216, 225]]], ["Interestingly, stomatitis is a common manifestation of primary HSV infection for young children, and has even been reported as an employment-related infection for healthcare workers.2 Oral hairy leukoplakia, as noted earlier, is increasingly seen as an EBV-related infection that is associated with HIV, manifesting itself as a lesion in the oral cavity?S. aureus and streptococciVincent's angina is considered a necrotizing anaerobic tonsillitis with pseudomembrane formation on tonsillar surfaces.", [["Oral hairy leukoplakia", "ANATOMY", 184, 206], ["lesion", "ANATOMY", 328, 334], ["oral cavity", "ANATOMY", 342, 353], ["pseudomembrane", "ANATOMY", 452, 466], ["tonsillar surfaces", "ANATOMY", 480, 498], ["stomatitis", "DISEASE", 15, 25], ["HSV infection", "DISEASE", 63, 76], ["infection", "DISEASE", 149, 158], ["hairy leukoplakia", "DISEASE", 189, 206], ["infection", "DISEASE", 265, 274], ["angina", "DISEASE", 390, 396], ["tonsillitis", "DISEASE", 435, 446], ["HSV", "ORGANISM", 63, 66], ["children", "ORGANISM", 87, 95], ["EBV", "ORGANISM", 253, 256], ["HIV", "ORGANISM", 299, 302], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 342, 353], ["S. aureus", "ORGANISM", 354, 363], ["pseudomembrane", "SIMPLE_CHEMICAL", 452, 466], ["tonsillar surfaces", "MULTI-TISSUE_STRUCTURE", 480, 498], ["children", "SPECIES", 87, 95], ["HIV", "SPECIES", 299, 302], ["S. aureus", "SPECIES", 354, 363], ["HSV", "SPECIES", 63, 66], ["HIV", "SPECIES", 299, 302], ["S. aureus", "SPECIES", 354, 363], ["stomatitis", "PROBLEM", 15, 25], ["primary HSV infection", "PROBLEM", 55, 76], ["Oral hairy leukoplakia", "PROBLEM", 184, 206], ["an EBV-related infection", "PROBLEM", 250, 274], ["HIV", "PROBLEM", 299, 302], ["a lesion in the oral cavity", "PROBLEM", 326, 353], ["S. aureus", "PROBLEM", 354, 363], ["streptococciVincent's angina", "PROBLEM", 368, 396], ["a necrotizing anaerobic tonsillitis", "PROBLEM", 411, 446], ["pseudomembrane formation on tonsillar surfaces", "PROBLEM", 452, 498], ["stomatitis", "OBSERVATION", 15, 25], ["primary", "OBSERVATION_MODIFIER", 55, 62], ["HSV", "OBSERVATION_MODIFIER", 63, 66], ["infection", "OBSERVATION", 67, 76], ["infection", "OBSERVATION", 149, 158], ["hairy", "OBSERVATION_MODIFIER", 189, 194], ["leukoplakia", "OBSERVATION", 195, 206], ["EBV", "OBSERVATION", 253, 256], ["infection", "OBSERVATION", 265, 274], ["lesion", "OBSERVATION", 328, 334], ["oral cavity", "ANATOMY", 342, 353], ["aureus", "OBSERVATION", 357, 363], ["necrotizing", "OBSERVATION_MODIFIER", 413, 424], ["anaerobic", "OBSERVATION_MODIFIER", 425, 434], ["tonsillitis", "OBSERVATION", 435, 446], ["pseudomembrane formation", "OBSERVATION", 452, 476], ["tonsillar", "ANATOMY", 480, 489], ["surfaces", "ANATOMY_MODIFIER", 490, 498]]], ["This infection is relatively rare today, but it is very serious when seen in immune deficiency because of complications including septic thrombophlebitis, bacteremia, and metastatic infection.", [["infection", "DISEASE", 5, 14], ["immune deficiency", "DISEASE", 77, 94], ["septic thrombophlebitis", "DISEASE", 130, 153], ["bacteremia", "DISEASE", 155, 165], ["infection", "DISEASE", 182, 191], ["This infection", "PROBLEM", 0, 14], ["immune deficiency", "PROBLEM", 77, 94], ["complications", "PROBLEM", 106, 119], ["septic thrombophlebitis", "PROBLEM", 130, 153], ["bacteremia", "PROBLEM", 155, 165], ["metastatic infection", "PROBLEM", 171, 191], ["infection", "OBSERVATION", 5, 14], ["septic", "OBSERVATION_MODIFIER", 130, 136], ["thrombophlebitis", "OBSERVATION", 137, 153], ["bacteremia", "OBSERVATION", 155, 165], ["metastatic", "OBSERVATION_MODIFIER", 171, 181], ["infection", "OBSERVATION", 182, 191]]], ["Multiple anaerobes, especially F. necrophorurn, are implicated in this syndrome.", [["F. necrophorurn", "SPECIES", 31, 46], ["F. necrophorurn", "SPECIES", 31, 46], ["Multiple anaerobes", "PROBLEM", 0, 18], ["this syndrome", "PROBLEM", 66, 79], ["anaerobes", "OBSERVATION", 9, 18]]], ["In a related infection, acute necrotizing ulcerative gingivitis (Vincent's gingivitis), a large spirochete seems to be a key pathogen; however, clinical microbiology laboratories are not asked to do cultural studies for diagnosis of this latter condition.", [["ulcerative", "ANATOMY", 42, 52], ["infection", "DISEASE", 13, 22], ["ulcerative gingivitis", "DISEASE", 42, 63], ["Vincent's gingivitis", "DISEASE", 65, 85], ["ulcerative gingivitis", "PATHOLOGICAL_FORMATION", 42, 63], ["a related infection", "PROBLEM", 3, 22], ["acute necrotizing ulcerative gingivitis", "PROBLEM", 24, 63], ["Vincent's gingivitis", "PROBLEM", 65, 85], ["a large spirochete", "PROBLEM", 88, 106], ["a key pathogen", "PROBLEM", 119, 133], ["clinical microbiology laboratories", "TEST", 144, 178], ["cultural studies", "TEST", 199, 215], ["this latter condition", "PROBLEM", 233, 254], ["infection", "OBSERVATION", 13, 22], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["necrotizing", "OBSERVATION_MODIFIER", 30, 41], ["ulcerative", "OBSERVATION_MODIFIER", 42, 52], ["gingivitis", "OBSERVATION", 53, 63], ["large", "OBSERVATION_MODIFIER", 90, 95], ["spirochete", "OBSERVATION", 96, 106]]], ["A Gram stain of the lesion is often helpful if a high percentage of spirochetal forms are recognized.NasopharyngitisIn children, inflammatory involvement of the nasal passages frequently occurs with acute pharyngitis.", [["lesion", "ANATOMY", 20, 26], ["nasal passages", "ANATOMY", 161, 175], ["NasopharyngitisIn", "DISEASE", 101, 118], ["pharyngitis", "DISEASE", 205, 216], ["children", "ORGANISM", 119, 127], ["nasal", "ORGAN", 161, 166], ["children", "SPECIES", 119, 127], ["A Gram stain", "TEST", 0, 12], ["the lesion", "PROBLEM", 16, 26], ["inflammatory involvement of the nasal passages", "PROBLEM", 129, 175], ["acute pharyngitis", "PROBLEM", 199, 216], ["lesion", "OBSERVATION", 20, 26], ["inflammatory", "OBSERVATION_MODIFIER", 129, 141], ["nasal", "ANATOMY", 161, 166], ["passages", "OBSERVATION", 167, 175], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["pharyngitis", "OBSERVATION", 205, 216]]], ["This infection, purulent nasopharyngitis, is due to a mixture of aerobic and anaerobic organisms, consistent with the flora of the oral cavity?", [["oral cavity", "ANATOMY", 131, 142], ["infection", "DISEASE", 5, 14], ["purulent nasopharyngitis", "DISEASE", 16, 40], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 131, 142], ["This infection", "PROBLEM", 0, 14], ["purulent nasopharyngitis", "PROBLEM", 16, 40], ["aerobic and anaerobic organisms", "PROBLEM", 65, 96], ["the flora of the oral cavity", "PROBLEM", 114, 142], ["infection", "OBSERVATION", 5, 14], ["purulent", "OBSERVATION_MODIFIER", 16, 24], ["nasopharyngitis", "OBSERVATION", 25, 40], ["anaerobic organisms", "OBSERVATION", 77, 96], ["consistent with", "UNCERTAINTY", 98, 113], ["flora", "OBSERVATION", 118, 123], ["oral cavity", "ANATOMY", 131, 142]]], ["A rare form of chronic granulomatous infections of the nasal passages, encompassing the sinuses and occasionally the pharynx and larynx, is rhinoscleroma.", [["granulomatous", "ANATOMY", 23, 36], ["nasal passages", "ANATOMY", 55, 69], ["sinuses", "ANATOMY", 88, 95], ["pharynx", "ANATOMY", 117, 124], ["larynx", "ANATOMY", 129, 135], ["rhinoscleroma", "ANATOMY", 140, 153], ["granulomatous infections", "DISEASE", 23, 47], ["rhinoscleroma", "DISEASE", 140, 153], ["nasal", "ORGAN", 55, 60], ["sinuses", "ORGAN", 88, 95], ["pharynx", "ORGAN", 117, 124], ["larynx", "ORGAN", 129, 135], ["rhinoscleroma", "CANCER", 140, 153], ["chronic granulomatous infections of the nasal passages, encompassing the sinuses and occasionally the pharynx and larynx", "PROBLEM", 15, 135], ["rhinoscleroma", "PROBLEM", 140, 153], ["rare form of", "UNCERTAINTY", 2, 14], ["chronic", "OBSERVATION_MODIFIER", 15, 22], ["granulomatous", "OBSERVATION_MODIFIER", 23, 36], ["infections", "OBSERVATION", 37, 47], ["nasal passages", "OBSERVATION", 55, 69], ["sinuses", "ANATOMY", 88, 95], ["pharynx", "ANATOMY", 117, 124], ["larynx", "ANATOMY", 129, 135], ["rhinoscleroma", "OBSERVATION", 140, 153]]], ["Associated with Klebsiella pneumoniae subsp. rhinoscleromatis, the disease is characterized by nasal obstruction developing over a prolonged period, appearing as a tumor-like growth with local extension.", [["nasal", "ANATOMY", 95, 100], ["tumor", "ANATOMY", 164, 169], ["rhinoscleromatis", "DISEASE", 45, 61], ["nasal obstruction", "DISEASE", 95, 112], ["tumor", "DISEASE", 164, 169], ["Klebsiella pneumoniae", "ORGANISM", 16, 37], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 95, 112], ["tumor", "CANCER", 164, 169], ["Klebsiella pneumoniae subsp", "SPECIES", 16, 43], ["Klebsiella pneumoniae subsp", "SPECIES", 16, 43], ["Klebsiella pneumoniae subsp", "PROBLEM", 16, 43], ["rhinoscleromatis", "PROBLEM", 45, 61], ["the disease", "PROBLEM", 63, 74], ["nasal obstruction", "PROBLEM", 95, 112], ["a tumor-like growth", "PROBLEM", 162, 181], ["local extension", "PROBLEM", 187, 202], ["Klebsiella", "OBSERVATION_MODIFIER", 16, 26], ["pneumoniae", "OBSERVATION", 27, 37], ["disease", "OBSERVATION", 67, 74], ["nasal", "ANATOMY", 95, 100], ["obstruction", "OBSERVATION", 101, 112], ["tumor", "OBSERVATION", 164, 169], ["growth", "OBSERVATION_MODIFIER", 175, 181], ["local", "OBSERVATION_MODIFIER", 187, 192]]], ["Another gramnegative rod species, K. ozaenae, can also be recovered from upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 73, 96], ["respiratory tract infections", "DISEASE", 79, 107], ["K. ozaenae", "ORGANISM", 34, 44], ["upper", "ORGANISM_SUBDIVISION", 73, 78], ["respiratory tract", "ORGANISM_SUBDIVISION", 79, 96], ["K. ozaenae", "SPECIES", 34, 44], ["K. ozaenae", "SPECIES", 34, 44], ["Another gramnegative rod species", "PROBLEM", 0, 32], ["upper respiratory tract infections", "PROBLEM", 73, 107], ["gramnegative rod species", "OBSERVATION", 8, 32], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory tract", "ANATOMY", 79, 96], ["infections", "OBSERVATION", 97, 107]]], ["This organism may contribute to the infre-quent condition, ozaena, characterized by a chronic, mucopurulent nasal discharge (often foul smelling) thought to be caused by a secondary mixed anaerobic infection.Tooth-Associated InfectionDental problems may stimulate requests for microbiologic assessment, with the most common being root canal infections, with or without periapical abscess, followed by orofacial odontogenic infections, with or without osteomyelitis of the jaw, and perimandibular space infections.", [["nasal", "ANATOMY", 108, 113], ["root canal", "ANATOMY", 330, 340], ["periapical abscess", "ANATOMY", 369, 387], ["orofacial odontogenic", "ANATOMY", 401, 422], ["jaw", "ANATOMY", 472, 475], ["perimandibular space", "ANATOMY", 481, 501], ["ozaena", "DISEASE", 59, 65], ["anaerobic infection", "DISEASE", 188, 207], ["InfectionDental problems", "DISEASE", 225, 249], ["root canal infections", "DISEASE", 330, 351], ["periapical abscess", "DISEASE", 369, 387], ["orofacial odontogenic infections", "DISEASE", 401, 433], ["osteomyelitis of the jaw", "DISEASE", 451, 475], ["perimandibular space infections", "DISEASE", 481, 512], ["nasal", "ORGAN", 108, 113], ["root canal", "MULTI-TISSUE_STRUCTURE", 330, 340], ["periapical abscess", "PATHOLOGICAL_FORMATION", 369, 387], ["jaw", "ORGAN", 472, 475], ["the infre-quent condition", "PROBLEM", 32, 57], ["a chronic, mucopurulent nasal discharge", "PROBLEM", 84, 123], ["foul smelling", "PROBLEM", 131, 144], ["a secondary mixed anaerobic infection", "PROBLEM", 170, 207], ["InfectionDental problems", "PROBLEM", 225, 249], ["microbiologic assessment", "TEST", 277, 301], ["root canal infections", "PROBLEM", 330, 351], ["periapical abscess", "PROBLEM", 369, 387], ["orofacial odontogenic infections", "PROBLEM", 401, 433], ["osteomyelitis of the jaw", "PROBLEM", 451, 475], ["perimandibular space infections", "PROBLEM", 481, 512], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["mucopurulent", "OBSERVATION_MODIFIER", 95, 107], ["nasal", "ANATOMY", 108, 113], ["secondary", "OBSERVATION_MODIFIER", 172, 181], ["mixed", "OBSERVATION_MODIFIER", 182, 187], ["anaerobic", "OBSERVATION_MODIFIER", 188, 197], ["infection", "OBSERVATION", 198, 207], ["root canal", "ANATOMY", 330, 340], ["infections", "OBSERVATION", 341, 351], ["without", "UNCERTAINTY", 361, 368], ["periapical", "ANATOMY", 369, 379], ["abscess", "OBSERVATION", 380, 387], ["orofacial", "ANATOMY", 401, 410], ["odontogenic", "OBSERVATION", 411, 422], ["osteomyelitis", "OBSERVATION", 451, 464], ["jaw", "ANATOMY", 472, 475], ["perimandibular space", "ANATOMY", 481, 501], ["infections", "OBSERVATION", 502, 512]]], ["The bacteriology is similar in all of these situations, involving primarily anaerobic bacteria and streptoc, 51 A possible exception is perimandibular space infections that may also involve staphylococci and Eikenella corrodens in a relatively high percentage (15%) of patients.", [["perimandibular space infections", "DISEASE", 136, 167], ["Eikenella corrodens", "DISEASE", 208, 227], ["Eikenella corrodens", "ORGANISM", 208, 227], ["patients", "ORGANISM", 269, 277], ["Eikenella corrodens", "SPECIES", 208, 227], ["patients", "SPECIES", 269, 277], ["Eikenella corrodens", "SPECIES", 208, 227], ["The bacteriology", "TEST", 0, 16], ["anaerobic bacteria", "PROBLEM", 76, 94], ["perimandibular space infections", "PROBLEM", 136, 167], ["staphylococci", "PROBLEM", 190, 203], ["Eikenella corrodens", "PROBLEM", 208, 227], ["similar", "OBSERVATION_MODIFIER", 20, 27], ["anaerobic bacteria", "OBSERVATION", 76, 94], ["perimandibular space infections", "OBSERVATION", 136, 167], ["Eikenella corrodens", "OBSERVATION", 208, 227], ["relatively", "OBSERVATION_MODIFIER", 233, 243], ["high", "OBSERVATION_MODIFIER", 244, 248], ["percentage", "OBSERVATION_MODIFIER", 249, 259]]], ["The streptococci are microaerophilic or facultative in growth requirements, and usually a-hemolytic.", [["streptococci", "CELL", 4, 16], ["The streptococci", "PROBLEM", 0, 16], ["microaerophilic", "PROBLEM", 21, 36], ["facultative in growth requirements", "PROBLEM", 40, 74], ["streptococci", "OBSERVATION", 4, 16], ["microaerophilic", "OBSERVATION_MODIFIER", 21, 36], ["facultative", "OBSERVATION_MODIFIER", 40, 51], ["growth requirements", "OBSERVATION", 55, 74]]], ["These are implicated in up to 30% of cases that are associated with a preceding dental infection.", [["infection", "DISEASE", 87, 96], ["a preceding dental infection", "PROBLEM", 68, 96], ["infection", "OBSERVATION", 87, 96]]], ["The B. fragilis group organisms are found in root canal infections, orofacial odontogenic infections, and bacteremia secondary. to dental extraction in 5% to 10% of patients.", [["root canal", "ANATOMY", 45, 55], ["orofacial odontogenic", "ANATOMY", 68, 89], ["infections", "DISEASE", 56, 66], ["orofacial odontogenic infections", "DISEASE", 68, 100], ["bacteremia", "DISEASE", 106, 116], ["B. fragilis", "ORGANISM", 4, 15], ["root canal", "MULTI-TISSUE_STRUCTURE", 45, 55], ["patients", "ORGANISM", 165, 173], ["B. fragilis group", "SPECIES", 4, 21], ["patients", "SPECIES", 165, 173], ["B. fragilis", "SPECIES", 4, 15], ["The B. fragilis group organisms", "PROBLEM", 0, 31], ["root canal infections", "PROBLEM", 45, 66], ["orofacial odontogenic infections", "PROBLEM", 68, 100], ["bacteremia", "PROBLEM", 106, 116], ["dental extraction", "TREATMENT", 131, 148], ["fragilis", "OBSERVATION", 7, 15], ["root canal", "ANATOMY", 45, 55], ["infections", "OBSERVATION", 56, 66], ["orofacial", "ANATOMY", 68, 77], ["odontogenic", "OBSERVATION_MODIFIER", 78, 89], ["infections", "OBSERVATION", 90, 100], ["bacteremia", "OBSERVATION", 106, 116]]], ["Anaerobic cocci (both Peptostreptococcus and Veillonella), pigmented Prevotella and Porphyromonas, the Prevotella oralis group, and Fusobacteriurn spp are found in about 20% to 50% of these conditions.", [["Porphyromonas", "GENE_OR_GENE_PRODUCT", 84, 97], ["Prevotella oralis", "ORGANISM", 103, 120], ["Fusobacteriurn spp", "ORGANISM", 132, 150], ["Prevotella oralis group", "SPECIES", 103, 126], ["Fusobacteriurn spp", "SPECIES", 132, 150], ["Prevotella oralis", "SPECIES", 103, 120], ["Anaerobic cocci", "TEST", 0, 15], ["both Peptostreptococcus and Veillonella)", "TEST", 17, 57], ["pigmented Prevotella", "PROBLEM", 59, 79], ["Porphyromonas", "PROBLEM", 84, 97], ["the Prevotella oralis group", "TEST", 99, 126], ["Fusobacteriurn spp", "TEST", 132, 150], ["cocci", "OBSERVATION", 10, 15], ["Porphyromonas", "ANATOMY", 84, 97]]], ["Oral bacteria are clearly important in other dental processes, such as caries and periodontitis, but clinical laboratories are not traditionally involved in culturing in such cases.", [["caries", "DISEASE", 71, 77], ["periodontitis", "DISEASE", 82, 95], ["Oral bacteria", "PROBLEM", 0, 13], ["caries and periodontitis", "PROBLEM", 71, 95], ["clinical laboratories", "TEST", 101, 122], ["bacteria", "OBSERVATION", 5, 13], ["periodontitis", "OBSERVATION", 82, 95]]], ["Typically, periodontal infections have been managed by mechanical cleansing and empiric therapy.", [["periodontal", "ANATOMY", 11, 22], ["periodontal infections", "DISEASE", 11, 33], ["periodontal infections", "PROBLEM", 11, 33], ["mechanical cleansing", "TREATMENT", 55, 75], ["empiric therapy", "TREATMENT", 80, 95], ["periodontal", "OBSERVATION_MODIFIER", 11, 22], ["infections", "OBSERVATION", 23, 33]]], ["A better understanding of the pathogenesis of this disease process is leading to a greater recognition of the role of bacterial originating agents and the modifying role of host defenses.21 When periodontal disease develops, it appears that the local microflora are able to penetrate the gingival epithelium and bring about an inflammatory response.", [["periodontal", "ANATOMY", 195, 206], ["gingival epithelium", "ANATOMY", 288, 307], ["periodontal disease", "DISEASE", 195, 214], ["gingival epithelium", "TISSUE", 288, 307], ["this disease process", "PROBLEM", 46, 66], ["bacterial originating agents", "TREATMENT", 118, 146], ["periodontal disease", "PROBLEM", 195, 214], ["the local microflora", "PROBLEM", 241, 261], ["an inflammatory response", "PROBLEM", 324, 348], ["disease", "OBSERVATION", 207, 214], ["gingival epithelium", "ANATOMY", 288, 307], ["inflammatory", "OBSERVATION", 327, 339]]], ["This inflammation significantly contributes to the subsequent destruction of the periodontium.", [["periodontium", "ANATOMY", 81, 93], ["inflammation", "DISEASE", 5, 17], ["periodontium", "ORGAN", 81, 93], ["This inflammation", "PROBLEM", 0, 17], ["the subsequent destruction of the periodontium", "PROBLEM", 47, 93], ["inflammation", "OBSERVATION", 5, 17], ["destruction", "OBSERVATION", 62, 73], ["periodontium", "ANATOMY", 81, 93]]], ["Another recent report suggests that a direct smear of plaque taken from the subgingival area (showing numerous spirochetes), and even culture with susceptibility testing may be useful for a specific diagnosis and antimicrobial therapy.\"", [["plaque", "ANATOMY", 54, 60], ["subgingival area", "ANATOMY", 76, 92], ["plaque", "PATHOLOGICAL_FORMATION", 54, 60], ["a direct smear", "TEST", 36, 50], ["plaque", "PROBLEM", 54, 60], ["the subgingival area", "TEST", 72, 92], ["numerous spirochetes", "PROBLEM", 102, 122], ["culture", "TEST", 134, 141], ["susceptibility testing", "TEST", 147, 169], ["antimicrobial therapy", "TREATMENT", 213, 234], ["plaque", "OBSERVATION", 54, 60], ["numerous", "OBSERVATION_MODIFIER", 102, 110], ["spirochetes", "OBSERVATION", 111, 122]]], ["Such an approach to specifically target the microbial plaque is consistent with the most recent understanding of disease pathogenesis.", [["plaque", "ANATOMY", 54, 60], ["the microbial plaque", "PROBLEM", 40, 60], ["disease pathogenesis", "PROBLEM", 113, 133], ["microbial", "OBSERVATION_MODIFIER", 44, 53], ["plaque", "OBSERVATION", 54, 60], ["consistent with", "UNCERTAINTY", 64, 79], ["disease", "OBSERVATION", 113, 120]]], ["The common microbial species for this infection are given in Table 1 .", [["infection", "DISEASE", 38, 47], ["The common microbial species", "PROBLEM", 0, 28], ["this infection", "PROBLEM", 33, 47], ["common", "OBSERVATION_MODIFIER", 4, 10], ["microbial species", "OBSERVATION", 11, 28], ["infection", "OBSERVATION", 38, 47]]], ["This new approach is advocated based upon the evidence that specific therapy of anaerobic infection can be important for improved healing and a reduced need for surgery in the management of periodontal disease.\"ActinornycosisInfection with Actinomyces israelii may complicate any intraoral surgery or trauma.", [["periodontal", "ANATOMY", 190, 201], ["intraoral", "ANATOMY", 280, 289], ["infection", "DISEASE", 90, 99], ["periodontal disease", "DISEASE", 190, 209], ["ActinornycosisInfection", "DISEASE", 211, 234], ["Actinomyces israelii", "DISEASE", 240, 260], ["trauma", "DISEASE", 301, 307], ["periodontal", "ORGAN", 190, 201], ["Actinomyces israelii", "ORGANISM", 240, 260], ["Actinomyces israelii", "SPECIES", 240, 260], ["Actinomyces israelii", "SPECIES", 240, 260], ["anaerobic infection", "PROBLEM", 80, 99], ["improved healing", "PROBLEM", 121, 137], ["surgery", "TREATMENT", 161, 168], ["periodontal disease", "PROBLEM", 190, 209], ["ActinornycosisInfection", "PROBLEM", 211, 234], ["Actinomyces israelii", "PROBLEM", 240, 260], ["intraoral surgery", "TREATMENT", 280, 297], ["trauma", "PROBLEM", 301, 307], ["infection", "OBSERVATION", 90, 99], ["periodontal", "ANATOMY", 190, 201], ["disease", "OBSERVATION", 202, 209], ["Actinomyces", "OBSERVATION", 240, 251], ["surgery", "OBSERVATION", 290, 297], ["trauma", "OBSERVATION", 301, 307]]], ["This organism is part of the usual oral flora, and therefore is not acquired from external sources.", [["oral flora", "ANATOMY", 35, 45], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["flora", "PATHOLOGICAL_FORMATION", 40, 45], ["This organism", "PROBLEM", 0, 13], ["the usual oral flora", "PROBLEM", 25, 45]]], ["Infections usually present as an indolent swelling, abscess, or mass lesion.% When this organism is suspected, the laboratory should be notified, as it may be missed as part of an otherwise mixed infection unless the microbiology technologists are alerted to look specifically for this anaerobe.", [["abscess", "ANATOMY", 52, 59], ["mass lesion", "ANATOMY", 64, 75], ["Infections", "DISEASE", 0, 10], ["swelling", "DISEASE", 42, 50], ["abscess", "DISEASE", 52, 59], ["infection", "DISEASE", 196, 205], ["Infections", "PROBLEM", 0, 10], ["an indolent swelling", "PROBLEM", 30, 50], ["abscess", "PROBLEM", 52, 59], ["mass lesion", "PROBLEM", 64, 75], ["an otherwise mixed infection", "PROBLEM", 177, 205], ["this anaerobe", "PROBLEM", 281, 294], ["indolent", "OBSERVATION_MODIFIER", 33, 41], ["swelling", "OBSERVATION", 42, 50], ["abscess", "OBSERVATION", 52, 59], ["mass", "OBSERVATION", 64, 68], ["mixed", "OBSERVATION_MODIFIER", 190, 195], ["infection", "OBSERVATION", 196, 205]]], ["Submit pus with grains of \"sulfur granules\" in an anaerobic transport media for the highest recovery of this pathogen.Suppurative ParotitisAcute suppurative parotitis (sialadenitis) is seen in very ill patients, especially those that are dehydrated, malnourished, elderly, or recovering from surgery.5l It is associated with painful, tender swelling of the parotid gland.", [["parotid gland", "ANATOMY", 357, 370], ["sulfur", "CHEMICAL", 27, 33], ["suppurative parotitis", "DISEASE", 145, 166], ["sialadenitis", "DISEASE", 168, 180], ["sulfur", "CHEMICAL", 27, 33], ["pus", "ORGANISM_SUBSTANCE", 7, 10], ["sulfur", "SIMPLE_CHEMICAL", 27, 33], ["granules", "ORGANISM_SUBSTANCE", 34, 42], ["patients", "ORGANISM", 202, 210], ["parotid gland", "ORGAN", 357, 370], ["patients", "SPECIES", 202, 210], ["pus", "PROBLEM", 7, 10], ["sulfur granules", "PROBLEM", 27, 42], ["an anaerobic transport media", "TREATMENT", 47, 75], ["this pathogen", "PROBLEM", 104, 117], ["Suppurative ParotitisAcute suppurative parotitis", "PROBLEM", 118, 166], ["sialadenitis", "PROBLEM", 168, 180], ["surgery", "TREATMENT", 292, 299], ["painful, tender swelling of the parotid gland", "PROBLEM", 325, 370], ["pus", "OBSERVATION", 7, 10], ["sulfur granules", "OBSERVATION", 27, 42], ["suppurative", "OBSERVATION_MODIFIER", 145, 156], ["parotitis", "OBSERVATION", 157, 166], ["sialadenitis", "OBSERVATION", 168, 180], ["very", "OBSERVATION_MODIFIER", 193, 197], ["ill", "OBSERVATION_MODIFIER", 198, 201], ["dehydrated", "OBSERVATION", 238, 248], ["malnourished", "OBSERVATION_MODIFIER", 250, 262], ["associated with", "UNCERTAINTY", 309, 324], ["painful", "OBSERVATION_MODIFIER", 325, 332], ["tender", "OBSERVATION_MODIFIER", 334, 340], ["swelling", "OBSERVATION", 341, 349], ["parotid gland", "ANATOMY", 357, 370]]], ["Purulent drainage may be evident at the opening of the duct of the gland in the mouth.", [["duct", "ANATOMY", 55, 59], ["gland", "ANATOMY", 67, 72], ["mouth", "ANATOMY", 80, 85], ["duct", "MULTI-TISSUE_STRUCTURE", 55, 59], ["gland", "ORGAN", 67, 72], ["mouth", "ORGANISM_SUBDIVISION", 80, 85], ["Purulent drainage", "PROBLEM", 0, 17], ["drainage", "OBSERVATION", 9, 17], ["opening", "OBSERVATION", 40, 47], ["duct", "ANATOMY", 55, 59], ["gland", "ANATOMY", 67, 72], ["mouth", "ANATOMY", 80, 85]]], ["S. aureus is the major pathogen, but on occasion viridans streptococci and oral anaerobes may play a role.", [["oral anaerobes", "ANATOMY", 75, 89], ["S. aureus", "ORGANISM", 0, 9], ["viridans streptococci", "ORGANISM", 49, 70], ["oral anaerobes", "PATHOLOGICAL_FORMATION", 75, 89], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "SPECIES", 0, 9], ["S. aureus", "PROBLEM", 0, 9], ["the major pathogen", "PROBLEM", 13, 31], ["viridans streptococci", "PROBLEM", 49, 70], ["oral anaerobes", "PROBLEM", 75, 89], ["aureus", "OBSERVATION", 3, 9], ["major", "OBSERVATION_MODIFIER", 17, 22], ["pathogen", "OBSERVATION", 23, 31]]], ["A chronic bacterial parotitis has been described that also commonly involves s. aureus.", [["parotitis", "DISEASE", 20, 29], ["s. aureus", "ORGANISM", 77, 86], ["s. aureus", "SPECIES", 77, 86], ["s. aureus", "SPECIES", 77, 86], ["A chronic bacterial parotitis", "PROBLEM", 0, 29], ["s. aureus", "PROBLEM", 77, 86], ["chronic", "OBSERVATION_MODIFIER", 2, 9], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["parotitis", "OBSERVATION", 20, 29], ["aureus", "OBSERVATION", 80, 86]]], ["Less often, other salivary glands may be involved with a bacterial infection, usually also because of dudal obstruction.", [["salivary glands", "ANATOMY", 18, 33], ["bacterial infection", "DISEASE", 57, 76], ["dudal obstruction", "DISEASE", 102, 119], ["salivary glands", "ORGAN", 18, 33], ["other salivary glands", "PROBLEM", 12, 33], ["a bacterial infection", "PROBLEM", 55, 76], ["dudal obstruction", "PROBLEM", 102, 119], ["salivary glands", "ANATOMY", 18, 33], ["bacterial", "OBSERVATION_MODIFIER", 57, 66], ["infection", "OBSERVATION", 67, 76], ["obstruction", "OBSERVATION", 108, 119]]], ["The mumps virus is traditionally the major viral agent involved in parotitis; however, with prevalent childhood vaccination, infection with mumps virus is now rarely found.", [["mumps virus", "DISEASE", 4, 15], ["parotitis", "DISEASE", 67, 76], ["infection", "DISEASE", 125, 134], ["mumps virus", "DISEASE", 140, 151], ["mumps virus", "ORGANISM", 4, 15], ["mumps virus", "ORGANISM", 140, 151], ["mumps virus", "SPECIES", 4, 15], ["mumps virus", "SPECIES", 140, 151], ["The mumps virus", "PROBLEM", 0, 15], ["parotitis", "PROBLEM", 67, 76], ["infection", "PROBLEM", 125, 134], ["mumps virus", "PROBLEM", 140, 151], ["mumps virus", "OBSERVATION", 4, 15], ["parotitis", "OBSERVATION", 67, 76], ["infection", "OBSERVATION", 125, 134]]], ["Influenza virus and enteroviruses occasionally cause parotitis.", [["Influenza virus and enteroviruses", "DISEASE", 0, 33], ["parotitis", "DISEASE", 53, 62], ["Influenza virus", "ORGANISM", 0, 15], ["enteroviruses", "ORGANISM", 20, 33], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["enteroviruses", "PROBLEM", 20, 33], ["parotitis", "PROBLEM", 53, 62], ["virus", "OBSERVATION", 10, 15], ["parotitis", "OBSERVATION", 53, 62]]], ["Diagnosis of viral infection is usually done serologically.", [["viral infection", "DISEASE", 13, 28], ["viral infection", "PROBLEM", 13, 28], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28]]], ["Infrequently, Mycobacterium tuberculosis may involve the parotid gland in conjunction with pulmonary tuberculosis.Symptomatic acute sinusitis caused by bacterial infection usually develops during the course of a viralWhen bacterial sinusitis develops, the infection typically is caused by the microbial flora of the oral cavity, from bacteria being trapped in the sinus cavity owing to inflammation and swelling of the ostiomeatal area mucosa from a viral infection, thus occluding normal drainage, or much less frequently (5% to 10%) by direct extension from a dental source of infection.", [["parotid gland", "ANATOMY", 57, 70], ["pulmonary", "ANATOMY", 91, 100], ["oral cavity", "ANATOMY", 316, 327], ["sinus cavity", "ANATOMY", 364, 376], ["ostiomeatal area mucosa", "ANATOMY", 419, 442], ["Mycobacterium tuberculosis", "DISEASE", 14, 40], ["pulmonary tuberculosis", "DISEASE", 91, 113], ["sinusitis", "DISEASE", 132, 141], ["bacterial infection", "DISEASE", 152, 171], ["bacterial sinusitis", "DISEASE", 222, 241], ["infection", "DISEASE", 256, 265], ["inflammation", "DISEASE", 386, 398], ["viral infection", "DISEASE", 450, 465], ["infection", "DISEASE", 579, 588], ["Mycobacterium tuberculosis", "ORGANISM", 14, 40], ["parotid gland", "ORGAN", 57, 70], ["pulmonary", "ORGAN", 91, 100], ["oral cavity", "ORGAN", 316, 327], ["sinus cavity", "MULTI-TISSUE_STRUCTURE", 364, 376], ["mucosa", "MULTI-TISSUE_STRUCTURE", 436, 442], ["Mycobacterium tuberculosis", "SPECIES", 14, 40], ["Mycobacterium tuberculosis", "SPECIES", 14, 40], ["Mycobacterium tuberculosis", "PROBLEM", 14, 40], ["pulmonary tuberculosis", "PROBLEM", 91, 113], ["Symptomatic acute sinusitis", "PROBLEM", 114, 141], ["bacterial infection", "PROBLEM", 152, 171], ["a viral", "TREATMENT", 210, 217], ["bacterial sinusitis", "PROBLEM", 222, 241], ["the infection", "PROBLEM", 252, 265], ["the microbial flora of the oral cavity", "PROBLEM", 289, 327], ["bacteria", "PROBLEM", 334, 342], ["the sinus cavity", "PROBLEM", 360, 376], ["inflammation", "PROBLEM", 386, 398], ["swelling of the ostiomeatal area mucosa", "PROBLEM", 403, 442], ["a viral infection", "PROBLEM", 448, 465], ["normal drainage", "TREATMENT", 482, 497], ["infection", "PROBLEM", 579, 588], ["Mycobacterium tuberculosis", "OBSERVATION", 14, 40], ["parotid gland", "ANATOMY", 57, 70], ["pulmonary", "ANATOMY", 91, 100], ["tuberculosis", "OBSERVATION", 101, 113], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["sinusitis", "OBSERVATION", 132, 141], ["bacterial", "OBSERVATION_MODIFIER", 152, 161], ["infection", "OBSERVATION", 162, 171], ["bacterial", "OBSERVATION_MODIFIER", 222, 231], ["sinusitis", "OBSERVATION", 232, 241], ["infection", "OBSERVATION", 256, 265], ["microbial flora", "OBSERVATION", 293, 308], ["oral cavity", "ANATOMY", 316, 327], ["bacteria", "OBSERVATION_MODIFIER", 334, 342], ["sinus cavity", "ANATOMY", 364, 376], ["inflammation", "OBSERVATION", 386, 398], ["swelling", "OBSERVATION", 403, 411], ["ostiomeatal", "ANATOMY_MODIFIER", 419, 430], ["area mucosa", "ANATOMY", 431, 442], ["viral", "OBSERVATION_MODIFIER", 450, 455], ["infection", "OBSERVATION", 456, 465], ["normal", "OBSERVATION_MODIFIER", 482, 488], ["drainage", "OBSERVATION", 489, 497], ["much", "OBSERVATION_MODIFIER", 502, 506], ["less", "OBSERVATION_MODIFIER", 507, 511], ["infection", "OBSERVATION", 579, 588]]], ["Sinusitis tends to be self-limited, usually lasting 1 to 3 weeks, but is important because it affects approximately 2 million Americans each year.", [["Sinusitis", "DISEASE", 0, 9], ["Sinusitis", "PROBLEM", 0, 9]]], ["It not only results in direct morbidity and visits to physicians, but bacterial sinusitis is the most commonly recognized cause of subdural empyema, responsible for 56% of cases in a recent se Other complications include local extension into the orbit and other bones of the skull, and development of chronic sinusitis.", [["subdural", "ANATOMY", 131, 139], ["orbit", "ANATOMY", 246, 251], ["bones", "ANATOMY", 262, 267], ["skull", "ANATOMY", 275, 280], ["bacterial sinusitis", "DISEASE", 70, 89], ["subdural empyema", "DISEASE", 131, 147], ["sinusitis", "DISEASE", 309, 318], ["subdural empyema", "PATHOLOGICAL_FORMATION", 131, 147], ["orbit", "ORGAN", 246, 251], ["bones", "ORGAN", 262, 267], ["skull", "ORGAN", 275, 280], ["bacterial sinusitis", "PROBLEM", 70, 89], ["subdural empyema", "PROBLEM", 131, 147], ["local extension into the orbit and other bones of the skull", "PROBLEM", 221, 280], ["chronic sinusitis", "PROBLEM", 301, 318], ["sinusitis", "OBSERVATION", 80, 89], ["subdural", "ANATOMY", 131, 139], ["empyema", "OBSERVATION", 140, 147], ["local", "OBSERVATION_MODIFIER", 221, 226], ["extension", "OBSERVATION", 227, 236], ["orbit", "ANATOMY", 246, 251], ["bones", "ANATOMY", 262, 267], ["skull", "ANATOMY", 275, 280], ["chronic", "OBSERVATION_MODIFIER", 301, 308], ["sinusitis", "OBSERVATION", 309, 318]]], ["Most studies of the microbiology of acute sinusitis have dealt with maxillary infection because it is the most common type and the only one accessible for puncture and aspiration.63 Bacterial cultures should be positive in nearly three fourths of patients with acute sinusitis.", [["maxillary", "ANATOMY", 68, 77], ["cultures", "ANATOMY", 192, 200], ["sinusitis", "DISEASE", 42, 51], ["maxillary infection", "DISEASE", 68, 87], ["sinusitis", "DISEASE", 267, 276], ["maxillary", "ORGAN", 68, 77], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["acute sinusitis", "PROBLEM", 36, 51], ["maxillary infection", "PROBLEM", 68, 87], ["puncture", "TEST", 155, 163], ["aspiration", "PROBLEM", 168, 178], ["Bacterial cultures", "TEST", 182, 200], ["acute sinusitis", "PROBLEM", 261, 276], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["sinusitis", "OBSERVATION", 42, 51], ["maxillary", "ANATOMY", 68, 77], ["infection", "OBSERVATION", 78, 87], ["most common", "OBSERVATION_MODIFIER", 106, 117], ["puncture", "OBSERVATION", 155, 163], ["aspiration", "OBSERVATION", 168, 178], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["sinusitis", "OBSERVATION", 267, 276]]], ["In a study involving young adults, H. influenzae was USE OF THE CLINICAL MICROBIOLOGY LABORATORY 787 recovered from 50% and S. pneumoniae from 19% of patients.", [["H. influenzae", "ORGANISM", 35, 48], ["S. pneumoniae", "ORGANISM", 124, 137], ["patients", "ORGANISM", 150, 158], ["H. influenzae", "SPECIES", 35, 48], ["S. pneumoniae", "SPECIES", 124, 137], ["patients", "SPECIES", 150, 158], ["H. influenzae", "SPECIES", 35, 48], ["S. pneumoniae", "SPECIES", 124, 137], ["a study", "TEST", 3, 10], ["S. pneumoniae", "PROBLEM", 124, 137]]], ["Streptococcus pyogenes and M . catarrhah were also found, in addition to normal skin ' flora such as Proprionibacferium actzes.", [["skin ' flora", "ANATOMY", 80, 92], ["Streptococcus pyogenes", "ORGANISM", 0, 22], ["M . catarrhah", "ORGANISM", 27, 40], ["skin", "ORGAN", 80, 84], ["Streptococcus pyogenes", "SPECIES", 0, 22], ["M . catarrhah", "SPECIES", 27, 40], ["Streptococcus pyogenes", "SPECIES", 0, 22], ["M . catarrhah", "SPECIES", 27, 40], ["Proprionibacferium actzes", "SPECIES", 101, 126], ["Streptococcus pyogenes", "PROBLEM", 0, 22], ["catarrhah", "PROBLEM", 31, 40], ["normal skin ' flora", "PROBLEM", 73, 92], ["Proprionibacferium actzes", "TREATMENT", 101, 126], ["skin", "ANATOMY", 80, 84]]], ["Anaerobes were considered pathogens in only 2% of cases of acute sinusitis.", [["sinusitis", "DISEASE", 65, 74], ["Anaerobes", "TREATMENT", 0, 9], ["pathogens", "PROBLEM", 26, 35], ["acute sinusitis", "PROBLEM", 59, 74], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["sinusitis", "OBSERVATION", 65, 74]]], ["Among children, s. pneumoniue, H. influenzae, and M. cafarrhulis appear most comm0n.3~ ,~ A recent review also found that oral infection can result in distant infection at several unexpected sites.48 Not only did the authors find expected infections, such as brain abscess, osteomyelitis, and mediastinal abscess due to Bacteroides spp, Fusobacterium spp, streptococci, and Peptostreptococcus spp, but also hepatobiliary infection from Actinomyces spp, Fusobacteriurn spp, and oral streptococci.", [["oral", "ANATOMY", 122, 126], ["brain abscess", "ANATOMY", 259, 272], ["mediastinal abscess", "ANATOMY", 293, 312], ["hepatobiliary", "ANATOMY", 407, 420], ["oral", "ANATOMY", 477, 481], ["oral infection", "DISEASE", 122, 136], ["infection", "DISEASE", 159, 168], ["infections", "DISEASE", 239, 249], ["brain abscess", "DISEASE", 259, 272], ["osteomyelitis", "DISEASE", 274, 287], ["mediastinal abscess", "DISEASE", 293, 312], ["hepatobiliary infection", "DISEASE", 407, 430], ["children", "ORGANISM", 6, 14], ["s. pneumoniue", "ORGANISM", 16, 29], ["H. influenzae", "ORGANISM", 31, 44], ["M. cafarrhulis", "ORGANISM", 50, 64], ["oral", "ORGANISM_SUBDIVISION", 122, 126], ["brain", "ORGAN", 259, 264], ["mediastinal abscess", "PATHOLOGICAL_FORMATION", 293, 312], ["Bacteroides spp", "ORGANISM", 320, 335], ["Fusobacterium spp", "ORGANISM", 337, 354], ["Peptostreptococcus spp", "ORGANISM", 374, 396], ["hepatobiliary", "ORGAN", 407, 420], ["Actinomyces spp", "ORGANISM", 436, 451], ["Fusobacteriurn spp", "ORGANISM", 453, 471], ["oral streptococci", "ORGANISM", 477, 494], ["children", "SPECIES", 6, 14], ["H. influenzae", "SPECIES", 31, 44], ["M. cafarrhulis", "SPECIES", 50, 64], ["Fusobacterium spp", "SPECIES", 337, 354], ["Peptostreptococcus spp", "SPECIES", 374, 396], ["Actinomyces spp", "SPECIES", 436, 451], ["Fusobacteriurn spp", "SPECIES", 453, 471], ["s. pneumoniue", "SPECIES", 16, 29], ["H. influenzae", "SPECIES", 31, 44], ["M. cafarrhulis", "SPECIES", 50, 64], ["Actinomyces spp", "SPECIES", 436, 451], ["H. influenzae", "PROBLEM", 31, 44], ["oral infection", "PROBLEM", 122, 136], ["distant infection", "PROBLEM", 151, 168], ["expected infections", "PROBLEM", 230, 249], ["brain abscess", "PROBLEM", 259, 272], ["osteomyelitis", "PROBLEM", 274, 287], ["mediastinal abscess", "PROBLEM", 293, 312], ["Bacteroides spp", "PROBLEM", 320, 335], ["Fusobacterium spp", "PROBLEM", 337, 354], ["streptococci", "PROBLEM", 356, 368], ["Peptostreptococcus spp", "PROBLEM", 374, 396], ["hepatobiliary infection", "PROBLEM", 407, 430], ["Actinomyces spp", "TEST", 436, 451], ["Fusobacteriurn spp", "TEST", 453, 471], ["oral streptococci", "PROBLEM", 477, 494], ["influenzae", "OBSERVATION", 34, 44], ["infection", "OBSERVATION", 127, 136], ["distant", "OBSERVATION_MODIFIER", 151, 158], ["infection", "OBSERVATION", 159, 168], ["infections", "OBSERVATION", 239, 249], ["brain", "ANATOMY", 259, 264], ["abscess", "OBSERVATION", 265, 272], ["osteomyelitis", "OBSERVATION", 274, 287], ["mediastinal", "ANATOMY", 293, 304], ["abscess", "OBSERVATION", 305, 312], ["Peptostreptococcus spp", "OBSERVATION", 374, 396], ["hepatobiliary", "ANATOMY", 407, 420], ["infection", "OBSERVATION", 421, 430], ["streptococci", "OBSERVATION", 482, 494]]], ["48 In patients with solid tumors or leukemia, when fever develops in the presence of granulocytopenia ( 4 0 0 granulocytes/mm3), oral lesions are present in a majority of the patients (>70%), and often this is the only source site of potential bacteremia recognized.& During and after immunosu pression, C. albicans, Histoplasma capsulatum, C yptococcus neoformans, HSV, Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, H. influenzae, Acinetobacter spp, S. aureus, S. epidermidis, and Streptococcus pneumoniae.", [["solid tumors", "ANATOMY", 20, 32], ["leukemia", "ANATOMY", 36, 44], ["granulocytes", "ANATOMY", 110, 122], ["oral lesions", "ANATOMY", 129, 141], ["tumors", "DISEASE", 26, 32], ["leukemia", "DISEASE", 36, 44], ["fever", "DISEASE", 51, 56], ["granulocytopenia", "DISEASE", 85, 101], ["bacteremia", "DISEASE", 244, 254], ["Histoplasma capsulatum", "DISEASE", 317, 339], ["Proteus mirabilis", "DISEASE", 418, 435], ["Streptococcus pneumoniae", "DISEASE", 502, 526], ["patients", "ORGANISM", 6, 14], ["solid tumors", "CANCER", 20, 32], ["leukemia", "CANCER", 36, 44], ["oral lesions", "PATHOLOGICAL_FORMATION", 129, 141], ["patients", "ORGANISM", 175, 183], ["C. albicans", "ORGANISM", 304, 315], ["Histoplasma capsulatum", "ORGANISM", 317, 339], ["C yptococcus neoformans", "ORGANISM", 341, 364], ["HSV,", "ORGANISM", 366, 370], ["Pseudomonas aeruginosa", "ORGANISM", 371, 393], ["Klebsiella pneumoniae", "ORGANISM", 395, 416], ["Proteus mirabilis", "ORGANISM", 418, 435], ["H. influenzae", "ORGANISM", 437, 450], ["Acinetobacter spp", "ORGANISM", 452, 469], ["S. aureus", "ORGANISM", 471, 480], ["S. epidermidis", "ORGANISM", 482, 496], ["Streptococcus pneumoniae", "ORGANISM", 502, 526], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 175, 183], ["C. albicans", "SPECIES", 304, 315], ["Histoplasma capsulatum", "SPECIES", 317, 339], ["C yptococcus neoformans", "SPECIES", 341, 364], ["HSV", "SPECIES", 366, 369], ["Pseudomonas aeruginosa", "SPECIES", 371, 393], ["Klebsiella pneumoniae", "SPECIES", 395, 416], ["Proteus mirabilis", "SPECIES", 418, 435], ["H. influenzae", "SPECIES", 437, 450], ["Acinetobacter spp", "SPECIES", 452, 469], ["S. aureus", "SPECIES", 471, 480], ["S. epidermidis", "SPECIES", 482, 496], ["Streptococcus pneumoniae", "SPECIES", 502, 526], ["C. albicans", "SPECIES", 304, 315], ["Histoplasma capsulatum", "SPECIES", 317, 339], ["C yptococcus neoformans", "SPECIES", 341, 364], ["HSV", "SPECIES", 366, 369], ["Pseudomonas aeruginosa", "SPECIES", 371, 393], ["Klebsiella pneumoniae", "SPECIES", 395, 416], ["Proteus mirabilis", "SPECIES", 418, 435], ["H. influenzae", "SPECIES", 437, 450], ["Acinetobacter spp", "SPECIES", 452, 469], ["S. aureus", "SPECIES", 471, 480], ["S. epidermidis", "SPECIES", 482, 496], ["Streptococcus pneumoniae", "SPECIES", 502, 526], ["solid tumors", "PROBLEM", 20, 32], ["leukemia", "PROBLEM", 36, 44], ["fever", "PROBLEM", 51, 56], ["granulocytopenia", "PROBLEM", 85, 101], ["granulocytes", "TEST", 110, 122], ["oral lesions", "PROBLEM", 129, 141], ["potential bacteremia", "PROBLEM", 234, 254], ["immunosu pression", "TREATMENT", 285, 302], ["C. albicans", "PROBLEM", 304, 315], ["Histoplasma capsulatum", "TEST", 317, 339], ["C yptococcus neoformans", "PROBLEM", 341, 364], ["HSV", "PROBLEM", 366, 369], ["Pseudomonas aeruginosa", "PROBLEM", 371, 393], ["Klebsiella pneumoniae", "PROBLEM", 395, 416], ["Proteus mirabilis", "PROBLEM", 418, 435], ["H. influenzae", "PROBLEM", 437, 450], ["Acinetobacter spp", "PROBLEM", 452, 469], ["S. aureus", "PROBLEM", 471, 480], ["S. epidermidis", "PROBLEM", 482, 496], ["Streptococcus pneumoniae", "PROBLEM", 502, 526], ["solid", "OBSERVATION_MODIFIER", 20, 25], ["tumors", "OBSERVATION", 26, 32], ["leukemia", "OBSERVATION", 36, 44], ["granulocytopenia", "OBSERVATION", 85, 101], ["oral", "ANATOMY", 129, 133], ["lesions", "OBSERVATION", 134, 141], ["majority", "OBSERVATION_MODIFIER", 159, 167], ["bacteremia", "OBSERVATION", 244, 254], ["Histoplasma capsulatum", "OBSERVATION", 317, 339], ["Klebsiella pneumoniae", "OBSERVATION", 395, 416], ["aureus", "OBSERVATION", 474, 480], ["epidermidis", "OBSERVATION", 485, 496], ["Streptococcus pneumoniae", "OBSERVATION", 502, 526]]], ["Thus, bacteremia and fungemia arising from the oral cavity can be very diverse and challenging. the microbial flora in the mouth can harbor such diverse pa tf: ogens asSUMMARYOur knowledge regarding the pathogenesis of infections relative to the oral cavity is rapidly expanding, similar to our overall understanding of how infectious diseases impact our daily lives.", [["oral cavity", "ANATOMY", 47, 58], ["mouth", "ANATOMY", 123, 128], ["oral cavity", "ANATOMY", 246, 257], ["bacteremia", "DISEASE", 6, 16], ["fungemia", "DISEASE", 21, 29], ["infections", "DISEASE", 219, 229], ["infectious diseases", "DISEASE", 324, 343], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 47, 58], ["mouth", "ORGANISM_SUBDIVISION", 123, 128], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 246, 257], ["bacteremia", "PROBLEM", 6, 16], ["fungemia", "PROBLEM", 21, 29], ["the oral cavity", "PROBLEM", 43, 58], ["the microbial flora in the mouth", "PROBLEM", 96, 128], ["infections", "PROBLEM", 219, 229], ["the oral cavity", "PROBLEM", 242, 257], ["bacteremia", "OBSERVATION", 6, 16], ["fungemia", "OBSERVATION", 21, 29], ["oral cavity", "ANATOMY", 47, 58], ["microbial flora", "OBSERVATION", 100, 115], ["mouth", "ANATOMY", 123, 128], ["infections", "OBSERVATION", 219, 229], ["oral cavity", "ANATOMY", 246, 257]]], ["The complexity of the flora within the oral cavity is quite unique and often makes diagnosis difficult; however, it is becoming more apparent that accurate dia testing is important from the standpoint of focusing appropriate t erapy on pathogens within this crucial body site, and avoiding overuse of antimicrobial agents in settings of infection where they have no demonstrated benefit.", [["oral cavity", "ANATOMY", 39, 50], ["body site", "ANATOMY", 266, 275], ["infection", "DISEASE", 337, 346], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 39, 50], ["body", "ORGANISM_SUBDIVISION", 266, 270], ["the flora within the oral cavity", "PROBLEM", 18, 50], ["accurate dia testing", "TEST", 147, 167], ["appropriate t erapy", "TREATMENT", 213, 232], ["pathogens", "PROBLEM", 236, 245], ["antimicrobial agents", "TREATMENT", 301, 321], ["infection", "PROBLEM", 337, 346], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["flora", "OBSERVATION", 22, 27], ["oral cavity", "ANATOMY", 39, 50], ["infection", "OBSERVATION", 337, 346]]], ["New diagnostic methods are being developed to detect pathogens and rapidly delineate resistance patterns.", [["New diagnostic methods", "TEST", 0, 22], ["pathogens", "PROBLEM", 53, 62]]], ["Many will be based YtiC on new genetic assays, but they must be cost effective, sensitive, and spe Another growing challenge is to provide adequate lab support to outpatient offices and clinics, without compromising the specimen culture or turnaround times.", [["YtiC", "SIMPLE_CHEMICAL", 19, 23], ["new genetic assays", "TEST", 27, 45], ["the specimen culture", "TEST", 216, 236]]], ["So many patients are being seen away from hospital laboratories that we need ways to diagnose sinusitis, pharyngitis, abscess, and other infections of the oral cavity without killing the anaerobes and other significant facultative bacteria, and without ruining the direct stains by overgrowth or inflammatory cell degradation during specimen transport.", [["abscess", "ANATOMY", 118, 125], ["oral cavity", "ANATOMY", 155, 166], ["anaerobes", "ANATOMY", 187, 196], ["cell", "ANATOMY", 309, 313], ["specimen", "ANATOMY", 333, 341], ["sinusitis", "DISEASE", 94, 103], ["pharyngitis", "DISEASE", 105, 116], ["abscess", "DISEASE", 118, 125], ["infections", "DISEASE", 137, 147], ["patients", "ORGANISM", 8, 16], ["abscess", "PATHOLOGICAL_FORMATION", 118, 125], ["oral cavity", "ORGANISM_SUBDIVISION", 155, 166], ["cell", "CELL", 309, 313], ["patients", "SPECIES", 8, 16], ["sinusitis", "PROBLEM", 94, 103], ["pharyngitis", "PROBLEM", 105, 116], ["abscess", "PROBLEM", 118, 125], ["other infections of the oral cavity", "PROBLEM", 131, 166], ["killing the anaerobes", "PROBLEM", 175, 196], ["other significant facultative bacteria", "PROBLEM", 201, 239], ["the direct stains", "TEST", 261, 278], ["overgrowth", "PROBLEM", 282, 292], ["inflammatory cell degradation", "PROBLEM", 296, 325], ["specimen transport", "TEST", 333, 351], ["pharyngitis", "OBSERVATION", 105, 116], ["abscess", "OBSERVATION", 118, 125], ["infections", "OBSERVATION", 137, 147], ["oral cavity", "ANATOMY", 155, 166], ["anaerobes", "OBSERVATION", 187, 196], ["significant", "OBSERVATION_MODIFIER", 207, 218], ["facultative", "OBSERVATION_MODIFIER", 219, 230], ["bacteria", "OBSERVATION", 231, 239], ["inflammatory cell degradation", "OBSERVATION", 296, 325]]], ["These results need to be available quickly enough to give useful information for office diagnosis in order to effect therapy.", [["therapy", "TREATMENT", 117, 124]]], ["To optimize both diagnosis and treatment, a key to the future will be better communication between the clinical practitioner and laboratory, with an increasing emphasis on training expertise in medical microbiology and infectious diseases.", [["infectious diseases", "DISEASE", 219, 238], ["treatment", "TREATMENT", 31, 40], ["infectious", "OBSERVATION", 219, 229]]]], "PMC7349471": [["BackgroundHuman coronaviruses are a group of RNA viruses able to cause respiratory, gastrointestinal and central nervous system diseases.", [["respiratory", "ANATOMY", 71, 82], ["gastrointestinal", "ANATOMY", 84, 100], ["central nervous system", "ANATOMY", 105, 127], ["respiratory, gastrointestinal and central nervous system diseases", "DISEASE", 71, 136], ["BackgroundHuman coronaviruses", "ORGANISM", 0, 29], ["gastrointestinal", "ORGANISM_SUBDIVISION", 84, 100], ["central nervous system", "ANATOMICAL_SYSTEM", 105, 127], ["BackgroundHuman coronaviruses", "SPECIES", 0, 29], ["BackgroundHuman coronaviruses", "PROBLEM", 0, 29], ["RNA viruses", "PROBLEM", 45, 56], ["respiratory, gastrointestinal and central nervous system diseases", "PROBLEM", 71, 136], ["coronaviruses", "OBSERVATION", 16, 29], ["gastrointestinal", "ANATOMY", 84, 100], ["central", "ANATOMY_MODIFIER", 105, 112], ["nervous system", "ANATOMY", 113, 127]]], ["The first human coronavirus (HCoV) was detected in the mid-1960s [1].", [["human", "ORGANISM", 10, 15], ["coronavirus", "ORGANISM", 16, 27], ["HCoV", "CANCER", 29, 33], ["human", "SPECIES", 10, 15], ["coronavirus", "SPECIES", 16, 27], ["human coronavirus", "SPECIES", 10, 27], ["HCoV", "SPECIES", 29, 33]]], ["In December 2019, the seventh coronavirus known to infect humans was found in China (Wuhan city, Hubei Province) [2].", [["coronavirus", "ORGANISM", 30, 41], ["humans", "ORGANISM", 58, 64], ["humans", "SPECIES", 58, 64], ["humans", "SPECIES", 58, 64]]], ["On 12 January 2020, the World Health Organization (WHO) announced the temporarily named nCoV-2019, now called SARS-CoV-2, as the novel coronavirus pathogen responsible for the increasing number of new pneumonia cases [3, 4].", [["coronavirus pathogen", "DISEASE", 135, 155], ["pneumonia", "DISEASE", 201, 210], ["SARS-CoV-2", "ORGANISM", 110, 120], ["coronavirus", "ORGANISM", 135, 146], ["SARS-CoV", "SPECIES", 110, 118], ["the novel coronavirus pathogen", "PROBLEM", 125, 155], ["new pneumonia cases", "PROBLEM", 197, 216], ["new", "OBSERVATION_MODIFIER", 197, 200], ["pneumonia", "OBSERVATION", 201, 210]]], ["Since that day, the number of cases in China and progressively in many other parts of the world has increased (Fig. 1), and with it, the number of people who died because of this infection as the primary or contributory cause of preexisting illness [5].", [["infection", "DISEASE", 179, 188], ["illness", "DISEASE", 241, 248], ["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["this infection", "PROBLEM", 174, 188], ["preexisting illness", "PROBLEM", 229, 248], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["infection", "OBSERVATION", 179, 188]]], ["On 11 March 2020, the WHO stated that the novel coronavirus outbreak was a pandemic (Fig. 2).", [["coronavirus", "DISEASE", 48, 59], ["coronavirus", "ORGANISM", 48, 59], ["the novel coronavirus outbreak", "PROBLEM", 38, 68]]], ["The scientific community is still making numerous efforts to clarify the etiology, pathogenicity, and characteristics of the virus to establish the mechanisms underlying human-to-human transmission and possible treatments [6\u201310].", [["human", "ORGANISM", 170, 175], ["human", "ORGANISM", 179, 184], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 170, 175], ["human", "SPECIES", 179, 184], ["pathogenicity", "PROBLEM", 83, 96], ["the virus", "PROBLEM", 121, 130]]], ["Although there are many cases of recovery, the number of deceased subjects has increased with the spread, particularly affecting older subjects with previous severe pathologies [11, 12].", [["previous severe pathologies", "PROBLEM", 149, 176], ["many", "OBSERVATION_MODIFIER", 19, 23], ["increased", "OBSERVATION_MODIFIER", 79, 88], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["pathologies", "OBSERVATION", 165, 176]]], ["The first detection of the virus in Italy was in a case of two Chinese tourists from Wuhan who were later treated at the Spallanzani Hospital of Rome.", [["the virus", "PROBLEM", 23, 32], ["virus", "OBSERVATION", 27, 32]]]], "9313219675ddfa18b0667b701433123acc3c39da": [["P athogens are detected by host pattern recognition receptors (PRRs) that sense various microbial motifs collectively known as pathogen-associated molecular patterns (PAMPs) and subsequently elicit antimicrobial innate immune responses 1, 2 .", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 32, 61], ["PRRs", "GENE_OR_GENE_PRODUCT", 63, 67], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 127, 165], ["P athogens", "DNA", 0, 10], ["host pattern recognition receptors", "PROTEIN", 27, 61], ["PRRs", "PROTEIN", 63, 67], ["pathogen-associated molecular patterns", "PROTEIN", 127, 165], ["PAMPs", "PROTEIN", 167, 172], ["pathogen", "PROBLEM", 127, 135]]], ["Microbe-derived nucleic acids are potent PAMPs that elicit PRRmediated host immune responses 3 .", [["nucleic acids", "CHEMICAL", 16, 29], ["Microbe", "SIMPLE_CHEMICAL", 0, 7], ["nucleic acids", "TREATMENT", 16, 29], ["potent PAMPs", "TREATMENT", 34, 46]]], ["The recognition of invading RNA viruses by cytoplasmic sensors (RIG-I and MDA5) and endosomal toll-like receptors (TLRs) has been extensively characterized 3 .", [["cytoplasmic", "ANATOMY", 43, 54], ["endosomal", "ANATOMY", 84, 93], ["cytoplasmic", "ORGANISM_SUBSTANCE", 43, 54], ["RIG-I", "GENE_OR_GENE_PRODUCT", 64, 69], ["MDA5", "GENE_OR_GENE_PRODUCT", 74, 78], ["endosomal", "CELLULAR_COMPONENT", 84, 93], ["toll-like receptors", "GENE_OR_GENE_PRODUCT", 94, 113], ["TLRs", "GENE_OR_GENE_PRODUCT", 115, 119], ["cytoplasmic sensors", "PROTEIN", 43, 62], ["RIG-I", "PROTEIN", 64, 69], ["MDA5", "PROTEIN", 74, 78], ["endosomal toll-like receptors", "PROTEIN", 84, 113], ["TLRs", "PROTEIN", 115, 119], ["invading RNA viruses", "PROBLEM", 19, 39], ["cytoplasmic sensors", "TEST", 43, 62], ["invading RNA viruses", "OBSERVATION", 19, 39]]], ["The appearance of naked DNA in the cytoplasm of mammalian cells also triggers DNA sensor-mediated signal transduction 4 .", [["cytoplasm", "ANATOMY", 35, 44], ["mammalian cells", "ANATOMY", 48, 63], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["cytoplasm", "ORGANISM_SUBSTANCE", 35, 44], ["mammalian cells", "CELL", 48, 63], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["naked DNA", "DNA", 18, 27], ["mammalian cells", "CELL_TYPE", 48, 63], ["naked DNA", "PROBLEM", 18, 27], ["DNA sensor", "TEST", 78, 88], ["naked DNA", "OBSERVATION", 18, 27], ["mammalian cells", "OBSERVATION", 48, 63]]], ["Many cytosolic DNA sensors have been identified, including AIM2 5-7 , DAI 8 , DDX41 9 , DNA-PK 10 , IFI16 11 , a form of RNA polymerase III 12, 13 , and cyclic GMP-AMP (cGAMP) synthase (cGAS) 14, 15 .", [["cytosolic", "ANATOMY", 5, 14], ["GMP", "CHEMICAL", 160, 163], ["AMP", "CHEMICAL", 164, 167], ["cyclic GMP-AMP", "CHEMICAL", 153, 167], ["cGAMP", "CHEMICAL", 169, 174], ["DNA", "CELLULAR_COMPONENT", 15, 18], ["AIM2", "GENE_OR_GENE_PRODUCT", 59, 63], ["DAI 8", "GENE_OR_GENE_PRODUCT", 70, 75], ["DDX41 9", "GENE_OR_GENE_PRODUCT", 78, 85], ["DNA-PK 10", "GENE_OR_GENE_PRODUCT", 88, 97], ["IFI16", "GENE_OR_GENE_PRODUCT", 100, 105], ["RNA polymerase III 12", "GENE_OR_GENE_PRODUCT", 121, 142], ["cyclic GMP-AMP (cGAMP) synthase", "GENE_OR_GENE_PRODUCT", 153, 184], ["AIM2 5-7", "DNA", 59, 67], ["DAI 8", "DNA", 70, 75], ["DDX41 9", "DNA", 78, 85], ["DNA-PK 10", "DNA", 88, 97], ["IFI16 11", "DNA", 100, 108], ["RNA polymerase III 12, 13 , and cyclic GMP-AMP (cGAMP) synthase (cGAS) 14, 15", "PROTEIN", 121, 198], ["Many cytosolic DNA sensors", "TEST", 0, 26], ["AIM2", "TEST", 59, 63], ["DAI", "TEST", 70, 73], ["DDX41", "TEST", 78, 83], ["DNA-PK", "TEST", 88, 94], ["IFI16", "TEST", 100, 105], ["RNA polymerase III", "TEST", 121, 139], ["cyclic GMP-AMP (cGAMP) synthase (cGAS)", "TEST", 153, 191], ["cytosolic DNA", "OBSERVATION", 5, 18]]], ["Particularly, recent studies have shown that cGAS functions as the primary cytosolic DNA sensor that triggers production of type I interferons (IFNs) and other inflammatory cytokines, such as tumor necrosis factor-\u03b1 and interleukin-6, upon DNA transfection and DNA virus infection 14, 15 .", [["cytosolic", "ANATOMY", 75, 84], ["tumor necrosis", "DISEASE", 192, 206], ["infection", "DISEASE", 271, 280], ["cGAS", "GENE_OR_GENE_PRODUCT", 45, 49], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["type I interferons", "GENE_OR_GENE_PRODUCT", 124, 142], ["IFNs", "GENE_OR_GENE_PRODUCT", 144, 148], ["tumor necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 192, 215], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 220, 233], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["DNA", "CELLULAR_COMPONENT", 261, 264], ["cGAS", "PROTEIN", 45, 49], ["type I interferons", "PROTEIN", 124, 142], ["IFNs", "PROTEIN", 144, 148], ["inflammatory cytokines", "PROTEIN", 160, 182], ["tumor necrosis factor-\u03b1", "PROTEIN", 192, 215], ["interleukin-6", "PROTEIN", 220, 233], ["recent studies", "TEST", 14, 28], ["cGAS functions", "PROBLEM", 45, 59], ["the primary cytosolic DNA sensor", "PROBLEM", 63, 95], ["type I interferons (IFNs)", "PROBLEM", 124, 149], ["other inflammatory cytokines", "PROBLEM", 154, 182], ["tumor necrosis factor", "PROBLEM", 192, 213], ["interleukin", "TEST", 220, 231], ["DNA transfection", "TREATMENT", 240, 256], ["DNA virus infection", "PROBLEM", 261, 280], ["inflammatory", "OBSERVATION_MODIFIER", 160, 172], ["tumor", "OBSERVATION_MODIFIER", 192, 197], ["necrosis", "OBSERVATION", 198, 206]]], ["Following activation, cGAS converts ATP and GTP into the dinucleotide cGAMP [16] [17] [18] . cGAMP is a second messenger that binds to stimulator of interferon genes (STING), which in turn induces the recruitment of TANK-binding kinase 1 (TBK1) and interferon regulatory factor-3 (IRF-3) 18, 19 .", [["ATP", "CHEMICAL", 36, 39], ["GTP", "CHEMICAL", 44, 47], ["dinucleotide", "CHEMICAL", 57, 69], ["cGAMP", "CHEMICAL", 93, 98], ["ATP", "CHEMICAL", 36, 39], ["GTP", "CHEMICAL", 44, 47], ["dinucleotide", "CHEMICAL", 57, 69], ["cGAS", "SIMPLE_CHEMICAL", 22, 26], ["ATP", "SIMPLE_CHEMICAL", 36, 39], ["GTP", "SIMPLE_CHEMICAL", 44, 47], ["cGAMP", "GENE_OR_GENE_PRODUCT", 93, 98], ["interferon", "GENE_OR_GENE_PRODUCT", 149, 159], ["STING", "GENE_OR_GENE_PRODUCT", 167, 172], ["TANK-binding kinase 1", "GENE_OR_GENE_PRODUCT", 216, 237], ["TBK1", "GENE_OR_GENE_PRODUCT", 239, 243], ["interferon regulatory factor-3", "GENE_OR_GENE_PRODUCT", 249, 279], ["IRF-3", "GENE_OR_GENE_PRODUCT", 281, 286], ["cGAS", "PROTEIN", 22, 26], ["cGAMP", "PROTEIN", 93, 98], ["interferon genes", "DNA", 149, 165], ["STING", "DNA", 167, 172], ["TANK-binding kinase 1", "PROTEIN", 216, 237], ["TBK1", "PROTEIN", 239, 243], ["interferon regulatory factor-3 (IRF-3) 18, 19", "PROTEIN", 249, 294], ["ATP", "PROBLEM", 36, 39], ["GTP into the dinucleotide cGAMP", "TEST", 44, 75], ["interferon genes", "TREATMENT", 149, 165], ["TANK-binding kinase", "TEST", 216, 235], ["TBK1", "TEST", 239, 243], ["interferon regulatory factor", "TEST", 249, 277]]], ["Then, the TBK-mediated activation of the IRF-3 pathway induces the expression of type I IFNs.", [["TBK", "CHEMICAL", 10, 13], ["TBK", "GENE_OR_GENE_PRODUCT", 10, 13], ["IRF-3", "GENE_OR_GENE_PRODUCT", 41, 46], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 81, 92], ["TBK", "PROTEIN", 10, 13], ["IRF-3", "PROTEIN", 41, 46], ["type I IFNs", "PROTEIN", 81, 92], ["the TBK", "TEST", 6, 13], ["type I IFNs", "PROBLEM", 81, 92]]], ["Thus cGAS-mediated DNA sensing signals through various adaptor molecules to ultimately induce potent antiviral innate immunity.", [["cGAS", "GENE_OR_GENE_PRODUCT", 5, 9], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["cGAS", "PROTEIN", 5, 9], ["adaptor molecules", "PROTEIN", 55, 72], ["cGAS", "TEST", 5, 9], ["various adaptor molecules", "TREATMENT", 47, 72], ["potent antiviral innate immunity", "TREATMENT", 94, 126]]]]}